













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
PhD - The University of Edinburgh - 2017 
Markers of iron status and cardiometabolic 
disease risk: An exploration of the 
association based on cross-sectional and 
prospective studies in multiple populations 





















Declaration of own work 
I declare that this doctoral thesis is entirely my own work and has not been submitted 
for any other degree or qualification. Any publication derived from the chapters and 
mentioned as product of this research is my own work in terms of conception, data 




Signature      Date 



























The aim of this thesis is to contribute to the understanding of iron metabolism, as a 
factor associated with cardiometabolic risk, by undertaking secondary data analyses. 
The objectives were to identify gaps in existing knowledge in terms of populations 
studied and alternative iron markers, and to attempt to fill the gaps with additional 
analyses and interpretation. Serum ferritin was the most widely available measure of 
iron status but the role of serum transferrin and soluble transferrin receptor (sTfR) 
levels was considered where available. I have taken a life-course approach with 
analyses in childhood and adulthood, and have included both intermediate factors 
such as the metabolic syndrome (MetS), and disease diagnoses of diabetes and 
cardiovascular disease as outcomes. 
Chapter one presents a review of empirical research literature on the relationship 
between iron metabolism and cardiometabolic risk, concepts surrounding iron 
markers and the study outcomes. This chapter also describes the gaps in 
understanding the iron-cardiometabolic risk relationship, which are subsequently 
explored in chapters two to six.  
Chapter two explores the link between serum ferritin and transferrin and MetS in 
cross-sectional and prospective studies of 725 Spanish children and 567 Chilean 
adolescents. I found associations between both ends of the ferritin distribution and 
MetS or glucose metabolism markers in different paediatric populations. For 
instance, whereas in the Spanish children there was a decrease of 0.02 SD units in the 
change of MetS score over time for every SD unit increase in ferritin, in the Chilean 
male adolescents being in the highest tertile of ferritin (v. the lowest) was associated 
with an increase of 0.25 SD units of MetS score. Furthermore, sustained high ferritin 
levels at various time points and gradual increase of ferritin during childhood were 
associated with higher MetS score in adolescence.    
The third chapter describes the association between serum ferritin status and MetS in 
adults in two cross-sectional studies of Scottish populations (2,047 individuals from 
Shetland Islands and 8,563 subjects from the Scottish Health Surveys (SHeS) 1995-
1998). I also examined the overall association between ferritin, MetS and each MetS 
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component in adults, by conducting a meta-analysis and investigating potential 
relevant sources of heterogeneity for the association. Interestingly, ferritin levels 
were positively associated with MetS in the Scottish populations, but the association 
was not independent of the effect of covariates, mainly body mass index (BMI) and 
transaminase levels [Men Odds ratio (OR) 95% confidence interval (CI) 1.43(0.83-
2.46); Postmenopausal women OR (95%CI) 1.09(0.62-1.90); Premenopausal women 
OR (95%CI) 1.02(0.42-2.46), P>0.05]. The meta-analysis supported this finding by 
describing hepatic injury markers and BMI as the major attenuating factors of the 
ferritin-MetS association.  
Chapter four investigates the association between sTfR or ferritin, and MetS in 725 
Croatian adults in a cross-sectional study. There was no evidence of an association 
between sTfR and MetS [Men OR (95%CI) 1.35(0.90-2.02); Postmenopausal women 
OR (95%CI) 0.73(0.47-1.15); Premenopausal women OR (95%CI) 0.87(0.66-1.17), 
P>0.05]. In contrast serum ferritin, was positively and independently associated with 
MetS in men and postmenopausal women (P<0.05) [Men OR (95%CI) 1.78(1.31-
2.42); Postmenopausal women OR (95%CI) 1.71(1.12-2.62); Premenopausal women 
OR (95%CI) 1.24(0.85-1.80)]. These contrasting results suggest that different iron 
markers reflect different physiological processes other than iron metabolism.  
Chapter five evaluates the longitudinal association between serum ferritin and 
several cardiometabolic disease outcomes (CMDs) in the nationally representative 
SHeS 1995 and 1998 (n = 6,497). I found an independent positive longitudinal 
association between ferritin and cerebrovascular disease (CEVD), which was 
strengthened by using higher cut-points for increased ferritin [higher v. lowest sextile 
fully adjusted Hazard ratio(HR) 95%CI 2.08 (1.09-3.94), P=0.024], and a not 
significant association with coronary heart disease (CHD) after adjustment for 
covariates. My analyses confirmed the widely established association with type 2 
diabetes (T2D) [whole sample fully adjusted HR 95% CI 1.59(1.10-2.34), P=0.006], 
even with serum ferritin within the normal range. The above set of observations 
confirm ferritin as biomarker mainly related to the development of T2D and 




Chapter six investigates whether ferritin is associated with risk for cardiovascular 
complications among people with T2D using cross-sectional study designs in two 
populations with differing baseline cardiovascular risk (Spanish study SIDIAP 
n=38,617) and (Edinburgh Type 2 Diabetes Study (ET2DS) n= 821) with additional 
analysis of follow-up data for ET2DS. Interestingly, ferritin levels were negatively 
associated with prevalence of cardiovascular disease, mainly CHD, in people with 
T2D in both studies [ET2DS OR (95%CI): 0.80(0.67-0.96), P=0.020; SIDIAP study: 
0.85(0.83-0.88), P<0.001). Ferritin was also negatively associated with incident 
cardiovascular disease in ET2DS: HR 95% CI: 0.39(0.16-0.93), P=0.035. Therefore, 
the association between iron status and CMD risk in people with T2D appears to 
differ from that in general populations in which a positive association has been more 
commonly described. 
In conclusion, serum ferritin is associated with cardiometabolic risk in different ways 
in a variety of populations. Inconsistent associations for other iron markers suggest 
that iron biomarkers reflect factors other than iron homeostasis that influence 
cardiometabolic risk. The association between iron markers and MetS appears to 
differ between populations. This thesis illustrates the complex relationship between 
iron metabolism markers, MetS and CMD, and identifies the need for further 
research on the topic in order to extend knowledge about pathophysiology and the 








The aim of this thesis was to help understand whether different measures of iron 
stores affect risk of metabolic syndrome (a combination of high waist measurement, 
high blood pressure, moderately high blood sugar levels below the level for 
diagnosing diabetes and abnormal blood fat levels), diabetes and cardiovascular 
disease. I used information collected in other research studies that had been done in 
children, adults and people who already had diabetes. Ferritin was the most widely 
available measure of iron status, but transferrin and soluble transferrin receptor 
(sTfR) levels were available in some studies. I found that there was a link between 
low ferritin and increasing cardiometabolic risk in children over time and that there 
was a link between high ferritin and higher cardiometabolic risk in adolescents. 
There was link between ferritin and metabolic syndrome in Croatian adults but no 
link was found in Scottish adults. I did not find a link between sTfR and risk of 
diabetes and cardiovascular disease in the Croatian study. Scottish adults with higher 
ferritin were more likely to develop diabetes during 14 years of follow-up than those 
with lower levels. People with diabetes with lower levels of ferritin were at higher 
risk of heart attack or stroke than people with higher levels. My findings show that 
these measures of iron status have a complicated relationship with risk of metabolic 
syndrome, diabetes and cardiovascular disease. Improving the understanding of this 
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Chapter 1  
Introduction and overview of concepts, study 
variables, and rationale for general 
methodological approaches of the thesis 
1.1 Introduction: General overview and framing of the 
PhD thesis 
The aim of this thesis is to contribute to the understanding of iron metabolism, as a 
factor associated with risk of cardiometabolic disease (CMD), by undertaking 
secondary data analyses. In particular, the aim was to identify gaps in existing 
knowledge in terms of populations studied and alternative iron markers and to fill 
these gaps with additional analyses and interpretations.  
This chapter presents the background to the thesis and includes biological and 
epidemiological observations which suggest that iron may be a causal factor in the 
development of type 2 diabetes (T2D) and cardiovascular disease (CVD). Evidence 
against the presence of a causal relationship is also considered. Although there were 
several longitudinal analyses in this thesis, the goal was to describe patterns of 
association rather than attributing causality. There still are multiple gaps in the 
knowledge on the topic, some of which will be addressed in further observational 
studies before considering whether the information add further support for the role of 
iron metabolism as a risk factor for CMD. I have taken a life-course approach with 
analyses in childhood and adulthood, including an intermediate risk factor, such as 
metabolic syndrome (MetS), and diabetes and CVD as outcomes, using longitudinal 
study designs where available. Serum ferritin was the most widely available measure 
of iron status but the roles of serum transferrin and soluble transferrin receptor 
(sTfR) levels were considered where data were available. 
In addition, this introductory chapter provides the rationale behind the research 
questions and chapters of the thesis, with information about exposure and outcome 
variables, as well as the justification for methodological decisions. 
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1.1.1 Background to the research 
Although the term “epidemic” is usually applied to infectious diseases, it has also 
been used to describe the increasing prevalence of CVD and diabetes, collectively 
described as CMD (1). Currently, ischemic heart disease and cerebrovascular disease 
(CEVD) are the top leading causes of natural death in the world, closely followed by 
diabetes and, according to projections for 2030, this scenario will not change (2). 
These diseases are attributed to the interaction between environmental and genetic 
factors that lead to arterial obstructions and alteration of glucose metabolism (3). 
Overweight/obesity, smoking, hypercaloric diets, and physical inactivity have been 
identified as well-known risk factors for CMD, and insulin resistance (IR) and 
resulting impairment of glucose metabolism have been implicated as a possible 
mechanism or earlier event (4). IR refers to the decreasing biological effect of insulin 
on tissues or organs sensitive to this hormone (liver, and adipose and skeletal muscle 
tissues) (5). Likewise, the cluster of metabolic, anthropometric, and vascular 
abnormalities, that is described as the metabolic syndrome has become an important 
tool to estimate the early risk of CMD and is associated with IR (6). However, CMD 
is a multi-factorial disorder and the exploration of potential new risk factors is 
necessary in order to obtain and a better understanding of CMD mechanisms and 
assessment of CMD risk. 
The hypothesis that iron metabolism may be a potential risk factor for CMD in the 
general population arose from a variety of observations (7). In 1981, Sullivan 
suggested that lower iron stores may partly explain the lower risk of CVD in women 
than men. In addition, CVD and diabetes have been documented as frequent 
complications of hereditary hemochromatosis (HH), a genetic disease characterised 
by high body iron accumulation. Similarly, pathological conditions characterised by 
iron overload such as thalassemia are frequently associated with IR. Iron 
concentration is increased in thalassemia owing to therapy by multiple transfusions 
as supportive treatment, and patients with normal or impaired glucose tolerance have 
shown evidence of increased pancreatic β-cell activity, reflected by high levels of C-
peptide, a structure present in the proinsulin molecule and released when insulin is 
synthesised (8).  
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In addition to inherent iron overload in the case of HH, dysmetabolic-hepatic iron 
overload syndrome (DIOS) is a kind of acquired iron overload (9). The main 
difference between HH and DIOS is that whereas in HH both transferrin saturation 
and serum ferritin are increased (> 45% and 300 µg/L respectively), in DIOS only 
ferritin levels are raised (10). This increased ferritin in DIOS is generally due to fatty 
liver and inflammation and patients with DIOS may present MetS features, 
hyperuricemia as well as altered levels of liver enzymes (9, 10). 
A possible mechanism behind the relationship between iron excess and T2D and 
CVD is increased oxidative stress due to the pro-oxidant properties of iron (11, 12). 
The ferrous iron participates through the Fenton reaction in the formation of highly 
toxic free radicals as superoxide and hydroxyl anions, which can induce lipid 
peroxidation, damage in the mechanism of endothelial vasodilation, decrease in 
insulin signalling, and atherosclerotic plaque development (13, 14). In HH, the iron 
accumulation in the islets and pancreatic acini can directly damage insulin secretion 
because  cells are highly sensitive to free radicals (15). Moreover, an in vitro study 
reported the susceptibility of insulin to nitrosation by peroxynitrite (where free 
radicals are generated by combining nitric oxide with superoxide radicals); 
moreover, this structural alteration showed marked reduction in the hypoglycaemic 
effect of insulin in a group of monkeys who were administered the modified 
hormone, compared to the control group with unmodified insulin (16).  
Of note, the relationship between iron and glucose metabolism is bidirectional (9). 
Insulin stimulates cellular uptake of many nutrients, including hexose sugars, amino 
acids, cations, and anions. This hormone causes a rapid and marked stimulation of 
the uptake of iron by adipocytes by redistributing TfR from the intracellular side of 
the membrane to the cell surface (11). These receptors are located along with insulin-
dependent glucose transporters and insulin-like growth factor II receptors in the 
microsomal membranes of adipocytes, suggesting the regulation of iron uptake by 
insulin in addition to its known effects on glucose transport. Similarly, it has been 
found that insulin is responsible for the increased ferritin synthesis in cultured rat 
glioma cells (11). Recently, it was observed that gluconeogenesis triggered by 
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starvation induces iron deposition in the liver and stimulates hepcidin production – 
the hormone that down-regulates intestinal iron absorption (9). 
Serum ferritin level is the most commonly used measure of iron stores and has been 
found to be associated with the risk of CMD in several studies (17-19). However, the 
association between measures of iron status and risk of CMD is still unclear. 
However no association between ferritin and risk of CMD in crude or adjusted 
analyses has been reported in other studies (20-22). Ferritin is an acute phase 
reactant, and inflammation is commonly associated with MetS and atherosclerosis 
and some studies suggest that inflammation rather than iron overload contributes to 
the association (23, 24). The role of chance, bias and/or confounding in the above 
discrepant findings will be considered later on in the respective discussion sections 
of chapters as well as in the conclusion chapter of this PhD thesis. Studies of the 
association between other measures of iron status such as transferrin and sTfR and 
risk of T2D and IR have also reported inconclusive findings. For instance, whereas a 
positive association has been described between serum transferrin and MetS in 
French and Swiss populations (7, 22), lower levels of transferrin in individuals with 
MetS have been described in people from an Italian village (25). Meanwhile sTfR 
levels were not found to be associated with incident T2D in English and Finnish 
cohorts (26, 27). In recent years, four meta-analyses have summarised and reported 
evidence of an association between ferritin and incidence of T2D (16-19). However 
the authors of the meta-analyses conclude that their findings may be affected by 
publication bias and unmeasured confounding, and that further research is needed to 
investigate whether there is a causal relationship between iron metabolism and 
incident diabetes.  
Although iron excess is the most common derangement of iron status reported in 
relation to the risk of T2D and MetS, a systematic review of iron status and CVD 
showed that associations might exist with both iron excess and iron deficiency but 
they may be confounded by nutritional status (28). A similar U-shaped pattern for 
the relationship of iron status with mortality was observed among individuals with 
T2D and CVD. In 287 people with diabetes and stable coronary artery disease, both 
low and high serum ferritin levels were associated with 5-year all-cause mortality 
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(29). Studies involving animals and in vitro models are consistent with 
epidemiological observations. Iron deficiency has been associated with elevation in 
fasting blood glucose despite increased insulin sensitivity in animal models (30), and 
a dose-response relationship has also been described between anaemia and 
hyperglycaemia in rats (31). Similarly, iron deficiency has been found to be a 
promoter of increased lipid synthesis in the white adipose tissue of rats, enhanced 
expression of lipogenic genes, and dyslipidaemia (9). However, the specific 
mechanisms underlying the above findings are unclear (9).  
The aim of this PhD is to describe the relationship between markers of iron status 
and risk of CMD (including MetS and its components, diabetes, and CMD) in order 
to address some of the gaps in existing knowledge.  
1.1.2 Iron metabolism 
Iron is a metal present in food in two forms: the divalent compound, ferrous, and the 
trivalent compound, ferric. The ferrous form is found mainly in meat and offal while 
ferric iron is primarily found in vegetables. Ferrous iron is highly soluble in gastric 
and duodenal juices and is the form in which iron can be absorbed by the intestinal 
cells, and only a small fraction of ferric iron can be converted to the ferrous form in 
the gut (32). Once iron is within the intestinal cells, it is again transformed into the 
ferric form and is bound by a circulating protein called transferrin, which transports 
iron to different tissues. In the tissues, iron plays a role in diverse metabolic 
functions and can be stored, mainly in the liver. In the bone marrow, it forms part of 
haemoglobin in the red blood cells. Old erythrocytes are removed from the 
circulation and broken down, releasing the iron, which is then recycled for new heme 
production, making iron metabolism very efficient (33). 
Transferrin is a glycoprotein that transports iron in the blood and contributes to 
regulation of iron homeostasis. Transferrin has only two binding sites for ferric iron, 
and it can exist as apo-transferrin (no sites occupied), monoferric (single site 
occupied), or diferric form (both sites occupied with iron). The last form has the 
highest affinity for the TfR located in the cell membranes, whereas the monoferric 
and apo-proteic forms have intermediate and the lowest affinity for the receptor, 
6 
 
respectively (34). Diferric transferrin is recognised by a receptor in the liver, which 
stimulates the synthesis of the HFE (high Fe or human hemochromatosis protein), 
which in turn stimulates the hepatic synthesis and release of the hormone hepcidin 
(35). Hepcidin acts on intestinal cells to suppress the absorption of dietary iron in 
response to iron excess, mediated by elevated levels of diferric transferrin. In 
contrast, apo-transferrin and monoferric transferrin do not activate the above 
suppressor mechanism for absorption of dietary iron by intestinal cells (35).  
Ferritin is an intracellular protein that stores iron and releases it in a controlled 
manner. Ferritin can bind approximately 4500 iron atoms and store iron in the ferric 
form (36). In addition, the storing of iron in the ferric form protects against the 
deleterious pro-oxidant effects of ferrous iron. Ferritin production increases with 
increasing absorption of dietary iron (36). 
Ferritin is also an acute phase reactant with levels increasing in the presence of 
inflammation/infection (23). In contrast, transferrin levels decrease during acute 
phase reactions (37). This is related to a survival mechanism in situations of 
infection, since iron sequestration by ferritin and the suppression of iron transport in 
the bloodstream prevents pathogens from using iron for their metabolism and growth 
(36). 
In summary, the different iron markers play the following roles in iron metabolism: 
Ferritin: iron storage 
Transferrin: transport of iron in the bloodstream 
Transferrin receptor: transport of iron bound to transferrin into the cells. Hepatic 
TfRs are involved in sensing iron status – the first step in modulation of intestinal 
iron absorption 
Hepcidin: suppression of intestinal iron absorption in response to a low iron demand 
(adequate or excess iron stores) 
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Although ferritin and TfRs do not circulate in the bloodstream, soluble fractions of 
these proteins are released into the circulation, which can be measured and used to 
represent measures of ferritin and TfRs (with the latter known as sTfRs)(38, 39). 
Iron markers show opposite patterns in conditions of iron deficiency and iron 
overload as follows: 
Iron deficiency results in low ferritin and high transferrin and sTfR levels. 
When cellular iron levels are low, storage of iron by ferritin is not possible 
because the available iron is quickly metabolised. Therefore, the levels of 
transferrin and sTfR are increased in compensation to transport and take up 
as much iron as possible into the cells, which are in a high demand state (35). 
Iron excess or overload results in high ferritin and low transferrin and sTfR 
levels. In the case of iron excess, the ferritin level increases to store the 
residual iron not needed for metabolic functions. Meanwhile, the levels of 
transferrin and sTfR decrease because the cellular demands are low (35). 
There is an increase in hepcidin in response to cellular iron overload and a 
decrease in high demand status, such as iron deficiency. However, the levels 
of hepcidin decrease when iron excess is the result of classic HH, in which 
mutations occurs in the HFE gene preventing hepcidin increase.  
1.1.3 Concepts and definitions of outcome variables 
In this PhD thesis, the main outcome variables are MetS, diabetes, and CVD. MetS 
components, IR and glycosylated haemoglobin, are variables that are closely linked 
to risk of CMD; findings on these additional outcomes will be presented in the 
appendix as supplementary material. The definitions and epidemiological data 
related to the outcomes are given below. 
Metabolic syndrome 
According to the joint statement by several associations (40), MetS is defined as a 
“complex of interrelated risk factors for CVD and diabetes. These factors include 
dysglycemia, raised blood pressure, elevated triglyceride levels, low high-density 
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lipoprotein cholesterol levels, and obesity (particularly central adiposity)”. MetS is 
also frequently associated with prothrombotic and proinflammatory states (41).  
Appendix Table 1 presents the definitions and criteria of MetS for adults, as 
specified by several organisations. The different definitions require the presence of 
three out of the five factors or components to meet the criteria for MetS. Differences 
in MetS definitions arise from the differences in cut-off points for MetS components 
or components mandatorily required to define MetS, such as central adiposity in 
terms of increased waist circumference (WC) in the case of the International 
Diabetes Federation (IDF) definition.  
In particular, the WC criterion has been the most difficult to reach consensus on 
owing to ethnic variations in adiposity distribution in addition to sex differences. The 
joint statement definition, also known as the harmonised definition, addressed this 
issue by defining different cut-points for increased WC according to ethnicity and 
geographical location as well as for men and women (40).  
The concept and clinical utility of MetS has been controversial within the diabetes 
and endocrine research community. For some academics, although MetS is 
recognised as a cluster of cardiometabolic alterations, it lacks a core feature linking 
these alterations (42). IR has been proposed to be that feature, but this view has its 
criticisms as IR is difficult to estimate and differentially related to the individual 
MetS components (42). Despite the debate, MetS has been found to increase the risk 
of CVD by two-fold according to a meta-analysis of 87 studies (951,083 subjects) 
(41). However, there is still a need for large studies and meta-analyses on the risk of 
CMD conferred by the cluster and each of its individual components to determine 
whether there is a greater risk posed by the cluster. Those who defend the clinical 
utility of MetS, view the cluster as a factor for calling attention to patients at 
increased risk of CMD that might benefit from prophylactic treatments and as a 
stimulus for additional research on the etiological mechanisms of the 
cardiometabolic alterations and therapies to simultaneously reduce multiple risk 
factors (43). Given the above controversy, this PhD thesis investigated the 




The prevalence of MetS in the world is highly variable and ranges between less than 
10% up to 84%, depending on different factors such as the definition used, sex, age, 
race, and ethnic distribution of the population studied (44). The IDF has estimated 
that around 25% of the world population has MetS (44). MetS is more prevalent in 
overweight people than in those with normal weight (45). A review comparing 
studies which used the ATP-III definition for MetS, highlighted that the prevalence 
of MetS is higher in US (23.7–34.6%) than in European populations (10–23.6%) 
(45). the same review reported that two Latin-American studies reported high MetS 
prevalence (31.2% and 35.1%) (45).  
Diabetes mellitus 
A report by the World Health Organization (WHO) defines diabetes mellitus as “a 
metabolic disorder of multiple aetiologies characterized by chronic hyperglycaemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from defects 
in insulin secretion, insulin action, or both. Type 1 diabetes encompasses cases 
which are primarily due to pancreatic islet beta-cell destruction and are prone to 
ketoacidosis. Type 2 includes the common major form of diabetes, which results from 
defect(s) in insulin secretion, almost always with a major contribution from insulin 
resistance” (46). 
The global prevalence of diabetes was estimated to be 2.8% in 2000 and 6.4% in 
2010 with prevalence projections for 2030 between 4.4% and 7.7% (47, 48). In 
Scotland, there was an increase in T2D prevalence between 2004 and 2015 (3.2% to 
5.1%), which was largely explained by the reduction in mortality over this period 
rather than by increases in incidence (49). According to the Diabetes Scotland report 
of 2015, it has been estimated that around 500,000 people are at high risk of 
developing T2D, and 480,000 people in Scotland will be living with diabetes by 
2035 (50). 
Cardiovascular diseases  
In this thesis, only ischaemic heart disease, i.e. history of angina pectoris or heart 
attack, and CEVD, i.e. transient ischaemic attack or stroke (ischemic and/or 
haemorrhagic), were considered as CVD outcomes because these are the major forms 
of the disease. According to the WHO, coronary or ischaemic (or ischemic) heart 
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disease “is characterized by reduced blood supply to the heart caused by disease of 
the blood vessels supplying the heart muscle (51). The two leading manifestations of 
ischaemic heart disease are angina pectoris and acute myocardial infarction (AMI). 
Angina pectoris is defined by the WHO as a pressure-like pain in the chest that is 
induced by exertion or stress and relieved within minutes after cessation of effort or 
using sublingual nitroglycerin. Unstable angina represents a spectrum of clinical 
states that fall between stable angina and acute myocardial infarction (MI). Chest 
pain is subjective and there is no ‘gold standard’ for estimating the prevalence of 
angina in populations. Unstable angina is generally associated with hospital 
admission in developed countries but stable angina is managed in the community” 
(51).  
For stroke, the WHO has the following definition: “rapidly developing clinical signs 
of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours 
or longer or leading to death, with no apparent cause other than of vascular origin” 
(52). Transient ischemic attack (TIA) is defined in a similar way but with a duration 
of less than 24 hours (52).  
According to the WHO, in 2012, CVD and coronary heart disease (CHD) were 
estimated to account for 31.4% and 13.2% of global deaths, respectively (53). For 
2030, CEVD is expected to account for 10.6% of deaths in the world (2). Age-sex 
standardised mortality rates per 100,000 inhabitants for all heart diseases in Scotland 
were around 300 in 2006 and 200 in 2014 (54). Despite this reduction in mortality 
over time, the prevalence of CHD in Scotland has been stable between 2004/2005 
and 2014/2015 at approximately 4%, and the prevalence of stroke has been around 
2% during 2003–2013 but with a slight increase from 2010 till 2013 (55). Within the 
UK, in 2014, Scotland had the highest prevalence of CVD (4.3%), second to the 
North of England (4.5%) (56). 
Insulin resistance 
As mentioned previously, IR is defined as the reduced biological effect of insulin on 
tissues or organs that normally respond to this hormone (5). The main biological 
effect of insulin is to stimulate glucose uptake by tissues and thus decrease the 
circulating levels of carbohydrates. IR is initially characterised by compensatory 
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hyperinsulinemia, given the decreased glucose uptake in the tissues (5). The 
"euglycemic-hyperinsulinemic clamp" is currently considered the "gold standard" for 
estimating IR and consists of intravenous administration of high doses of insulin and 
glucose infusion to maintain steady blood glucose levels within the normal range, 
according to the periodic monitoring of blood glucose in response to insulin (57). 
The glucose infusion rate is the evaluation parameter and the higher it is the greater 
the insulin sensitivity (57). However, this technique is invasive and expensive, 
requires training and a specialist software, and the patient requires hospital stay of 
around three hours for the procedure (57). Another method is the "short insulin 
tolerance test" in which a baseline blood sample and five samples after an insulin 
injection are taken at intervals of three minutes. The evaluation parameter in this 
short test is the slope of a graph of glucose concentration against time, with slopes 
closer to zero indicating increased IR (58). In 1985, Mathews et al., proposed an 
equation using an iterative testing model called Homeostatic Model Assessment 
Insulin Resistance (HOMA-IR) in which higher values reflect greater IR. HOMA-IR 
is calculated by multiplying the basal concentrations of glucose and insulin (mIU/L), 
and dividing this product by 22.5, if the glucose concentration is in mmol/L or by 
445 if it is in mg/dL (59). HOMA-IR has been validated against estimates of insulin 
sensitivity derived from clamps in several studies, and estimates of IR have shown 
good correlation (Spearman coefficient= -0.85, P < 0.0001 (60); r = -0.725, P < 
0.0001 (61)). Because of its practicality, the HOMA-IR index has been used in many 
research studies as an estimate of IR, including data sets described in this thesis in 
which relevant information was available. 
 
Glycosylated haemoglobin 
Glycosylated haemoglobin, also known as glycated haemoglobin, glycohaemoglobin, 
HbA1c, HbA1, or A1C, consists of haemoglobin portions formed from haemoglobin 
and glucose in a non-enzymatic way during a slow process (62). While blood 
measurements of glucose provide immediate information on glucose levels, 
glycosylated proteins, such as HbA1C, give long-term information on glycaemic 
history of around 120 days (62). HbA1C is commonly used as a marker for diabetic 
control, and compared to fasting glucose, it has shown similar predictions for risk of 
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diabetes and stronger association with risk of CVD in the general population (63). 
Increasing erythrocyte lifespan can increase HbA1C values. The lifespan of 
erythrocytes increases in situations of decreased erythropoiesis as a consequence of 
iron or vitamin B12 deficiency, lack of erythropoietin in renal failure, and bone 
marrow suppression in pregnancy and alcoholism (64). In contrast, situations of 
haemolysis lead to decreased values of HbA1C (64). An HbA1c of 6.5% is 
recommended as a cut-off point for diagnosing diabetes (65). A value of less than 
6.5% does not exclude diabetes diagnosed using glucose tests (65).  
 
1.2 Overview of and rationale for the thesis chapters  
As mentioned previously, this thesis evaluates the association between levels of iron 
metabolism markers and cardiometabolic risk using both cross-sectional and 
longitudinal study designs in a variety of populations. The life-course approach is 
reflected in the use of data for both children and adults to investigate whether the 
association patterns are consistent. The outcomes include MetS and its components 
as risk factors for CMD as well as CMDs. Figure 1 depicts a general scheme of the 
thesis, which shows gaps in knowledge on the association of ferritin levels (and other 
iron markers) with MetS, its components, T2D and CVD, that I investigated in this 
thesis. 
 
Chapter 2 describes the association patterns between iron markers and MetS in 
paediatric populations. It is well known that the risk for developing CMD starts in 
early stages of life, and prevalence and consequences of risk factors such as 
hypercaloric diet, obesity, and physical inactivity have been widely explored in 
children. In the light of the relevance of early detection of CMD, it is also important 
to investigate the effects of potential new risk factors or biomarkers identified in 
adults, such as iron metabolism, among children. So far, there is little information 
available on the association between iron metabolism and metabolic profiles in 
children. This chapter consists of cross-sectional and longitudinal analyses in two 
cohorts of Spanish and Chilean children. The analysis involving Spanish children 
provided the opportunity to study both serum transferrin and ferritin levels as 
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exposures, and the Chilean cohort provided the opportunity to evaluate repeated 
measurements of ferritin throughout 11 years’ follow-up as the exposure.  
 
The third chapter of this thesis includes cross-sectional studies investigating the 
association between serum ferritin and MetS and its components in two Scottish 
adult populations and a systematic review/meta-analysis of that association including 
the findings of the Scottish studies. These are the first studies to investigate the 
ferritin-MetS association in British or Scottish populations. There are two meta-
analyses on this association, but neither of them focused on the associations with 
individual MetS components. Between 2014 and 2015, several new articles on the 
topic not included in the previous meta-analyses were published. In addition, there is 
a dearth of narrative syntheses of the studies, and the potential sources of 
heterogeneity have not been studied well enough. Hence, the systematic 
review/meta-analysis is an attempt to cover these aspects.  
 
The cross-sectional association between serum TfR levels (sTfR), MetS and its 
components, and IR in an adult population is presented in Chapter 4. There are few 
other studies of sTfR as the iron marker that have investigated the association with 
cardiometabolic risk factors. The chapter uses data from a Croatian population and 
also describes the association between serum ferritin and MetS. 
 
Chapter 5 comprises longitudinal analyses, describing the association of ferritin with 
the incidence of diabetes and CVD, using data from Scottish Health surveys 1995-
1998 linked to the national diabetes register, hospital admission and mortality 
records. No previous similar studies have been performed in Scottish populations and 
no previous studies have simultaneously described the associations between ferritin 
and outcomes of T2D, CHD, and CEVD; there is very little information on the 
association between ferritin and CEVD in particular. 
 
Chapter 6 describes the studies on the association between iron status and 
cardiovascular complications in people with T2D using data from the Edinburgh 
Type 2 Diabetes Study and the SIDIAP study (data from primary health care centres 
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in Catalonia). Little attention has been given to associations between iron status and 
complications of diabetes. If iron metabolism is a causal factor or one of several 
metabolic abnormalities implicated in the development of CMD in general 
populations, iron misbalance could potentiate the risk of cardiovascular outcomes in 
people who already have diabetes. I have not identified any previously published 
similar large or longitudinal studies that have used multivariable adjustment.  
 
Chapter 7, the concluding chapter, collates the information presented in the earlier 
chapters and discusses potential interpretations of the findings in light of the 
strengths and limitations of the work. Recommendations for future studies and 


















1.3 Rationale behind general methodological 
approaches in this thesis 
1.3.1 Choice of iron markers 
In this PhD thesis, I have focused on three serum proteins – ferritin, sTfR, and 
transferrin – with different functions in iron metabolism - as the exposures of 
interest. There are other iron markers such as total iron binding capacity (TIBC) and 
transferrin saturation percentage (%TS). I identified the following disadvantages of 
these additional iron markers which is why I excluded them from further study: 
 Estimation of TIBC and transferrin saturation require the measurement of serum 
iron, a marker susceptible to diverse sources of error such as incomplete 
dissociation of iron from binding proteins; loss during the precipitation process; 
and interferences by copper, haemoglobin, bilirubin, and lipids (66). TIBC and 
serum iron have also shown greater between-day variation than other iron 
markers (67).  
 TIBC and %TS are less commonly measured and it is common to find more 
missing values for these iron markers even in databases where the variables are 
included, as laboratory techniques to measure them require larger amounts of 
blood serum samples than for serum iron proteins. 
 Although having as many iron makers as possible could be useful in terms of 
comparing and contrasting specific findings for different markers, this also 
further increases the potential for type 1 errors as a consequence of multiple 
testing. 
 
1.3.2 Definition of exposure variables 
Serum levels of ferritin, transferrin, and sTfR were used as continuous variables and 
as categorical variables by using quantiles to explore linear and non-linear 
relationships. Tertiles were used when samples by sex and/or menopausal status were 
smaller than 500 individuals to facilitate better comparability between the highest 
and lowest categories. Quartiles of the iron markers were used when sub-groups were 
larger than 500. In Chapter 6, quintiles, not quartiles, of ferritin were shown because 
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by using quintiles, the longitudinal association evaluated was clearer. The 
implications of this pattern are discussed. 
 
1.3.3 Choice of covariates 
In most of the analyses reported in this thesis, the adjustment variables included age, 
sex, menopausal status, body mass index (BMI), markers of clinical/subclinical 
inflammation and hepatic function, smoking status, alcohol consumption, and 
presence of CMD, where appropriate.  
 
Markers of iron status, such as ferritin, vary across different life stages. Iron stores 
are high in new-borns until the first two months and decrease during infancy. Ferritin 
levels rise again at adolescence, and peak concentrations for men have been 
identified between 30 and 39 years (68). Aging has been linked to decrease in ferritin 
presumably due to a combination of physiological and pathological factors (69).  
  
Iron status differs markedly by sex and menopausal status with lower levels of iron 
stores found in women than men and in premenopausal than post-menopausal 
women (70). This implies the potential for confounding or effect modification. 
Therefore, the descriptive and analysis tables from each study included in the thesis 
present either results stratified by groups of sex/menopausal status or by sex-
menopausal specific quantiles of the iron markers.  
 
The remaining set of confounding factors was chosen on the basis of the possible 
association of acute phase or subclinical inflammation (discussed above), adiposity, 
and liver dysfunction with both the levels of iron markers and outcome variables.  
 
Several studies have reported associations between markers of subclinical 
inflammation and liver function such as transaminases with cardiovascular risk 
factors, risk of diabetes, and CVD (71, 72). Since ferritin, sTfR, and transferrin are 
synthesised in the liver, hepatic dysfunction can lead to an increase in their 
circulating levels owing to destruction of hepatic cells (73). Besides its well-known 
association with higher cardiovascular risk, adiposity can influence the markers of 
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iron status. The higher the adipose mass the higher the iron stores, since adipocytes 
contain ferritin (74). Adiposity can also increase ferritin levels via subclinical 
inflammation induced by inflammatory cytokines released by adipose tissue (75). 
However, obesity-related chronic inflammation can less commonly lead to iron 
deficiency because high levels of circulating ferritin have an inhibitory effect on 
intestinal iron absorption (75).  
 
Smoking and alcohol consumption are common adjustments in analyses with 
cardiometabolic outcomes (76, 77). These lifestyle variables are important potential 
confounders owing to their association with both CMD risk factors and MetS 
components. In contrast, there is no major evidence of the association between 
smoking and alcohol intake and iron markers. However, alcoholic liver disease may 
lead to increased levels of ferritin.  
Although physical activity and caloric intake influence the risk of CMD, they were 
not included as main covariates owing to the potential for over-adjustment, given 
their effect on BMI (78). BMI appears to be more strongly associated with CMD 
than physical activity (79), and overweight/obesity may promote physical inactivity 
(80). Physical activity and caloric intake are also extremely difficult to measure 
reliably (81, 82). In addition, the nutritional epidemiology course I attended in 2015 
recommended minimising the number of covariates and avoiding or minimising 
adjustments for inter-related covariates.  
 
Where available, adjustment for T2D and CVD was conducted for the iron markers-
MetS association, as a sensitivity analysis. This is because established CMD could 
influence iron marker levels and create the potential for reverse causality.  
 
1.3.4 Metabolic syndrome and assessment of prevalence in 
adults and children 
There are several definitions of MetS in adults based on clusters of MetS components 
based on levels of selected cardiovascular risk factors above or below the specific 
cut-off points. For the analyses I conducted this PhD thesis, I adopted the harmonised 
definition for MetS in adults which was agreed upon in 2009 by a group of 
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international endocrinology and cardiovascular research associations (40). In 
contrast, there is no consensus on the definition of MetS for children and adolescents. 
There are some proposed definitions for children older than 10 or 12 years using 
categorical variables of risk factors, similar to those used for adults (83-85). The use 
of these definitions in cross-sectional studies involving children results in lower 
statistical power since MetS and most of its components defined using categorical 
variables tend to have a low prevalence in paediatric populations. As the studies in 
my thesis included children younger than 10 years and since I needed to ensure 
sufficient statistical power, I decided to use continuous variables on the basis of Z 
scores to describe MetS and its components. This approach has been used previously 
for research on cardiovascular risk in childhood (86) and it is described further in the 
relevant chapter.  
 
1.3.5 Multiple testing 
Every analysis in this PhD thesis describes associations of iron markers with at least 
three or more outcomes. The analyses with more outcomes are those in which 
associations with the five MetS components are also evaluated. This multiple testing 
might lead to “false positive” associations, mistakenly rejecting the null hypothesis 
as a result of type 1 errors. However, methods for correction of P values for multiple 
testing using Bonferroni adjustments were not used in the present thesis. The 
following bullet points based on some previous criticisms for such corrections 
provide support to this approach: 
 
-Bonferroni adjustment is focused on the null hypothesis, which is rarely of interest 
to the researchers (87). These adjustments are intended to minimise type I errors but 
at the expense of increasing the likelihood of type II errors or false non-significant 
associations, rejecting the alternative hypothesis (87, 88). For instance, MetS and its 
components form a special case as a group of outcomes since MetS is a cluster of 
metabolic alterations, but it is possible that each metabolic alteration or component 
could have an association pattern with the exposure variable that differs from that of 
the cluster. I decided that dividing the common accepted level of significance, 0.05, 
by the number of tests conducted, as Bonferroni adjustments demand, was too 
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conservative for exploratory analyses such as those conducted in this PhD thesis. For 
instance, if taking into account a total number of 18 tests as a result of six 
associations evaluated (MetS and its five components) in three sub-groups of sex and 
menopausal status, a P value lower than 0.002 would be set as significant. The 
requirement for significance would be even lower and difficult to satisfy if 
explorations with different iron markers, kind of exposure variable (continuous and 
categorical), are also considered in the number of tests.  
-The interpretation of Bonferroni-corrected p values is based on how many tests are 
conducted, which is irrelevant in clinical practice. For example, abnormal or normal 
levels of a biomarker would not be determined depending on whether levels of other 
biomarkers were also tested in the same individual (87). Another very important 
weakness of the Bonferroni approach is that it is difficult to have a reliable estimate 
of the number of tests performed. The association between a diverse and large 
number of exposure variables and a single outcome may be performed by different 
researchers throughout the existence of the dataset (87).  
 
In light of the above points, this PhD thesis reports non-corrected p values for the 
associations reported to avoid missing important findings and the maximum 
probability to accept a false positive finding was set as 0.05, by using two-tailed 
significance tests, given that either iron deficiency or iron excess could be associated 
with the outcomes. The associations obtained are discussed according to the 
coherence and plausibility of the results, considering the potential impact of multiple 
testing and recommending replication in future studies.  
 
This chapter has covered aspects of iron metabolism as well as concepts on outcome 
variables of this thesis work. Similarly, it has provided the rationale for the general 
methodological decisions throughout the different analyses in the chapters. The next 
chapter will describe the association between iron markers and MetS in two cohorts 





Chapter 2  
Iron markers and cardiometabolic risk in 
paediatric populations 
2.1 Introduction 
To date, little is understood about whether there is an association between iron and 
cardiometabolic risk in early life. Children have a lower capacity for iron storage 
than adults since this physiological function becomes fully developed in adulthood. It 
is not known whether changes in iron stores across infancy and adolescence are 
associated with MetS and if these changes could have an additive effect on 
cardiometabolic risk. Whether iron excess, iron deficiency, or both are involved in 
higher cardiometabolic risk during childhood is also unknown. Therefore, two 
studies were conducted in paediatric cohorts from Spain and Chile to evaluate cross-
sectional and longitudinal associations between ferritin levels, MetS, and its 
components. In addition, associations with serum transferrin were also studied in the 
Spanish cohort, and the relationship between changes in ferritin during childhood 
and MetS risk in adolescence were investigated in the Chilean cohort.  
 
2.2 Methods 
2.2.1 Subjects  
The present chapter used data from two cohorts: Spanish and Chilean children. The 
Spanish cohort consisted of school-aged children of European ancestry aged 3.4–14 
years old (8.2 ± 2.0 years) who were included in a cross-sectional study of 
cardiovascular risk factors in prepubertal children. The subjects were consecutively 
recruited from among those seen in the primary care setting in the Alt Empordà and 
Girona regions in north-eastern Spain between 2009 and 2014. Participation ranged 
from 50% to 70% among the different centres. Of the 832 participants whose data 
were analysed at baseline, 207 children [94 boys and 109 girls] were studied again 
after a mean follow-up of 3.7 ± 0.8 years [range 2–6]. For the analyses of this 
chapter, the final sample after removing cases with missing values for 
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exposure/outcome variables or covariates consisted of 726 subjects at baseline (376 
boys and 350 girls) and 173 (83 boys and 90 girls) with follow-up data. Inclusion 
criteria of the original study at baseline were 1) European ancestry; 2) age between 5 
and 14 years; and 3) no pubertal development, as judged by a specifically trained 
nurse using Tanner criteria (breast stage I; testicular volume < 4 mL) (89, 90). To 
avoid findings biased by acute or chronic illness, the exclusion criteria were as 
follows: 1) major congenital anomalies; 2) abnormal blood count and 
liver/kidney/thyroid functions; 3) evidence of chronic illness or prolonged use of 
medication; and 4) acute illness or use of medications in the month preceding 
potential enrolment. The study protocol was approved by the Institutional Review 
Board of Dr. JosepTrueta Hospital. Signed consent for participation in the study was 
obtained from parents.  
 
The Chilean cohort included infants of low/middle socio-economic status from urban 
Santiago recruited between 1991 and 1996 for a trial of iron supplementation. The 
infants, recruited at 4 months, were healthy, full-term singleton infants weighing 3 kg 
or more at birth. At 6 months, those who did not have iron-deficiency anaemia were 
randomised to receive iron supplementation or usual nutrition between 6 and 12 
months. The cohort was assessed for developmental outcomes, including ferritin 
levels, in infancy and at 5, 10, and 16 years (91). At 16 years, participants were also 
assessed for obesity and cardiovascular risk (92). Three samples from the cohort 
were evaluated: 1) participants with no missing values for ferritin and covariates at 5 
years and for cardiometabolic risk outcomes at 16 years (n = 565); 2) participants 
with no missing values for ferritin and covariates at 10 years and for cardiometabolic 
risk outcomes at 16 years (n = 381); and 3) participants with no missing values for 
ferritin, covariates, and cardiometabolic risk outcomes at 16 years (n = 567). A 
sample with no missing values for the study variables at any stage of the follow-up 
was also evaluated (n = 379). The study was approved by the institutional review 
boards of the University of Michigan, the Institute of Nutrition and Food Technology 
(University of Chile), and the University of California, San Diego. Participants and 
their primary caregiver provided informed and written consent, which was obtained 
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according to the norms for Human Experimentation, Code of Ethics of the World 
Medical Association (Declaration of Helsinki, 1995). 
 
2.2.2 Clinical assessments 
Standardised procedures were conducted to measure the height to the nearest 0.1 cm 
using Harpenden (Spanish Cohort) and Holtain (Chilean Cohort) stadiometers and 
weight to the nearest 0·1 kg using a Seca scales in the Spanish and Chilean cohorts. 
The BMI (kg/m2) was then calculated as weight divided by the square of height. WC 
was measured with a non-elastic flexible tape at the high point of the iliac crest 
around the abdomen and recorded to the nearest 0.1 cm. Measurements were taken 
twice, where a third of the measurements of the difference between the first two 
exceeded 0.3 kg for weight, 0.5 cm for height, and 1.0 cm for the waist. Age- and 
sex-adjusted Z-score values for BMI were calculated using regional normative data 
for the Spanish children and the CDC reference for the Chilean cohort (93, 94). 
Categories of weight status were defined according to BMI Z score cut-off points as 
follows: underweight, ≤1; normal weight, -1 to 1; overweight, >1 and <2; and obese, 
>2 (95). 
 
Blood pressure (BP) was measured in the supine position on the right arm after a rest 
period of 10–15 min; an electronic sphygmomanometer (Dinamap Pro 100; GE 
Healthcare, Chalfont St. Giles, United Kingdom) with cuff size appropriate for arm 
circumference was used in the Spanish cohort, while for the Chilean cohort, standard 
mercury sphygmomanometers were used. In both cohorts, averages of three readings 
taken at 5-min intervals were recorded for each subject. 
 
Fasting serum total glucose, cholesterol, triglycerides, HDL-cholesterol (HDL-C), 
insulin, adiponectin, and high-sensitivity C-reactive protein (hs-CRP) levels were 
measured after a 12-h overnight fast. Insulin levels were measured by 
immunochemiluminescence in the Spanish cohort (IMMULITE 2000; Diagnostic 
Products, Los Angeles, CA) and by RIA in the Chilean cohort (Diagnostic Products 
Corporation, Los Angeles, CA, USA). Also, hs-CRP level was measured with a 
sensitive latex-based immunoassay in both cohorts. In the Spanish cohort, serum 
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glucose level was measured using the hexokinase method, HDL cholesterol, using 
the homogenous method of selective detergent with accelerator, and serum 
triglycerides, using the glycerol-phosphate-oxidase and peroxidase methods. In the 
Chilean cohort, glucose level was measured with an enzymatic colorimetric test 
(QCA S.A., Amposta, Spain) and cholesterol profile (HDL-C and triglycerides, 
mg/dL) was determined by dry analytical methodology (Vitros®; Ortho Clinical 
Diagnostics Inc., Raritan, NJ, USA). Glycosylated haemoglobin (HbA1C), available 
in the Spanish cohort, was measured by high-performance liquid chromatography 
(Bio-Rad, Munich, Germany) and a Jokoh HS-10 autoanalyser. In the Spanish 
cohort, serum alanine transaminase (ALT) and gamma glutamyltranspeptidase 
(GGT) were measured by colorimetry using automated tests, and serum transferrin 
by routine laboratory tests (Beckman, Fullerton, CA). Serum ferritin was measured 
by microparticle enzyme immunoassay (AxSYMTM; Abbot Laboratories, USA). 
 
In the Spanish cohort, anaemia was defined as haemoglobin <11g/dL for children <5 
years, < 11.5 g/dL for children 5 to 11 years, and < 12 g/dL for children aged 12 
years and older (96). Serum ferritin < 7 µg/L was categorised as iron deficiency (97). 
 
2.2.3 Metabolic syndrome and insulin resistance 
As mentioned in chapter 1 I decided to evaluate continuous MetS scores instead of 
using paediatric MetS definitions. The latter approach would have had lower 
statistical power as few cases met the categorical criteria from MetS definitions (e.g. 
high glucose as glucose > 100 mg/dL). Similarly, there is no consensus on the cut-off 
values for the different components of MetS in children and adolescents. A 
continuous variable of Z score or scale of SD units for MetS was created from the 
average of Z scores of blood pressure, glucose, triglycerides, HDL cholesterol, and 
WC (86). The distribution of these MetS components was normalised, if required, 
before calculating the Z scores. Details on these transformations are provided in the 
data analysis section of each cohort. The Z scores of diastolic and systolic blood 
pressures (DBP and SBP, respectively) were averaged to get a single Z score for 
blood pressure, and the HDL-C Z score was multiplied by -1 before obtaining the 
overall MetS score to ensure that all of the components of MetS had the same 
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positive association with regard to cardiometabolic risk. IR was estimated by using 
the formula of the HOMA-IR as: (glucose[mg/dL] × insulin [mU/mL])/44.5(59). 
 
2.2.4 Data analysis 
The analyses were conducted with female and male subjects separately, given the 
differences by sex in cardiometabolic outcomes in both cohorts. The study variables 
were described as median (and interquartile range) and proportion, and the 
differences were estimated by Mann-Whitney U test and Chi-square test. Linear 
regression analyses were used to evaluate the association between the iron markers 
and the MetS Z score in both cohorts. In the Spanish cohort, continuous exposure 
and outcome variables were used to compensate for the limited statistical power in 
the prospective analysis. In the Chilean cohort, the exposure variable of ferritin was 
used as tertiles and the outcome, MetS score, as continuous. This categorisation of 
ferritin aimed to enable a comparison of associations at single time points with 
associations on patterns of sustained high/high vs. low/low ferritin during the follow-
up of this cohort (more details below).  
 
Association analyses: Spanish cohort 
Multivariate linear regression analyses were conducted by sex and in the whole 
sample to evaluate and adjust cross-sectional associations of age (quintiles)/sex-
specific Z scores for ferritin and transferrin (exposure variables) with the age/sex-
specific Z scores of MetS and MetS-related variables (SBP, DBP, WC, glucose, 
triglycerides, and HDL-C), HbA1C, and HOMA-IR at baseline (outcome variables). 
Subclinical inflammation and/or infection, hepatic disorders, and overweight/obesity 
are associated with increased ferritin levels and are associated with an increase in 
cardiometabolic risk markers and could confound any association. Therefore, the 
regression coefficients were adjusted for the above-mentioned potential confounders 
in terms of age, CRP levels, ALT and GGT levels, BMI Z score, and also sex (for 
analyses of the whole sample). Relationships with SBP and DBP were additionally 
adjusted for height since this variable has an influence on blood pressure during 
growth. Since outcome and exposure variables were standardised by quintiles of age, 
I also compared models with and without age (continuous variable) as covariate to 
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identify any effect of this adjustment. Changes per year of follow up in MetS, MetS-
related markers, and HOMA-IR were calculated as: (measurement 2 - measurement 
1)/years of follow-up. Associations between Z scores of the iron markers at baseline 
and the change per year in the score for MetS-related markers and HOMA-IR, 
adjusting for covariates at baseline, were estimated using linear regression. The 
adjustment in these longitudinal associations also included baseline values of the 
outcomes (e.g. the associations between ferritin Z score and change in MetS score 
was further adjusted for MetS Z score at baseline). This approach was chosen as the 
baseline values may have some influence on the change outcomes according to a 
weak correlation between the change in MetS Z score and the average calculated 
from MetS score at baseline and MetS score after follow-up (Spearman coefficient 
0.176, P = 0.021)(98). Before calculating the Z scores (ferritin and MetS 
components) and conducting the analyses, skewed variables were log-transformed 
[ferritin, WC (baseline), triglycerides CRP, ALT, GGT] to approximate to the normal 
distribution, except CRP levels which were normalised using the natural logarithm of 
1/CRP.  
 
Association analyses: Chilean cohort 
Ferritin levels were defined in tertiles at 5, 10, and 16 years for participants with data 
available at that time point. Patterns of ferritin levels were created from different 
combinations of high ferritin (highest tertile) and low-moderate ferritin (lowest and 
middle tertile) for intervals 5 and 10 years, 10 and 16 years, and 5 and16 years. 
Possible patterns were the following: high/ high (or persistently high), high/ low-
moderate, low-moderate/ high, and low-moderate/low-moderate (or persistently low-
moderate) which was the reference category for comparisons. Patterns of ferritin 
using the three time points were additionally calculated but assuming low number of 
cases for some categories (high/high/high, high/high/low-moderate, and so forth). I 
also calculated the slope of ferritin concentration per year (99) and used this 
parameter as continuous and categorical variable (tertile). Multiple linear regression 
was used to evaluate associations of ferritin tertiles (with lowest tertile as reference) 
at each stage of follow-up and patterns and slope of ferritin across the follow-up with 
the variation in MetS Z score. For the patterns of repeated ferritin measurements, 
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low/moderate ferritin levels (tertiles 1 and 2) at both stages of an interval or at all of 
the stages of follow-up were used as reference. Associations between ferritin level at 
each stage and Z scores or SD units of MetS components and IR were evaluated by 
linear regression with ferritin in SD units. Before calculating Z scores (ferritin and 
MetS components) and performing the regression analysis, the variables with skewed 
distribution were transformed to approximate to normal distribution. Ferritin, SBP, 
DBP, and CRP values were log-transformed in girls and boys; WC and triglycerides, 
in girls; and HDL-C, in boys. In boys, WC was transformed as (1/square of WC 
values)*-1 and triglycerides as (1/square root of triglycerides values)*-1. There were 
few covariates available to adjust the associations and these were: BMI Z score, 
Tanner stage, and haemoglobin levels. For the cross-sectional associations at 16–17 
years old, CRP was available and, therefore, used in the adjustment model. 
Adjustment for sex and age was not needed since the analyses were conducted by sex 
and at the specific age of follow-up. All analyses were performed using Stata 
Statistical Software: Release 14. College Station, Texas. 
 
2.3 Results 
The Spanish and Chilean paediatric cohorts included in this chapter were not 
comparable since the age ranges and design of the studies were very different. The 
Spanish children were 3–14 years old and, all of them were prepubertal, whereas the 
Chilean children were evaluated at specific ages of 5, 10, and 16–17 years and 
cardiovascular risk outcomes were measured at 16–17 years. Differences were also 
observed in ferritin levels and MetS score between the two cohorts. The Spanish 
children had higher ferritin levels [median (interquartile range) 36 (26–52) µg/L] 
than the Chilean children at all groups (5 [21.6(14.6–30.4) µg/L], 10 [26.5(20.4–
35.7) µg/L], and 16–17 years [26.3(15.7–30.4) µg/L]. In contrast, the Chilean 
children had a higher MetS score [median (interquartile range) -0.05 (-0.37 to 0.35) 
µg/L] vs. 0.008(-0.4 to 0.38)]. This difference in cardiometabolic risk was expected 




2.3.1 Findings in the Spanish cohort 
A comparison between included and excluded children revealed modest differences 
in the study variables. Initially, the included children were older and had higher 
values of BMI Z score, WC, SBP, and GGT and lower HDL-C levels than the 
excluded children (Appendix Table 2). However, most of these differences appeared 
to be attributed to the difference in age, since only the difference in BMI and SBP 
remained significant after adjustment for age (Appendix Table 2). Among the 
included children, at baseline, those with follow-up data were younger and had lower 
values of the iron markers and the rest of the study variables, except HDL-C and 
HbA1C levels, than those without follow-up data (Appendix Table 3). After 
adjusting for age, the above differences persisted for BMI Z score, iron markers, 
insulin and HOMA-IR, WC, and blood pressure (Appendix Table 3).  
 
In the whole group, the median and interquartile ranges for ferritin and transferrin 
were 36(26–52) µg/L and 274(251–298) mg/dL. The characteristics of the study 
population are presented by sex in Table 1. At baseline, boys were significantly older 
and had higher levels of glucose, and GGT than girls. Girls had higher values of 
DBP, triglycerides, CRP, and insulin than boys. In the subgroup of those with 
follow-up data, boys had higher levels of HDL-C and HbA1C, and girls had higher 
values of insulin and triglycerides than the opposite sex. There were no significant 
differences by sex in the anthropometric variables at baseline and after follow-up. 
Differences by sex for MetS score were not calculated, as the scores were sex-
specific. Ferritin (log-transformed) and transferrin were negatively correlated (r = -




Table 1 Description of the Spanish cohort at baseline and outcome variables after follow-up (sub-sample) 
 Baseline After follow-up 
 Girls (n=350) Boys (n=376) P value Girls (n=90) Boys (n=83) P value 
Age (years)            7.7 (6.3-9.5) 8.1(6.6-10.1) 0.038 10.6(9.9-11.5) 10.8(9.7-11.7) 0.614 
Cardio metabolic risk variables 
Waist (cm) 62.0(54.0-73.0) 64.2(53-76.7) 0.103 67(61-80) 67(60-77) 0.623 
SBP (mmHg) 106 (99-114) 107(99-114) 0.925 105(96-111) 102(95-110) 0.427 
DBP (mmHg) 61(56-66.2) 59.5(54-65) 0.015 58(52-62.2) 57.5(52-62) 0.637 
Glucose (mg/dL) 86(82-91) 88(83-92) 0.003 87(82-91) 88(84-92.7) 0.163 
TG (mg/dL) 55(45-75) 53(41-72.7) 0.011 58(46-73) 49(40-60) <0.001 
HDL-C (mg/dL) 54(46-62.3) 55.8(47.5-65) 0.170 54.5(47-62.2) 62(53-70) 0.002 
Insulin (ulU/ml) 4.6(2.0-8.6) 3.7(1.0-7.2) 0.004 5.0(2.7-8.9) 3.9(1.6-6.5) 0.030 
HOMA-IR 0.98(0.40-1.89) 0.80(0.21-1.63) 0.011 1.08(0.56-1.89) 0.80(0.33-1.45) 0.051 
HbA1c(%) 5.3(5.1-5.5) 5.3(5.2-5.5) 0.215 5.2(5.0-5.5) 5.4(5.2-5.5) 0.007 
MetS score -0.02(-0.37 to 0.38) 0.03(-0.43 to 0.39)  -0.03(-0.39 to 0.33) -0.15(-0.53 to 0.28)  
Iron markers 
Ferritin (µg/L) 35.9(25.8-53) 36(25-50) 0.642    
Transferrin (mg/dL) 271(249-296) 276.5(253.2-302) 0.129    
Covariates 
Height (cm) 130(120.1-141) 133(122-143.8) 0.033    
BMI Z score 0.53(-0.53 to 1.66) 0.51(-0.57 to 1.76) 0.890    
CRP (mg/L) 0.90(0.30-2.42) 0.60(0.22-2.20) 0.005    
ALT(U/L) 17(14-20) 18(14-21) 0.068    
GGT(U/L) 12(11-15) 13(11-15) 0.040    
Data are median (interquartile range). SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. 
MetS, Metabolic syndrome.HbA1C, glycosylated haemoglobin. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass index. 




The prevalence of underweight and overweight/obesity was 11.0% and 39.8%, 
respectively. Anaemia was found in 26 (3.6%) children. Only two children had iron 
deficiency with ferritin levels <7 µg/L and 13 had ferritin levels <10 µg/L. Among 
482 children, whose serum albumin was measured, none had low values of albumin 
(<3.2 g/dL), an indicator of under nutrition. At baseline, all the children were pre-
pubertal.  
 
Table 2 Cross-sectional and prospective relationships between age and sex-specific standardized 
values of iron markers at baseline and MetS and glucose metabolism markers 
 Ferritin SD units at baseline (µg/L) 
 Model 1 Model 2 
 βeta (95% CI) P βeta (95% CI) P 
MetS Z score 
at baseline 
 








MetS Z score 
per year of 
follow-up 
 




-0.02(-0.04 to 0.004) 
 
0.017 
 Transferrin SD units at baseline (mg/dL) 
MetS Z score 0.05 (0.01 to 0.10) 0.009 0.002 (-0.03 to 0.03) 0.887 
Change in 
MetS Z score 
per year of 
follow-up 
 





0.01 (-0.007 to 0.03) 
 
0.179 
Model 1: adjusted for age and sex. Model 2: adjusted for model 1 plus CRP, ALT and GGT 
levels and BMI Z score. For the prospective association, the above models also included MetS 
Z score at baseline as covariate. Significant associations are shown in bold. 
 
Iron markers and MetS  
At baseline, there were positive age/sex-adjusted cross-sectional associations of 
ferritin and transferrin Z scores with the MetS Z score, which were attenuated after 
further adjustments (Table 2). In sharp contrast, the prospective analysis showed an 
inverse association between the ferritin Z score and the change in MetS score per 
year of follow-up that was independent of covariates (Table 2). For every SD unit 
increase in ferritin, there was a decrease of 0.02 SD units in the change of MetS 
score. Transferrin levels were not longitudinally associated with the change in MetS 




In the analyses by sex, the above prospective inverse association between ferritin and 
change in MetS, described in the whole sample using the iron markers and the 
change in MetS Z score, was generally present in both girls and boys (Table 3). No 
additional trends or significant associations by sex were observed.  
 
Table 3 Cross-sectional and prospective relationships between age and sex-specific standardized 
values of iron markers at baseline and MetS and glucose metabolism markers 
Girls  
 Ferritin SD units at baseline (µg/L) 
 Model 1 Model 2 
 βeta (95% CI) P βeta (95% CI) P 
MetS Z score at 
baseline 
0.10 (0.04 to 0.16) 0.001 0.04 (-0.007 to 0.08) 0.098 
Change in MetS 
Z score per year 
of follow-up 
-0.02 (-0.05 to 0.001) 0.061 -0.02 (-0.05 to 0.004) 0.099 
 Transferrin SD units at baseline (mg/dL) 
MetS Z score 0.02 (-0.03 to 0.09) 0.342 0.002 (-0.04 to 0.04) 0.909 
Change in MetS 
Z score per year 
of follow-up 
0.02 (-0.01 to 0.05) 0.204 0.01 (-0.01 to 0.04) 0.334 
Boys  
 Ferritin SD units at baseline (µg/L) 
 βeta (95% CI) P βeta (95% CI) P 
MetS Z score at 
baseline 
0.04 (-0.02 to 0.10) 0.210 -0.01 (-0.06 to 0.03) 0.599 
Change in MetS 
Z score per year 
of follow-up 
-0.03 (-0.06 to 0.001) 0.059 -0.03 (-0.06 to 0.003) 0.075 
 Transferrin SD units at baseline (mg/dL) 
MetS Z score 0.08 (0.02 to 0.14) 0.008 -0.001 (-0.04 to 0.04) 0.946 
Change in MetS 
Z score per year 
of follow-up 
0.01 (-0001 to 0.04) 0.294 0.01 (-0.02 to 0.04) 0.441 
Model 1: adjusted for age and sex. Model 2: adjusted for model 1 plus CRP, ALT and GGT 
levels and BMI Z score. For the prospective association, the above models also included MetS 





Additional associations between iron markers and MetS components, 
HbA1C, and insulin resistance  
In the cross-sectional analysis of the whole sample, ferritin Z score at baseline was 
inversely associated with the Z scores of fasting glucose and HbA1C, and no 
statistically significant prospective associations were observed between ferritin and 
the change over time in MetS-related variables, HbA1C and IR (Appendix Table 4). 
Transferrin Z score was positively associated with HDL-C Z score and the fall in the 
Z score of this marker over time (Appendix Table 4). There were age and sex-
adjusted cross-sectional positive associations between ferritin and SBP, DBP, 
triglycerides, HDL-C levels, and HOMA-IR in crude analyses that did not remain 
statistically significant after adjustments for inflammatory, hepatic injury, and body 
mass markers. 
 
The above cross-sectional associations in the whole sample between ferritin and 
fasting glucose Z scores and between transferrin and HDL-Z scores were observed in 
boys but not girls (Appendix Table 5). The prospective inverse association described 
for the whole sample between transferrin Z score and the change in HDL-C per year 
of follow-up was found only in girls (Appendix Table 5). There were also two sex-
specific associations not seen in the whole sample; in boys, the ferritin Z score was 
positively associated with the change in HDL-C Z score over time, and in girls, this 
iron marker was also inversely associated with the fall in the triglyceride Z score 
over time (Appendix Table 5). However, in addition to simply identifying a 
statistically significant/ non-significant finding it is important to take into account the 
finding of wide confidence intervals with Beta coefficient values close to zero in 
some of the above associations (e.g. adjusted ferritin-glucose and transferrin-HDL-C 
in boys, Appendix Table 5) These suggest the findings are close to being consistent 
with the null hypothesis. Low statistical power contributes to these patterns and 
makes it difficult to establish whether any differences are clinically significant.  
 
 
Removal of age, and baseline values of outcomes (in the longitudinal analyses), did 
not substantially affect the effect estimates and statistical significance of the 
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associations described above. Additional adjustments for anaemia or haemoglobin 
levels did not affect the relationships described previously. 
 
2.3.2 Findings in the Chilean cohort 
On comparing the distribution of study variables between included and excluded 
children at the different time points of evaluation (5, 10, 16–17 years old) there were 
minimal differences (Appendix Table 6). Haemoglobin levels were slightly higher in 
the 16–17-year-olds included, and the BMI was higher in the 10-year-olds in 
comparison with the excluded of the same age groups (Appendix Table 6). Also, 
among those included, there was a higher proportion of children assigned to receive 
high iron supplementation when they were infants (6–12 months of life) (Appendix 
Table 6).  
 
The study variables are described by sex and age at follow-up in Table 4. No 
differences by sex were found at 5 years of age for ferritin (µg/L), haemoglobin, and 
BMI Z score. At 10 years of age, girls had higher sexual development than boys 
(Table 4). At adolescent stage, boys had higher levels of ferritin, haemoglobin, SBP 
and DBP, and glucose and girls had higher sexual development and HDL-C and 
insulin levels (Table 4). Lower ferritin levels in girls were expected because of 
menstruation, which typically begins at Tanner stage IV. The slope for average 
annual change in ferritin across the follow-up was higher in boys than girls 
[mean(SD) 0.67 (1.82) v. -0.50(1.38), P < 0.001]. 
 
Prevalence of underweight was 3% at 5 years, 5% at 10 years, and 7 % at 
adolescence. Prevalence of overweight/obesity was, in general, similar to that found 
in the Spanish cohort: 44.1%, 44.4%, and 34% at 5 years, 10 years, and at 
adolescence, respectively. None of the children had anaemia when they were 5 and 






Table 4 Description of study variable in the Chilean cohort 
 
Ferritin levels in the highest tertile at five years (compared to the lowest tertile) were 
positively associated with MetS risk Z scores in adolescence (age 16-17) in boys 
(Figure 2), and this association was unaffected by adjustment for baseline BMI Z 
scores and haemoglobin levels. Also, in boys, at adolescence, there was a significant 
 Girls Boys P value 
At 16-17 years n=270 n=297  
Ferritin (µg/L) 19.1(11.7-28.2) 32.7(22.7-7.1) <0.0001 
Haemoglobin (g/dL) 13.7(13-14.3) 15.9(15-16.6) <0.0001 
CRP (mg/L) 0.45(0.15-1.35) 0.38(0.12-1.20) 0.2849 
BMI Z score 0.67(0.03 to 1.26) 0.42(-0.22 to 0.42) 0.0813 
Tanner stage 
(n(%)) 
   
2 0.0% 0.6  
 
<0.0001 
3 5.9 16.4 
4 53.3 56.9 
5 40.7 25.9 
Waist (cm) 79.6(72.5-88.3) 78.4(73.5-86.4) 0.7939 
SBP (mmHg) 108(100-113.5) 115(108-122) <0.0001 
DBP (mmHg) 68(61-71) 70(65-75) <0.0001 
Glucose (mg/dL) 86.1(80.9-92.1) 90.7(84.4-96.7) <0.0001 
TG (mg/dL) 74.9(57.9) 73.7(56.1-102.2) 0.9309 
HDL-C (mg/dL) 41.5(35.1-49.5) 36.6(30.8-42.2) <0.0001 
Insulin (ulU/ml) 7.1(5.1-10.3) 6.2(4.3-9.7) 0.0399 
HOMA-IR 1.48(1.05- 2.15) 1.40(0.96-2.17) 0.3315 
MetS score* -0.01(-0.36 to 0.33) -0.07(-0.38 to 0.38)  
At 5 years n=268 n=297  
Ferritin (µg/L) 22.3(15.3-32.3) 21.3(14.3-29.1) 0.0954 
Haemoglobin (g/dL) 12.9(12.5-13.4) 12.9(12.4-13.5) 0.9584 
BMI Z score 0.87(0.23-1.57) 0.83(0.18-1.55) 0.8449 
At 10 years n=183 n=198  
Ferritin (µg/L) 27.4(21.1-36.8) 25.6(19.8-34.9) 0.5094 






BMI Z score 0.87(0.01-1.42) 0.94(0.26-1.56) 0.0900 
Tanner stage    
1 39.3 70.7  
<0.0001 2 43.1 29.2 
3 16.9 --- 
4 0.5 --- 
*Difference by sex does not apply since MetS Z scores were calculated as sex specific. SBP, 
systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL 
cholesterol. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass 
index. CRP, C reactive protein.  
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cross-sectional association between ferritin levels in the highest tertile and increasing 
MetS risk Z score, independent of adjustment for BMI Z score, CRP levels, 
haemoglobin levels, and Tanner stage (Figure 2). No significant associations were 
found between ferritin levels at 10 years and MetS Z scores at adolescence (age 16-
17). In girls, no significant associations were found between ferritin levels at any age 
and MetS Z scores in adolescence (Figure 2). 
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Figure 2 Linear regression for longitudinal (A and B) and cross-sectional (C) associations between 
tertiles of ferritin at the three points of follow-up and the MetS Z score at adolescence. 
 
A, n= 565. B= n=381. C, n=567.    Reference.   Unadjusted.   Adjusted: Longitudinal 
associations with ferritin at 5 and 10 years were adjusted for the respective baseline BMI Z score and 
haemoglobin level, and tanner stages for 10 year’s evaluation; Cross-sectional association at 16-17 
years were adjusted for BMI Z score, CRP level, haemoglobin level and tanner stage. [Means (SD)] of 




The above analysis was replicated by using only the sample with no missing values 
for the main variables and covariates for all the three points of follow-up (n = 379). 
The associations with MetS remained similar: in girls at 5, 10, and 16–17 years, the 
adjusted beta coefficients (highest vs. lowest tertile of ferritin) were -0.03(-0.21 to 
0.14) P=0.689, 0.05(-0.12 to 0.24) P=0.524, and 0.12(-0.05 to 0.31) 
P=0.172,respectively); in boys, the adjusted beta coefficients were 0.23(0.04 to 0.42, 
P=0.015), 0.10(-0.09 to 0.29, P =0.297), and 0.35(0.16 to 0.54) P < 0.001), 
respectively. 
 
Having high, compared to low/moderate, ferritin levels at two or more time periods 
between 5 and 16 years was related to higher MetS risk Z score at age 16-17 in boys 
only (P < 0.05) (Figure 3). A sensitivity analysis by adjusting the associations in 
Figure 3 for baseline values of covariates along with changes in these across the 
intervals, showed very similar beta coefficients to those reported in Figure 2 
(Appendix Table 7).  
The presence of high ferritin levels at the three time points was positively associated 
with MetS risk Z score in boys [beta(95%CI) = 0.31(0.11 to 0.52)] but not in girls 
(Appendix Table 8). However, the number of children included in some cells was 
very small (Appendix Table 8).  
 
The effect of having persistently high ferritin levels at 10 and 16 years or at all three 
ages had a slightly stronger association with MetS Z scores in boys (beta coefficients 
0.30 and 0.31, respectively) than for the association at single points mentioned 
previously in Figure 3 [beta coefficients = 0.23(5 yr), 0.11(10 yr), 0.21(16–17 yr)]. 
 
The slope values for ferritin levels per year, as continuous variables, were marginally 
and positively associated with higher MetS risk Z score in girls but not in boys. 
When comparing highest and lowest tertiles of slope, the association with MetS risk 






Figure 3 Linear regressions associations between MetS Z score at 16/17 years and patterns of 
combined high (H) and low/moderate (L/M) ferritin concentration throughout the follow-up. 
 
   Reference.   Unadjusted.   Adjusted: associations were adjusted for the values of BMI Z score 
and haemoglobin level and tanner stage(if applicable) at the end of the interval (e.g interval 5-10 years 
included covariates of BMI Z score, haemoglobin levels, and tanner stage at 10 years old). For major 
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comparability of the intervals of follow-up, this analysis used cases with no missing values for all of 
the three points of measurements (n=379 at each stage).   
 
Table 5 Beta coefficients for MetS Z score by slope of ferritin concentration across the three stages 
of follow-up 
 Girls 
 Unadjusted Adjusted* 
 Beta (95% CI) P value Beta (95% CI) P value 
Slope of ferritin 
(continuous) 
0.06 (0.005 to 0.11) 0.031 0.04 (-0.002 to 0.09) 0.062 
Slope of ferritin      
Tertile 1 0(Reference)  0(Reference)  
Tertile 2 0.07 (-0.10 to 0.26) 0.406 0.09 (-0.06 to 0.25) 0.255 
Tertile 3 0.25 (0.06 to 0.44) 0.008 0.21 (0.05 to 0.38) 0.007 
 Boys 
 Unadjusted Adjusted* 
 Beta (95% CI) P value Beta (95% CI) P value 
Slope of ferritin 
(continuous) 
0.01 (-0.03 to 0.05) 0.671 0.01 (-0.02 to 0.04) 0.471 
Slope of ferritin      
Tertile 1 0(Reference)  0(Reference)  
Tertile 2 -0.01 (-0.23 to 0.19) 0.870 0.01 (-0.13 to 0.17) 0.823 
Tertile 3 0.08 (-0.13 to 0.29) 0.450 0.10 (-0.04 to 0.26) 0.179 
  
Appendix Table 9 shows the results of linear regression analyses for relationships 
between sex-specific Z score of ferritin level at the three points of follow-up and sex-
specific Z scores for MetS components and IR at adolescence. In girls, the Z scores 
for ferritin levels at 10 and 16–17 years of age were significantly (P = 0.046 and P = 
0.014, respectively) and independently associated with the Z score of IR but not with 
any of the MetS components at the adolescent stage. In boys, ferritin level Z score at 
5 years old was inversely associated with the Z score of HDL-C in adolescence in 
unadjusted and adjusted models, whereas significant unadjusted associations with Z 
scores of WC, HDL-C and IR did not remain significant after adjustment for 
covariates. In adolescence, there were significant cross-sectional associations 
between Z scores of ferritin and fasting glucose, triglycerides, and IR independent of 
adjustment for covariates in boys only.  
Further adjustment for trial groups of iron supplementation at infancy did not affect 
the associations previously described. A similar pattern was observed when 
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haemoglobin levels were removed from the adjustment models. There were no 
significant findings on analysing female and male sexes together (P > 0.05), 
presumably owing to the marked differences by sex in the outcomes at adolescence.  
2.4 Discussion 
The ferritin-cardiometabolic risk relationship was different in the two paediatric 
cohorts. While serum ferritin was inversely associated with cardiometabolic risk, 
fasting glucose, and glycosylated haemoglobin levels in the Spanish children, iron 
stores at prepubertal age were positively associated with cardiometabolic risk in 
Chilean adolescents. Moreover, in this latter cohort, patterns of sustained high levels 
of ferritin throughout childhood were associated with adverse metabolic profile in 
adolescence. In the Chilean girls, linear increases in ferritin, in terms of the slope of 
ferritin levels from measurements at 5, 10 and 16 years, were independently 
associated with MetS risk. The above findings highlight iron metabolism as a factor 
associated with cardiometabolic risk from early life and suggest that there may be 
differences in the association by sex and age. 
 
2.4.1 Contrast with previous studies 
Only five studies conducted to date on the association of ferritin and other iron status 
markers with cardiometabolic risk variables in children were identified from a 
systematic literature search performed in May 2016. All studies use cross-sectional 
designs and four involved Asian paediatric populations (Table 6). All these studies 
included children and/or adolescents from general populations, except the study by 
Bougle and Brouard of overweight and obese Canadian children (100). This latter 
study is the only one, along with the present studies, that reported associations 
adjusted for inflammation markers. Lee et al., similar to our study, evaluated 
outcomes of MetS and its components (101) but with adjustments for age and sex 
only. The other studies evaluated MetS components (categorical or continuous 
variables). In general, the studies reported higher ferritin values than those reported 
in the Chilean and the Spanish cohorts, showed no significant association between 
ferritin and most of the cardiometabolic risk outcomes, and did not include robust 
adjustments (Table 6). Unadjusted and adjusted associations tended to be consistent 
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in the studies reviewed. Zhu et al. did not find an association between ferritin and 
any MetS component in 1126 Chinese children (102). Ferritin levels were 
significantly and positively associated with WC in the studies by Lee et al. and Jeon 
et al. involving Korean children (101, 103) and with triglycerides in the studies by 
Bougle and Brouard and Kim et al. (100, 104), and were inversely associated with 
HDL-C in the studies by Bougle and Brouard, Kim et al., and Lee et al. (100, 101, 
104). None of the studies reported associations between ferritin and fasting glucose 
or blood pressure.  
 
Although ferritin was, in general, not associated with the MetS components in the 
studies by Lee et al. and Zhu et al., there were a few contrasting associations with 
sTfR. While Lee et al. described unadjusted higher levels of sTfR in children with 
MetS (101), Zhu et al. found an inverse association between sTfR and high 
triglycerides and low HDL-C with and without adjustments for age, gender, physical 
activities, and dietary behaviours (102). These latter authors also reported an inverse 
association between transferrin and low HDL-C. The findings by Zhu et al. are 
coherent with the iron excess-cardiometabolic risk pattern, since lower levels of sTfR 
and transferrin represent high iron status. It is unclear if the positive association of 
sTfR-MetS in the study of Lee et al., which reflected lower iron status for MetS, 
would be independent of the confounding factors.  
The contrasting and significant cross-sectional findings in Chilean boys with regard 
to the above studies could be explained in terms of differences in age range and study 
design. In the Chilean cohort, participants were evaluated at the same age at each 
evaluation and cardiometabolic risk outcomes were observed at the adolescent stage 























































7 and 10 50.5 1350 1-Metabolic 
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levels by having or 
not MetS] 
2-Glucose, WC, 
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Mean (SD)  
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Survey V  
2010 
10-18 54.4 849 High glucose as  
≥ 100 mg/dL 
High TG  as ≥ 100 
mg/dL 
Low HDL-C as  
≤ 40 mg/dL 












30.6 (1.3) μg/L 
Boys 
50.5 (2.3) μg/L 
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41.7 (22.9) μg/L 
With HOMA-
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7-14 46.5 1126 High glucose as ≥ 5.6 
mmol/L 
High TG  as ≥ 1.7 
mmol/L 
Low HDL-C as < 
1.03 mmol/L 
Categorical 
(quartiles , and 
first/lowest 
quartile  as 
reference) 
Median(IR)  
None of the 
MetS 
components 












































14 High SBP (≥90th) 
High DBP (≥90th)  
High WC (≥90th ). 
[Logistic regression 
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51.8 726 1-Metabolic 
syndrome score at 
baseline and after 3.7 
± 0.8 years 
(continuous)  
2-Glucose, WC, 
HDL-C, SBP, DBP, 
TG, HOMA-IR and 




















 Age, sex, CRP, 
ALT and GGT 
levels and BMI 





MetS Z score at 
baseline as 
covariate. 
* found in PUBMED by applying the searching: iron AND (cardiometabolic risk OR cardiovascular risk OR metabolic syndrome) AND (children OR adolescents) (until 
May 25/2016). [in vitro studies, genetic studies and those conducted adults populations or patients with diseases were not included]. WC, waist circumference. LDL-C, 




When contrasting results from the Spanish cohort with previous findings from 
studies in children, including those from the Chilean cohort, it is important to take 
into account some differences among the studies. Although the Spanish cohort had a 
similarly wide age range as the studies cited in Table 6, I applied more robust 
adjustment for potential confounding factors. Several positive cross-sectional 
associations between ferritin and MetS components were lost after adjusting for 
covariates, with a major attenuating effect by transaminases and BMI. The positive 
associations found in the Chilean cohort might have been attenuated if it had been 
possible to adjust for markers of hepatic function. 
 
Longitudinal association of ferritin-MetS and discrepancy between the 
Chilean and Spanish cohorts 
The longitudinal and cross-sectional positive associations between ferritin at each 
stage of childhood (except at 10 years) and MetS observed in the Chilean cohort 
were significant in boys but not in girls. This sex difference may be explained by a 
threshold effect derived from higher levels of cardiometabolic risk factors in boys at 
the adolescent stage, rather than by higher iron stores in boys since at 5 years, there 
was no significant sex difference in ferritin levels. However, there are not a 
consistent findings about differences by sex in the ferritin-MetS association in adults. 
There are studies showing either stronger or sex-specific significant association in 
men (7, 105) or women (pre and postmenopausal) (106-108) or significant 
associations in both sexes (22). All studies consistently described higher MetS 
prevalence or incidence in postmenopausal women and men than in premenopausal 
women, and higher ferritin levels in men than in pre- and postmenopausal women.  
In contrast, low iron status (and not iron excess) was prospectively associated with a 
higher MetS risk score in the Spanish children. Some previous epidemiological 
studies found increased cardiometabolic risk in subjects with low iron status. 
Inconsistent direction and patterns of associations have been found between iron 
markers (iron intake, transferrin saturation, and serum ferritin concentration) and risk 
of CHD in longitudinal studies in adults (28). Nutritional status is an important 
potential confounding factor, at least in some populations. There is increasing 
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evidence describing the double burden of malnutrition and cardiometabolic risk, 
particularly in developing countries. Coexistence of at least one nutritional 
deficiency (iron or vitamin A) and one cardiometabolic risk factor (among 
overweight/obesity, abdominal obesity, hypertension, hyperglycaemia, diabetes, or 
dyslipidaemia) was observed in 23.5% of a West-African population, and this 
phenomenon was significantly higher in the low-income group (109). Interestingly, 
iron deficiency has been associated with elevation in fasting blood glucose despite 
increased insulin sensitivity in animal models (110). A dose-response relationship 
has been described between anaemia and hyperglycaemia in rats (31). However, 
mechanisms underlying this association are still unknown.  
 
Along with the longitudinal association with MetS, there were another two inverse 
cross-sectional associations of serum ferritin with fasting glucose and HbA1C in the 
Spanish children, supporting the association between low iron status and 
cardiometabolic risk. HbA1C shows a spurious increase in the case of iron deficiency 
owing to an increase in the lifespan of erythrocytes. In the absence of concomitant 
rise of glucose levels in iron deficiency, an isolated finding of association between 
increased HbA1C and iron deficiency is spurious, as recently noted in a systematic 
review (111). Therefore, the inverse ferritin-HbA1C association described here does 
not appear to be entirely spurious.  
 
The Spanish children did not show evidence of malnutrition on the basis of serum 
albumin (measured in 482 subjects) and no differences in weight or nutritional score 
were identified between children with low and high ferritin levels. Additional 
adjustment for anaemia did not affect the associations between iron status and 
cardiometabolic risk. The findings could be related to subclinical iron deficiency or 
life-course physiological transitions. 
 
Subclinical iron deficiency, a possible explanation for the findings, is supported by a 
recent recommendation for higher cut-off points to establish iron deficiency in adults 
(serum ferritin <30 µg/L instead of <12 µg/L) (112), and normal ranges for children 
also need to be reviewed. However, against the above hypothesis is the fact that 
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Chilean children who showed a marked positive ferritin-cardiometabolic risk 
association had lower ferritin concentrations than the Spanish cohort. This 
observation along with the previous comparison of the existing few paediatric studies 
implies that the association between iron metabolism markers and cardiometabolic 
risk during infancy and childhood may differ by populations and geographical 
regions but not simply as a consequence of different levels of iron stores. In fact, the 
MetS score was higher in the Chilean children, and thus, a different distribution in 
cardiometabolic risk markers might explain the discrepancies in statistical 
significance and/or the direction observed in the two cohorts evaluated in this 
chapter. 
 
With regard to the life-course physiological transition approach, the metabolic 
processes related to glucose homeostasis may be more iron-dependent in early stages 
of life than in adulthood. Changes in cardiometabolic risk markers could be sensitive 
to modest reductions in iron status within the narrow normal range suggested for 
children as opposed to for adults. Children do not accumulate as much iron as adults 
since their body compartments are still developing, and negative balance of iron 
storage is a more common finding than iron excess with physiological implications.  
 
 
Pattern of repeated ferritin measurements and metabolic syndrome: 
Chilean cohort 
The relationship between repeated measurements of ferritin and MetS appeared to 
differ by sex. In boys, a pattern of sustained high ferritin levels throughout the 
follow-up was significantly associated with MetS risk, but in girls, a linear change in 
ferritin levels across follow-up, but not the pattern of sustained high ferritin, was 
associated with MetS risk. This suggests that in girls, increases in ferritin across 
childhood, regardless of the starting point, are associated with adolescent 
cardiometabolic risk, and in boys, the association is markedly influenced by the 
threshold effects of ferritin and/or cardiometabolic risk outcomes. There are no 
studies on the trajectories of ferritin and cardiometabolic risk in adults although one 
study evaluated changes in ferritin with regard to development of MetS after 6.5 
years’ follow-up (113). In this study conducted in a Finnish population, men or 
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women who had incident MetS also had higher changes in ferritin values between 
baseline and the end of the follow-up (113). Further study of patterns of sustained 
high ferritin and slopes from repeated measurements of ferritin over time and their 
associations with cardiometabolic risk and outcomes in other paediatric populations 
to determine if the differences by sex in the present study are replicated. 
 
Ferritin and insulin resistance 
Ferritin was not associated with HOMA-IR in the Spanish cohort in cross-sectional 
or prospective analyses, and in the Chilean children this association was significant 
only in girls in terms of association with ferritin levels at 10 years of age. In addition, 
none of the three studies that investigated the relationship between ferritin and 
HOMA-IR in Table 6 found these variables significantly associated (100, 101, 104). 
This finding in Chilean girls is inconsistent with the lack of association between 
ferritin (at 10 and 16 years) and MetS score in the same sub-group. Given that the 
relationship between iron and glucose/insulin metabolism is bi-directional (9), 
insulin levels could potentially modulate iron stores throughout the growth process in 
girls. It is also plausible that the ferritin-insulin association is driven by an additional 
unknown factor not measured in this study, or it may also be a chance finding.  
 
Transferrin, cardiometabolic risk and insulin resistance: Spanish cohort  
The Spanish but not the Chilean cohort included the evaluation of an additional iron 
marker. Interestingly, although there was no evidence of a ferritin-IR association, 
transferrin was significantly associated with IR in the whole sample of the Spanish 
children. Transferrin levels were also positively associated with HbA1C, HDL-C, 
changes in SBP and DBP per year of follow-up, and with the fall in HDL-C levels 
over time. The direction of the above associations show the potential role of low iron 
status (the higher transferrin levels the lower the body iron), supporting the findings 
on ferritin and MetS in the Spanish cohort. However, ferritin and transferrin were 
individually associated with different cardiometabolic risk markers, making it 
difficult to conclude a consistent and solid pattern of low iron status-cardiometabolic 
risk. Among the paediatric studies in Table 6, only the one by Zhu et al. included 
serum transferrin as an additional iron marker. In this study of a Chinese general 
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paediatric population, there was only an isolated inverse association between 
transferrin and HDL-C levels in both the unadjusted model and model adjusted for 
age, sex, physical activity, and dietary habits (102). The direction of this association 
is opposite to that described in the Spanish children I have reported in this chapter. In 
the same study involving Chinese children, ferritin levels were not related to MetS-
related variables although a positive association with total cholesterol was found. 
The Chinese and Spanish children had relatively comparable age ranges and HDL-C 
levels. However, iron status was lower in the Spanish cohort [transferrin mean (SD) 
276 ± 36.4 vs. 240 ± 43 µg/dL; ferritin median (IQR) 36 (25–52) vs. 56(41–75)]) 
(Table 6), but it is still difficult to deduce the potential reason behind the discrepant 
findings between the two studies other than the role of chance. The inverse 
transferrin-HDL-C association described in the Chinese children might be not 
significant after further adjustment for BMI, transaminases, and CRP levels. On the 
other hand, the positive associations between transferrin, HOMA-IR, HDL-C, and 
blood pressure in the Spanish children are in line with cross-sectional and 
prospective associations reported in a French adult population (7). 
 
In the study by Zhu et al., involving Chinese children, sTfR levels (which were not 
available for the cohorts described in this chapter), were inversely related to HDL-C 
and WC (102). This finding on sTfR associations is paradoxical, since the directions 
of the associations with HDL-C and WC would be expected to be opposite if there 
were a consistent link with cardiometabolic risk (higher WC, lower HDL-C). This 
observation supports the previously proposed idea of physiological transitions 
instead of true cardiometabolic risk involved in the relationships between iron 
markers and metabolic profile variables in school-aged children (5–12 years).  
 
2.4.2 Limitations 
Several limitations have to be mentioned here. In the case of the Chilean cohort 
analysis, first, because of unavailability of variables, there was no evaluation of 
cross-sectional associations between ferritin levels and cardiometabolic risk at 5 and 
10 years since cardiometabolic risk outcomes were measured only at the adolescent 
stage. Second, there were no available measures of subclinical/clinical inflammation 
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at 5 and 10 years, meaning it is not possible to investigate the potential for ferritin 
acting as an acute phase reactant. However, in general, the children can be expected 
to have had good health status when they attended the appointments for blood 
samples. Adjustment for BMI Z score might partly have corrected the associations 
for the potential effect of adiposity-related subclinical inflammation on ferritin 
levels. It is also important to bear in mind that CRP levels in adolescence were not 
associated with cardiometabolic risk and IR and did not affect the associations in the 
multivariable models (data not shown). Third, unlike the Spanish cohort analysis, the 
associations reported in the Chilean children were not adjusted for hepatic function 
markers such as transaminases. Serum ferritin levels could be increased via the 
release of proteins from damaged hepatocytes although, again, it is suggested that 
liver damage is rare in children. With regard to the limitations of the study involving 
Spanish children, the follow-up was achieved only for almost a quarter of the whole 
sample, so the longitudinal findings for that cohort may not be generalisable and 
should be considered with caution since the power was limited. Similarly, several 
associations described in this Spanish cohort may still lack clinical relevance given 
their broad confidence intervals with values close to being consistent with a null 
effect and thus larger studies in prepubertal populations are required to establish 
whether a true effect exists. Unlike the case of the Chilean cohort, in the Spanish 
cohort, it was not possible to adjust for changes in sexual maturity since there were 
few cases with available information on Tanner stage after follow-up. In addition, the 
multiple statistical tests imply the likelihood of chance findings reported in this 
chapter. 
 
2.4.3 Strengths  
The two analyses in this chapter have some relevant strengths. To the best of my 
knowledge, these are the first studies evaluating longitudinal association between 
ferritin levels and cardiometabolic risk in paediatric populations. Moreover, the 
Chilean cohort analysis is the first study analysing patterns of three repeated 
measurements of ferritin over time regarding cardiometabolic risk. Both studies are 
the first to adjust the ferritin-cardiometabolic risk association in children for systemic 
inflammation markers, such as CRP levels. The evaluation of the children at specific 
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ages in the Chilean cohort allowed a more precise characterisation of the association 
in terms of a more homogeneous group of subjects than previous studies in children 
with wider age ranges. In the Spanish cohort, there was simultaneous evaluation of 
markers of iron storage and transport with regard to IR, MetS, and its components 




The association between markers of iron status and cardiometabolic risk in children 
is complex and it appears that both low and high iron status may be related to 
cardiometabolic risk in different populations. It is uncertain if the association 
between high ferritin and higher cardiometabolic risk reported in the Chilean cohort, 
commonly described in adults, would remain significant after adjustments for hepatic 
function markers. Similarly, the association between low iron status and 
cardiometabolic risk reported in the Spanish cohort requires replication in larger 
samples. 
 
Both serum ferritin levels at different time points in childhood and patterns of 
sustained high concentration throughout childhood were associated with MetS and 
IR but with differences by sex in the Chilean children. Patterns of sustained high 
ferritin and slopes from repeated measurements of ferritin over time should be tested 
for cardiometabolic outcomes in adults and other paediatric populations to establish 
whether the difference by sex in the present study is replicable. 
 
The next chapter will evaluate similar associations to those presented here, in two 
populations of Scottish adults, along with a meta-analysis of observational studies on 









Chapter 3  
Cross-sectional studies in Scottish adult 
populations and a systematic review/meta-
analysis of observational studies on serum 
ferritin, metabolic syndrome and its 
components 
3.1 Introduction 
Studies of the association between iron status, MetS, and its components in adult 
populations that have not previously been studied have the potential to add to 
existing knowledge. I did not find previous studies on the association between 
ferritin levels and MetS or its components in British populations. The Viking Health 
study performed in Shetland 2013–2015 includes measurements of ferritin and all the 
components of MetS. The nationally representative Scottish Health Surveys (SHeS) 
performed in 1995 and 1998 included measurements of ferritin and three out of the 
five MetS-related variables: WC, HDL-C, and blood pressure. In this chapter, I have 
used these two studies to investigate whether ferritin levels were independently 
associated with MetS and its components in these two Scottish populations.  
 
Several systematic reviews and meta-analyses have described positive associations 
between ferritin and risk of T2D (19, 114-116), but there is limited evidence for the 
association between ferritin and MetS. One recent meta-analysis reported an overall 
positive association but did not investigate associations of ferritin with individual 
components of the MetS (18). Moreover, the role of important confounders such as 
BMI and hepatic function markers or threshold effects of ferritin levels in the 
associations reported in published studies is not always clear. Several recent studies 
on the topic have been published between 2014 and 2015 which have not been 
included in previous meta-analyses, justifying an updated review to address the gaps 
mentioned above with more statistical power. Therefore, I conducted a systematic 
review and meta-analysis of ferritin, MetS, and its individual components, adding the 





3.2.1 Study 1: Viking Health study – Shetland and SHeS 
1995–1998 
Study population 
The Viking Health Study – Shetland (VIKING) is a genetic epidemiology study on a 
relatively isolated population in the north of Scotland. For this study, 2,105 
volunteers with at least two Shetlandic grandparents were examined over two years 
from March 2013 to March 2015. Each participant attended a measurement clinic 
and a venepuncture clinic to give a fasting blood sample at a dedicated research 
centre in Lerwick, Shetland Islands. The final sample consisted of 2,047 individuals 
after excluding 58 individuals with missing values for ferritin, MetS-related 
variables, insulin and glycosylated haemoglobin (HbA1C), or covariates. Ethical 
approval was issued by the Multi-centre Research Ethics Committee for Scotland, 
and all participants gave written informed consent.  
 
In the SHeS Study, the participants were adults who took part in the Scottish Health 
Surveys 1995 and 1998. The surveys were based on a randomly selected, nationally 
representative, general population sample (see The Scottish Health Surveys websites 
for more detail) (117, 118). All participants were interviewed and asked questions 
about their health and lifestyle behaviours, and consent for measurement of weight 
and height and collection of blood sample was requested. The measurements of 
ferritin and outcome variables of WC, blood pressure, and HDL-C were available for 
10,271 participants (59.4%). Glucose, triglycerides, HbA1C, and insulin were not 
measured. Among those with available measures of exposure and outcome variables, 
8,879 had no missing values for covariates, which are listed in the data analysis 
section. I excluded children (individuals younger than 18 years old, n = 115), and 
1998 data for individuals who took part in both SHeS surveys (n = 23). The final 
sample consisted of 8,653 people. The secondary analyses of the SHeS datasets were 
approved by the Ethics Research Subgroup from the Centre for Population Health 




Biochemical and clinical variables 
Blood was collected via venepuncture after overnight fasting in the VIKING study, 
whereas in the SHeS, fasting samples were not collected, given that the only 
biochemical cardiovascular risk factors to be measured were cholesterol markers. 
After food intake, these markers of lipid profile appear to be, at most, minimally 
changed and have shown good prediction of increased risk for cardiovascular disease 
(119). In the VIKING study, glucose, triglycerides, and HDL-C were measured by 
using enzymatic-colorimetric methods. The same method was used for HDL-C in 
both the VIKING study and SHeS. Fibrinogen level was calculated from INR and 
APTT on a Sysmex CA560 in the VIKING study and by nephelometric method (clot 
turbidity) in the SHeS. Coulter analysers were used to measure haemoglobin, and the 
nitroanilide method was used for GGT in the SHeS. In the VIKING study, 
transaminases (GGT, aspartate transaminase [AST], and alanine transaminase 
[ALT]), insulin, haemoglobin, and HbA1C were measured by using standard 
Beckman-Coulter reagents in a Beckman-Coulter DxC600i combined chemistry and 
immunochemistry analyser.  
 
In both the SHeS, blood pressure was measured using mercury sphygmomanometers 
with an appropriately sized cuff in a sitting position after 15 minutes of rest. Phase I 
and V (disappearance) Korotkoff sounds were used to identify SBP and DBP (120). 
In the VIKING study, digital sphygmomanometers were used. In the SHeS, three 
blood pressure readings were taken and the average of the second and third readings 
was used for the analyses. In the VIKING study, two readings after at least 10 
minutes of supine rest were taken to calculate the average blood pressure. Body 
weight and height were measured using standard techniques and instruments (121). 
BMI was calculated as weight in kg/height in metres squared (122). WC was 
measured from the midpoint between the lateral iliac crest and the lowest rib using a 
flexible steel tape measure (123). The criterion of smoking included the following 
categories: never smoker, ex-regular or ex-occasional smoker, and current smoker. In 
the SHeS, the criterion of alcohol intake included the following categories, using 
rating units per week: 1) non-drinker or ex-drinker, 2) trivial drinker < 1 rating unit 
per week, and 3) drinker ≥ 1 rating unit per week. In the VIKING study, alcohol 
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intake had three categories: non-drinker or rarely, trivial drinker (special occasions or 
one to three days per month), and drinker (one or more days per week). Anaemia was 
defined as haemoglobin <13 g/dL in men and <12 g/dL in women (124). Overweight 
and obesity were defined as having a BMI ≥25 and BMI ≥30, respectively. 
 
Metabolic syndrome, its components, and insulin resistance 
Cut-off points from the international consensus definition for MetS were used as 
follows (40): high triglycerides (HTG) at ≥1.7 mmol/L, low HDL-C at <1.0 mmol/L 
in men and <1.3 in women, high fasting glucose (HFG) at ≥5.6 mmol/L, high blood 
pressure (HBP) as SBP ≥130 mm/Hg and/or DBP ≥85 mm/Hg (or antihypertensive 
drug treatment), and high WC ≥94 cm in men and ≥80 cm in women. MetS was 
defined as the presence of three or more variables meeting the definitions above. In 
the case of high glucose and triglyceride levels, these MetS components did not 
include additional cases with specific lowering treatment since this information was 
not available in the VIKING study. IR was estimated by homoeostatic model 
assessment using the formula: fasting glucose levels [mmol/L] × fasting insulin 
levels/22.5 (125), which was only available for the VIKING participants. 
 
Data analysis 
For both studies, medians and their interquartile ranges or proportions were used for 
description of continuous and categorical study variables, respectively, in the whole 
sample and by groups according to sex and menopausal status, and the differences 
were estimated via Mann-Whitney U test for continuous variables and by 2 test for 
categorical variables. Since both ferritin levels and cardiometabolic risk factors vary 
with sex and menopausal status, all the analyses of association between ferritin and 
MetS and its components were conducted by using logistic regression modelling in 
separate groups of men and pre- and post-menopausal women. Ferritin levels were 
used as a categorical variable of sex- and menopausal-specific quartiles and also as a 
continuous Z score of log-transformed ferritin. Associations between ferritin and 
MetS or its components were described before and after adjusting for potential 
confounders which were age, fibrinogen, GGT levels, smoking, alcohol 
consumption, and BMI. In the VIKING study, there was additional adjustment for 
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AST and ALT. For the SHeS, the year of the survey was also part of the adjustment 
since despite using consistent methods, there were changes in the laboratory where 
total and HDL cholesterol levels were measured in 1998. The set of confounding 
factors was chosen on the basis of possible influence of acute phase or subclinical 
inflammation, adiposity, and liver dysfunction on levels of ferritin and/or outcome 
variables. In the SHeS analysis, survey weights were used to adjust for 
disproportionate sampling, differing selection probabilities, and differential non-
response. This weighting was applied in order to provide comparability with the 
studies on ferritin and MetS that used national survey data, all of which applied 
survey weights to produce nationally representative estimates of prevalence. More 
details of the survey weights in SHeS are provided in the data analysis section of 
chapter 5. In the VIKING study, the relationships between ferritin, IR, and HbA1C 
were additionally evaluated using multiple linear regression analyses to adjust for the 
potential confounders as listed above. Values of ferritin, HbA1C, HOMA-IR, 
fibrinogen, and transaminase were log-transformed to approximate to normal 
distribution before conducting linear regression analyses. I conducted sensitivity 
analyses on the basis of exclusion of individuals with anaemia, very high ferritin 
(>300 µg/L), potential inflammation/infection (fibrinogen > 4.7 g/L), and/or liver 
disease (ALT > 39 U/L, AST > 52 U/L, or GGT > 64 U/L). All analyses were 
processed using STATA 8.0 software (Statistics/Data Analysis, Stata Corporation, 
4905 Lakeway Drive, College Station, TX 77845, USA, 800-STATA-PC). 
 
3.2.2 Study 2: Systematic review and meta-analysis  
Search strategy  
Along with a fellow PhD student (Eduardo Ensaldo-Carrasco) I searched and 
selected articles from PubMed and EMBASE databases up to 31st August 2015. The 
following search terms were used: metabolic syndrome.mp. or metabolic syndrome 
X; ferritin or ferritin blood level or iron or body iron stores.mp. No restrictions 
regarding study design or article type were applied in the search, but unpublished 
reports were not considered. There were no disagreements about which studies to 
include between my colleague and me, so advice from a third researcher was not 
needed. Full texts and abstracts in English language regardless of language used in 
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the full text article were considered. The reference lists of the selected studies were 
read in order to find additional relevant studies. Although I intended to register the 
protocol of this systematic review/meta-analysis in the International Prospective 
Register of Systematic reviews “PROSPERO”, this was not possible because 
PROSPERO requires protocols of systematic reviews to be registered before the 
extraction of data has started. The findings of this systematic review/meta-analysis 
are presented according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidance. The data extraction, risk assessment of bias and 
data analysis, which are described further below, were conducted by me alone. 
 
Prevalence of MetS components were a secondary outcome in this systematic 
review/meta-analysis. However, I did not include specific search terms of MetS 
components (e.g. glucose, glycaemia, blood sugar levels, blood pressure) since in a 
systematic review conducted for my first year PhD review in 2014, studies on iron 
markers and individual MetS components or MetS-related variables that did not 
include MetS as outcome were heterogeneous in terms of effect estimates and 
adjustments (many of them unadjusted), which would have made a quantitative 
analysis difficult. Studies on MetS as outcome were used to describe associations 
with MetS components as well, so the individual association between ferritin and 




Eligibility criteria were studies that included participants from the general adult 
population with descriptions of associations, stratified by gender and age groups or 
adjusting for these covariates at a minimum. Study populations exclusively 
composed of pregnant women, obese individuals, or people with a specific diagnosis 
were not considered. Studies of animals or genetic polymorphisms and reports of in 
vitro experiments were also excluded. The following selection issues were addressed 
by me alone. If two or more studies were based on the same population and same 
study design, I included the study with larger sample size. If the sample sizes were 
similar between studies of similar populations, I selected the study with more robust 
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adjustment. If there were two studies with the same population but with different 
designs, I selected both studies, but they were analysed separately (see more detail 
below in data analysis).   
 
Data extraction and risk of bias  
The data extracted from the selected articles were name of the study, publication 
year, country, time of survey or baseline survey, age (range or estimates), study 
design, sample size, percentage of male individuals, duration of follow-up, 
prevalence/incidence of MetS, MetS definition, ferritin levels, cut-off values for high 
ferritin, and covariates for adjustments. Additional data extracted consisted of 
exclusion criteria such as pregnancy/breastfeeding, anaemia, hepatic diseases, very 
high iron status, and inflammation/infection. Risk of bias was evaluated according to 
modified criteria of the Newcastle-Ottawa scale modified by Orban and Huth (19) in 
terms of representativeness, adjustment for confounders, description of exposure and 
outcome, and duration of follow-up (if prospective design) (Appendix Newcastle-
Ottawa scale). The maximum and minimum scores were 7 and 0, respectively, and 
the higher the score the lower the likelihood of bias. Although representativeness is 
very complex to evaluate because a study can be representative of a specific location 
or group of people, I defined a study as representative if it was based on a 
national/regional health/nutrition survey, an epidemiological population-based study, 
or if, for instance, random selection was reported in the recruitment of participants. 
 
Data synthesis and analysis 
Odds ratios (ORs), hazard ratios (HRs) or relative risks (RRs), and their confidence 
intervals were extracted from the results described in the studies. Four studies 
describing mean ferritin levels reported by categories of MetS (yes/no) were retained 
for the systematic review but excluded from the meta-analyses. For these studies I 
did not use any method to derive the ORs for the association between mean ferritin 
levels and MetS, since these methods assume normal distribution of the variable, and 
distribution of ferritin is frequently skewed across diverse general populations (26, 
126, 127). In addition, a meta-analysis of mean differences for the four studies was 
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not feasible owing to different effect estimates reported, in terms of normal mean, 
standardised mean, and mean of change in ferritin levels.  
 
I decided to conduct the meta-analysis on ferritin and MetS by using two approaches: 
meta-analysis of cross-sectional studies and prospective studies [meta-analysis 1] and 
meta-analysis of cross-sectional studies only [meta-analysis 2]. The main rationale 
behind that decision was that there were few prospective studies, and it was 
necessary to ensure higher statistical power for sub-group and meta-regression 
analyses. The other reason was that few populations reported both cross-sectional 
and longitudinal associations, so it was relevant to determine the effect of both kinds 
of estimates on the pooled estimates and subgroup analyses. The meta-analysis on 
ferritin and MetS components did not require a similar approach since all of the 
studies describing associations between ferritin and MetS components were cross-
sectional in design, with the only exception being Vari et al. who reported both 
cross-sectional and prospective associations(7). I used cross-sectional findings from 
the study by Vari et al. for this meta-analysis of the association between ferritin and 
MetS components.  
 
I pooled estimates from the studies by using an inverse-variance weighted random-
effects model. The I2 statistic was used to estimate heterogeneity in terms of the 
proportion of total variation in the estimates of meta-analysis explained by 
heterogeneity. For the meta-analysis 1 of cross-sectional and prospective studies, 
because most of the studies provided OR as effect estimate, hazard ratios, ORs and 
relative risks were assumed to approximate the same effect estimate of OR. I 
conducted sub-group and meta-regression analyses to evaluate the potential factors 
accounting for heterogeneity in the associations between ferritin-MetS and between 
ferritin-Mets components throughout the selected studies. The factors were: study 
design (cross-sectional or prospective), type of effect estimate (OR, HR, relative 
risk), geographic region (Asia, Europe, America), adjustment for BMI (yes/no), 
adjustment for CRP (yes/no), adjustment for any inflammatory marker (yes/no), 
adjustment for hepatic function markers (yes/no), sample size (<500 or ≥500), 
sample size (<1000 or ≥1000), ferritin assay (quimiolumominescence QLA, 
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radiometry, RIA; inmunoturbidimetry, TIA; others), average ferritin levels reported, 
and cut-off points reported for the highest category of ferritin levels. For these latter 
two factors, I calculated tertiles and quartiles specific of sex and menopausal status 
or whole population as reported in each study selected. The VIKING and SHeS 
studies were assigned to the corresponding tertile and quartile groups according to 
how their values fitted in the ranges of those categories. I did not use data extracted 
on exclusion criteria of the studies for additional subgroup analyses, to avoid higher 
likelihood of findings by chance. Effect estimates of the VIKING study were part of 
the meta-analyses for MetS and its components, and findings from the SHeS were 
included in the meta-analysis for MetS components only. Publication bias was 
evaluated by using Begg’s and Egger’s test as well and visualisation of funnel plots. 
All analyses were processed using STATA 14.0 software (Statistics/Data Analysis, 
Stata Corporation, 4905 Lakeway Drive, College Station, TX 77845, USA, 800-
STATA-PC). 
3.3 Results 
3.3.1 Study 1: Viking Health study – Shetland and SHeS 1995-
1998 
Differences between selected and excluded individuals from the VIKING study and 
the SHeS 1995–1998 are shown in Appendices Tables 10 and 11, respectively. 
Individuals included in the analysis of the VIKING study had slightly higher values 
of ferritin and GGT and lower values of HDL than the subjects who were excluded 
because of missing data. In the SHeS 1995–1998, most of the study variables were 
significantly different between included and excluded subjects but without a clear 
pattern or trend for higher or lower values of risk factors and covariates in one group 
or the other. Compared to the people that were excluded the people that were 
included were slightly older; had smaller proportions of postmenopausal women and 
higher proportions of men; and higher values of BMI, HDL-C, and DBP. On the 
other hand, the people who were excluded had higher values of GGT and fibrinogen 
and higher proportions of current smokers and people with CVD and diabetes than 




Table 7 describes the study variables from the VIKING study and SHeS. The 
population in the VIKING study was older (median (IQR) age in years [51(38.9–
63.2) vs. 40(31–52)]) and had higher values of DBP and WC than the SHeS 
population. The SHeS participants had higher values of GGT and a higher proportion 
of current smokers than VIKING participants (Table 7). Prevalence of overweight 
was 56.2% and 66.8% in VIKING and SHeS, respectively. Obesity was present in 
18.2% of the individuals from SHeS and in 24.4% from the VIKING study. The 
distribution of other common variables between the studies appeared to be similar.  
 
Ferritin levels (median and interquartile range) were statistically significantly higher 
in subjects with MetS in each sex and menopausal status category [Premenopausal 
women: MetS (prevalence 8.6%) 31(16-64) µg/L v. No MetS 25(15-40) µg/L, P= 
0.047; Postmenopausal women MetS (prevalence 22 %) 68(32-95) µg/L v. No MetS 
57(37-78) µg/L, P=0.016; Men MetS (prevalence 22.2%) 111(63-163) µg/L v. No 
MetS 87(57-129) µg/L, P= 0.001]. 
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Table 7 Distribution of iron status and cardiometabolic risk in the study cohorts 
 Viking Health study –
Shetland (2013-2015) 
Scottish Health Surveys 
 (1995 & 1998) 
n 2047 8653 
Age (years) 51(38.9-63.2) 41(31-52) 
Pre-MW/ Post-MW/ Men % 28.7/30.5/40.6 33.6/20.1/46.3 
BMI (kg/m2) 26.7(24.1-29.9) 25.6(23.1-28.6) 
Ferritin(µg/L) 56(29-97) 62(33-108) 
Fibrinogen (g/L) 3.3(2.9-3.8) 2.9(2.4-3.5) 
GGT U/L 16(12-24) 20(14-32) 
ALT U/L 22(17-29) N.M 
AST U/L 22(19-26) N.M 
HDL-C (mmol/L) 1.4(1.2-1.7) 1.4(1.2-1.7) 
SBP (mmHg) 127(116-142) 126(117-137) 
DBP (mmHg) 75(69-82) 70(63-79) 
WC (cm) 91.2(81.5-100.8) 85.2(76.3-94.2) 
Glucose (mmol/L) 4.8(4.5-5.1) N.M 
TG (mmol/L) 0.9(0.6-1.3) N.M 
Insulin mU/mL 37.1(25.8-54) N.M 
HOMA-IR 7.8(5.3-11.8) N.M 
HbA1C (%) 5.30(5.10-5.50) N.M 
MetS and its components n (%)*   
High blood pressure 1032(50.4) 3783(41.9) 
Low HDL-C 350(17.1) 1646(18.4) 
High WC 1366(66.7) 3651(40.0) 
High glucose 147(7.2)  
High triglycerides 244(11.9)  
MetS 374(18.3)  
Smoking n(%)   
Never smoker  1133(55.3) 3349(39.9) 
ex-regular or ex-occasional smoker 747(36.5) 2376(27.2) 
Current smoker 167(8.2) 2928(32.9) 
Alcohol consumption n(%)   
Category 1* 84(4.1) 687(7.1) 
Category 2* 152(7.4) 1001(10.1) 
Category 3* 1811(88.5) 6965(82.7) 
Cardiovascular disease n(%) 64(3.1) 206(2.0) 
Diabetes n(%) 46(2.2) 153(1.5) 
Data are median (interquartile range) or n(%). Comparison between groups by Mann-Whitney 
U and 2 test. N.M, not measured. Pre-MW, premenopausal women. Post-MW, postmenopausal 
women. BMI, body mass index. TG, triglycerides. SBP, systolic blood pressure. DBP, diastolic 
blood pressure. WC, waist circumference. HOMA-IR, homeostatic model assessment insulin 
resistance. * VIKING: non-drinker or rarely, trivial drinker (special occasions or 1 to 3 days 
per month), and drinker (1 or more days per week) ; SHeS 95-98: 1) non-drinker or ex-drinker, 
2) trivial drinker < 1 rating unit per week and 3) drinker ≥ 1 rating unit per week. * For the 
SHeS study n is on the basis of unweighted values but percentage(%) is weighted by survey 
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 Viking Health study –
Shetland (2013-2015) 
Scottish Health Surveys 
 (1995 & 1998) 
weights to produce nationally representative estimates of prevalence. More details of the survey 
weights in SHeS are provided in the data analysis section of chapter 5. 
 
In unadjusted analyses, high ferritin levels were associated with MetS in men and 
postmenopausal women of the VIKING study (Table 8). In terms of MetS 
components, there were also several significant positive crude associations of ferritin 
in the highest quartile compared to the lowest quartile with MetS components in the 
VIKING and SHeS studies, mainly in men and postmenopausal women (Appendix 
table 12). However, the above associations between ferritin, MetS, and some MetS 
components did not remain significant after adjusting for covariates, with the 
exception of the associations: ferritin-HDL-C in postmenopausal women, ferritin-
WC in men (SHeS) and postmenopausal women (VIKING) (Table 8, Appendix 
Table 13). On the other hand, in premenopausal women from the SHeS, ferritin 
levels in the middle quartiles (2 and 3) were significantly and inversely associated 
with high blood pressure in unadjusted and adjusted analyses. Given this observation, 
I furtherly examined a potential U or J-shape association using quartiles 2 and 3 
together as reference. Both quartiles 1(Q1) and 4(Q4) of serum ferritin were 
positively associated with high blood pressure in premenopausal women although 
only the association with quartile 1 reached statistical significance, P< 0.05 [ferritin 
Q1  v. Q2-3 fully adjusted OR(95%CI) 1.49(1.14-1.94) P=0.003; ferritin Q4  v. Q2-3 
fully adjusted OR(95%CI) 1.23(0.94-1.61) P=0.116].  
 
A similar pattern of no association with MetS was observed when using serum 
ferritin as a continuous variable (Z score of log-ferritin) (Table 9). There were no 
additional significant associations between the ferritin Z score and each MetS 
component to those reported by using ferritin quartiles (P > 0.05), with the exception 
of a significant association with increased WC in postmenopausal women in SHeS 
[unadjusted OR (95% CI) 1.56 (1.29–1.88) P < 0.001, adjusted OR (95% CI) 1.53 
(1.07–1.51) P = 0.005] (Appendix table 14). 
 
In the VIKING study, ferritin levels were inversely associated with HbA1C in 
unadjusted and adjusted linear regression models in men and both groups of women 
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of the study (Appendix Table 15). HOMA-IR, although significantly associated in 
unadjusted models, was not independently associated with ferritin levels, even after 
increasing statistical power by considering the whole sample of the VIKING study 
with adjustment for sex and menopausal status (Appendix Table 15).  
 
I conducted additional adjustments for prevalent cardiovascular disease and diabetes 
but this did not substantially modify the effect estimates for the associations 
previously described in the VIKING and SHeS studies.  
 
In the VIKING study, the exclusion of cases of iron deficiency (n= 183, 8.9%), or 
serum ferritin >300µg/L (n=38, 1.8%) did not affect the above associations.  The 
same was true when individuals with potential inflammation (high fibrinogen levels) 
(n= 160, 7.8 %) and/or liver disease (n=147, 7.1%) were removed from the analyses, 
with the exception of two associations. One of them was a significant association 
between ferritin Z score and low HDL-C in men, not observed in the previous 
findings [unadjusted OR (95% CI) 1.57 (1.15–2.13) P = 0.004, adjusted OR (95% 
CI) 1.39 (1.0009–1.92) P = 0.044]. The other one was the relationship between 
ferritin and HOMA-IR in the VIKING study, which became significant after 
adjustments but only in men [Beta (95% CI) -0.07 (-0.13 to -0.01) P = 0.019]. 
However, the above associations presented confidence intervals containing values of 
adjusted O.R and Beta coefficient too close to 1.00 and zero, respectively, which 
implies that these associations may not exist or are too small to be of clinical 
relevance. In addition, the adjusted ferritin-HOMA-IR association was negative in 
contrast with a positive effect estimate in the unadjusted regression [Beta (95% CI) 
0.03 (-0.03 to 0.10) P = 0.382]. This may be a chance finding.  
 
In the SHeS study, the few significant associations between ferritin and some MetS 
components reported previously in Appendix Table 13 were attenuated in sensitivity 
analyses. Lower statistical power might have been the cause, since both effect 
estimates and statistical significances decreased. In the SHeS, when individuals with 
high ferritin (n= 631, 7.2%) were removed, the significant association between high 
serum ferritin and high WC in men was attenuated [adjusted OR (95%CI) 1.25(0.92-
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1.70), P=0.138]. Removal of subjects with potential inflammation (n=680, 7.8%) 
and/or liver disease (n=270, 3.1%) weakened the same association in men [adjusted 
OR (95%CI) 1.22(0.89-1.68), P= 0.207], and also the significant inverse ferritin- 
HDL-C association reported in postmenopausal women [adjusted OR (95%CI) 
1.41(0.87-2.28), P= 0.158]. Exclusion of subjects with iron deficiency (n= 631, 
7.2%) did not alter any of the findings described for the whole sample. No other 
substantial modifications were observed in sensitivity analyses. 
Adjustment for BMI had a major effect on the association between high ferritin and 
MetS in the VIKING study and on the associations between high ferritin and 
increased WC, blood pressure, and low HDL-C in the SHeS. Adjustment for age and 
GGT levels also attenuated the associations with increased WC and blood pressure in 






Table 8 Odds ratios (95% CI) for MetS by sex- and menopausal-specific quartiles (Q) of serum ferritin in the VIKING study 
 
 
  Unadjusted Adjusted* 
 Q1 
 
Q2 Q3 Q4 P for 
trend 
Q2 Q3 Q4 P for trend 
Premenopausal 
women 
≤ 15 µg/L 16-25 µg/L 26-41 µg/L > 41 µg/L  16-25 µg/L 26-41 µg/L > 41-67.1 µg/L  













          
Postmenopausal 
women 
≤ 34 µg/L  35-54 µg/L 55-84 µg/L > 84 µg/L  35-54 µg/L 55-82 µg/L > 84-450 µg/L  













          
Men ≤ 58 µg/L 59-89 µg/L 90-138 µg/L >138 µg/L  35-55 µg/L 90-138 µg/L >138 -772 µg/L  













* Adjusted for age, alanine-aminotransferase levels, aspartate-aminotransferase levels, glutamyl-transferase levels, fibrinogen levels, smoking, alcohol 







Table 9 Unadjusted and adjusted odds ratios (95% CI) for metabolic syndrome by SD units of serum ferritin (log-transformed) in the VIKING study 
 Unadjusted Adjusted* 
 Ferritin Z score P value Ferritin Z score P value 
Premenopausal women 1.44(1.06-1.96) 0.018 1.05(0.75-1.44) 0.789 
Postmenopausal women 1.26(1.03-1.53) 0.022 1.07(0.86-1.33) 0.491 
Men 1.27(1.07-1.51) 0.005 1.07(0.89-1.28) 0.464 
* Adjusted for age, alanine-aminotransferase levels, aspartate-aminotransferase levels, glutamyl-transferase levels, fibrinogen levels, smoking, alcohol 
consumption, and BMI. Significant associations are shown in bold (p<0.05).  
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3.3.2 Study 2: Systematic review and meta-analysis  
 
Studies with the same population and decisions made 
Lee et al. (108), Cho et al. (128), Kang et al. (129), and Yoo et al. (130) conducted 
studies using the Korean National Health and Nutrition Examination Survey 
(KNHANES) but at different times. The latter two studies used mixed populations 
from the 2007 and 2008 surveys, whereas Lee et al. described the 2007 data, and Cho 
et al. described the 2008 data. The study by Yoo et al. was excluded because it has a 
smaller sample size than the one by Kang et al. I confirmed with the Korea Centres 
for Disease Control and Prevention, that the possibilities for samples from 2007 and 
2008 surveys to overlap were minimal since only about 5 households have been 
surveyed twice between 2007 and 2015 in the KNHANES. Therefore, I decided to 
include the studies by Lee et al. and Cho et al. instead of the one by Kang et al., 
which had a slightly larger sample size but included overlapping populations with the 
above studies. This strategy allowed me to include two studies from independent 
Korean populations in the meta-analysis, providing more cases than one single study. 
Additionally, the study by Cho et al., specifically involving women, provided some 
balance against the large proportion of articles selected involving male populations 
only. 
 
Han et al. (131) and Li et al. (132) used data from the China Health and Nutrition 
Survey, 2009, and had comparable samples sizes (1.4% difference in sample size 
between study populations). I selected the study by Li et al. for its robust statistical 
adjustment.  
The cross-sectional study by Ryoo et al. (133) and the longitudinal study by Park et 
al. (134) included some similar subjects/cases, so they were entered separately into 
the meta-analyses. 
 
Hamalainen et al. and Kilani et al. published both cross-sectional and longitudinal 
population-based studies from Pieksamaki (Finland) (113, 135) and from Lausanne 
(Switzerland) (22, 136), and both sets of analyses were included for the appropriate 




There were only two studies in languages other than English, i.e. Chinese and 
Korean cross-sectional studies by Xiao et al. (137) and Ryu et al. (138), respectively. 
Coincidently, another study by Yoon et al. was selected, as it was conducted in the 
same cohort of the study by Ryu et al. (Korean Rural Genomic Cohort) but with 
prospective design and written in English language.  
 
Studies selected  
Figure 4 summarises the process of identifying and selecting the studies. We 
identified 22 studies that described the association between ferritin and MetS of 
which 18 were included in the meta-analyses and systematic review and four only 
contributed to the systematic review (Table 10). The VIKING study provided a 
further study to include in the ferritin-MetS meta-analysis. Among the studies 
selected, nine also provided information on associations between ferritin and MetS 
components, and thus along with the VIKING study and SHeS, there were 11 studies 




Figure 4 Flow chart for the selection of eligible studies included in the systematic review/meta-
analysis of the association between ferritin and metabolic syndrome 
  
 
MetS definitions, geographic location, and types of source 
Among the studies selected (Table 10), with regards to MetS definitions, 14 
exclusively used NCEP ATP III criteria, of which seven had modifications of the 
WC criterion or used revised criteria for Asian or Asian-American individuals. One 
study specifically used the IDF criteria, another used the Japanese criteria, six used 
the harmonised definition (including the VIKING study), and one used three 
definitions (NCEP ATP III, IDF, and revised NCEP ATP III criteria). Three studies 
were prospective only, and two reported cross-sectional and prospective evaluations. 
The rest of the studies were cross-sectional analyses. Thirteen studies were 
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conducted in Asian populations, eight in Europe, one in Israel, and one in the US. 
Nine used information from national/regional surveys of health or nutrition, five 
involved samples from population-based studies, three involved participants 
identified from medical health centres or social security numbers, two involved 
employees who underwent an annual health check-up, two involved a cohort of 
subjects born in specific years, and two involved individuals from a factory and six 
offices. The SHeS study, which was not used for the meta-analysis of MetS but for 
that of MetS components, used criteria from the harmonised MetS definition, 
reported cross-sectional associations, and used information from a national survey 
(Table 10).  
73 
 
Table 10 Characteristics of the studies included in the systematic review and meta-analysis and in the systematic review only of the association between ferritin and 
metabolic syndrome (seven pages table) 





















































DESIR/NP 30-65 49.7 944 21% 
(Men), 8% 
(Premenopausal 






No  No  None 
Zelber-










24-70 52.7 349 NP as a total NCEP ATP-III No No Non-alcoholic 
fatty liver disease 









>20 45.9 1294 9.4%(men) and 
18%(women) 










NHAPC/ 2005 50-70 43 3289 42.3% NCEP ATP-III Yes  Yes  Alcohol intake, 
smoking, family 
history of chronic 
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exercise, intake of 
energy, iron, 
hemoglobin, 















NP/2008 20-89 52.7 1209
0 

























cut-off points)  
Yes No Alcohol intake, 
smoking, 
educational level, 
AST and ALT. 
Ryoo et Cross- Korea/ NP/2008 40.5 ± 100 1858 13.8 NCEP ATP-III  No No Alcohol intake, 
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>40  49.8 861 13.3 Harmonized 
definition 






















































betel nut intake, 
76 
 


























family history of 
chronic diseases  












No Yes Nationality, 














35-75 47.2 5498 29.4%(Men) 
8.3%(premenopau
sal women) and 
25.5%(postmenop
ausal women) 
NCEP ATP-III Yes Yes Alcohol intake, 



















19-65 100 3386 27.1 Harmonized 
definition 





































g Area Males 
Health and 
Examination 






Yes No  Physical activity, 
family history of 
chronic diseases, 
alcohol intake and 
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35-75 42.8 3271 22.6%(Men), and 
16.5 % 
(women 
NCEP ATP-III Yes Yes Alcohol intake, 













18-92 40.7 2047 18.3% Harmonized 
definition 
Yes Yes Fibrinogen levels, 




































STUDIES INCLUDED ONLY IN THE SYSTEMATIC REVIEW  

































>18 44.3 1391 21.9% Harmonized 
definition 



























































41.8 691 Incidence :18% Harmonized 
definition 

















NP/2007 41.2 ± 
10.4 
years 




No No None 
* Or mean (SD) of age if age range not provided. ** This study used BMI instead of waist circumference as surrogate for central obesity. *** The SHeS 




One study exclusively involved post-menopausal women (144), another, only women 
(both pre and post-menopausal) (128), and four, only men (133, 134, 143, 145). 
Information on adjustment variables used in the studies is shown in Table 10. Since 
basic adjustments for age and sex were the inclusion criteria for this systematic 
review, all of the studies showed either adjustments or stratified results for age and 
sex Twelve studies, including the VIKING study and SHeS, reported adjustment for 
BMI (22, 106, 108, 113, 128, 136, 140-142, 145), 11 for CRP levels as marker of 
sub-clinical/clinical inflammation, (22, 25, 105, 106, 108, 113, 132, 134-136, 140, 
141), and 6 reported adjustments for both covariates (22, 106, 113, 136, 140, 141). 
One from those with no covariate of CRP, adjusted for white blood cell count or 
other inflammatory markers (133), and in the two Scottish studies, fibrinogen levels 
were used as inflammatory marker. Eleven studies and the two studies involving 
Scottish populations reported adjustments for hepatic function in terms of 
transaminase levels (22, 105, 108, 128, 134, 136, 141-144) or non-alcoholic fatty 
liver disease (139), two, for family history of chronic diseases (140, 142), and four, 
for HOMA-IR (105, 128, 133, 134), of which three did not adjust for BMI (105, 133, 
134). With the exception of six studies (7, 25, 107, 135, 139, 146), all others adjusted 
for alcohol intake. Two articles included education level as covariate (107, 108), out 
of which one additionally adjusted for variables such as urban or rural residence and 
income (107). However, this latter study did not adjust for other factors.  
 
Exclusion criteria 
As complementary information for the adjustments mentioned above, Appendix 
Table 16 lists the exclusion criteria for each study. From 17 studies that included pre-
menopausal women, only four described pregnancy as an exclusion criterion (106-
108, 139).  
 
Five studies excluded subjects with inflammation by clinical evaluation and high 
levels of CRP or WBC (7, 106, 140, 141, 143) (Appendix Table 16), and among 
these, three had further adjustment for an inflammatory marker in the analyses (106, 
140, 141). Nine of the remaining 17 articles with no exclusion of subjects with 
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evidence of active inflammation, included adjustment for some inflammatory marker 
(22, 25, 105, 113, 132-136). Hepatic disorders based on infectious and/or chronic 
diseases and/or high levels of transaminases or transferases were the exclusion 
criteria in six studies (106, 108, 133, 134, 141, 145), of which three had further 
adjustment for a hepatic function marker. Half of the 16 studies with no exclusion of 
individuals with evidence of hepatic disorders adjusted for levels of transaminases or 
transferases (22, 105, 128, 136, 139, 142-144). Four studies excluded subjects with 
anaemia or iron deficiency (7, 106, 108, 141), adjustment for anaemia and/or 
haemoglobin levels was conducted in four studies (25, 128, 142, 144), two more 
adjusted for use of iron supplements (22, 136), and in another study, anaemia was an 
additional exposure variable (107) (Appendix Table 16). Subjects with probable HH 
were excluded in 11 studies on the basis of high levels of iron status markers (mostly 
high ferritin) (7, 22, 106, 108, 133, 134, 136, 140, 142, 143, 145), and one more 
study excluded confirmed homozygote individuals for C282Y mutation in the HFE 
gene and adjustment for heterozygote status for this mutation was conducted in the 
same study (25) (Appendix Table 16).  
 
Only six studies excluded patients with cardiovascular disease and/or hypertension 
(105, 133, 134, 141, 144, 146) and among these, three additionally excluded subjects 
under diabetic and/or lipid/blood pressure lowering treatments (105, 134, 146) 
(Appendix Table 16). Of note, two of these three latter studies were prospective 
(105, 134) and their rationale for exclusion of those under medications was mainly 
that of excluding cases with MetS components such as high blood pressure, glucose, 
and triglycerides at baseline. However, one of these prospective studies further 
adjusted the associations for diabetes status (134). The rest of studies with no 
exclusion of people with the above diseases did not report stratified results or 
adjustment for diabetic and/or cardiovascular disease status. Four of the six 
prospective studies excluded individuals with MetS at baseline (22, 105, 134, 145) 
(Appendix Table 16) whereas the remaining two adjusted or stratified for having 




Average ferritin concentrations and cut-off values defining high ferritin 
Median/mean values of ferritin levels and cut-offs of ferritin defining high 
concentration reported in the studies selected are shown in Appendix Tables 17 and 
18 for meta-analyses 1 and 2, respectively. The values are grouped by 
sex/menopausal status/sex-specific tertiles and quartiles. The values for the Scottish 
studies were located in the lowest categories of average ferritin concentrations and 
cut-offs for high ferritin (Appendix Tables 17 and 18). All of the studies described 
cut-offs for high ferritin lower than suggested reference values (>200 µg/L in 
women, >300 µg/L in men) (18), with the exception of Kilani et al. (326 µg/L in 
men) (22, 136) and Tang et al. (459.9 [cross-sectional study] and 426.6 µg/L 
[prospective study] in men) (145).  
 
Risk of bias 
Appendix tables 19 and 20 describe our evaluation of risk of bias in cross-sectional 
and prospective studies, respectively. The median score for risk of bias, which is 
inversely related to opportunity of bias, was 4. Two cross-sectional studies, i.e. Sun 
et al. and Jehn et al., reached the maximum possible score of 7 for lower risk of bias 
(Appendix Table 19). Of note, many studies with very robust adjustments did not 
obtain high scores, presumably because one of the assessment criteria was the 
simultaneous adjustment for BMI and inflammatory markers. Failure to report 
coefficients of variation in ferritin measurements was another common reason for not 




Figure 5 Forest plot describing the association between ferritin and metabolic syndrome in 
observational studies (cross-sectional and prospective [Meta-analysis 1]). 
 
Studies are stratified by sex, menopausal status or presented both sexes depending on the way the 
association was reported in each article. Diamonds are pooled estimates from inverse variance 





Ferritin and metabolic syndrome: Results of the meta-analysis and 
meta-regression  
Information from 81,801 individuals was obtained when cross-sectional and 
prospective studies were analysed together (meta-analysis 1; 17 studies). The pooled 
OR for MetS by high levels of ferritin (vs. lowest levels) was 1.74 (95% CI: 1.54–
1.97) [heterogeneity P < 0.001; I2 80.5%] (Figure 5). When prospective effect 
estimates were replaced by cross-sectional effect estimates in the case of articles or 
populations providing both associations (meta-analysis 2; 16 studies; 85282 
participants), the pooled OR for MetS for the highest levels of ferritin (vs. lowest 
levels) was 1.65 (95% CI: 1.41–1.93) [heterogeneity P < 0.001; I2 79.2%] (Appendix 
Figure 1). The overall ORs for MetS components by high levels of ferritin (vs. 
lowest levels) (meta-analysis 3) are described in detail in Appendix Figures 2-6: high 
fasting glucose 1.69 (1.47–1.94) [heterogeneity P < 0.001; I2 74.7%]; increased WC 
1.52 (1.32–1.76) [heterogeneity P < 0.001; I2 66.0%]; high triglycerides 1.96 (1.64–
2.34) [heterogeneity P < 0.001; I2 82.6%]; low HDL-C 1.45 (1.30–1.62) 
[heterogeneity P = 0.001; I2 56.6%]; and high blood pressure 1.08 (0.98–1.18) 
[heterogeneity P = 0.010; I2 46.7%]. 
 
Pooled ORs for MetS by sub-groups are shown in Table 11. The meta-regression 
analysis with study characteristics as independent variables (Table 11) showed that 
the pooled estimates for association between ferritin and MetS was stronger with 
RIA as the laboratory method for ferritin measurement than with other methods 
(Table 11) [meta-regression Exp(b) (95% CI): 0.89 (0.81–0.99), P = 0.033]. 
Adjustment for hepatic markers attenuated the association between ferritin and MetS 
[Exp(b) (95% CI): 0.77 (0.61–0.98), P = 0.036]. Higher cut-off points for upper 
category of ferritin levels reported in the studies (tertiles and quartiles of those values 
specific for sex/menopausal status according to the report) had a positive but 
statistically marginal significant effect on the pooled association between ferritin and 
MetS [Exp(b) (95% CI): 1.11 (0.98–1.26), P = 0.080]. Adjusting for BMI was 
associated with a marginal negative influence on the association between ferritin and 
MetS [Exp(b) (95% CI): 0.82 (0.65–1.04), P = 0.110]. When effect estimates from 
cross-sectional associations only were used, findings from meta-regression were in 
line with the above, with a clearer attenuating effect of adjusting for BMI [Exp(b) 
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(95% CI): 0.71 (0.52–0.96), P = 0.030], although the influence of the cut-off point 
for the upper category of ferritin levels was not observed (Appendix Table 21).  
 










Study design     
Cross-sectional 22(12) 1.77(1.50-2.10) 70.8  
Prospective 11(5) 1.60(1.42-1.80) 0.0 0.490 
Measure of association      
Odds ratio 28(14) 1.72(1.50-1.97) 67.0  
Hazard ratio 4(2) 1.68(1.41-2.01) 0.0  
Relative risk 1(1) 2.84(1.40-5.76) -- 0.425 
Region     
Asia 19(11) 1.84 (1.54-2.19) 72.6  
Europe 11(5) 1.54 (1.36-1.75) 0.0  
America 3(1) 2.22 (1.60-3.09) 7.5 0.686 
Adjusted for BMI     
No 15(9) 1.93(1.57-2.37) 75.6  
Yes 18(8) 1.61(1.44-1.81) 10.3 0.110 
Adjusted for CRP     
No 18(10) 1.61(1.46-1.78) 0.0  
Yes 15(7) 1.90(1.53-2.36) 62.2 0.128 
Adjusted for at least one inflammatory marker 
No 15 (9) 1.65(1.49-1.83) 0.0  
Yes 18 (8) 1.78 (1.45-2.18) 74.7 0.506 
Adjusted for at least one hepatic function marker 
No 21(11) 2.00(1.58-2.54) 79.2  
Yes 12(6) 1.60(1.46-1.76) 0.0 0.036 
Ferritin assay     
RIA 10(4) 2.08(1.60-2.71) 76.3  
QLA 5(4) 1.60(1.30-1.97) 37.9  
TIA 9(5) 1.65(1.40-1.94) 13.8  
Other 9(4) 1.52(1.31-1.77) 0.0 0.033 
Sample size     












≥1000 1910) 1.80(1.53-2.12) 74.3 0.365 
Risk of bias     
score < median 18(11) 1.86(1.55-2.23) 72.8  
score ≥ median 15(6) 1.62(1.41-1.85) 17.0 0.204 
Mean/median ferritin levels (Sex/menopausal-specific tertiles) 
Tertile 1 12 1.70(1.28-2.27) 79.7  
Tertile 2 10 1.90(1.64-2.19) 22.9  
Tertile 3 11 1.60(1.38-1.85) 19.3 0.597 
Mean/median ferritin levels (Sex/menopausal-specific quartiles) 
Quartile 1 7 1.50(1.25-1.80) 8.9  
Quartile 2 9 1.88(1.33-2.67) 79.6  
Quartile 3 9 1.98(176-2.23) 2.3  
Quartile 4 8 1.53(1.29-1.80) 18.8 0.867 
Cut-off point reported for highest category of ferritin levels  
(Sex/menopausal-specific tertiles) 
Tertile 1 11 1.50(1.31-1.71) 0.0  
Tertile 2 10 1.98(1.50-2.60) 8.1  
Tertile 3 9 1.87(1.62-2.15) 9.5 0.103 
Cut-off point reported for highest category of ferritin levels  
(Sex/menopausal-specific quartiles) 
Quartile 1 7 1.53(1.33-1.77) 0.0  
Quartile 2 8 1.51(1.26-1.80) 0.0  
Quartile 3 9 2.28(1.77-2.93) 73.6  
Quartile 4 6 1.73(1.46-2.04) 0.0 0.080 
* The first number describes sex/menopausal status groups from each study, and second 
number (in parenthesis) means number of studies.  
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The meta-regression analysis also showed that the pooled estimates of association 
between ferritin and high blood pressure were attenuated in studies adjusting for 
BMI and hepatic function markers (Appendix Table 22). On the other hand, 
adjusting for CRP strengthened the association of ferritin with high triglycerides and 
high glucose (Appendix Table 22). In studies with higher risk of bias, high ferritin 
was more strongly associated with high triglycerides, WC, and blood pressure (P < 
0.039) (Appendix Table 22). The ferritin-low HDL-C association was stronger in 
studies involving Asian populations than in those involving European and American 
populations (P = 0.054) (Appendix Table 22). In addition, higher cut-off points used 
to define high ferritin concentrations were more strongly associated with high 
triglycerides (P = 0.019 for quartiles/P = 0.043 for tertiles of those cut-off points) and 
high blood pressure (P = 0.028 for quartiles/P = 0.043 for tertiles of those cut-off 
points) (Appendix Table 22). 
 
Findings from studies for the systematic review but not included in the 
meta-analysis 
All articles described significantly higher levels of ferritin in cases with MetS. 
Iwanaga et al. (146) and Martinelli et al. (25) reported P values for the comparison of 
mean ferritin levels, adjusting for age and sex only in their cross-sectional studies. 
Meanwhile, Hamalainen et al. reported ferritin means standardised for age, sex, CRP, 
smoking, and physical activity in a cross-sectional study (135). These authors also 
investigated the longitudinal association between changes in ferritin levels and MetS 
and its components after 6.5 years of follow-up, adjusting for age and baseline 
smoking and values of CRP, ferritin, and BMI (113). In this study, the authors did 
not exclude cases with MetS or its components at baseline and compared the findings 
based on the presence or absence of the outcomes at baseline. There were significant 
increases in ferritin levels for men when MetS was present after follow-up and not at 
baseline of the study. The same was true for women regardless of the presence of 
MetS at baseline. In men, developing high triglycerides was associated with positive 
change in ferritin levels regardless of that MetS component being present at baseline. 
In women, developing high glucose was associated with positive change in ferritin 





The exclusion of any single study did not substantially affect the pooled estimates for 
associations between ferritin, MetS, and its components. The pooled estimate for 
association with MetS ranged from 1.55 (1.35–1.78) to 1.82 (1.60–2.07) for the 
analysis of cross-sectional and prospective studies and from 1.64 (1.52–1.76) to 1.79 
(1.57–2.03) for analysis of cross-sectional studies only, after excluding individual 
studies. 
 
Pooled ORs (95% CI) for association between highest compared to lowest quantile/ 
category of ferritin and MetS components ranged as follows: HBP 1.04 (0.93–1.16) 
to 1.13 (1.04–1.23); low HDL-C 1.36 (1.25–1.48) to 1.49 (1.31–1.68); HFG 1.57 
(1.39–1.76) to 1.75 (1.50–2.05); high WC 1.48 (1.30–1.69) to 1.57 (1.35–1.83); and 
HTG 1.81 (1.58–2.07) to 2.06 (1.69–2.51). 
 
The significant findings and trends on sources of heterogeneity for the associations 
evaluated in general, persisted across the sensitivity analysis. In meta-analysis 1, the 
sensitivity analysis showed that adjusting for hepatic function markers or BMI 
remained significant attenuating factors of the ferritin-MetS association. Only the 
exclusion of the VIKING study slightly affected the significance of adjustment for 
BMI as a factor of influence in the meta-regression analysis (P = 0.059).  
 
In meta-analysis 2, adjusting for hepatic function markers and ferritin assay retained 
its influence in the ferritin-MetS association after excluding any single study apart 
from the study of Li et al. (P > 0.05). The positive trend for cut-off values for high 
ferritin and strengthening of ferritin-MetS association was lost when six studies were 
individually removed from the meta- regression analysis (P > 0.1).  
 
The strengthening of the association between ferritin and high blood pressure and 
triglycerides by quartiles of cut-off values reported for high ferritin persisted in the 
sensitivity analyses (P < 0.05 for high triglycerides, P < 0.064 for high blood 
pressure). The same was true when investigating the effect of adjusting for BMI as a 
factor of influence in the association between ferritin and high blood pressure (P < 
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0.05). The effects of adjusting for CRP or other inflammatory markers and type of 
ferritin assay on the ferritin-high glucose association were not consistent across the 
sensitivity analysis. The individual exclusion of two studies attenuated the effect of 
world region in the association between ferritin and low HDL-C (P > 0.1).  
 
Apart from the modifications described above, no other substantial changes in 
findings from meta-regression analysis were observed in sensitivity analyses.  
 
Publication bias 
The funnel plot for the ferritin-MetS association was asymmetrical with most of the 
studies located on the top left of the diagram (Figure 6). However, according to 
Begg’s and Egger’s tests, there was no evidence for publication bias (P > 0.05). 
 
Figure 6 Funnel plot of the standard error of the natural logarithm of the effect estimate versus the 
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Each point represents the association reported by sex/menopausal groups accordingly to figure 5. The 




3.4 Discussion  
There were contrasting findings in the association between ferritin and MetS or its 
components in cross-sectional analyses of two Scottish populations and the meta-
analysis/systematic review. The meta-analysis suggested a positive overall 
association between ferritin and MetS but I found that the association was not 
independent of covariates in the VIKING study. Similarly, there was little or no 
evidence of association between ferritin and selected MetS components in the SHeS 
analysis after adjustment for covariates. The meta-regression for the ferritin-MetS 
association also identified weaker associations when the studies adjusted for BMI 
and hepatic function, as in the VIKING study and SHeS. Moreover, subgroup and 
meta-regression analyses also showed that in studies with higher cut-off points 
defining upper categories of ferritin levels, the association with MetS tended to be 
stronger. The association between ferritin and high triglycerides or blood pressure 
was markedly stronger in studies with higher cut-off points for high ferritin. In fact, 
cut-off points to define high ferritin in the VIKING study and SHeS were among the 
lowest ones reported. With regard to the overall association between ferritin and 
MetS components, stronger positive associations were observed with triglycerides 
and fasting glucose in comparison with other components.  
 
Ferritin and MetS: Comparison with previous systematic review/meta-
analyses 
In the present meta-analysis, we describe a similar pooled overall positive OR for 
ferritin and MetS to that recently reported by Abril-Ulloa et al. (18), [(1.76 (95% CI: 
1.57–1.97) vs. 1.73 (1.54–1.95) respectively]. However, the present meta-analysis 
had several differences from the previous one. First, the inclusion criteria of the 
present systematic review/meta-analysis required adjustment for at least age and sex. 
Second, there were four additional prospective studies (22, 105, 113, 145) and six 
additional cross-sectional studies (25, 136, 143-146). Third, I explored adjustment 
for BMI and hepatic function markers and threshold effects of ferritin values across 
study populations as sources of influence on the overall ferritin-MetS association. 
Lastly, associations between ferritin and individual MetS components were also 




The work of Abril-Ulloa et al. was followed by another meta-analysis on ferritin and 
MetS in late 2015, with only eight studies selected between 2006 and 2014 and with 
no sub-group analysis and narrative synthesis (147). The authors reported a pooled 
OR (95% CI) of 1.20(0.69–1.71) for the association. The low statistical power in this 
study may have influenced the lack of a statistically significant association. I was 
unable to identify relevant differences in the inclusion/exclusion criteria to explain 
the low number of studies selected in comparison to the study of Abril-Ulloa et al. 
and the present meta-analysis.  
 
Factors influencing the ferritin-MetS association 
Neither Abril-Ulloa et al. (18) nor I found that study design, kind of effect estimate, 
geographic area, and study size influenced the ferritin-MetS association. The trend 
identified but not discussed by Abril-Ulloa et al. of a stronger association in studies 
which used immunoradiometric assays for ferritin measurement than in those which 
used other assays (P = 0.091) (18), was statistically significant (P = 0.044) in the 
present meta-analysis. In contrast to the study of Abril-Ulloa et al. (18), in this 
updated meta-analysis, adjustment for CRP levels was not identified as a source of 
heterogeneity for the ferritin-MetS association. A possible explanation is that Abril-
Ulloa et al. (18) included some articles reporting unadjusted associations (23, 148, 
149). I found that adjusting for CRP strengthened the pooled association with 
triglycerides, similar to the effect observed by Abril-Ulloa et al. for the ferritin-MetS 
association which was unexpected. CRP levels are considered a confounder since 
inflammation increases ferritin levels because ferritin is also a phase-acute reactant 
(9), and cardiometabolic risk has been widely associated with inflammatory response 
(72). One would expect effect estimates for ferritin-MetS or ferritin-triglycerides 
association to be attenuated in CRP-adjusted models rather than the pattern observed. 
 
There were no differences in average ferritin levels or cut-off values for high ferritin 
by category of laboratory assay (data not shown). Therefore, the influence of the 
assay in the heterogeneity of ferritin-MetS association cannot be attributed to the 
threshold effect of the values of ferritin measurement. Since the meta-analysis by 
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Abril-Ulloa et al. also described a similar finding (18), possible explanations should 
be considered. However, there are no major differences in the accuracy of the current 
methods for measuring serum ferritin to explain the heterogeneity observed. The 
heterogeneity of the ferritin-MetS association by ferritin assay could also be a chance 
finding.  
 
Adjusting for BMI and hepatic function markers (mostly transaminases) attenuated 
the pooled ferritin-MetS association across the studies evaluated. BMI is a well-
known anthropometric predictor of CMD (150) and is positively correlated with iron 
stores (74). Obesity, estimated as high BMI, is also associated with both iron 
deficiency and increased ferritin. It appears that adipocytokines stimulate synthesis 
and secretion of the hormone hepcidin which inhibits intestinal iron absorption and 
release by tissues, causing iron deficiency (75). Similarly, low-grade inflammation in 
obesity can lead to increasing ferritin levels even in the context of iron deficiency 
(75). Iron excess in obesity could be explained by mechanisms of IR affecting iron 
homeostasis (151, 152). Thus, adjusting for BMI allows investigation of whether any 
ferritin-MetS association exists independently of obesity. More than half of the 
studies included did not adjust for BMI, and their authors did not give a rationale for 
not using BMI as covariate. Meanwhile, because ferritin is mostly produced in the 
liver, damage to hepatic cells positively influences circulating ferritin levels because 
it gets released into the bloodstream (73). In addition, pathological hepatic iron 
excess, such as in HH, can lead to liver injury and concomitant increased levels of 
transaminases (153). Similarly, hepatic function markers have been associated with 
cardiovascular risk factors (71) and CMD (154). In future research, the role of 
adjustment for BMI, hepatic function markers for evaluating confounding, effect 
modification, and potential underlying mechanisms should be considered.  
 
Ferritin and MetS components  
Stronger associations were observed between ferritin and high triglycerides or high 
fasting glucose than with other components of the MetS. There is growing 
experimental evidence that metabolism of glucose and of iron are interrelated and in 
a bidirectional way (9, 11). For instance, in murine models, starvation-induced 
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gluconeogenesis promoted iron hepatic deposition, and high hepatic stores of iron 
caused hyperinsulinemia by decreasing insulin extraction or affecting insulin 
signalling (9). This latter effect of iron could promote dyslipidaemia owing to high 
triglycerides. The association between ferritin and triglycerides could also be two-
way based on findings in animals, where high-fat diets stimulated intrahepatic 
deposition of iron (9). In light of the above, high levels of glucose and triglycerides 
appear to be the components that make the largest contribution to a positive 
association between ferritin and MetS. The finding that the association between 
ferritin and MetS remained significant after adjustment for IR (HOMA-IR) in the 
four studies that included this adjustment is interesting. In two of these studies that 
showed unadjusted and adjusted associations, a marked attenuation of the association 
was observed only in one (OR (95%CI) 3.45 (3.03–3.92) to 1.99 (1.70–2.33)) (133). 
The above points imply that association between ferritin and MetS is not entirely 
explained by the associations with hyperinsulinemia and that there are alternative and 
still unknown, underlying mechanisms.  
  
The subgroup analysis of the association of ferritin and MetS components suggested 
the presence of heterogeneity between the studies, some of which were similar to 
those described for the ferritin-MetS association. For instance, the high blood 
pressure-ferritin association was weaker when the studies adjusted for BMI and 
hepatic function markers as was found for the association with MetS. The 
associations between ferritin and high triglyceride and high blood pressure were 
significantly influenced by the cut-off value for high ferritin reported in the studies, 
as found in the association with MetS (meta-analysis 2). On the other hand, there 
were other sources of influence specific to individual associations between ferritin 
and other MetS components. The isolated finding of stronger association between 
ferritin and low HDL-C in studies from Asia seems to be related to a meta-analysis 
of 23 studies from the Asia-Pacific region on prevalence of cardiovascular risk 
factors. This meta-analysis highlighted that prevalence of the low HDL-C phenotype 
was higher in Asian populations in comparison with populations from Australia and 
New Zealand (155). The reason behind this difference in prevalence is still not clear 
but iron status could be related to a complex interaction of nutritional and genetic 
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factors that affect the phenotype (155). Meanwhile, studies with greater risk of bias 
can overestimate specific associations between ferritin and increased WC, 
triglycerides, and blood pressure on the basis of low representativeness and/or non-
adjustment for BMI. It is unclear why these factors were not similarly found as 
sources of influence in the ferritin-MetS association. The above finding suggests that 
each component of MetS may have specific patterns of association with ferritin 
regardless of the pattern with the risk cluster.  
 
Interpretation of findings from the Scottish studies in the context of key 
findings from the meta-analysis 
There were no independent associations between ferritin and MetS or its components 
or between ferritin and IR in the VIKING study. In the SHeS, there were only 
associations between increasing ferritin and low HDL-C in postmenopausal women 
and with high WC in men. Although the meta-analysis identified a pooled positive 
significant association between ferritin and MetS, our negative findings in the 
Scottish studies are similar to those of several studies included in the meta-analysis. 
Zelberg et al. did not find a significant association in an Israeli population, Kilani et 
al., in men or premenopausal women. Interestingly, along with the latter study, the 
studies by Jehn et al., Kim et al., Lee et al., and Shi et al. failed to find an 
independent association in men, a demographic subgroup with higher iron status. 
There were no consistent associations by sex or menopausal status, with some studies 
reporting associations in women but not in men and others reporting the reverse.  
 
The non-significant associations in the Scottish studies could be explained if there is 
a threshold effect of ferritin concentrations on the association with MetS. and more 
consistently with high triglycerides and blood pressure. The findings of the meta-
regression showed a strengthening of the ferritin-MetS association when higher cut-
off points were used to define the highest ferritin levels. This apparent threshold 
effect was also seen for the pooled associations of serum ferritin with high 
triglycerides and blood pressure. The Scottish studies were located in the lowest 
sex/menopausal-specific tertiles and quartiles for those ferritin cut-off points, so it is 
possible that ferritin levels were too low to trigger a significant independent 
association with MetS or several of its components. Excluding people with anaemia 
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or iron deficiency from the Scottish population did not affect the finding that ferritin 
levels were lower than those in other studies. 
 
Another reason for the general lack of independent associations in the Scottish 
studies could be, at least partially, related to high prevalence of confounding factors. 
BMI values affected the associations found in men and postmenopausal women in 
the VIKING study and SHeS. More than half of the individuals in both Scottish 
studies were overweight or obese, with the prevalence of overweight and obesity 
being 70% and 24%, respectively, in the VIKING study. Moreover, Scotland has the 
second highest prevalence of obesity among the members of the Organisation for 
Economic Co-operation and Development after the United States of America (156), 
reaching figures of 22% and 24% of Scottish men and women, respectively, in 2003 
(156), in line with the 24% obesity prevalence in the VIKING study (2013–2015). 
The association between ferritin levels and cardiometabolic risk markers could differ 
between populations of different countries owing to genetic and/or ethnic differences 
influencing the amount of body iron and interaction with other dietary and non-
dietary factors. Given this complex matrix of influences, differences in distribution 
of confounding factors and the strength of the associations of these with iron and 
outcome variables are likely to exist. 
 
Inverse associations in SHeS and VIKING 
Ferritin levels and high blood pressure showed a U-shaped trend in their association 
among premenopausal women from the SHeS. This finding might be plausible since 
both low and high iron status may be related to cardiometabolic risk, although 
potential theoretical mechanisms for iron deficiency are still unclear. I did not find 
studies reporting a similar association, but iron deficient compared to non-deficient 
subjects have shown higher pulmonary blood pressure (157). In contrast, a recent 
study did not find difference in the prevalence of pulmonary hypertension by low and 
normal iron status in African-American individuals (158). The ferritin-high blood 
pressure association in premenopausal women could be due to chance, since there 
were no other inverse or U-shaped associations between ferritin and other MetS 




The association between ferritin and HbA1C was the only cardiometabolic risk 
outcome independently associated with ferritin in the VIKING study. However, this 
relationship was unexpectedly inverse and taking into account the absence of 
association between ferritin and other cardiometabolic risk markers, this could also 
be a chance finding. In addition, the inverse association might be spurious in terms of 
increased HbA1c in individuals with iron deficiency due to an increase in the 
erythrocyte lifespan. This spurious increase in HbA1c with iron deficiency is not 
accompanied by concomitant rise in glucose indices (111), which is coherent with 
the pattern found in the VIKING study.  
 
Strengths and limitations 
To the best of my knowledge, this study appears to be first meta-analysis on ferritin, 
MetS, and its individual components. This analysis has also described for first time 
the association between ferritin and MetS in Scottish or British populations. In 
addition, the investigation of the influence of adjustments for body mass and hepatic 
function and of threshold effects of ferritin on the ferritin-MetS association across 
the studies represents another novel contribution. On the other hand, some findings 
from the subgroup and meta-regression analysis were not consistent throughout the 
sensitivity analysis. This implies limitations in statistical power or chance findings 
arising from multiple testing. Given the different assumptions in the calculation of 
effect estimates from prospective and cross-sectional studies, analysing them 
together might not be appropriate, although no heterogeneity by effect estimate or 
study design was detected in the subgroup meta-regression analysis. However, this 
potential limitation was balanced by conducting an additional meta-analysis specific 
to cross-sectional studies with all the studies reporting associations as ORs.  
 
In conclusion, the meta-analysis suggests a significant overall positive association 
between ferritin and MetS but this association was not observed after adjustment for 
a variety of factors in the two Scottish populations described in the present chapter. 
Hepatic function, BMI, and type of ferritin assay appear to influence the ferritin-
MetS association. Threshold effects of high ferritin concentration on the associations 
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with MetS, high triglycerides and blood pressure, and different distributions of 
confounding factors may explain the lack of independent association between ferritin 
and MetS or its components in the Scottish studies. High triglycerides and glucose 
are the MetS components most strongly associated with ferritin levels and could 
explain most of the association with the risk cluster known as MetS. The next chapter 
describes the association between sTfR levels and MetS or insulin resistance in 









































Chapter 4  
Soluble transferrin receptor levels and its 
association with metabolic syndrome and 
insulin resistance in Croatian adults  
 
4.1 Introduction 
There are other important proteins in iron metabolism in addition to ferritin, such as 
transferrin and TfR (159, 160). TfRs are of particular interest to researchers since 
they act as a sensor for body iron demands. Iron transport in the plasma is carried out 
by transferrin, which donates iron to the cells through its interaction with a specific 
membrane receptor, the TfR. A soluble form of the TfR has been identified in human 
serum. Soluble TfR (sTfR) is a truncated monomer of the tissue receptor, lacking its 
first 100 amino acids, which circulates in the form of a complex of transferrin and its 
receptor. The higher the body iron stores, the lower the TfR levels in cell membranes 
which in turn down-regulates intestinal iron absorption (161). Increased levels (> 5 
and 4.4 mg/L in men and women respectively) of TfRs in cell membranes reflect 
body iron deprivation, and intestinal iron absorption is up-regulated as a 
compensatory mechanism. Levels of sTfR are proportional to tissue concentrations 
(162). sTfR and ferritin levels are influenced by the acute phase response of 
inflammation, so their measurement should include additional measurements of 
inflammatory markers (163).  
 
The association between sTfR and cardiometabolic risk factors has not been widely 
investigated. A recent meta-analysis of eight studies reported conflicting results for 
the association between sTfR and T2D and described the limited power of the 
included studies owing to small sample sizes (19). Only one study described the 
association between sTfR and MetS (135) but did not adjust for BMI, few studies 
have evaluated the association between sTfR and some MetS components (164, 165), 
and concomitant examination of the association between sTfR and IR has not been 
conducted. Most of these studies reported no evidence of an association between 
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sTfR and MetS and very few reported associations with MetS components. The 
primary aim of this thesis chapter was to investigate whether sTfR levels were 
associated with MetS, its components, IR, and HbA1C in a relatively large and well-
characterised population. The secondary aim was to describe the association between 
ferritin and the outcomes mentioned above.  
 
4.2 Material and Methods 
4.2.1 Participants 
The participants were identified from the 10,001 Dalmatians research programme, 
namely the sub-cohort recruited from the island of Vis in Croatia. A total of 1,029 
subjects were initially recruited, aged 18–93 years, from the villages of Vis and 
Komiza during 2003 and 2004 within a larger genetic epidemiology study (166-168). 
In the original study, the only eligibility criterion was age of 18 years or above. sTfR 
and ferritin levels were measured in 774 subjects, of whom 49 subjects with missing 
values for covariates (age, fibrinogen, glycosylated haemoglobin, smoking and 
alcohol consumption, BMI, and history of CMD) were excluded, resulting in a study 
population of 725 people. Distribution of exposure, adjustment variables, and 
outcomes were similar among those with and without missing data with the 
exception of fibrinogen levels, which were higher in those with complete data. 
Ethical approval was issued by the Multi-centre Research Ethics Committee for 
Scotland (MREC) under designation MREC 01/0/71, and all participants gave 
written informed consent. 
 
4.2.2 Clinical and anthropometric measurements 
Anthropometric measurements included height measured using a stadiometer, 
weight, and WC (measured half-way between the lowest rib and iliac crest). Blood 
pressure was measured in a seated position, after at least five minutes of rest. Two 
measurements were made, and only the second one was recorded, in order to reduce 
the “white coat” effect. Menopausal status was confirmed on the basis of self-report 
with pre-menopausal status defined as continuing menstruation and post-menopausal 
status, absence of menstruation. Physical activities at work and at leisure were self-




4.2.3 Biochemical measurements 
Blood samples were taken after overnight fasting. Classical biochemical analyses of 
the blood sample included the following: triglycerides, using UV photometry with 
glycerolphosphate-oxidase (GPO PAP) (Olympus kit OSR60118); HDL cholesterol, 
using homogeneous enzyme method with modified polyethylene glycol and 
cyclohexane-sulphate (Olympus kit OSR6195); glucose, using UV hexokinase 
photometry; and HbA1C (whole-blood sample), using cation exchange, 
immunochemistry electrophoresis, and affinity linking, compatible with the 
DCCT/UK PDS standard. The measurements of HbA1C and glucose were performed 
using Olympus kit OSR6192, OSR6121, and OSR6221. Manufacturer’s reagents 
were used with their internal quality control (ODC003 or ODC004 for glucose and 
ODC022 for HbA1C). Fibrinogen was measured by the Clauss method using an 
MDA 180 coagulometer (Biomerieux, Marcy l’Etoile, France) with reagents from 
the manufacturer. The calibrant used was the 8th British Standard (NIBSC). 
Electrochemiluminescence immunoassay (Roche) was used to measure ferritin and 
Tina-quant® immunoturbidimetry (Roche), to measure sTfR. The laboratory was 
ISO accredited and daily internal controls were performed (calibrator 66300). 
Repeated measurements of the sub-set of samples provided very high agreement 
(kappa 0.92 for the lowest pair of estimates). The coefficient of variation was less 
than 5% for each biochemical measurement. The biochemical assays were conducted 
by using an OLYMPUS AU400 chemistry immunoanalyzer. IR was estimated by the 
homoeostatic model of assessment using the following formula: glucose levels 
[mmol/L] × insulin mU/L/22.5 (59).  
 
4.2.4 Metabolic syndrome 
The following cut-off points from the international consensus definition for MetS 
were used (40): triglycerides ≥1.7 mmol/L, HDL-C <1.0 mmol/L in men and <1.3 in 
women, glucose ≥5.6 mmol/L (or drug treatment for elevated glucose), SBP ≥130 
mm/Hg and/or DBP ≥85 mm/Hg (or antihypertensive drug treatment), and WC ≥94 
cm in men and ≥80 cm in women. Information on lipid-lowering medications was 
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not available to complement the component of high triglycerides. MetS was defined 
as the presence of three or more variables meeting the definitions above.  
 
4.2.5 Data analysis 
The analyses were stratified by sex/menopausal status and by adjusting for 
sex/menopausal status in analyses of the whole cohort. All continuous study 
variables were summarised as median (interquartile ranges) by sex/menopausal status 
and differences were tested using the Mann-Whitney U test. Logistic regression 
models were used to describe the associations between sTfR and ferritin as exposure 
variables, with MetS and its components as outcome variables. sTfR and ferritin 
were used as continuous variables in terms of standard deviation units of their log-
transformed levels (Z scores or standardised values) to facilitate interpretation of 
ORs. ORs of each outcome are therefore described for each standard deviation in 
log-transformed iron marker. Unlike the analyses in chapter 3, in this analysis the 
iron markers were not additionally treated as categorical variables of quantiles 
because the pre-menopausal women group was small and there were small numbers 
by categories of ferritin in preliminary explorations of the dataset, e.g. there were no 
cases of high triglycerides in the highest tertile of ferritin. Multivariable models with 
age, levels of fibrinogen, smoking (never smoker, ex-smoker, and current smoker), 
alcohol consumption (no/yes), and BMI as covariates were used to investigate 
whether the associations were independent of these potential confounding factors. 
This set of confounding factors was chosen on the basis of possible influence of 
acute phase or subclinical inflammation in terms of fibrinogen levels (169, 170) and 
general adiposity on levels of iron markers and/or outcome variables. Relationships 
between measures of iron status and IR and HbA1C were described using multiple 
linear regression analyses adjusting for potential confounders as listed above with 
additional adjustment for treatment with insulin and/or hypoglycaemic drugs 
(yes/no). The normality of distributions was assessed using histograms and 
Kolmogorov-Smirnov tests. For the linear regressions, transformed values of skewed 
variables were used as follows: logarithm of sTfR, ferritin, HOMA-IR values, BMI 
and fibrinogen values, square of age, and square root of glycosylated haemoglobin. 
The above set of arithmetic functions allowed the best approximation to the normal 
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distribution for each variable. Self-reported CVD (heart attack, stroke) and diabetes 
and self-reported physical activities at work and at leisure (sitting [reference], light, 
moderate, and hard) were additionally used as covariates in sensitivity analyses. In 
order to avoid collinearity, treatment with insulin and/or hypoglycaemic drugs 
(yes/no) was not considered in the multivariable model when diabetes was used as 
covariate. As in Chapter 3, I conducted sensitivity analyses on the basis of exclusion 
of individuals with anaemia, very high ferritin (>300 µg/L), and potential 
inflammation/infection (fibrinogen > 4.7 g/L). A P value <0.05 was considered 
statistically significant. Data were analysed using Stata version 11.0 (StataCorp). 
4.3 Results 
There were modest differences between the included and excluded subjects.. The 
group of excluded individuals had a higher proportion of men and lower fibrinogen 
concentrations than the people that were included (Appendix Table 23). 
  
The study involved a total of 725 subjects, stratified in 3 groups by sex/menopausal 
status (Table 12). Men had higher values of ferritin than women, while 
postmenopausal women had higher values of ferritin than premenopausal women. 
Postmenopausal women had significantly higher levels of sTfR than men, while the 
comparison with pre-menopausal women yielded insignificant results (Table 12). 
HOMA-IR was higher among men and postmenopausal women than among pre-
menopausal women with a similar pattern observed for MetS components. 
Prevalence of high WC was above 60% in all groups (Table 12) and prevalence of 
MetS was above 50% in postmenopausal women and men. Prevalence of MetS was 
higher among post-menopausal women than men and pre-menopausal women (Table 
12). There was an inverse correlation between sTfR and ferritin levels (log-
transformed values of both markers) (r = -0.396, P < 0.001).  
 
sTfR levels (median and interquartile range) were similar for people with and 
without MetS in each sex and menopausal status group: 




Postmenopausal women MetS 3.09(2.62-3.65) v. No MetS 3.17(2.73-3.91) µg/L, 
P=0.825;  
Men MetS 2.99(2.56-3.76) v. No MetS 3.09(2.62-3.65) µg/L, P= 0.828. 
 
Ferritin levels (median and interquartile range) were higher in subjects with MetS in 
postmenopausal women and men:  
Premenopausal women MetS 31.6(9.9-59.7) v. No MetS 24.2(13.7-40) µg/L,  
P= 0.319; 
Postmenopausal women MetS 69.5(42-106.1) v. No MetS 38.2(25.4-73.2) µg/L, 
P=0.002;  
Men MetS 176.7(108.3-305.3) µg/L v. No MetS 121(73-178.5) µg/L, P<0.001. 
 
There was no statistically significant association between standardised values of 
sTfR and MetS (Table 13) and its components (Appendix Table 24) in any of the 
sex/menopausal status groups or in the whole sample (Appendix Table 25). Since the 
high prevalence of MetS and some components could limit the power of the study to 
detect an association with sTfR, I additionally conducted linear regression analysis 
between log-sTfR and log-transformed values of WC, HDL-C, glucose, triglycerides, 
SBP, and DBP. The adjusted linear regressions did not show significant relationships 
(Appendix Table 26). Further adjustment for treatment with insulin and/or 
hypoglycaemic drugs in associations with glucose, and for anti-hypertensive 














Men P values 









n 151 290 284    
Age (years) 40 (33-47) 67(57-74) 57 (46-68.7) < 0.001 < 0.001 < 0.001 
BMI (kg/m2) 26.6(21.6-27) 28.3(25.4-30.9) 27.6(25.2-29.6) < 0.001 < 0.001 0.013 
Ferritin (µg/L) 25.5(12-45.9) 65.9 (38.6-102.2) 141.3 (90.5-233.7) < 0.001 < 0.001 < 0.001 
sTfR (mg/L) 3.19(2.63-4.05) 3.17 (2.73-3.90) 3.07 (2.62-3.68) 0.758 0.069 0.038 
Glucose (mmol/L) 5.0(4.6-5.4) 5.6(5.0-6.2) 5.5(5.0-6.1) < 0.001 < 0.001 0.504 
TG (mmol/L) 1.2(0.9-1.5) 1.5(1.1-2.0) 1.5(1.1-2.3) < 0.001 < 0.001 0.542 
HDL-C (mmol/L) 1.16(1.09-1.25) 1.14(0.98-1.23) 1.13(0.96-1.22) 0.011 0.001 0.410 
SBP (mmHg) 118(108-128) 145(130-161) 138(123-150) < 0.001 < 0.001 < 0.001 
DBP (mmHg) 75(68-80) 81(75-89) 81(75-89) < 0.001 < 0.001 0.820 
WC (cm) 83(76.9-91.5) 99.2(91.7-105.4) 98.3(92-105.1) < 0.001 < 0.001 0.403 
Insulin mU/L 5.0(4.0-8.0) 7.0(5.0-11) 6.0(4.0-9.0) < 0.001 < 0.001 0.147 
HOMA-IR 1.17(0.78-1.89) 1.69(1.06-2.93) 1.58(1.01-2.60) < 0.001 < 0.001 0.141 
HbA1C (%) 5.1(4.9-5.4) 5.5(5.2-5.7) 5.2(5.0-5.6) < 0.001 < 0.001 < 0.001 
Fibrinogen (g/L) 3.5(2.9-4.0) 3.9(3.4-4.5) 3.5(2.9-4.1) < 0.001 0.714 < 0.001 
MetS and its components n(%)      
High blood pressure¶ 43(28.3) 237(81.7) 198(69.7) < 0.001 < 0.001 0.001 
High glucose † 27(17.8) 148(51.0) 131(46.1) < 0.001 < 0.001 0.208 
Low HDL-C 137(90.7) 277(95.5) 82(28.9) 0.040 <0.001 <0.001 
High triglycerides 25 (16.6) 118(40.7) 117(41.2) < 0.001 < 0.001 0.902 
High WC 94 (62.3) 278(95.9) 191(67.3) < 0.001 0.296 < 0.001 
MetS 51(33.8) 257(88.6) 144(50.7) < 0.001  0.001 <0.001 
Smoking n (%)       
Yes 64(42.4) 47(16.2) 85(29.9)    
No 58(38.4) 184(63.4) 73(25.7)    
Ex-smoker 29(19.2) 59(20.3) 126(44.4) < 0.001 < 0.001 < 0.001 
Alcohol consumption n (%) 79(52.3) 108(37.2) 230(81) 0.002 < 0.001 < 0.001 
Cardiovascular disease n (%) 12(7.9) 150(51.7) 102(35.9) < 0.001 < 0.001 < 0.001 
Diabetes n (%) 3(2.0) 27(9.3) 20(7.0) 0.002 0.017 0.201 
Data are median (interquartile range) or n (%). Comparison between groups by Mann-Whitney U and 2 test. BMI, body mass index. sTfR, soluble transferrin receptor. 
TG, triglycerides. SBP, systolic blood pressure. DBP, diastolic blood pressure. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic syndrome. HOMA-
IR, homeostatic model assessment insulin resistance. † Includes additionally individuals who reported current use of oral hypoglycemic medications or insulin regardless 




Table 13 Odds ratios (95% CI) for metabolic syndrome per sex/menopausal-specific SD of the iron 
markers in the study subjects categorised by sex and menopausal status 
 Z score log-sTfR  Z score log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
Premenopausal women 
MetS 1.32 (0.90-1.92) 1.35 (0.90-2.02) 1.13 (0.80-1.59) 1.35 (0.90-2.02) 
Postmenopausal women 
MetS 0.99 (0.69-1.43) 0.73 (0.47-1.15) 1.65 (1.17-2.31) 1.71 (1.12-2.62) 
Men     
MetS 1.05 (0.83-1.33) 0.87 (0.66-1.17) 1.90 (1.44-2.50) 1.78 (1.31-2.42) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes) and 
BMI. TG, triglycerides. BP, blood pressure.. WC, waist circumference. HDL-C, HDL 
cholesterol. MetS, metabolic syndrome. Significant associations are show in bold (P<0.05). 
 
Standardised values of ferritin were significantly associated with MetS in men and 
postmenopausal women (Table 13). Ferritin was also significantly associated with 
higher odds of having MetS components (except high blood pressure) in men, in 
unadjusted models and models adjusted for age, fibrinogen levels, alcohol intake, 
and smoking (Appendix Table 24). In the whole sample, the adjusted associations 
found for ferritin and MetS and its components were similar to those reported in men 
(Appendix Table 25).  
 
In a separate analysis for women adjusting for menopausal status, sTfR was not 
associated with MetS or its components, and ferritin was independently associated 
with high triglycerides and MetS (Appendix Table 27).  
 
sTfR levels were positively associated with IR in postmenopausal women and men: 
postmenopausal women (Beta = 0.34 [0.05 to 0.63], P = 0.020) and men (Beta = 0.44 
[0.14 to 0.75], P = 0.004) (Appendix Table 28). In the whole sample, sTfR levels 
were associated with IR (P < 0.05), but no association was observed for ferritin in 
similar analyses (Appendix Table 28). The relationship between sTfR and HOMA-IR 
was driven by the relationship between sTfR and insulin levels, which was similarly 
significant (Appendix Table 28), whereas adjusted association with glucose levels 




In the unadjusted analysis, HbA1C, a marker of longer-term glucose metabolism, 
was significantly associated with sTfR in men and with ferritin in the whole sample, 
but after adjustments, there were no significant independent associations (Appendix 
Table 29).  
 
I additionally used diabetes, cardiovascular disease and categories of physical 
activity as covariates in the adjustment models, but the estimates of the associations 
described above between the iron markers, MetS, IR, and HbA1C and the statistical 
significance did not change substantially. 
 
In sensitivity analyses, the exclusion of subjects with very high ferritin (n=65) 
attenuated all of the significant associations previously described, presumably partly 
due to the lower sample size (ORs decreased and P>0.05), with exception of the 
ferritin-MetS association in postmenopausal women, whose OR and 95%CI 
remained similar [adjusted OR (95%CI) 1.64(1.05-2.54), P=0.027]. However, the 
statistical significance of this association was attenuated after removal of individuals 
with iron deficiency (n=66) [adjusted OR (95%CI) 1.71(0.93-3.14), P=0.080], as 
well as the ferritin-high WC association described in men [adjusted OR (95%CI) 
1.43(0.91-2.24), P=0.115]. Exclusion of subjects with potential inflammation and/or 
infection (high fibrinogen levels) (n=99) attenuated the ferritin-high glucose and 
ferritin-high WC associations in men. On the other hand, the previous non-significant 
association between serum ferritin and high triglycerides in postmenopausal women 
reached statistical significance [adjusted OR (95%CI) 1.37(1.02-1.85) P=0.035]. No 
other substantial modifications were observed in sensitivity analyses for significant 
or non-significant association described in the original sample. 
 
4.4 Discussion 
In this study of a population with high prevalence of MetS, sTfR levels were 
associated with IR but not with MetS. Conversely, serum ferritin was statistically 
significantly associated with MetS. These findings suggest that different iron-related 




The lack of association between sTfR levels and MetS is consistent with findings in 
studies of different sizes ranging from 155 to 1,969 subjects (Table 14). A Finnish 
study involving middle-aged subjects from the general population also found no 
significant association when controlling for confounding factors (Table 14) (135). In 
the same study, levels of sTfR levels were significantly higher in individuals with 
high WC (compared to normal WC) in adjusted analyses (135). A small study 
reported lower levels of sTfR in subjects with MetS in a sex-stratified analysis, but 
no additional adjustments were conducted (149) (Table 14). A significant positive 
age-sex-adjusted correlation of sTfR with WC but no evidence of a relationship with 
HDL-C and triglyceride levels in participants from the EPIC-Postdam study has also 
been reported (164) (Table 14). DBP and triglycerides increased across quartiles of 
sTfR but no association was found with WC, LDL-C, HDL-C, SBP, and fasting 
glucose levels in 1,262 women after adjustment for covariates (165) (Table 14). 
Different adjustments, statistical approaches, and discrepancies in methods 
measuring sTfR concentrations could contribute to the heterogeneity of results from 
different studies. Various commercial sTfR assays give disparate values because of 
the lack of an international standard. For instance, Hamalainen et al. reported similar 
sTfR levels (mean 2.9 mg/L) and prevalence of MetS (48% in men and 52% in 
women) to those we reported (135). Very high sTfR levels (mean 9.09 mg/L) with 
lower prevalence of some MetS components (high WC, 31%, low HDL, 43%) were 
reported by Aderibigbe et al. (165). Meanwhile, Montonen et al. reported lower 
median sTfR levels across ferritin quintiles between 1.0 and 1.9 mg/L (164). In 
addition, it is important to note that the above studies included diverse populations in 
Europe and South Africa which may have influenced the association patterns, sTfR 
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NP, Not provided. sTfR, soluble transferrin receptor. WC, waist circumference. LDL-C, LDL cholesterol.  HDL-C, HDL cholesterol. TG, triglycerides. DBP, diastolic blood 
pressure. SBP, systolic blood pressure. FG, fasting glucose. * Studies found in PUBMED and EMBASE by applying the searching “metabolic syndrome OR blood pressure OR 
fasting glucose OR waist circumference OR triglycerides OR HDL cholesterol” AND “transferrin receptor” (until July/2015). [Only studies in adults were included and in vitro 




The finding of a positive association between sTfR and IR in postmenopausal 
women and men in this chapter is consistent with the unadjusted findings of 
Fernandez-Real et al. (171) and Huth et al. (172). Fernandez-Real et al. described an 
inverse association between sTfR levels and insulin sensitivity estimated by minimal 
modelling in 221 Spanish individuals (97 non-obese with normal glucose tolerance, 
36 with impaired glucose tolerance, and 88 with T2D) (171). There was no evidence 
of association between sTfR and fasting glucose or insulin but positive correlation 
between sTfR with values of glucose and insulin during an oral glucose tolerance test 
was reported (171). I reported similar findings to Huth et al. who found that sTfR 
levels were significantly and positively correlated to HOMA-IR in 2,893 participants 
of the population-based Cooperative Health Research in the Region of Augsburg 
(KORA) F4 study (Germany) (172). In contrast, Arija et al. did not find significant 
correlation between sTfR and HOMA-IR, adjusting for sex, age, and BMI in Spanish 
non-diabetic individuals (n = 302), as observed in group of non-diabetic subjects 
who later developed diabetes (n = 153) (173). The relationship between sTfR and 
glucose metabolism might be easier to identify in the postprandial than in fasting 
state since Fernandez-Real reported a correlation with glucose concentrations after 
an oral glucose test tolerance test (171). In addition, an insulin-sensitising 
intervention of dietary change combined with exercise was associated with a 
decrease in sTfR levels in obese individuals (171). I found that additional adjustment 
for physical activity did not substantially affect the non-significant associations of 
sTfR with MetS and its components, but the measurement of physical activity is 
imperfect. In terms of genetic factors, a significant association between presence of 
transferrin receptor-1 gene (TRFC) polymorphisms (rs3817672, 210AG, S142G) and 
T2D has been described (174). In addition, individuals with 210A--G polymorphism 
showed higher sTfR levels, which correlated positively with glucose levels whereas 
in non-carriers, there was no relationship between those markers (174). These 
associations with polymorphisms were not confirmed in genetic consortia databases 
(175). However, other studies found other SNPs linked to both T2D and sTfRs. For 
instance, significant associations have been observed for loci in TPMRSS6 with sTfR 
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(P   = 3.47 × 10-6) and T2D risk (176). These findings imply that a common third 
factor influences both circulating sTfR levels and diabetes susceptibility. 
 
Although the finding of a positive association between sTfR and IR suggests that low 
iron status, in terms of high sTfR, is associated with cardiometabolic risk, this is not 
consistent with the absence of a concomitant association with MetS or its 
components in this cross-sectional study. A potential explanation is the effect of 
insulin on sTfR levels. Insulin upregulates erythropoiesis (177), of which sTfR is a 
surrogate. sTfR represents a valuable quantitative assay of marrow erythropoietic 
activity as well as a marker of tissue iron deficiency (178). Marrow erythropoietic 
activity appears to be the most important determinant of sTfR levels, causing 
variations up to 8 times below and up to 20 times above average normal values 
(178). The erythroblasts rather than reticulocytes are the main source of serum sTfR, 
whose levels decrease when erythropoietic activity is low and increase in situations 
of haemolysis or ineffective erythropoiesis (178). As insulin has been described to 
upregulate erythropoiesis (177), bone marrow could still be sensitive to insulin in 
hyperinsulinemia despite peripheral IR in the liver or muscle (the classical insulin 
sensitive tissues). If this is the case, sTfR might appear to be spuriously elevated and 
would not reflect the insulin sensitivity in other tissues. In addition, up-regulation in 
the expression of TfRs by insulin via a hypoxia inducible factor, as observed in 
human hepatic cells (HepG2) (179), is an alternative explanation.  
 
There were differences by sex and menopausal status in the relationship of ferritin 
with MetS and its components since significant associations were found in men and 
postmenopausal women, but not in premenopausal women in our study. 
Theoretically, in men and postmenopausal women, the relationship between ferritin 
and cardiometabolic risk might be more obvious owing to higher iron accumulation 
than in women who lose iron during menstruation. However, as observed and 
discussed in the meta-analysis in chapter 3, there were studies reporting significant 
association between ferritin and MetS in pre-menopausal women but not in men. 
Similarly, the ferritin-MetS association may not be related to the potential threshold 
effect of ferritin concentration mentioned in the previous chapter, since high ferritin 
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concentration (the cut-point at 75th percentile) in men and postmenopausal women of 
Croatia-Vis study fit in the middle range of cut-points reported for increased ferritin 
of the studies reported. In addition, since effect estimates (unadjusted and adjusted) 
for the non-statistically significant ferritin-MetS association in premenopausal 
women were smaller than for post-menopausal women and men, then lack of 
evidence for an association may not be due to low statistical power. It is not known 
to what extent adjustment for transaminases might have attenuated the significant 
association between ferritin and MetS described in this Croatian population as liver 
function tests were not measured in the study population. 
 
 
Neither ferritin nor sTfR was associated with HbA1c, whether or not diabetes was 
included as a covariate in the models. This finding is consistent with the lack of 
association between ferritin and HbA1C reported in the 3876 participants of 
NHANES III (1988–1994) (180). Previously, Fernandez-Real et al. (181) and 
Rajpathak et al. (182) described significant weak correlations (r = 0.14 and r = 0.12) 
between sTfR and HbA1C in 221 men and 560 overweight individuals, respectively. 
However, in the first study, the correlation was unadjusted, and the second only 
adjusted for age and sex, and it is not known if metabolic and adiposity covariates 
might have attenuated the relationships. Of note, the associations between sTfR and 
HbA1C do not appear to have been evaluated using robust multivariate analyses in 
the existing literature. Therefore, further population-based studies are needed to 
confirm the absence of association between HbA1C and markers of iron metabolism 
after multivariate adjustment in general populations. 
 
To the best of my knowledge, the present study is the first to investigate the 
association between sTfR and both MetS and IR by means of a robust multivariable 
analysis. I also extended the finding by Hamalainen et al. describing the absence of a 
significant independent relationship between STfR and MetS by performing 
additional adjustments for BMI, alcohol consumption, CVD, and diabetes. The key 
limitations of this study include of the relatively small number of pre-menopausal 
women and the inability to adjust for hepatic dysfunction since markers such as 
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transaminases were not measured in the original study. In the original project, there 
were no specific questions about the use of lipid-lowering medications, so 
associations with components of low HDL-C and high triglyceride could be 
underestimated since these components did not include individuals with prescribed 
medication, which might have affected these values. The cross-sectional design of 
the study means that it is not possible to provide evidence of a causal relationship 
between iron status and cardiometabolic risk factors. In addition, some findings may 
be due to chance.  
 
The analysis in this chapter was conceived and conducted before the analyses and 
meta-analyses on ferritin and MetS described in Chapter 3. Supplementary analyses 
of the association between ferritin and MetS were performed so that they could be 
compared with the findings on STfR. The findings on the ferritin-MetS association in 
this Croatian population could have been part of the meta-analysis in Chapter 3. 
However, the work described in this chapter was in process of submission and peer-
review for publication when Chapter 3 was being developed which meant that it was 
not eligible for inclusion in the meta-analysis. The results for the Croatian 
population, are consistent with the meta-analysis of the sub-group of studies without 
adjustment for liver injury markers. 
 
In conclusion, this study showed that sTfR levels are associated with IR but not with 
MetS, independent of age, subclinical/chronic inflammation, smoking and alcohol 
habits, glycosylated haemoglobin, and CMD, in a population with a high prevalence 
of MetS and abdominal obesity. It is possible that sTfR level is a poor marker of 
erythropoiesis or iron metabolism in subjects with IR or hyperinsulinemia, and its 
levels are spuriously elevated and thus not associated with MetS or its components. 
There is a complex relationship between markers of iron status and cardiometabolic 
risk, with inconsistent associations with different markers. The next chapter 
examines the association between ferritin and different CMDs in a prospective study 






Chapter 5  
A prospective cohort study of the relationship 
between serum ferritin and incident 
cardiometabolic diseases in Scottish adults 
5.1 Introduction 
As mentioned in the introductory chapter, increased iron stores, reflected by high 
serum ferritin levels, have been associated with the development of T2D diabetes 
(115). Reports in the association between iron stores and other CMDs for which 
diabetes is also a risk factor, such as CHD, are inconsistent (183). Few studies have 
investigated the association between iron metabolism and CEVD. To date, no 
published study has focused on simultaneous evaluation of associations between iron 
stores and all the above CMDs in the same population or in nationally representative 
samples. In addition, threshold effects of ferritin concentration on the risk for CMD 
or the shape of the relationships have not been investigated in most of the previous 
studies.  
In Scotland, despite the fact that the incidence of CHD decreased by around 30% 
between 2005 and 2014, CHD persists as a leading cause of illness and death (184). 
In the UK in 2014, Scotland had one of the highest prevalence rates of CVD (4.3%), 
along with the North of England (4.5%) (56). Prevalence of all types of diabetes has 
increased over the last decade in Scotland, from 3.2% to 5.1%, with decreasing 
mortality and stabilised incidence contributing to this pattern (185). Moreover, the 
prevalence of obesity, a well-known CMD risk factor, also increased between the 
1990s and the 2000s (186), and unhealthy diet has been found to be more common in 
Scotland than in the rest of the UK (187). However, there is no information on iron 
biomarkers as a potential novel risk factor for CMD in the Scottish population.  
The description of the relationship of serum ferritin with all types of CMDs in a 
population at high cardiovascular risk would allow a better understanding of the link 
between iron metabolism and overall cardiometabolic risk. In light of the above, I 
conducted a study to investigate the risk of diabetes, CHD, and CEVD in participants 
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in the 1995 and 1998 Scottish health surveys (SHeS), who were followed-up until 
2011, providing a wide range of serum ferritin levels. These two surveys are the only 
ones (until recently) for which consent for data linkage was interpreted as including 
the diabetes register. The most recently available linked data provided information 
on all incident outcomes to the end of 2011.  
5.2 Methods 
5.2.1 Study population 
The SHeS 1995 and 1998 included participants aged 16–74 years. The surveys 
randomly selected a nationally representative, general population sample (see The 
Scottish Health Surveys websites for more detail) (117, 118). All participants were 
interviewed for health and lifestyle behaviours, and consent for measurement of 
weight and height and collection of a blood sample was requested. The SHeS also 
has a prospective element on the basis of linkage to hospitalizations and mortality. 
This linkage is facilitated by the Information Service Division (ISD) which collects 
and updates data on deaths from the General Register Office and morbidity derived 
from hospital discharge data in Scottish Morbidity Records (SMR) and provides 
linkage to SHeS data(188). There is also a retrospective element with data - linked to 
morbidity since 1981. Around 90% of SHeS participants provided consent for data 
linkage (188). As a consequence of the wording of the consent for data linkage only 
data from the 1995 and 1998 SHeS have been linked to diabetes register data. There 
were 9,568 participants whose ferritin levels were measured and who agreed to have 
their data linked to the Scottish Morbidity Record (SMR), the Scottish Diabetes 
Register, and death records. Among these, I excluded cases of prevalent T2D, CHD, 
and CEVD at baseline (defined as interview day), subjects who had type 1 diabetes 
(T1D) at baseline or who developed T1D during the follow-up, cases with missing 
values for covariates (listed in data analysis section), and those below the set age 
limit (age ≥18 years). Appendix Figure 7 describes the selection of the analytical 
sample (n= 6497). The secondary analysis of the SHeS-linked dataset was approved 
by the Ethics Research Subgroup of the Centre for Population Health Sciences of the 





Biochemical and clinical variables 
Methods for measurement of biochemical and clinical variables are the same as 
described in chapter 3 for the cross-sectional SHeS analysis. Physical activity levels, 
an additional variable used in this analysis, were estimated as a summary of self-
reported work, walking, and sport activities in categories of intensity levels as 
inactive, light, moderate, and vigorous (189). 
 
 
5.2.2 Cardiovascular outcomes and T2D 
Incident CHD and CEVD were defined as any relevant code ICD-10(190) (I20-I25, 
I60-I67, G45) or ICD-9(191) (410-414, 430-437) for fatal and non-fatal episodes of 
these diseases recorded in hospital admissions during the follow-up period. Incident 
cases of T2D were taken from relevant codes ICD-10 and ICD-9 (E11-E14, 250) 
recorded during hospital admission during the study follow-up and from the linked 
data of the Scottish Diabetes Register which has been complete since 2004. Codes 
for unspecified diabetes were included as incident T2D assuming that most of these 
cases accounted for this type of diabetes.  
 
5.2.3 Data analysis 
Medians and their interquartile ranges and proportions were used for description of 
continuous and categorical study variables, respectively, in the whole sample and by 
sex-specific and self-reported menopausal status-specific quartiles of ferritin 
concentration. Trends of distribution of study variables across ferritin quartiles were 
tested by the Jonckheere-Terpstra test(192) (continuous variables) and 2 test 
(categorical variables). For the analyses of association, ferritin levels were used as 
both continuous and categorical variables. For the continuous approach, I calculated 
a sex/menopausal status-specific Z score for ferritin, after log-normalisation of the 
ferritin values. The Z score enabled reporting of the risk for CMD by increasing SD 
units of log-ferritin. The categorical approach involved the use of sex/menopausal-
specific quartiles of ferritin, with the lowest quartile as the reference category. Cox 
regression models were used to examine the longitudinal associations between 
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ferritin and CMD. HRs were described as unadjusted, age- and sex/menopausal 
status-adjusted, and additionally adjusted for potential confounders, which were 
fibrinogen, GGT levels, smoking, alcohol consumption, total cholesterol, HDL-C, 
SBP and DBP, and BMI. This set of confounding factors was chosen on the basis of 
the possible influence of acute phase or subclinical inflammation, adiposity, liver 
dysfunction, and cardiovascular risk factors on values of ferritin and/or outcome 
variables. As mentioned in Chapter 3, the year of the survey was also part of the 
adjustment because there were changes in laboratories where measurements of total 
and HDL-C were taken in 1998, although the methods did not differ. 
The proportional hazards assumption was tested by the Schoenfeld residuals test and 
graphical method. The follow-up years were calculated from the date of survey 
interview (1995 or 1998) to the first mention of T2D, cardiovascular event, death, or 
end of December 2011. Potential threshold effects of ferritin concentration were 
additionally investigated by comparing extreme quintiles and sextiles. Sensitivity 
analyses were performed on the basis of exclusion of subjects with clinically 
increased ferritin (>200 µg/L in women and >300 µg/L in men), potential liver 
disease (defined as GGT >84 IU/L in men and >44 IU/L in women), evidence of 
inflammation or infection (defined as fibrinogen levels >4.7 g/L in 1995 and >3.8 
g/L in 1998), and sex/menopausal status-specific analyses.  
Further adjustments for physical activity, self-reported hypertension, WC, and CRP 
levels as a more systemic inflammatory marker, were also conducted. The 
adjustment for CRP was only performed for the participants from the SHeS 1998 in 
which this marker was measured. Before conducting the association analyses, the 
continuous covariates with skewed distributions (fibrinogen, GGT, CRP, and WC) 
were log-transformed to approximate to normal distributions. To explore the shape of 
the relationship between serum ferritin and each incident CMD, I used restricted 
cubic splines with knots at the following percentiles of ferritin: 5th, 27.5th, 50th, 
72.5th, and 95th, as suggested by Harrell (193).  
Survey weights were applied to adjust for disproportionate sampling, differing 
selection probabilities, and differential non-response, but unweighted analyses were 
also conducted to test the consistency of the effect estimates and confidence intervals 
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and are presented in the appendix material. The SHeS described the weighting 
method as follows: “by applying two sets of weights: the first is needed in order to 
correct for the unequal probabilities of selection of addresses, and the second to 
correct for the unequal probabilities of selection of households and of individuals 
within households. These corrections are made by applying weights which are 
inversely proportional to the selection probabilities for the relevant postcode sectors 
and addresses. However, this weighting does not correct for variations in response 
level by region or by different groups of people. If there are such variations a further 
stage of weighting can be applied. For the Health Survey data it was decided to 
apply two further weights: the first to correct for differing rates of response between 
the seven regions; and the second to correct for the under-representation of men and 
young people in the achieved sample, so that the age and sex distribution of the 
sample would resemble that for the Scottish population”. All analyses were 
processed using STATA 14.0 software (Statistics/Data Analysis, Stata Corporation, 
4905 Lakeway Drive, College Station, TX 77845, USA, 800-STATA-PC).  
5.3 Results 
Differences between included and excluded individuals in this analysis are shown in 
Appendix Table 30. The excluded subjects had higher values of all cardiovascular 
risk factors. These differences were expected taking into account the fact that among 
the excluded individuals, some had T2D and CVD. Serum ferritin and GGT levels 
were not significantly different between included and excluded individuals.  
The study variables by sex/menopausal status-specific ferritin quartiles are described 
in Table 15. Age, fibrinogen, GGT, BMI, total cholesterol, and blood pressure 
significantly increased across ferritin quartiles. The same pattern was observed for 
prevalence of current smokers and higher alcohol intake, and for the proportion of 
subjects who developed diabetes, CHD, and CEVD during follow-up. In contrast and 
as expected from the other risk factor patterns, HDL-C levels decreased with higher 
levels of ferritin. There was also a trend of a slightly increasing higher proportion of 
participants from SHeS 1995 vs. participants from 1998 throughout ferritin quartiles 
(Table 15). Ferritin levels were higher in men than women, and higher in post-
menopausal women than pre-menopausal women (P < 0.05, data not shown). 
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During follow-up, 4.9% of the participants developed T2D, 5.3% developed CHD, 
and 2.3% developed CEVD. The incidence of T2D and CEVD was higher in post-
menopausal women than in men [T2D 8.1% vs. 5.5%, CEVD 4.7% vs. 2.2%] and the 
incidence of CHD was comparable in these 2 groups, i.e. 7.0% and 7.2%, 
respectively. In pre-menopausal women, the incidence of CHD, T2D, and CEVD 
was 2.4%, 1.7%, and 1.3%, respectively. Deaths from CHD and CEVD occurred in 
1.0% and 0.4% of the participants, respectively, while T2D was reported as the cause 
of death for only 2 people. Proportions of deaths from CHD were comparable in 
post-menopausal women and men at 1.4% and 1.3%, respectively. The proportion of 
deaths from CEVD was higher in post-menopausal women than men, i.e. 0.9% vs. 
0.3% and was 0.2% in post-menopausal women.  
Table 16 shows the HRs for the longitudinal association of serum ferritin levels, as Z 
score and quartiles, with the different CMDs. In unadjusted and age- and 
sex/menopausal status-adjusted models, ferritin as a continuous variable and ferritin 
levels in the highest quartile (compared to the lowest quartile) were positively and 
significantly associated with all types of incident CMD. In fully adjusted models, all 
the HRs for associations by quartiles were in general attenuated as compared to 
unadjusted models. The fully adjusted hazard of T2D was 71% higher in individuals 
with high levels (highest quartile) of ferritin compared to people with low 
concentrations (lowest quartile), and an increase in SD units of log ferritin was 
associated with a 22% increase in hazard (P ≤ 0.001). The associations of ferritin 
with CEVD and CHD were no longer statistically significant after full adjustment for 
covariates although effect estimates remained above 1 and there was the suggestion 







Table 15 Baseline characteristics of participants from Scottish Health Surveys 1995-1998 with relevant data available and proportions developing outcome by sex-
and menopausal status-specific quartiles of ferritin level in the study cohort (n=6497) [weighted values]* 
  Ferritin (µg/L)  
 All Q1 Q2 Q3 Q4 P for 
trend 
Ferritin lrange by sex/menopausal status (µg/L)* 
Premenopausal women (Pre-W) (n=2239) 2.0-950 2.0-18 19-30 31-47 48-950  
Postmenopausal women (Post-W) (n=1343) 3.0-1000 3.0-34 35-58 58-91 92-1000  
Men (n=2915) 3.0-2251 3.0-61 62-96 97-151 152-2251  
Variables       
Age 41(31-52) 39(29-50) 40(30-50) 40(31-52) 44(34-54) <0.001 
Pre-W/Post-W/ Men (%) 32.9/16.6/50.5 32.9/16.4/50.7 32.2/16.9/50.9 33.3/17.2/49.5 33.0/15.9/51.1 0.887 
Ferritin (µg/L) 61(32-108) 25(13-43) 62(28-78) 91(42-116) 161(86-216.8) <0.001 
Fibrinogen (g/L) 2.9(2.4-3.5) 2.8(2.3-3.4) 2.9(2.4-3.4) 3.0(2.5-3.6) 3.1(2.6-3.7) <0.001 
GGT (IU/L) 20(14-32) 17(13-25) 18(14-27) 21(15-33) 27(18-45) <0.001 
Smoking status (%)       
Never smoker 39 45.4 41.1 36.1 33.0  
 
<0.001 
Ex-regular or Ex-occasional smoker 26.3 24.4 26.3 26.1 28.4 
Current smoker 34.7 30.2 32.6 37.8 38.6 






Never drank 4.2 5.1 5.4 3.6 2.6 
Ex-drinker 2.8 3.2 3.1 2.7 2.4 
Trivial drinker/Non-zero but under 1 10.3 12.6 10.7 9.1 8.5 
1-20  63.4 64.5 62.9 65.4 60.6 
≥ 21 19.3 14.6 17.8 19.2 26.0 
BMI (Kg/mts2)  25.7(23.1-28.6) 24.9(22.7-27.8) 25.3(22.8-28.1) 25.8(23.3-28.5) 26.6(24.1-29.9) <0.001 
HDL-cholesterol (mmol/L) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.1-1.7) 0.007** 
Total cholesterol (mmol/L) 5.4(4.7-6.2) 5.3(4.6-6.0) 5.4(4.6-6.2) 5.4(4.8-6.2) 5.6(4.9-6.4) <0.001 
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  Ferritin (µg/L)  
 All Q1 Q2 Q3 Q4 P for 
trend 
Systolic blood pressure (mmHg) 126(117-137) 125(117-135) 125(116.5-135) 125.5(116.5-137) 128.5(118-140) <0.001 
Diastolic blood pressure (mmHg) 70(63-79) 69(62-77) 69(62-78) 70(64-78) 73(65-81) <0.001 
Incident diabetes (%) 4.9 3.3 3.4 4.5 8.7 <0.001 
Incident coronary heart disease (%) 5.3 4.5 4.6 4.8 7.6 <0.001 
Incident cerebrovascular disease (%) 2.4 1.8 2.0 2.3 3.4 0.003 
Survey 1995/1998 (%) 50.1/49.9 44.6/55.4 50.8/49.2 52.6/47.4 52.6/47.4 <0.001 
*Samples sizes, quartiles and ranges of ferritin levels are based on unweighted values. ** Negative trend across quartiles is more evident in terms of rank 
values. 














Table 16 HRs and 95% CI for the incidence of diabetes and cardiovascular diseases by serum ferritin levels (weighted analysis) 
 
 Type 2 diabetes  Coronary heart disease Cerebrovascular disease 
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P for trend P<0.001 P<0.001 P=0.006 
 
P=0.002 P=0.070 P=0.700 P=0.007 P=0.065 P=0.253 
* Adjusted for age, sex/menopausal status, fibrinogen levels, GGT levels, alcohol intake, smoking, systolic blood pressure, diastolic blood pressure, total 
cholesterol, HDL cholesterol, body mass index and year of survey. 
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Figure 7 Comparison of hazard ratios for type 2 diabetes (T2D), coronary heart disease (CHD) and 
cerebrovascular disease (CEVD) for quintiles and sextiles of ferritin levels (v. respective lowest 
categories) with different levels of adjustment 
 
Ferritin highest quintile: Premenopausal women (Pre-MW) 53-950 µg/L, Postmenopausal women 
(Post-M) 102-1000 µg/L, Men 169-2251 µg/L. Ferritin highest sextile: Pre-MW 58-950 µg/L, Post-
MW 114-1000 µg/L, Men 183-2251 µg/L.   Reference (lowest quintile, sextile).   Unadjusted.  
 Adjusted for age and sex/menopausal status.  Adjusted for age, sex/menopausal status, 
fibrinogen levels, GGT levels, alcohol intake, smoking, systolic blood pressure, diastolic blood 
pressure, total cholesterol, HDL cholesterol, body mass index and year of survey. The above analysis 




When I explored the effect of using quintiles or sextiles to determine if the highest 
category of ferritin strengthened the associations with CMD, there was a suggestion 
of an effect for CEVD, although confidence intervals for HRs overlapped (Figure 
7C). The hazard of CEVD was approximately double in individuals with ferritin in 
the highest sextile compared to those in the lowest sextile [fully adjusted (HR) 95% 
CI 2.08 (1.09–3.94), P = 0.024]. The association with T2D was slightly stronger 
when comparing extreme quintiles or sextiles than when comparing extreme 
quartiles (Figure 7A), and no significant associations with CHD were observed 
(Figure 7B). It is worth noting that the sex/menopausal status-specific cut-off points 
for the highest quintile and sextile were in the clinical normal range for serum ferritin 
(≤300 µg/L) (Figure 7). 
In the sensitivity analyses, the exclusion of individuals with serum ferritin >300 µg/L 
or further adjustment for self-reported hypertension or physical activity and WC did 
not substantially affect the associations previously described. The ferritin-CEVD 
association remained unaffected when cases of subarachnoid haemorrhage were 
excluded (n=16). In participants from SHeS 1998, further adjustment for CRP levels 
did not alter the significant association between serum ferritin in the highest quartile 
(vs. lowest quartile) and incident T2D [unadjusted HR (95% CI): 2.18(1.22–3.90), P 
= 0.008; fully adjusted HR (95% CI): 2.16(1.20–3.89), P = 0.010]. In this same sub-
cohort, ferritin and incident CHD and CEVD were not significantly associated, and 
additional adjustment for CRP did not modify these non-significant associations.  
When the analysis was restricted to individuals without signs of inflammation and/or 
hepatic injury (n=5626), the association between ferritin, as upper quartile or 
continuous variable, and T2D was attenuated [ferritin Z score HR (95% CI) 1.12 
(0.97–1.31), P = 0.105; higher quartile vs. lowest HR (95% CI) 1.32 (0.87–2.09), P = 
0.177]. However, by comparing extreme quintiles, the association was still 
borderline statistically significant [HR (95% CI) 1.67 (1.02–2.75), P = 0.041]. The 
association between ferritin (extreme sextiles compared) with CEVD remained 
similar [HR (95% CI) 2.03 (1.01–4.08) P = 0.045].   
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I also evaluated the association with ischaemic CEVD specifically (92 incident 
cases) but no significant association was found with ferritin as a continuous variable 
or quantile (quartiles, quintiles, sextiles).  
Unweighted results of the description of study variables and Cox regression analyses 
showed similar patterns described above, although with some differences in P values 
for some associations (Appendix Tables 31-32 and Appendix Figure 8).  
Although there was no evidence of interaction between sex or menopausal status and 
ferritin levels in respect to developing CMD (P > 0.05 in weighted and unweighted 
interaction tests), I conducted analyses stratified by sex and menopausal status, with 
and without exclusion of individuals with particular characteristics as described for 
the sensitivity analyses in the whole sample. The purpose of these extra analyses was 
to compare the findings with a recent large European, multi-centre study on iron 
markers and incident T2D. In these analyses stratified by sex and menopausal status, 
the statistically significant ferritin Z score-T2D association persisted only in men 
[HR (95% CI) 1.20 (1.01–1.43), P = 0.033; pre-menopausal 1.25 (0.92–1.69), P = 
0.149; post- menopausal women 1.14 (0.87–1.49), P = 0.325]. When cases with 
ferritin levels above the normal range were excluded, a different pattern of 
association between ferritin Z score and T2D was observed in pre- menopausal 
women [HR (95% CI) 1.32 (0.96–1.82), P = 0.079] and men [HR (95% CI) 1.17 
(0.93–1.46) P = 0.159]. A similar pattern was observed when the analysis was 
restricted to subjects without high levels of fibrinogen and/or GGT [HRs (95% CI) 
pre- menopausal women 1.38 (0.95–1.99), P = 0.085; men 1.11 (0.92–1.34), P = 
0.246); post- menopausal women 0.92 (0.66–1.29), P = 0.658]. There were no 
statistically significant associations between serum ferritin, as Z score or quantiles, 
and CEVD or CHD in the analyses by sex and menopausal status. Combining data 
for pre- and post- menopausal women in a single category and adjusting for 
menopausal status, did not result in significant associations across the above 
mentioned sensitivity analyses. 
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Figure 8 Risk of cardiometabolic diseases by serum ferritin levels. 
 
Adjusted hazard ratios for A) T2D, B) CHD, and C) CEVD by serum ferritin levels .Ferritin levels 
higher than 500 µg/L were not used because confidence intervals tended to be very wide in this 




The relationship between serum ferritin levels and incident T2D was approximately 
linear (Figure 8A). In contrast with the findings by using sextiles of ferritin, the 
association between ferritin and CEVD was not observed when using cubic splines in 
terms of ferritin levels (Figure 8B). This is perhaps because the ferritin values used 
for the evaluation of non-linear relationships were not sex/menopausal status-specific 
as they were in the analyses with ferritin as sextiles. When sex/menopausal status-
specific Z scores of ferritin were used in the cubic splines analysis, a threshold effect 
of higher risk of CEVD appeared around +1.20 SD of log-ferritin, although 
confidence intervals in that region of the graph still included 1 (Figure 9). The above 
findings on the shape of the association between ferritin or ferritin Z score and 
incident CEVD remained unmodified by using six knots instead of five in the cubic 
spline analysis.  
Figure 9 Adjusted hazard ratios for CEVD by sex/menopausal specific Z score of ferritin levels. 
  
 
5.4 Discussion  
In the present study, I have reported the associations between iron stores and 
incidence of several CMDs in a nationally representative population at high 
cardiovascular risk over a mean follow-up of 14 years. I found a statistically 
significant association between high ferritin and development of CEVD when I used 
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higher percentiles to define high ferritin concentration. Interestingly, these cut-off 
points were still within the normal reference values of ferritin. The findings also 
confirm previous observations of an association between serum ferritin and T2D and 
no evidence of an association with CHD. The association between ferritin levels and 
T2D seemed to be more consistent in pre-menopausal women than in men in 
sensitivity analyses.  
5.4.1 Ferritin and T2D 
The results for the association between serum ferritin and incident T2D are 
consistent with the positive and significant association reported in a meta-analysis of 
prospective studies published up to 2012 (1). In this meta-analysis, the pooled 
relative risk (95% CI) for incident T2D for the highest ferritin quintile vs. the lowest 
quintile was 1.73 (1.35–2.22) (115). The association in the meta-analysis is slightly 
stronger than that in the Scottish population studied here [HR (95% CI) 1.59(1.10–
2.34), P = 0.006], presumably because several studies of the meta-analysis lacked 
adjustment for transaminase levels. In the present study of Scottish population, the 
HR for the association between highest compared to lowest quartile of ferritin levels 
and incident T2D decreased by 16% when GGT levels were added to the adjustment 
model [from 1.91 (1.32–2.77), P = 0.001 to 1.60 (1.10–2.34), P = 0.014]. Some few 
studies failed to find a significant independent association between serum ferritin and 
development of T2D. A case-cohort study of the Atherosclerosis Risk in 
Communities study (ARIC) (599 cases and 690 controls) did not find a significant 
association between ferritin levels in the highest quintile (v. the lowest) and T2D 
after adjustment for BMI and traditional cardiovascular risk factors [HR 95% CI 0.81 
(0.49–1.34) (20). However, the study did not disclose which covariate/s had more 
weight in the attenuation of the association. In a recent age and sex-matched case-
control prospective study (327 cases, 641 controls) involving Japanese workers, the 
association between ferritin and incident T2D was weakened after further adjustment 
for transaminase and lipid levels [HR (95% CI) 1.40 (1.01–1.93), P = 0.02 before 
adjustment; HR (95% CI) 1.20 (0.86–1.67), P = 0.16 after adjustment] (194). It is 
posssible that limited statistical power explains the non-statistically significant 
findings in the ARIC and Japanese cohorts.Recently, a large study conducted in a 
sub-cohort of the European multi-centre InterAct study was published, which 
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examined the association of serum ferritin and three other serum iron biomarkers 
(transferrin, serum iron, and percentage of transferrin saturation (TSAT) with 
incident T2D (195). This is the most detailed study to date on iron metabolism and 
T2D. Given the large sample size, the authors of this study were able to conduct sex-
specific analyses with multiple sensitivity analyses to characterise the associations. 
The authors found a significant association between serum ferritin and T2D in both 
sexes. However, the association was markedly attenuated in men but not in women 
when individuals with signs of inflammatory or hepatic disease, high alcohol intake, 
and who were overweight were excluded from the analysis. Similarly, the association 
was strengthened for women but not for men when their analysis was restricted to 
ferritin values lower than 1000 µg/L. The findings from the Scottish population are 
partly consistent with the patterns from the InterAct study. In the prospective 
Scottish study population, the significant association between ferritin and T2D 
persisted for men but not for women after adjustments. However, as described in the 
results section, by limiting the analysis to individuals without any sign of 
inflammatory or hepatic disease and with ferritin levels within the normal range, 
there was a higher effect estimate for association in pre-menopausal women than in 
men with borderline statistical significance.  
The above findings of a more consistent association between iron status and CMD 
among premenopausal women than among men within a healthier sub-population, do 
not appear to be explained by exclusion of cases of T2D and/or high ferritin in men. 
The proportion of cases with high fibrinogen and/or GGT levels in the highest 
ferritin quartiles in men and women were comparable (18% in premenopausal 
women and 21.3% in men). Moreover, a higher relative proportion of T2D cases in 
the highest ferritin quartile were excluded among pre-menopausal women (21% 
based on reduction of absolute proportions developing diabetes during follow-up 
from 3.8% to 2.6%) than among men (13%- absolute proportions before and after 
exclusions 10.3% and 8.9%) when individuals with potential clinical inflammation or 
liver disease were removed. The difference by sex in sensitivity analyses may be 
partly related to statistical artefact. Relative risks (or similar effect estimates such as 
hazard ratios) for detrimental factors tend to be higher in sub-populations with a 
lower absolute risk of the outcome of interest, such as women in this case, in 
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comparison with sub-populations with a higher absolute risk, such as men. In this 
analysis, absolute proportions of people developing T2D in the highest quartile of 
ferritin during follow-up for premenopausal women and men were 3.8% and 10.3%, 
respectively. In the lowest quartile ferritin, the absolute risk was 0.9% in 
premenopausal women and 3.7% in men. Higher relative risks may therefore be 
expected in the group at lower absolute risk, ie premenopausal women. In addition, 
during the long follow-up period of this study, in comparison with men, changes in 
iron stores and cardiometabolic risk may have been more marked in premenopausal 
women during subsequent perimenopause and postmenopause. However, further 
research and large longitudinal studies with repeated measurements of ferritin are 
required to test this hypothesis. 
Despite the similarities in patterns, it is important to bear in mind that sex-specific 
sensitivity analyses conducted in both the InterAct study and the SHeS could lead to 
chance findings due to multiple testing. Therefore, any sex-specific difference should 
be viewed with caution until further studies confirm this pattern. 
Another important aspect of the current evidence on the association between ferritin 
and T2D is whether there is potential for residual confounding. Two analyses in sub-
cohorts of the EPIC-Norfolk and the EPIC-Potsdam study included a broad set of 
covariates in their multi-variable models including classic risk factors and also 
adiponectin, interleukin 6, and fetuin, but none of these covariates attenuated the 
association of ferritin with T2D significantly (26, 164).  
In the present work, the association between ferritin and T2D was linear with no 
appreciable threshold effects, and this is consistent with the pattern reported in the 
EPIC-InterAct study. Potential threshold effects have been previously suggested in 
other studies, but those observations could be influenced by low statistical power 
(26, 115). 
5.4.2 Ferritin and CEVD 
As previously mentioned, there have been very few studies on ferritin and CEVD in 
general populations, and those that exist show inconclusive findings. Two 
longitudinal studies involving 1,134 Dutch post-menopausal women (aged 40–70 
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years, mean follow-up, 4.3 years) (196) and a sub-cohort (n = 1612) of the Busselton 
Health study (age 40–89 years,17-years of follow-up) (197) reported similar positive 
associations between serum ferritin levels in the highest tertile (vs. lowest) and stroke 
of any subtype but without reaching statistical significance in fully adjusted models 
[HR(95%CI) 1.45(0.76–3.85) and 1.43(0.78–2.64), respectively]. Analyses by sex in 
the Busselton Health study did not show statistically significant associations either. 
Both studies had comarable age ranges and number of incident cases of stroke 
(Dutch cohort, 63 cases; Busselton Health study’s sub-cohort, 55 women and 63 
men). In the Dutch cohort of post-menopausal women, by using serum ferritin ≥200 
µg/L compared to ferritin lower than that cut-off point, the positive association 
between ferritin and stroke of any subtype was borderline statistically significant 
[HR(95%CI) 1.77(1.03–3.05)]. Although the cut-off point for highest tertile of 
ferritin for men in the Busselton Health study was 233 µg/L, for women the cut-off 
point for this tertile was only 122 µg/L. Therefore, it is uncertain whether by 
comparing extreme values of ferritin, the association with stroke might have been 
strengthened in the Busselton Health Study.  
In this chapter of my thesis, by exploring additional higher cut-off points for 
increased ferritin, the association between serum ferritin and CEVD became more 
evident. Since CEVD is less common than T2D and CHD, it is likely that clearer 
associations can be observed when incident and/or prevalent cases are more 
concentrated into very high categories of distribution of a predictor variable, such as 
iron stores. Despite using sextiles of ferritin distribution, the cut-off points defining 
increased ferritin were still within the normal range for ferritin levels, and the 
exclusion of subjects with ferritin values > 300 µg/L did not affect the ferritin-CEVD 
association. This suggests that there may be an increased risk of CEVD in the general 
population that does not have extremely high concentrations of stored iron if this is 
not a chance finding. However, a graphical evaluation of the ferritin-CEVD 
relationship by using standardised values of ferritin in my analysis suggested, a 
threshold effect. Studies with more incident CEVD cases are required to establish 
whether this is a true finding, since statistical tools for testing non-linearity demand 
high statistical power. My analysis, to the best of my knowledge, is the first attempt 
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to graphically describe the shape of the association between serum ferritin level and 
the risk of CEVD.  
In the same Dutch cohort of post-menopausal women mentioned previously, the 
positive association between ferritin in the highest tertile and stroke was strengthened 
when only cases of ischemic stroke [HR (95%CI) 2.23 (1.05–4.73)] were considered 
(196). In contrast, in the present study involving the Scottish population, increased 
ferritin was not statistically significantly associated with ischaemic CEVD and this 
could be due to loss of power.  
 
The association between ferritin and CEVD has also been investigated by describing 
the association between ferritin and sub-clinical carotid atherosclerosis, a risk factor 
for stroke. As with stroke, the findings are conflicting, but low statistical power may 
contribute to the apparent lack of association. In the 1990s, cross-sectional and 
prospective analyses in the Brucneck study showed an association between ferritin 
levels and sonographically assessed carotid atherosclerosis in 847 men and 826 
women aged 40–79 years (198). In contrast, a study involving 105 and 66 Finnish 
men aged 50–60 years with and without cardiovascular disease, respectively, did not 
find serum ferritin, transferrin, or iron intake associated with carotid bifurcation 
atherosclerosis (199). The ARIC study did not find a significant association between 
ferritin and asymptomatic carotid atherosclerosis when 169 cases and 152 controls, 
matched for sex, were compared [adjusted OR (95% CI) 1.0 (0.851.19)] (200). 
Recently, a study involving 1,178 post-menopausal women, which used a high-
resolution ultrasonography to assess carotid atherosclerosis, reported a significant 
association [OR for increased bilateral carotid intima-media thickness (95%CI) 1.58 
(1.05–2.31), P < 0.05 for the top compared to bottom quartile of ferritin] (201).  
The potential mechanisms underlying the association between iron excess and stroke 
are still unclear, but endothelial alterations might play a key role in the aetiology of 
both ischemic and haemorrhagic subtypes. In terms of the ischaemic subtype, 
atherosclerosis would be a possible mediating process. As a consequence of its pro-
oxidant and deleterious effects on endothelial cells, iron may favour thickening of the 
intima-media in the main blood vessels to the brain and contribute to consequent 
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occlusion of the vascular lumen (202). In the case of haemorrhagic stroke, the 
literature has focused on iron as a cause of oxidative brain injury after intracerebral 
haemorrhage rather than as a potential risk factor (203). On the other hand, in my 
view, since long-standing hypertension is the most common trigger for haemorrhagic 
stroke (204), iron-related mechanisms for hypertension could support a link between 
iron stores and stroke. In fact, higher serum ferritin levels have been found in 
individuals with essential hypertension than in subjects without hypertension (205). 
Endothelial dysfunction, defined as the loss of vasodilation capability in blood 
vessels, which is strongly associated with hypertension, has been shown to improve 
with iron chelation therapy in a general population (206). Iron seems to directly 
inactivate nitric oxide (NO) synthase in the endothelium, an enzyme which catalyses 
the releasing of NO to promote vasodilation of the blood vessels (206). The negative 
impact of iron on this enzyme also appears to be via oxidative effects that would 
involve membrane lipid and low-density lipoprotein peroxidation (206). However, no 
recent experimental studies further investigated these mechanisms. Despite the above 
evidence, in multivariate models, blood pressure and/or self-reported hypertension 
did not substantially affect the ferritin-CEVD association reported here.  
5.4.3 Ferritin and the lack of an independent association with 
CHD 
Serum ferritin levels were associated with CHD in unadjusted and age/sex-
menopausal status-adjusted models but not in the fully-adjusted model used in these 
analyses. In this latter model, several cardiovascular risk factors, such as cholesterol 
markers, SBP, and BMI, markedly attenuated the ferritin-CHD association (data not 
shown). The lack of an independent association is consistent with the findings from a 
recent meta-analysis by Das et al. on several iron markers and CHD which evaluated 
17 prospective studies with a total of 9,236 cases of CHD and 156,427 participants 
(183). In this meta-analysis, the pooled association between serum ferritin in the 
highest tertile (vs. lowest tertile) and CHD was not significant [OR 95% (CI) 1.03 
(0.87–1.23)]. Paradoxically, transferrin saturation was significantly and inversely 
associated with incident CHD. The authors acknowledged difficulties in inferring 
causality due to potential reverse causality and residual confounding. However, they 
did not ignore the likely role of anaemia in the inverse association, since a higher 
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iron status could prevent the onset of anaemia, which is associated with symptomatic 
CHD(183). It is still unclear why the directions of associations with iron status 
markers are inconsistent. If iron deficiency and anaemia are related to CHD, the 
effect estimates for the relationship with serum ferritin should show an inverse 
significant pattern as well. This discrepancy reinforces the notion that the iron 
markers are differentially associated with cardiometabolic risk through mechanisms 
other than iron metabolism.  
 
Interestingly, as will be seen and discussed in the sixth chapter of this doctoral 
research thesis, serum ferritin showed an inverse association pattern with CHD in 
people with T2D, but underlying mechanisms for this disease-specific pattern have 
yet to be elucidated. It is unclear whether the presence of people with T2D within 
general populations may distort a positive association between ferritin and CHD in 
people without diabetes. Several studies from the meta-analysis of Das et al. included 
diabetes in their sets of covariates and, apparently, no modification of the ferritin-
CHD association by diabetes status was observed. However, if the ferritin-CHD 
pattern in T2D appears to be different from the expected positive pattern in general 
populations, future studies in large cohorts, where there could be many more cases of 
diabetes, should include sensitivity analyses after excluding people with diabetes. In 
the present study, the Scottish cohort was diabetes-free at baseline.  
 
The fully adjusted effect estimate described in this chapter for the non-significant 
positive association between high ferritin (comparison of extreme quartiles), [HR 
(95%CI) 1.08 (0.76–1.52)] is similar to those reported in three studies out of ten from 
the meta-analysis by Das et al. on ferritin and CHD (183). Among the remaining 
seven studies, four reported effect estimates much lower than 1.0, and three, higher 
than 1.0. However, Das et al. did not find any source of statistically significant 
heterogeneity among factors of location, degree of adjustment for confounders, sex, 
or case definition across meta-regression analyses (183). 
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5.4.4 Limitations and strengths  
Several limitations need to be acknowledged. SHeS did not measure serum 
triglycerides, and it is unknown to what extent this risk factor could have attenuated 
the associations found. Lipid- and blood pressure-lowering treatments were not part 
of the adjustments owing to many missing values for medications within the sample 
selected. The analysis also lacked evaluations for other iron markers. Two issues 
may have led to underestimating the total number of cases of T2D and people with 
undiagnosed diabetes may have been included in the non-diabetic population. First, 
there could be an underestimation of incident T2D cases between 1995 and 2003, 
because cases of T2D for people who died before 2004 were only identified using 
information on hospital admissions, since the Scottish Diabetes Register is only 
thought to have been complete since 2004. There is also potential for erroneous 
inclusion of people with undiagnosed diabetes both at baseline and follow-up in the 
non-diabetic group. However, the above issues did not affect the statistical power to 
find a consistent association between ferritin and T2D in the Scottish population, and 
this may be related to the long follow-up of this study, which is the longest to date.  
There was a high proportion of excluded cases with missing values for 
exposure/outcome variables or covariates (62.3%) and this may have introduced bias 
in the associations found. Estimation of outcome variables might have been affected 
by the loss of follow-up due to no link to the SMR. If the outcomes were 
overestimated, the associations with serum ferritin may have been biased toward the 
null hypothesis, as in the case of CHD. If the outcomes had been underestimated, it is 
possible that the loss of statistical power led to weaker associations, as observed for 
CEVD. Values of ferritin and biochemical covariates were conditioned to blood 
sample and performance of laboratory measurement.  Eligibility for a blood sample 
in the SHeS required the participant not to be pregnant, and not to have bleeding 
disorders or be under anticoagulant treatment. Although in general, the response 
rate.for blood samples was around 78-80%, the measurements of the analytes in the 
samples were highly variable and thus not complete for all the subjects. The causes 
of failure to determine the different analytes in the blood sample were not described 
in the SHeS, but usually, this is related to haemolysis of the sample, which is the 
rupture of red blood cells. Haemolysis interferes with chemical assays or signal of 
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detection of ferritin and other analytes in laboratory spectrometric systems(207). 
However, not all biochemical assays are affected by haemolysis and this explains the 
inconsistency of having incomplete data (e.g. some cases with transaminase 
measurement but not ferritin).   
Multiple imputation data techniques could potentially  help to counteract the negative 
effect of missing values by replacing missing values with hypothetical values 
modelled on the basis of explanatory variables of the missingness (208). On the other 
hand, in the present SHeS analysis imputation models may be misleading since the 
causes of the missingness for each particular variable are not entirely clear, or if 
clear, these were not recorded and assumptions made during imputation may 
introduce different forms of bias. Another potential disadvantage of an imputation 
approach in this chapter is that methods for imputing missing values for categorical 
variables or with a skewed distribution such as ferritin, are still a developing 
area(208). Although imputation for the analyses with continuous values of the log-
normalised ferritin Z score is feasible, imputation for the analyses with ferritin as 
quintiles would be more problematic, since quintiles are calculated from ferritin in its 
original units. In terms of plausibility in comparison to findings of other studies, the 
findings in this chapter do not appear to be seriously biased, but future studies on 
ferritin and cardimetabolic risk could compare results of analyses using complete 
case analyses and imputed data approaches because to date, there are not studies 
covering this methodological limitation. 
Time trends in background interventions for prevention and treatment of 
cardiovascular disease may mean that it is inappropriate to extrapolate findings from 
the SHeS analysis to contemporary populations given the long follow-up period for 
SHeS participants. For instance, the proportions of people who take aspirin and 
statins have increased over that time period and these treatments have been linked 
(along with angiotensin converting enzyme inhibitors, thrombolysis, and coronary 
artery bypass graft surgery) to a 25-55% of the fall in cardiovascular mortality rates 
in Scotland (2000-2010)(209). It is not clear how this might have affected the 
association between ferritin and cardiovascular outcomes. 
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To the best of my knowledge, this study is the first to have simultaneously evaluated 
the association between ferritin and incidence of several CMDs. Moreover, this is the 
first study in a nationally representative population. The study also explored different 
upper categories of ferritin concentration in relation to the risk of CMD and 
evaluated the potential non-linear relationships between ferritin and each CMD 
outcome.  
In conclusion, serum ferritin levels were positively and independently associated 
with incident T2D and with incident CEVD if higher cut-off points for upper ferritin 
levels were considered. The lack of an independent association between serum 
ferritin and CHD reported in previous studies was confirmed in this Scottish 
population. Further studies on ferritin and CEVD are required to confirm the 
association described here. The next chapter investigates the association between 




Chapter 6  
Cross-sectional and longitudinal analyses of 
serum ferritin and cardiovascular disease in 
people with type 2 diabetes  
6.1 Introduction 
Little attention has been paid to the possible involvement of iron in the development 
of chronic complications of diabetes. In the general population, iron has been 
hypothesised to promote the development of the atherosclerotic plaque through 
increased oxidative stress as a consequence of the pro-oxidant properties of iron (11).  
 
Iron imbalance could potentiate the risk for cardiovascular outcomes in people who 
already have T2D. So far, only one cross-sectional study involving 424 people has 
tested this hypothesis. The authors reported an apparently paradoxical decreased 
prevalence of macroangiopathy in men with T2D and increased serum ferritin levels, 
but adjustment for covariates was not performed (210). I did not find any previous 
longitudinal or larger cross-sectional studies evaluating the possible association 
between serum ferritin levels and cardiovascular events in people with T2D.  
 
In light of the above, I investigated potential associations of serum ferritin with CHD 
and CEVD with adjustment for covariates in two different cohorts of people with 
T2D, one from Scotland and the other from Catalonia, Spain using both cross-
sectional and prospective study designs. This multi-cohort approach was used to 
determine whether findings were consistent despite cardiovascular risk differences 





6.2.1 Study population 
ET2DS 
The Edinburgh Type 2 Diabetes Study (ET2DS) has been described in full 
previously (211). The ET2DS is an on-going prospective study with data available 
for eight years of follow-up in this study. Patients with T2D aged 60–75 years were 
selected at random from the Lothian Diabetes Register, a comprehensive register of 
patients with diabetes living in Lothian, Scotland, UK, which was established in 
2001. Baseline attendees (n = 1,066) have previously been shown to be representative 
of all those randomly selected to participate (n = 5,454) and therefore representative 
of the target population of older people with T2D in the general population [14]. At 
year 1, 939 participants visited a liver assessment clinic, and ferritin levels were 
measured for 876 of those participants. Therefore, year 1 was used as baseline for 
this study and the mean follow-up duration for the present analysis was 6.1 ± 1.7 
years. Of the 876 subjects with ferritin measurements, I excluded 55 individuals with 
missing values for covariates, resulting in a final sample of 821 participants. 
 
SIDIAP study – Primary Care Centres in Catalonia 
This cross-sectional study is based on the SIDIAP system, a computerised database 
containing anonymised patient records for the 5.8 million people registered with a 
GP in the Catalan Health Institute (the regional health authority). The SIDIAP 
database includes data from a software called ECAP used by general practitioners to 
record clinical information on patients (demographic characteristics, consultations 
with GPs, diagnoses, clinical variables, prescriptions, and referrals), laboratory test 
results, and medications obtained from pharmacists (provided by the CatSalut 
database) (212). The SIDIAP study has been described in full previously (212, 213). 
Out of 318,020 individuals with T2D aged 30–99 years registered in the SIDIAP 
database in 2011, 62,002 had at least one measurement of ferritin. The final sample 
for the analysis included 38,617 individuals after excluding cases with missing 




6.2.2 CVD events in the ET2DS and SIDIAP study 
The ET2DS has data on prevalent and incident (over seven years) CVD events, and 
the SIDIAP study, on prevalent CVD only. Prevalent and incident events for ET2DS 
up to year 4 were collected using a combination of record linkage (hospital discharge 
and death certification data), repeat self-report and GP questionnaires, repeat ECG, 
and inspection of clinical notes. Incident events between year 4 and year 8 were 
collected using a combination of record linkage and inspection of clinical notes. Data 
linkage for ET2DS was undertaken by National Health Service National Services 
Scotland to the Scottish Morbidity Record (SMR01) and death records– general and 
acute inpatient discharge records using ICD-10 (www.who.int/classifications/icd/en/) 
(and related ICD-9 [www.icd9data.com/2007/Volume1]) codes. CVD cases of the 
SIDIAP study were defined on the basis of record linkage to hospital and death 
records. 
 
Ischemic heart disease or CHD was defined in terms of primary diagnosis of angina 
or myocardial infarction (ICD-10 codes I20, I21, I22, I23). SIDIAP also included the 
category of “other acute ischaemic heart disease” (ICD-124). CEVD was defined in 
terms of stroke (ICD-10 codes I63, I64) and transient ischaemic attack (TIA) (ICD-
10 code G45) as primary diagnoses. The ET2DS also included ICD-10 code I61 for 
intracerebral haemorrhage, and the SIDIAP study also considered the ICD-10 code 
G46 for vascular syndromes of brain in case of CEVD. In the ET2DS, fatal cases of 
myocardial infarction and stroke had the respective ICD-10 codes as primary cause 
of death. The ET2DS also used inspection of clinical notes to confirm CVD cases 
(prevalent or incident) if non-primary ICD-10 codes for CHD or CEVD were 
reported, except in the cases of angina. 
  
6.2.3 Clinical examination and biochemical variables 
The SIDIAP included clinical and biochemical variables similar to the ones in the 
ET2DS, with the exception of fibrinogen, CRP, and transaminases levels, and liver 
disease which were available in the ET2DS only. In the SIDIAP study, white blood 
cell count (WBC) was used as a measure of inflammation, and triglyceride levels 
were also available. Triglyceride levels, although also measured in the ET2DS, had 
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very few valid cases and thus this marker was not used as a covariate in the ET2DS 
analysis.  
 
Systolic and diastolic brachial blood pressures were measured in the right arm to the 
nearest 2 mmHg with subjects in the supine position using a standard desk standing 
sphygmomanometer (Acceson™, AC Cossor & Son (Surgical) Ltd, Harlow, UK). 
Standing height was measured to the nearest mm, without shoes, using a wall-
mounted vertical rule. Weight was assessed to the nearest 0.1 kg without outdoor 
clothing or shoes using SECA 761 electronic weighing scales. BMI was then 
calculated as weight (in kg) divided by the square of height (in m).  
A questionnaire on smoking and alcohol consumption was self-completed at baseline 
in the ET2DS. If participants did not currently smoke or drink, they were asked about 
their smoking history and categorised as ever/never. This same categorisation was 
applied to the information collected on smoking and alcohol consumption in the 
SIDIAP system.  
Fasting venous blood samples were taken to measure biochemical markers:   
triglycerides, HDL-C, total cholesterol, and creatinine by using enzymatic-
colorimetric methods in both studies as well as fasting glucose in the ET2DS. In the 
ET2DS, GGT, AST, and ALT were measured by using the Elecsys 2010 
electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK). CRP was 
determined using a high sensitivity immunonephelometric assay, and fibrinogen was 
measured in plasma anticoagulated with trisodium citrate using the automated Clauss 
assay (MDA-180 coagulometer, Organon Teknika). In both studies, glomerular 
fitration rate (eGFR) was calculated according to The Modification of Diet in Renal 
Disease (MDRD) equation using the serum creatinine values.  In the SIDIAP study, 
WBC was carried out using coulter systems. In both studies, ferritin levels were 
measured by immunoturbidimetry (intra- and interassay coefficients of variation <8). 
In the ET2DS, the liver disease was assessed by examining evidence of fatty 
infiltration using ultrasonography (Sieman's Medical Systems Inc, Washington, 
USA), performed by a single ultrasonographer who was unaware of the clinical and 
laboratory profiles of the subjects.   
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6.2.4 Data analyses for the ET2DS and SIDIAP study 
Study variables were described as medians (interquartile ranges) for continuous 
variables or proportions for categorical variables. Ferritin levels were described using 
Z scores of the logarithm of ferritin values (i.e. as a continuous variable) and also as 
sex-specific quintiles (i.e. a categorical variable), in order to investigate potential 
linear and non-linear relationships. As mentioned previously in other chapters, the Z 
score of log-ferritin was chosen instead of ferritin or log-ferritin alone to facilitate the 
interpretation of effect estimates, in terms of changes in risk of the outcomes by 
changing standard deviations of the iron marker. As iron overload has been the most 
commonly reported factor for cardiometabolic risk in the general population, the 
lowest quintile of ferritin was used as the reference group. Baseline cross-sectional 
associations between ferritin and prevalent CVD were tested by using logistic 
regression. Longitudinal associations were evaluated by using Cox regression, and 
proportional hazards assumption was tested by the Schoenfeld residuals test and 
graphical method. For the analysis in the ET2DS, the years of follow-up were 
calculated from date of attendance at year 1 (baseline of this study) to the first of date 
of cardiovascular event, death, or end of December 2014. For individuals who 
developed both CHD and CEVD, the years of follow-up for incident or recurrent 
CVD were derived using the date of the first event during follow-up. Longitudinal 
associations were described by two approaches: 1) including people with prevalent 
CVD at baseline and adjusting for prevalent CVD, in order to have more statistical 
power and 2) excluding cases with prevalent CVD at baseline. In both cross-sectional 
and longitudinal analysis, the associations were described as unadjusted; adjusted for 
age and sex; and adjusted for age, sex, duration of diabetes, use of specific anti-
hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-
lowering drugs, smoking (ever/never), alcohol consumption (ever/never), BMI, SBP 
and DBP, HbA1c, fasting glucose, HDL-C, total cholesterol, CRP and fibrinogen, 
liver enzymes, liver disease, and eGFR. All the above covariates were measured at 
year 1 of the ET2DS, the baseline for this analysis, with exception of age, CRP and 
fibrinogen, whose values were taken from the baseline of the original ET2DS, year 
zero. The cross-sectional analysis in the SIDIAP study included the above mentioned 
covariates except fibrinogen, CRP, fasting glucose, and transaminases levels, but 
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additionally included WBC and triglyceride levels. Liver enzyme levels, glucose, 
cholesterol, CRP, and duration of diabetes had skewed distributions and were log-
transformed for the longitudinal analysis in the ET2DS. Skewed distribution of 
eGFR could not be approximated to normal distribution by any method of 
transformation and was used in its original form. The associations found did not 
differ whether untransformed or transformed variables were used in the analyses. 
The statistical tests were two-tailed to investigate associations with either low or high 
iron status. Further adjustment for anaemia (and haemoglobin levels), social class, 
and aspirin consumption were conducted to verify independent relationships where 
associations with iron status were found. A p value <0.05 was set as statistically 




Three differences were observed in the study variables between included and 
excluded subjects in the ET2DS (Appendix Table 33). The people who were 
included had lower values of transaminase levels, HbA1C, and eGFR than the people 
who were excluded. In the SIDIAP study, the included group was older, had more 
women, longer duration of diabetes, and higher proportions of pharmacological 
treatments and CVD than the excluded group (Appendix Table 34). The subjects 
excluded had higher prevalence of smoking (ever) and alcohol intake (ever) and 
higher levels of all biochemical and clinical variables with the exception of HbA1C, 
SBP, and HDL-C for which there was no significant statistical difference between 
the groups.  
 
Individuals in the ET2DS were younger, had higher ferritin levels, and higher 
proportion of subjects on lipid-lowering treatment and with history of smoking and 
alcohol consumption than those in the SIDIAP study (Appendix Table 35). The 
subjects from the SIDIAP study showed higher levels of DBP and serum total 
cholesterol and a larger proportion were treated with insulin (Appendix Table 35) 
than those from the ET2DS. At baseline, the prevalence of CHD, CEVD, and CVD 
was higher in the ET2DS than in the SIDIAP study (Appendix Table 35). In the 
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ET2DS, fasting glucose and inflammatory markers were also measured 
[median(interquartile range): glucose 6.4 (5.4–7.9) mmol/L; fibrinogen 3.5 (3.1–4.0) 
g/L; CRP 1.7 (0.8–4.0) mg/L; GGT 17 (10–31) U/L; ALT 31 (26–39) U/L; AST 29 
(24–35) U/L]. Prevalence of liver disease was 1.5 % (n = 12) in the ET2DS. In the 
SIDIAP study, triglyceride levels [median (interquartile range): 1.4 (1.0–1.9) 
mmol/L], and white blood cells count (as inflammatory marker) 
[median(interquartile range): 7200 (6000–8500) cells/µL] were measured. 
 
6.3.1 Cross-sectional associations  
As expected, serum ferritin levels were significantly lower in women than in men in 
both the ET2DS [median, interquartile range 56 (23–100) µg/L vs. 96.5 (45.5–179.2) 
µg/L (P < 0.0001)] and the SIDIAP study [46.1(21–101) µg/L vs. 97.0 (39.0–208) 
µg/L (P < 0.0001)]. In both studies, CVD was more prevalent in men than in women 
[in the ET2DS: CVD, 41% vs. 28.1% (P < 0.001), CHD, 36.3% vs. 24.3% (P < 
0.001), and CEVD, 10.9 vs. 6.3% (P = 0.018); in the SIDIAP study: CVD, 28.5 % v. 
16.3% (P < 0.001), CHD, 22.0% vs. 11.4% (P<0.001), and CEVD, 9.1% vs. 5.9% (P 
< 0.001)].  
 
SIDIAP study 
The study variables of the 38,617 patients with T2D are described by sex-specific 
quintiles of ferritin in Table 17. The proportion of subjects reporting alcohol intake 
increased across the quintiles of serum ferritin. In this large population, the duration 
of diabetes and proportion of individuals taking oral anti-hypoglycaemic drugs 
decreased across quintiles of ferritin. The same pattern occurred with values of 
HbA1C, SBP, and eGFR and with the proportion of cases with insulin, 
antihypertensive, and lipid-lowering treatments. There were positive dose-response 
relationships between serum ferritin concentration, serum total cholesterol, and 
triglyceride levels. There were higher proportions of people with CHD, CEVD, and 
CVD in the lower compared to the higher quintiles of ferritin (Table 17). 
 
Among subjects from the SIDIAP study, ferritin, both as a continuous variable or in 
quintiles, was significantly inversely related to the likelihood of having CHD, 
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CEVD, or either diseases (Table 18). Similar findings were obtained in analyses 
stratified by sex (Appendix Table 36).  
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Table 17  Characteristics of people with type 2 diabetes by sex-specific quintiles of ferritin level in the SIDIAP study (n=38617) 
 Ferritin (µg/L)  
 Q1 (n=7712) Q2(n=7740) Q3(n=7724) Q4(n=7732) Q5(n=7709) P for trend 
Sex Male/Female n 3283/4429 3275/4465 3296/4428 3290/4442 3279/4430  
Ferritin levels range by sex (µg/L)       
Men (n=14757) 3.0-31.3 31.4-69.9 70.0-131.1 131.2-244 244.1-3507.8  
Women (n=19847) 1.0-17.7 17.8-34.0 34.1-62.0 62.1-121 121.1-3682.1  
Variables       
Age (years) 74 (65-79) 75 (66-80) 74 (65-80) 72 (63-80) 71 (63-79) <0.001 
Duration of diabetes (years) 7.8 (5.4-11.5) 7.7 (5.2-11.1) 7.5 (4.6-10.8) 7 (3.6-9.9) 6.2 (2.6-8.8) <0.001 
Ferritin (µg/L)  13.3 (9.9-17) 31.6 (23.9-44.6) 57.6 (44.6-92) 110.1 (82-168.2) 273 (178.3-390.9) <0.001 
HbA1C (%) 7.1 (6.5-8) 7 (6.4-7.9) 6.9 (6.3-7.8) 6.8 (6.3-7.7) 6.8 (6.2-7.6) <0.001 
White blood cells count (cells/µL) 7.2 (6-8.5) 7.2 (6-8.5) 7.2 (6-8.6) 7.1 (6-8.5) 7.2 (6-8.6) 0.364 
Smoking [ever]n(%) 2463 (31.9) 2202 (28.4)  2220 (28.7) 2274 (29.4) 2328 (30.2) <0.001 
Alcohol consumption [ever] n(%)  1338 (17.3) 1374 (17.8) 1567 (20.3)  1706 (22.1) 1897 (24.6)  <0.001 
BMI (Kg/mts2)  29.4 (26.5-33) 29.4 (26.3-32.8) 29.3 (26.4-32.9) 29.3 (26.4-32.9) 29.3 (26.3-32.9) 0.217 
SBP mmHg 135 (125-142) 134 (125-141) 134 (125-141) 135 (125-141) 134 (125-140) <0.001 
DBP mmHg 73 (67-80) 73 (66-80) 74 (67-80) 73 (68-80) 75 (68-80) <0.001 
Total cholesterol mg/dl 4.52 (3.93-5.14) 4.57 (3.98-5.24) 4.62 (4.0-5.24) 4.68 (4.06-5.35) 4.73 (4.0-5.43) <0.001 
HDL-cholesterol mg/dl  1.21 (1.03-1.44) 1.21 (1.03-1.44) 1.24 (1.03-1.47) 1.24 (1.03-1.47) 1.21 (1.03-1.44) 0.403 
Triglycerides mg/dl  1.43 (1.06-1.97) 1.43 (1.06-1.97) 1.41(1.03-1.96) 1.42 (1.05-1.97) 1.51 (1.10-2.10) <0.001 
eGFR, mL/min/1.73 m2 * 60 (58.5-60) 60 (52.9-60) 60 (52.3-60) 60 (53.5-60) 60 (53.4-60) <0.001* 
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 Ferritin (µg/L)  
 Q1 (n=7712) Q2(n=7740) Q3(n=7724) Q4(n=7732) Q5(n=7709) P for trend 
Oral hypoglycaemic drugs n(%)  6503 (84.3) 6185 (79.9) 5952 (77.1) 5575 (72.1) 5116 (66.4) <0.001 
Antihypertensive drugs n(%)  6312 (81.8) 6506 (84.1) 6284 (81.4) 6066 (78.5) 5896 (76.5) <0.001 
Insulin therapy n(%) 2026 (26.3) 1997 (25.8) 1808 (23.4) 1606 (20.8) 1378 (17.9) <0.001 
Lipid-lowering drugs n(%) 4961 (64.3) 4869 (62.9) 4944 (64) 4669 (60.4) 4327 (56.1) <0.001 
CHD n(%) 1504 (19.5) 1429 (18.5) 1296 (16.8) 1034 (134) 880 (11.4) <0.001 
CEVD n(%) 668 (8.7) 626 (8.1) 572 (7.4) 511 (6.6) 435 (5.6) <0.001 
CVD n(%) 2008 (26) 1894 (24.5) 1723 (22.3) 1441 (18.6) 1220 (15.8) <0.001 
Data are median (interquartile range) or n (%). * Values higher than 60 were recorded as 60. P for trend across quintiles by Jonckheere-Terpstra Test 
(continuous variables) and 2 tests (categorical variables). Q, quintile. CI, confidence interval. HDL-C, HDL cholesterol. BMI, body mass index. eGFR, 
estimate glomerular filtration rate. HbA1C, glycosylated haemoglobin. SBP, systolic blood pressure. DBP, diastolic blood pressure.*Negative trend is 




Table 18 Odds ratios and 95% confidence interval for prevalent cardiovascular disease by ferritin 
levels in the SIDIAP study (n=38,617) 
 Model 1 Model 2 Model 3 
CHD    
Ferritin 
(Z score of log-ferritin) 
0.76 (0.73-0.79) 
P<0.001 
0.78 (0.75-0.81) P<0.001 0.83 (0.80-0.87) P<0.001 
Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.93 (0.86-1.01) 0.89 (0.82-0.97) 0.91 (0.83-0.99) 
Ferritin Quintile 3 0.83 (0.76-0.90) 0.81 (0.74-0.88) 0.85 (0.77-0.93) 
Ferritin Quintile 4 0.63 (0.58-0.69) 0.64 (0.59-0.70) 0.71 (0.64-0.78) 
Ferritin Quintile 5 0.53 (0.48-0.58) 0.55 (0.50-0.60) 0.62 (0.56-0.69) 
P for trend P<0.001 P<0.001 P<0.001 
CEVD    
Ferritin 




0.91 (0.86-0.95) P<0.001 0.92 (0.88-0.97) P=0.001 
Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.92 (0.82-1.03) 0.88 (0.78-0.99) 0.88 (0.78-0.99) 
Ferritin Quintile 3 0.84 (0.75-0.94) 0.82 (0.73-0.92) 0.83 (0.73-0.93) 
Ferritin Quintile 4 0.74 (0.66-0.84) 0.76 (0.67-0.85) 0.79 (0.70-0.89) 
Ferritin Quintile 5 0.63 (0.55-0.71) 0.66 (0.58-0.75) 0.69 (0.60-0.78) 
P for trend P<0.001 P<0.001 P<0.001 
CVD    
Ferritin 




0.82 (0.79-0.84) P<0.001 0.85 (0.83-0.88) P<0.001 
Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.92 (0.85-0.98) 0.87 (0.81-0.94) 0.88 (0.82-0.96) 
Ferritin Quintile 3 0.81 (0.75-0.87) 0.79 (0.73-0.85) 0.81 (0.73-0.88) 
Ferritin Quintile 4 0.65 (0.60-0.70) 0.65 (0.60-0.70) 0.71 (0.65-0.77) 
Ferritin Quintile 5 0.53 (0.49-0.57) 0.54 (0.50-0.59) 0.61 (0.55-0.66) 
P for trend P<0.001 P<0.001 P<0.001 
CHD, coronary heart disease. CEVD, cerebrovascular disease. CVD, cardiovascular disease. 
Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: adjusted for adjusted for age, 
sex, duration of diabetes, use of specific anti-hyperglycaemic agents, treatment with insulin, 
lipid-lowering drugs, blood pressure-lowering drugs, smoking status, alcohol consumption, 
BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, HDL-cholesterol, 
total cholesterol, white blood cells count, triglycerides level, and estimated glomerular filtration 





Study variables at baseline are described by sex-specific quintiles of ferritin in Table 
19. Duration of diabetes and values of blood glucose, CRP, transaminases, and DBP 
increased across quintiles of ferritin. As in the SIDIAP study, there were higher 
proportions of individuals reporting alcohol consumption across increasing levels of 
ferritin, and use of oral anti-hyperglycaemic drugs, and duration of diabetes 
decreased across increasing levels of ferritin. CVD prevalence tended to decrease 
across ferritin quintiles (P for trend = 0.092) (Table 19).  
 
Table 20 shows cross-sectional associations of ferritin with cardiovascular diseases 
at baseline. An inverse association of ferritin levels as continuous variable with CHD 
and any cardiovascular event was significant after adjustment for sex and age and 
remained significant after full adjustment. Analyses by sex showed that for women, 
but not for men, there was a significant inverse association between ferritin (highest 
vs. lowest quintile), CHD, and having any cardiovascular event after full adjustment 
[OR (95%CI) CHD 0.38 (0.15–0.97), P = 0.043; CVD: 0.40 (0.16–0.96), P = 0.041] 












Table 19 Baseline characteristics of people with type 2 diabetes by sex -specific quintiles of ferritin level in the ET2DS (n=821) 
 Q1 (n=162) Q2(n=164) Q3(n=167) Q4(n=164) Q5(n=164) P for trend 
Sex Male/Female n 84/78 85/79 85/82 84/80 84/80  
Ferritin levels range by sex (µg/L)      
Men (n=422) 7-36 37-74 75-123 124-198 199-1095  
Women (n=399) 5-20 21-38 39-69 70-119 120-605  
Variables       
Age (years) 69.9(65.5-72.7) 68.4(65.2-71.5) 68.6(65.2-72.5) 68.9(64.8-72.1) 69.7(65.5-72.8) 0.751 
Duration of diabetes (years) 9(5-14) 8(4-13) 8(5-11) 7(4-10) 5(3-10) <0.001 
Ferritin (µg/L) 17(11-25.2) 38(28-52) 75(55-98) 124(87-162.5) 246(177.5-338) <0.001 
Glucose mmol/L 6.2(5.0-8.0) 6.5(5.5-7.9) 6.3(5.3-7.5) 6.4(5.4-7.9) 6.7(5.8-8.2) 0.011 
HbA1C (%) 7.0(6.4-7.9) 7.0(6.5-7.7) 7.0(6.4-7.5) 7.0(6.4-7.7) 7.0(6.4-7.8) 0.525 
Fibrinogen (g/L) 3.5(3.1-4.0) 3.7(3.1-4.1) 3.6(3.0-4.21) 3.5(3.1-3.9) 3.5(3.1-4.0) 0.781 
CRP(mg/L) 1.5(0.7-3.0) 1.5(0.7-3.9) 1.8(0.8-4.6) 2.1(1.1-4.3) 2.2(1.0-4.5) <0.001 
GGT(U/L) 13(8-25.5) 14(9.0-23) 17(10-29) 17.5(10-31.7) 24.5(13-44.7) <0.001 
ALT(U/L) 29(24-34) 28(25-36) 31(25-36) 34(27.2-41) 36(28-47) <0.001 
AST(U/L) 27(22-32) 27(24-32) 28(24-33) 29(25-34.7) 33(27-41) <0.001 
Smoking [ever] n(%) 101(62.3) 89(54.3) 101(60.5) 103(62.8) 96(58.5)  
Alcohol consumption [ever] 
n(%) 
124(76.5) 129(78.7) 143(85.6) 136(82.9) 141(86) <0.001 
BMI (Kg/mts2)  30.8(27.6-34.4) 30.5(26.7-34.1) 30.2(27.3-33.8) 30.6(27.1-35.4) 30.7(27.9-34.0) 0.485 
SBP mmHg 132(120-142) 132(122-142) 130(122-140) 133(120-142) 134(124-144) 0.685 
DBP mmHg 68(60-74) 68(62-74) 70(62-76) 70(64-76) 70(64-78) 0.031 
HDL-cholesterol (mmol/L) 1.3(1.1-1.5) 1.3(1.1-1.5) 1.2(1.1-1.4) 1.2(1.0-1.4) 1.2(1.0-1.5) 0.006 
Total cholesterol (mmol/L) 4.1(3.7-4.6) 4.2(3.8-4.7) 4.1(3.6-4.8) 4.3(3.8-4.9) 4.2(3.7-4.8) 0.166 
eGFR, mL/min/1.73 m2 60(60-65.2) 60(60-71) 60(60-72) 60(60-73) 60(60-68.5) 0.757 
Oral hypoglycaemic drugs 
n(%) 
137(84) 134(81.7) 124(74.3) 119(72.6) 93(56.7) <0.001 
Antihypertensive drugs n(%) 145(89.5) 139(84.8) 147(88) 136(82.9) 138(84.1) 0.147 
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 Q1 (n=162) Q2(n=164) Q3(n=167) Q4(n=164) Q5(n=164) P for trend 
Lipid-lowering drugs n(%) 147(90.7) 132(80.5) 139(83.2) 137(83.5) 136(82.9) 0.168 
Insulin therapy n(%) 28(17.3) 25(15.2) 27(16.2) 21(12.8) 22(132.4) 0.250 
Liver disease n(%) 2(1.2) 0(0) 1(0.6) 6(3.7) 3(1.8) 0.102 
Outcomes at baseline n(%)       
CHD 59(36.4) 48(29.3) 50(29.9) 49(29.9) 44(26.8) 0.104 
CEVD 15(9.3) 15(9.1) 12(7.2) 19(11.6) 10(6.1) 0.576 
CVD (any cardiovascular 
event)  
67(41.4) 58(35.4) 52(31.1) 55(33.5) 53(32.3) 0.092 
Outcomes after follow-up       
Development of CHD  21(13) 12(7.3) 16(9.6) 20(12.2) 9(5.5) 0.107 
Development of CEVD  17(10.5) 7(4.3) 10(6.0) 9(5.5) 11(6.7) 0.306 
Development of CVD  35(21.6) 17(10.4) 24(14.4) 27(16.5) 20(12.2) 0.168 
Data are median (interquartile range) or n(%). P for trend across quintiles by Jonckheere-Terpstra Test (continuous variables) and 2 tests 
(categorical variables). Q, quintile. CI, confidence interval. HDL-C, HDL cholesterol.. BMI, body mass index. GGT, gamma-glutamyl 
transpeptidase. ALT, Alanine aminotransferase. AST, Aspartate aminotransferase. CRP, C reactive protein. eGFR, estimate glomerular 




Table 20 Odds ratios and 95% CI for prevalent cardiovascular events by ferritin levels in the 
ET2DS (n=821) 
 Model 1 Model 2 Model 3 
CHD    








Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.72(0.45-1.14) 0.74(0.46-1.19) 0.82(0.49-1.37) 
Ferritin Quintile 3 0.74(0.47-1.18) 0.76(0.48-1.22) 0.64(0.38-1.08) 
Ferritin Quintile 4 0.74(0.46-1.18) 0.76(0.47-1.21) 0.76(0.44-1.29) 
Ferritin Quintile 5 0.64(0.39-1.02) 0.63(0.39-1.02) 0.61(0.35-1.06) 
P for trend 0.104 0.103 0.094 
CEVD    








Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.98(0.46-2.09) 0.98(0.46-2.09) 1.09(0.49-2.39) 
Ferritin Quintile 3 0.75(0.34-1.67) 0.76(0.34-1.68) 0.69(0.30-1.60) 
Ferritin Quintile 4 1.28(0.62-2.62) 1.28(062-2.64) 1.44(0.66-3.15) 
Ferritin Quintile 5 0.63(0.27-1.46) 063(0.27-1.46) 0.77(0.31-1.92) 
P for trend 0.576 0.583 0.926 
CVD    








Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.77(0.49-1.21) 0.79(0.50-1.25) 0.88(0.54-1.45) 
Ferritin Quintile 3 0.64(0.40-1.00) 0.65(0.41-1.03) 0.53(0.32-0.88) 
Ferritin Quintile 4 0.71(0.45-1.12) 0.72(0.46-1.14) 0.70(0.41-1.17) 
Ferritin Quintile 5 0.67(0.43-1.06) 0.67(0.42-1.06) 0.64(0.37-1.10) 
P for trend 0.093 0.091 0.066 
CI, confidence interval. CHD, coronary heart disease. CEVD, cerebrovascular disease. CVD, 
cardiovascular disease. Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: 
adjusted for adjusted for age, sex, duration of diabetes, use specific anti-hyperglycaemic agents, 
treatment with insulin, lipid-lowering drugs, blood pressure-lowering drugs, smoking status, 
alcohol consumption, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), 
HbA1c, fasting glucose, HDL-cholesterol, total cholesterol, C reactive protein (CRP), fibrinogen, 
transferases levels, liver disease and estimated glomerular filtration rate (eGFR) at baseline. 
Significant associations are shown in bold (P<0.05). 
154 
 
Longitudinal findings (ET2DS) 
After a mean follow-up of 6.1 ± 1.7 years (median, 6.7; interquartile range, 6.3–6.9), 
the number (proportion) of people with incident or recurrent outcomes was as 
follows: 123 (15%) with either CHD and/or CEVD, 78 (9.5%) with CHD, and 54 
(6.6%) with CEVD. Nine people experienced both types of events during the follow-
up. Among participants without disease at baseline (n = 536) with a mean follow-up 
of 6.2 ± 1.5 years [median 6.7 (6.4–7.0)], there were 60 participants (11.2%) with 
incident CVD, 38 (7.1%) with incident CHD, and 25 (4.7%) with incident CEVD. 
There was no significant difference by sex in the number of incident or recurrent 
cases for CVD (57 men, 66 women), CHD (34 men, 38 women), or CEVD (32 men, 
22 women) during follow-up. There were 132 (16.1%) deaths during the follow-up, 
with 26 of the deaths (19.6%) due to CVD, of which 19 were attributable to CHD. 
 
HRs and 95%CI for incident/recurrent CVD are shown in Table 21 for both 
standardised values and quintiles of ferritin. When comparing the extreme quintiles, 
ferritin was inversely associated with development of CHD and CVD in unadjusted, 
partially adjusted, and fully adjusted models [Fully adjusted HR (95%CI) CHD: 0.39 
(0.16–0.93), P = 0.035; any cardiovascular event: 0.50 (0.27–0.88), P = 0.044]. 
Moreover, further adjustment for prevalent CVD at baseline (model 4) did not affect 
the estimates and significance of the association [CHD: 0.39 (0.16–0.94), P = 0.036; 
any cardiovascular event: 0.50 (0.27–0.94), P = 0.044] (Table 21). There were no 
significant associations when ferritin was included in models as a continuous 
variable. When restricting the analyses to 536 people without prevalent CVD at 
baseline (Appendix Table 38), the longitudinal inverse associations between extreme 
quintiles for CHD and CVD was observed again [model 1, P = 0.016; model 2, P = 
0.017] although the associations had a marginal significance in the fully adjusted 
model [CHD: 0.28 (0.07–1.14), P = 0.078; CVD: 0.42 (0.16–1.08), P = 0.074] 
(Appendix Table 38), presumably owing to lower statistical power.  
 
I considered additional potential confounders influencing the inverse ferritin-
cardiometabolic risk association in the ET2DS and SIDIAP study. In the ET2DS, 
almost half of the subjects reported having higher income occupations (managerial, 
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administrative, and professional), 67.1% underwent treatment with aspirin, and 
prevalence of anaemia was 11.8% (97/814, 7 missing values) although only the 
distribution of anaemia varied significantly by ferritin quintiles (prevalence 26.1 % 
in quintile 1 and 6.1 % in quintile 5, 2 test P > 0.001). In the SIDIAP study, 43.8% 
of patients reported receiving antiplatelet agents and 39.9% had anaemia, and the 
distribution of these variables significantly decreased across ferritin quintiles 
(Antiplatelet agents 51.6% in quintile 1 and 32.8% in quintile 5, 2 test P > 0.001; 
Anaemia 59.9 % in quintile 1 and 31.4 % in quintile 5, 2 test P > 0.001). 
 
The inverse associations between ferritin and CVD in the ET2DS and the SIDIAP 
study did not substantially change after further adjustment for the above covariates 
(P < 0.05). The same occurred when individuals with extremely high serum ferritin 
levels were excluded (>300 µg/L, n = 54 in ET2DS and n = 3,239 in SIDIAP study). 
After excluding individuals with iron deficiency in the ET2DS (ferritin<15 µg/L, 
n=72), the association of ferritin with prevalent CHD was weakened presumably due 
to lower statistical power [fully adjusted HR (95%CI) 0.84(0.66-1.07), P=0.179], but 
the association with incident/recurrent CHD remained similar [ferritin highest v. 
lowest quintile fully adjusted HR (95%CI) 0.37(0.14-0.97), P= 0.045]. On the other 
hand, the inverse association between higher ferritin (highest v. lowest quintile) and 
incident CHD in subjects with no prevalent CVD at baseline reached statistical 
significance and the association was slightly strengthened [HR (95%CI) 0.22(0.05-
0.95), P= 0.043]. However, this might be a chance finding since it was not consistent 
with the above effects of removing individuals with iron deficiency in a larger 
sample. No other substantial changes in effect estimates or statistical significance 
were observed when individuals with iron deficiency were removed. In addition, I 
performed an analysis limited to individuals aged 60–75 years of age from the 
SIDIAP study (n = 16,491), to confirm comparability of age group with the ET2DS 
cohort, and the associations between ferritin, CHD, CVED, and CVD remained 
similar. The same was true for associations between ferritin, CHD, and CVD in 
individuals younger than 60 years (n = 5,857). There was no evidence of a J or U-
shape association on comparing extreme quintiles and middle quintiles together (2, 3, 




Despite the differences previously described between included and excluded 
individuals in the SIDIAP study, the inverse association between ferritin and CVD 
outcomes in the excluded individuals was also statistically significant. To test the 
above, I used partial models of adjustment (age, sex, duration of diabetes, and one 
more covariate at the time) since a total adjustment was not feasible owing to 





Table 21 HRs and 95% CI for incident/ recurrent cardiovascular events by ferritin levels in the 
ET2DS (n=821) 
 Model 1 Model 2 Model 3 Model 4 
CHD     










Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.52(0.25-1.06) 0.54(0.26-1.10) 0.63(0.30-1.31) 0.63(0.30-1.31) 
Ferritin Quintile 3 0.70(0.36-1.34) 0.71(0.37-1.37) 0.68(0.34-1.37) 0.70(0.35-1.42) 
Ferritin Quintile 4 0.88(0.48-1.64) 0.91(0.49-169) 0.95(0.48-1.86) 0.97(0.49-1.92) 
Ferritin Quintile 5 0.38(0.17-0.84) 0.38(0.17-0.83) 0.39(0.16-0.93) 0.39(0.16-0.94)  
P for trend 0.132 0.122 0.170 0.186 
CEVD     










Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.37(0.15-0.90) 0.38(0.15-0.92) 0.54(0.21-1.35) 0.54(0.21-1.34) 
Ferritin Quintile 3 0.52(0.24-1.15) 0.53(0.24-1.17) 0.55(0.24-1.25) 0.56(0.24-1.28) 
Ferritin Quintile 4 0.47(0.21-1.06) 0.48(0.21-1.07) 0.57(0.23-1.38) 0.58(0.24-1.40) 
Ferritin Quintile 5 0.58(0.27-1.25) 0.57(0.27-1.23) 0.66(0.27-1.58) 0.66(0.27-1.59) 
P for trend 0.236 0.218 0.344 0.351 
CVD     










Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.43(0.24-0.77) 0.44(0.25-0.79) 0.54(0.29-0.98) 0.54(0.29-0.98) 
Ferritin Quintile 3 0.61(0.36-1.03) 0.62(0.37-1.05) 0.62(0.35-1.07) 0.64(0.37-1.11) 
Ferritin Quintile 4 0.70(0.42-1.16) 0.72(0.43-1.19) 0.78(0.45-1.35) 0.80(0.46-1.38) 
Ferritin Quintile 5 0.50(0.29-0.87) 0.49(0.29-0.86)  0.50(0.27-0.94)  0.50(0.27-0.94) 
P for trend 0.104 0.093 0.116 0.123 
HR, hazard ratio. CI, confidence interval. CHD, coronary heart disease. CEVD, 
cerebrovascular disease. CVD, cardiovascular disease. Model 1: unadjusted. Model 2: adjusted 
for age and sex. Model 3: adjusted for adjusted for age, sex, duration of diabetes, use specific 
anti-hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-
lowering drugs, smoking status, alcohol consumption, BMI, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), HbA1c, fasting glucose, HDL-cholesterol, total cholesterol, C 
reactive protein (CRP), fibrinogen, transferases levels, liver disease and estimated glomerular 
filtration rate (eGFR) at baseline. Model 4: Model 3 plus prevalent cardiovascular disease at 
baseline. Values of transaminases levels, glucose, cholesterol, CRP and duration of diabetes 




This chapter described independent, inverse cross-sectional, and prospective 
associations between ferritin levels and CVD in representative samples of people 
with T2D from Catalonia, Spain and from Scotland. The multivariate adjusted 
estimates are similar to the previous unadjusted cross-sectional observations by 
Hermans et al. (210), suggesting that the inverse association between ferritin levels 
and incident or recurrent CVD in people with T2D is also observed in larger samples 
in a prospective design and in populations at different levels of cardiovascular risk. 
This pattern differs from the pattern of iron excess and cardiometabolic risk 
commonly described in the general population. However, paradoxically, ferritin in 
both studies also presented positive cross-sectional associations with cardiovascular 
risk factors such as fasting glucose and diastolic blood pressure and negative 
association with HDL-C, as observed in general populations.  
 
6.4.1 Comparison with other studies 
As mentioned above, there are few other studies to which I can compare the findings 
in this chapter. Besides the cross-sectional evaluation by Hermans et al. (210), two 
studies investigated the iron status among people with vascular complications of 
diabetes, and their aims, outcomes, or design were different from those of the present 
study. In one of them, iron depletion by phlebotomy in people with diabetes and 
peripheral arterial disease (n = 636, controls 641) was not found to affect all-cause 
mortality or incidence of cardiovascular events (214). In the other one, both low and 
high ferritin levels, and high sTfR levels were associated with 5-year all-cause 
mortality rate in 287 people with diabetes and stable coronary artery disease (29). 
My results are similar in part to those of this latter study, in terms of a pattern of low 
iron status (low ferritin, high sTfR) being associated with poor prognosis in people 
with T2D, although I did not observe U or J-shaped associations. A nested case-
control study (n = 60 cases of myocardial infarction; 112 controls) from the 
Rotterdam Study cohort reported marginal association between high ferritin (highest 
tertile) and myocardial infarction with stronger associations in subgroups of smokers 
and people with diabetes (215). However, the very small sample size in those sub-
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groups (n = 34 subjects with diabetes) along with multiple testing did not provide 
conclusive evidence of the association.  
 
6.4.2 Cross-sectional and prospective associations – Inverse 
but slightly different  
The cross-sectional association of prevalent CVD with ferritin levels showed a clear 
inverse pattern in the ET2DS and SIDIAP study. In the ET2DS, the inverse cross-
sectional ferritin-CVD association was mainly based on CHD and the association in 
women, whereas in the SIDIAP study, there were associations of ferritin with all 
cardiovascular outcomes in both sexes. In the ET2DS, although the longitudinal 
inverse ferritin-incident/recurrent CVD association did not show a linear pattern as 
seen in the cross-sectional analysis of the same study, an inverse association between 
iron status and incident/recurrent CVD was observed when comparing extreme 
quintiles. Low iron status could explain the higher cardiovascular risk, since the ORs 
were lower than one across increasing quintiles of ferritin when compared with the 
lowest quintile of ferritin, which reflects iron deficiency. Although iron excess has 
been the most reported iron imbalance associated with IR and development of 
diabetes and MetS in general populations, its association with cardiovascular disease 
is still controversial. Iron excess reflected in high ferritin levels was positively 
associated with incident CHD in Finnish men but subsequent studies failed to 
replicate this association (157). In line with the findings of this chapter, a significant 
negative association between transferrin saturation and development of coronary 
artery disease or myocardial infarction has been identified in the general population 
in a recent meta-analysis, leading to the conclusion that high body iron stores could 
confer protection against development of CHD (183). However, as mentioned in the 
discussion in Chapter 5, in that meta-analysis, no significant association was found 
between serum ferritin, total iron-binding capacity, serum iron, and CHD. Similarly, 
recent research has been focused on anaemia/iron deficiency as a frequent 




6.4.3 Adjustment model and its lack of effects on the 
associations 
Since I found an inverse association between iron status and development of CHD, it 
is not surprising that covariates of body mass and markers of liver injury, glucose 
metabolism, and inflammation did not substantially attenuate the association. In 
general, these covariates are used as confounding factors for positive associations 
since they are related to increasing ferritin levels and higher cardiometabolic risk. 
The pattern of lower iron status and higher cardiovascular risk in people affected by 
T2D appears to be similar to the case of lower BMI and higher risk of diseases and 
death in certain populations, a phenomenon knowns as the obesity paradox. In people 
with T2D and cardiovascular complications, a modestly higher BMI is associated 
with lower risk of death(217). There is not a clear explanation for this phenomenon, 
although residual confounding from inaccurate measurement of smoking status, 




6.4.4 Implications of additional adjustments and controversy 
about the association between iron status and CVD 
Given the direction of the associations found, I evaluated additional covariates that 
might contribute to increased CVD risk across quintiles 1–5 of ferritin levels. 
Anaemia has been previously found to be a predictor of CHD among 14,410 
individuals (218). Ventricular remodelling, cardiac dysfunction, or myocardial 
ischemia could be an underlying mechanism (218). There have also been reports on 
decreased peripheral endothelial progenitor cells with impaired function and 
vulnerable plaque components in patients with acute coronary syndrome and 
anaemia (219). Anaemia is a common finding in patients with diabetes owing to the 
high burden of renal complications in this population (220). However, anaemia or 
haemoglobin levels did not substantially affect the inverse association of ferritin with 
prevalent or incident recurrent CHD in the studies reported in this chapter. This can 
be interpreted as follows: 1) low iron stores either with and without progression to 
impaired erythropoiesis are associated with prevalent cardiovascular complications 
in people with T2D, and deleterious effects of anaemia on vascular function are not 
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mediating that association, and 2) normal haemoglobin status is not the cause of an 
apparent protective effect of high ferritin for lower risk of incident CHD and CVD. 
The above findings support previous observations, indicating that iron deficiency is 
not the main cause of anaemia and, if present, it does not necessarily lead to anaemia 
in people with diabetes (221). 
 
Aspirin consumption is well known for promoting iron loss by occult bleeding, and 
low serum ferritin could be linked to the anti-inflammatory action of aspirin on 
cytokine-induced ferritin production in people with inflammatory conditions (222). 
Hermans et al., in their cross-sectional study, did not find significant differences in 
ferritin levels between groups of people reporting aspirin consumption, but they did 
not perform any statistical adjustment for aspirin intake (210). In the present 
analyses, aspirin treatment had no influence on the inverse association between 
ferritin and CHD/CVD in full multivariable models. In some populations, low 
income or deprived sub-groups may have low body iron stores (223) and high rates 
of chronic diseases due to malnutrition (224). However, adjustment for social class 
did not affect the cross-sectional and longitudinal associations described in this 
chapter. 
 
6.4.5 CEVD and ferritin levels 
Ferritin was associated with CEVD in people with T2D from the SIDIAP study only. 
There are only a few studies and conflicting findings on the association between 
serum ferritin and stroke or CEVD in the general population as discussed in Chapter 
5. In people affected by T2D, only the study by Hermans et al. showed that stroke 
was more common in men with diabetes and higher ferritin (highest quartile vs. the 
lowest). Future studies should focus on different kinds of CEVD in people with T2D 
for better characterisation of the relationship between iron and CVD. The ferritin-
CEVD association may require a large sample size to give adequate statistical power 




6.4.6 High iron status: Protective factor? 
The inverse association between iron status and CVD also suggests that high iron 
status is a protective factor against CVD in people with diabetes. Hermans et al. 
hypothesised this by highlighting the lesser known pleiotropic anti-oxidant properties 
of ferritin itself, potentially acting in a compensatory response to inflammation in 
T2D (210). Findings in murine models of oxidative stress-induced synthesis of iron 
proteins in diverse cell lines support this idea since inflammation is linked to 
increased oxidative stress (225). However, in the present study, the association was 
unaffected when adjusting for inflammatory markers such as CRP or fibrinogen 
levels.  
 
The findings may also be related to pleiotropic effects of ferritin on blood vessel 
formation. An in vitro study showed that ferritin stimulates proliferation of 
endothelial cells via inactivation of HKa, which is a potent angiogenesis inhibitor 
(226). Therefore, a higher iron status in T2D, in terms of high ferritin, might preserve 
the integrity of vascular tissue, decreasing the risk of cardiovascular injuries.  
 
High iron status as a protective factor for cardiometabolic risk in T2D could also be 
related to the course of T2D rather than the direct causal beneficial effects of ferritin. 
Systemic metabolic alterations triggered by T2D can encompass several regulatory 
pathways of iron metabolism affecting ferritin levels, circulating iron, and ultimately 
the cardiovascular risk attributable to iron. A recent study in mouse and in-vitro 
models confirmed that starvation leads to increased serum ferritin levels, hepatic and 
splenic iron retention, and decreased serum iron via gluconeogenesis, a persistently 
active pathway in T2D, with a subsequent increase in the levels of the hormone 
hepcidin (227). In other words, high ferritin levels in T2D could reflect circulatory 
iron depletion which would help avoid the pro-oxidant effects of iron on vascular 
function. It is also likely that T2D influences iron proteins through other mechanisms 





An increased level of circulating ferritin, as a mechanism to prevent oxidative 
damage, might be another plausible explanation for the inverse association between 
serum ferritin and CVD in T2D patients. Ferritin levels may have a dual role with 
regard to free iron and its harmfulness. High serum ferritin indicates high body iron 
accumulation, but these raised levels of the protein are also an attempt to catch the 
free iron and prevent oxidative damage. It can be assumed that there is residual free 
iron in iron overload despite very high levels of ferritin. Therefore, low ferritin levels 
may predispose one to oxidative damage by free iron if there is down-regulation of 
ferritin synthesis in T2D despite normal or high iron intake.  
 
 
6.4.7 Consistency of the association in two different 
populations 
Scotland and Catalonia have very different cardiovascular risk profiles even among 
people with T2D as illustrated by the higher prevalence of CVD in the ET2DS than 
in the SIDIAP populations. Scotland has one of the highest CHD mortality rates in 
Europe, and the decline in CHD mortality since 1994 now appears to be slowing in 
young adults (228, 229). Moreover, the prevalence of well-known CVD risk factors 
increased between 1995 and 2008 in the Scottish population (229). The prevalence of 
self-reported diabetes increased by 0.12% per year, and the prevalence of self-
reported hypertension was 4.3% higher in 2008 than in 1995 (229). Lower rates of 
coronary events were noted in the Catalan population than in the Scottish populations 
in the MONICA study, which compared risk factor prevalence and CVD outcomes 
among 21 countries during 10-year follow-up from early 1980’s till early 1990’s 
(230, 231). Lifestyle, mostly Mediterranean diet, seems to offer cardiovascular 
benefits in term of better lipid profiles, insulin sensitivity, and blood pressure, with 
concomitantly reduced CVD risk (232). Despite the differences mentioned above, the 
association between low ferritin and higher CVD risk was consistent in T2D patients 
in the Scottish and Catalan populations analysed in this chapter, mainly on the basis 
of CHD. Thus, geographical and cultural differences may not influence the iron-
cardiometabolic risk relationship in people with T2D. However, further studies in 




6.4.8 Paradox: Inverse association with established CVD but 
positive with cardiovascular risk factors 
It is important to highlight that there appears to be a coexistence of both iron excess 
and low iron status patterns with regard to cardiometabolic risk factors in people with 
T2D. In the analyses of this chapter, cross-sectional positive dose-response 
relationships of serum ferritin were observed with glucose, triglycerides, and blood 
pressure. Similarly, Hermans et al. found lower prevalence of cardiovascular 
complications but higher IR index in their population of people with diabetes with 
higher serum ferritin levels. However, it is unclear why there was no consistent 
pattern in the relationship between ferritin and CVD and its risk factors. Survival 
bias may be a possible explanation if cases with high ferritin had died prior to having 
the opportunity to join the ET2DS cohort. Future studies should also focus on 
longitudinal associations of iron markers and risk factors of CVD in people affected 
by T2D to examine if the conflicting pattern persists over time. 
 
6.4.9 Strengths and weaknesses 
To the best of my knowledge, the ET2DS is the first longitudinal study in which it 
has been possible to describe the association between body iron stores and 
cardiovascular complications in T2D patients. Additional strengths of this study 
included the use of large and representative samples of people with T2D and a broad 
set of covariates in an attempt to identify an independent association. 
 
CRP, haemoglobin, and fibrinogen levels were measured at the original baseline of 
the ET2DS, one year before the ferritin levels were measured. However, CRP and 
haemoglobin levels were related in a dose-response manner to ferritin quintiles, in 
line with the positive associations between these markers as observed in diverse 
populations (233, 234), although with variable and modest strength in the case of 
CRP (26, 140, 235).  
 
There were slight differences in definitions of CHD and CEVD between the ET2DS 
and the SIDIAP studies owing to the predetermined ways of establishing the disease 
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variables in each study. This may have led to biased findings on the ferritin-CEVD 
association, which was significant in the SIDIAP study only, but as mentioned 
previously, this discrepancy could also be related to the greater statistical power of 
the SIDIAP study. On the other hand, the inverse ferritin-CHD association was 
consistent in both studies.  
There is potential for selection bias in the SIDIAP cohort because serum ferritin 
measurement was probably performed in subjects suspected of having anaemia and 
iron disorders. Because of this, only around 10 % of the original SIDIAP sample 
could be used in the study. As mentioned in Chapter 5, multiple imputation 
techniques may help to deal with potential bias derived from missing values. The 
same disadvantages or limitations to impute data described in Chapter 5, are also 
applicable to this analysis.  It is important to take into account that adjustment for 
anaemia did not affect the significance of the associations in the SIDIAP analysis. In 
addition, although excluded individuals (those with incomplete data) had different 
characteristics from those who were included in the analysis, the association between 
ferritin and CVD was present in included and excluded individuals (in partial models 
in the latter group due to missing data). Major selection bias in the SIDIAP study 
seems unlikely given that the ET2DS showed similar patterns of associations. There 
was also a difference in the age ranges of the studies evaluated, but the sensitivity 
analysis using identical age ranges did not alter the findings. Data regarding 
oxidative stress markers were not available and these would allow more robust 
adjustments and better inferences about the probable underlying mechanisms. The 
findings of this analysis should not be generalised before replication in other 




In this chapter, serum ferritin levels were inversely associated with prevalent, 
incident, and recurrent CVD in people with T2D. Although the underlying 
mechanisms behind this association remain unclear and further studies of 
representative populations are required, subclinical/clinical inflammation, BMI, lipid 
levels, concomitant treatment, markers of liver injury, glucose metabolism markers, 
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anaemia, aspirin intake, and duration of diabetes do not appear to be the primary 
explanatory variables. Iron deficiency seems to be harmful for cardiovascular health 
in the case of T2D and high iron status could play a protective role. However, it is 
also plausible that T2D could selectively influence iron proteins through unknown 
mechanisms and that residual confounding could have contributed to the association. 
As recently proposed, whether replenishing iron stores in patients with coronary 
artery disease and iron deficiency is beneficial or not cannot yet be answered with 
certainty (157). 
The next chapter will summarise and contrast the findings throughout all the chapters 











Chapter 7  
Summary and conclusions 
The aim of this chapter is to summarise the findings of this doctoral thesis and to 
discuss them within the context of the overall reflections and recommendations 
emerging from this research study. More detailed discussions regarding the analyses 
conducted have been presented in each specific chapter. 
7.1 Summary 
Figure 10 provides a summary of the findings of this PhD thesis using the same 
scheme as in Figure 1 of the introductory chapter which showed the relationships and 
gaps to be explored.  
Chapter 1 presented a review of empirical research literature on the relationship 
between iron metabolism and cardiometabolic risk, concepts surrounding iron 
markers, and the study outcomes. This chapter also described the gaps in the 
understanding of the iron-cardiometabolic risk relationship, which were subsequently 
explored in Chapters 2 to 6.  
 
Chapter 2 focused on the first research question, which aimed to explore the link 
between serum ferritin and transferrin and MetS in children and adolescents. The 
association between serum ferritin and MetS has been investigated in many adult 
populations, but not in the early stages of life. The empirical analyses showed that 
iron stores, as reflected by ferritin levels, can be either positively or negatively 
associated with MetS and glucose metabolism markers in different paediatric 
populations. Furthermore, sustained high ferritin levels at various time points and 
increases in ferritin levels during childhood were associated with higher MetS score 










Figure 10 Summary of associations identified between iron markers and 
cardiometabolic outcomes across populations of children, adults, and people 
with T2D evaluated in this thesis. 
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The third chapter described the association between serum ferritin status and MetS in 
adults. No previous studies had evaluated this relationship in Scottish populations; 
therefore, data from two populations from this country were analysed. This chapter 
also looked at the overall association between ferritin, MetS, and each MetS 
component in adults, by conducting a meta-analysis and investigating potential 
relevant sources of heterogeneity in the association. Interestingly, ferritin levels in 
the Scottish population were positively associated with MetS, but the association was 
not independent of the effect of covariates, mainly BMI and transaminase levels. The 
meta-analysis supported this finding by describing hepatic injury markers and BMI 
as the major attenuating factors in the ferritin-MetS association. This chapter also 
described how the association may differ depending on the distribution of potential 
confounding factors in certain populations and that high fasting glucose and 
triglycerides are the MetS components most strongly associated with high serum 
ferritin levels.  
 
Chapter 4 investigated the association between iron status and MetS in adults using a 
serum marker of tissue iron demand – sTfR. The sTfR-MetS association had been 
examined in a single previous study with negative results. The analysis I conducted 
in a Croatian population did not show an association between sTfR and MetS either. 
In contrast, serum ferritin was positively associated with MetS in this population 
independently of covariates. These contrasting results suggest that different iron 
markers may reflect different physiological processes other than iron metabolism.  
Chapter 5 evaluated the longitudinal association between serum ferritin and several 
CMDs in the same population to extend the earlier work on the association between 
ferritin and CMD risk factors. Samples of the nationally representative Scottish 
Health Surveys (SHeS) 1995 and 1998 were used for this purpose. According to 
previous literature, the association between ferritin and different CMDs is 
heterogeneous. There is a well-established positive association with T2D, conflicting 
findings regarding the association with CHD, and sparse studies with inconclusive 
evidence on the association with CEVD. The analyses I conducted showed a positive 
longitudinal association between higher ferritin levels and CEVD, which was 
strengthened by using higher cut-points for increased ferritin levels and an 
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association with CHD in unadjusted analyses. My analyses confirmed the widely 
established association of ferritin with T2D, even with serum ferritin within the 
normal range. The above set of observations confirm that ferritin’s role as a 
biomarker of CMDs is mainly related to the development of T2D but led to more 
questions owing to dissimilar patterns of association with other CMDs.  
Chapter 6 addressed the final research question of this doctoral study by exploring 
whether ferritin is associated with the risk for cardiovascular complications among 
people with T2D. Interestingly, ferritin levels were negatively associated with the 
development of CVD, mainly CHD, in people with T2D in both cross-sectional and 
prospective studies. Moreover, this association was consistent in two populations that 
have different cardiovascular risks. Therefore, the pattern of iron status and 
cardiometabolic risk in people affected by T2D appears to differ from that in the 
general population, in which a positive association has been more commonly 
described. 
The nature of the inverse ferritin-CVD association in people with T2D requires 
further research in epidemiological or basic studies to identify potential for survival 
bias, confounders, mediators, and physiological mechanisms that could contribute to 
the association.  
Table 22 summarizes findings and also characteristics of the studies in this PhD 
thesis, including data on cut-points for high ferritin in each analysis which will be 









Table 22  Characteristics and findings of the analyses conducted in each chapter of this PhD thesis. 
Chapter  Population/ 
study 
















Exposures and outcomes 
Association found 
(“Significant” refers to 



















NA NA -Cross-sectional positive 
with MetS (Not significant) 
-Significant decrease in 
change in MetS score over 
follow-up by increasing SD 
units of ferritin  
Beta (95%CI) -0.02 (-0.05 



















NA NA -Significant (boys) 
Cross-sectional positive 
Beta (95%CI) 0.21(0.06 to 
0.37) P < 0.05 
Longitudinal positive  
Beta (95%CI) 0.23(0.04 to 
0.42) P < 0.05 
- Pattern of sustained higher 
ferritin across childhood and 
higher MetS score (boys) 




































NA -Significant association only 
with high WC in men and 
low HDL-C in Post-MW 
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Chapter  Population/ 
study 
















Exposures and outcomes 
Association found 
(“Significant” refers to 











































Men:   
22.2% 
 
NA -Not significant associations 
ferritin-MetS 
Pre-MW 
OR(95% CI) 1.02 (0.42-
2.46) 
Post-MW 
OR(95% CI) 1.09 (0.62-
1.90) 
Men 




























Men:  50.7% 
NA -Significant positive 
association ferritin-MetS  
Post-MW 




Chapter  Population/ 
study 
















Exposures and outcomes 
Association found 
(“Significant” refers to 




















Ferritin Pre-MW: 31 
Post-MW: 59 


















HR(95% CI) 1.59 (1.10-
2.34) 
-  with CEVD not 
Significant by using 
quartiles but significant 
 by comparing sextiles  
HR (95% CI) 2.08 (1.09–
3.94) 
- Not significant association 
ferritin-CHD 
HR (95% CI) 1.07 (0.76-
1.51) 
 
























Significant with CHD 









Chapter  Population/ 
study 
















Exposures and outcomes 
Association found 
(“Significant” refers to 
P<0.05 after adjustments) 
prevalent cardiovascular 
events) 














14757 men  
 









NA -Significant inverse 
association with CHD 
 HR (95% CI) 0.62 (0.56-
0.69) 
and CEVD 
HR (95% CI) 0.61 (0.55-
0.66) 







7.2 Findings in the context of criteria for causality 
The aim of this doctoral thesis was to describe associations between iron markers and 
cardiometabolic risk factors and outcomes rather than making conclusions about 
causality. However, contextualising my findings and reviewed literature against the 
different causality criteria (temporal relationship, strength of association, biological 
plausibility, reversibility, consistency, specificity, coherence, and analogy) 
postulated by Bradford and Hill (236), is useful in the discussion of the role of iron 
parameters as biomarkers of cardiometabolic risk: 
 
I conducted several longitudinal analyses that confirmed a temporal relationship 
between ferritin levels and cardiometabolic outcomes. However, both low and high 
ferritin levels were associated with cardiometabolic risk, suggesting that other factors 
influence the association. For example, the association between low iron status and 
CMD risk may only be observed in certain populations such as children or people 
affected by T2D. As I mentioned previously, the goal of this thesis was not to 
attempt to identify iron as an aetiological factor, but rather to explore the association 
between markers of iron status with different measures of cardiometabolic risk both 
before and after adjusting for key co-variates. A very recent review pointed out 
common misconceptions in the way prediction and aetiology have been presented in 
past and current literature (237). In prediction, confounding is not an issue because 
understanding disease is not its aim but obtaining an explanatory model composed of 
a strong combination of disease predictors (237). According to this review, absolute 
risk must be used in prediction, and relative risk in aetiological studies. Unlike 
aetiological studies, in prediction research, adjustment for confounding variables and 
causal interpretation should not be conducted (237). My PhD work appears to meet 
the criteria for classification as an aetiological study.  However, I examined 
consistency of the association patterns in diverse populations to examine 
generalisability and considered that iron might not be a causal factor in the 
development of CMD, which overlaps a little with the prediction approach.  
In most of the analyses, a dose-response relationship with cardiometabolic risk was 
also observed in terms of increasing association across quantiles of ferritin 
distribution, and a positive linear association between serum ferritin as continuous 
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variable and CMD risk. The linear relationships with serum ferritin were more 
evident for the outcomes of MetS Z score (Croatia-Vis) and T2D in adults analysed 
in this thesis, than for MetS and CVD in general adult populations. The adjusted 
relationships of serum ferritin with incident CEVD in SHeS (positive association) 
and with incident CHD in people with T2D from the ET2DS (negative association), 
were identified from the difference between the lowest and highest values of ferritin 
distribution and a dose response relationship was not always observed. However, as 
stated by Bradford and Hill (1965), the absence of a dose-response relationship does 
not exclude causal relationships (236).  
The strength of the association between serum ferritin and CMDs was in general 
weak to moderate. This was expected since CMD is multi-factorial and usually 
develops as a consequence of interaction between lifestyle, nutritional, 
environmental, and genetic factors. Therefore, serum ferritin, as for many potential 
biomarkers, is only likely to make a partial contribution to the risk. Although a 
moderate association does not rule out a biomarker as a potential causal factor (236), 
in the case of ferritin, this feature tilts the balance towards alternative mechanisms or 
explanations behind the relationship between iron metabolism and cardiometabolic 
risk. The discussion of this latter aspect links to the next causality criterion: 
biological plausibility. Iron is involved in biochemical reactions which generate free 
radicals (superoxide and hydroxyl ions) that have a potentially harmful effect on 
insulin signalling and endothelial function (11). Increased oxidative stress derived 
from body iron excess is the main theoretical underlying mechanism proposed to 
date for linking iron and cardiometabolic risk. IR observed in in vitro research with 
adipose, hepatic, and endothelial cells exposed to iron overload environments, 
provides evidence of iron causing CMD-related metabolic alterations (238-241). 
However, there are certain issues to be considered here. First, there is potential for 
reverse causality because increased oxidative stress can increase iron proteins in 
tissues and thus their circulating levels (225, 242-244). This might be a defensive 
counter-mechanism to avoid generation of free radicals because iron proteins such as 
ferritin and transferrin catch circulating free ferrous iron and prevent its use in redox 
reactions. Second, there is no epidemiological evidence on oxidative stress acting as 
a link between ferritin and cardiometabolic risk. To date, there are no longitudinal 
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studies on iron markers and MetS or T2D that have adjusted the associations for 
markers of oxidative stress to test possible mediating or co-incident effects. 
Similarly, some cross-sectional studies have reported higher levels of ferritin and 
oxidative stress in subjects with MetS, but in these studies, the oxidative stress 
markers were not used as covariates (146, 149).  
Reversibility is a key point in establishing causality, and research on iron depletion 
and cardiometabolic risk has shown discrepant findings. Frequent blood donations 
have been associated with a reduction of IR and concomitant iron depletion in cross-
sectional studies (245). In contrast, another cross-sectional study and a prospective 
study of 33,541 individuals did not find associations of blood donation with insulin 
sensitivity and development of T2D, respectively (246, 247). However, phlebotomy 
or blood donation has effects in addition to decreasing body iron stores. Frequent 
blood donation reduces risk of clotting and thrombosis presumably by replacement of 
old blood products by new ones (248), and this can also be expected to reduce risk of 
myocardial infarction and stroke. Frequent blood donors are also be more likely to be 
more health conscious than people who do not donate blood (249).  
 
The consistency of the association between iron and cardiometabolic risk varies 
depending on the outcome. While the ferritin-T2D association has been highly 
consistent across several studies as well as in this doctoral study, the ferritin-MetS 
association is very heterogeneous despite the significant pooled association reported 
in the meta-analysis presented in Chapter 3 of this thesis. Furthermore, all the studies 
included in the meta-analysis reported a significant association in at least one of the 
sex/menopausal status groups, but I identified discrepancies in the significance of the 
association in these groups in several studies.  
 
It is also noteworthy that serum ferritin was not independently related to MetS in the 
cross-sectional VIKING study but was independently associated with incident T2D 
in the SHeS 95–98 prospective follow-up study. If a biomarker is associated with 
CMD with apparently no marked confounding effects from other CMD risk factors, 
it would be expected to show the same pattern with a cluster of risk factors such as 
MetS. In other words, if MetS is on the causal pathway from ferritin to incident T2D, 
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BMI, the main confounder of the ferritin-MetS association in the VIKING study, 
could have been expected to significantly attenuate the association with the 
development of T2D in the SHeS 95–98. BMI was slightly higher in the VIKING 
than in the SHeS 95–98 longitudinal study [median (IQR) 26.7(24.1–29.9) vs. 
25.7(23.1–28.6) kg/m2]. Although this difference might not be strong enough to 
support the discrepancy between the studies, it is possible that the BMI-ferritin 
relationship differs between populations, even those from within the same 
geographical region, in this case Scotland. In fact, the VIKING study involved 
inhabitants of Shetland Islands who are in genetic terms “isolates”. There are also 
differences in distribution of obesity, physical activity levels and diabetes prevalence 
between Shetland and Scotland as a whole. Prevalence of obesity is higher in 
Shetland than in Scotland (32 % v. 27.4%) (250), but physical activity levels and 
prevalence of diabetes are respectively higher and lower in Shetland than Scotland 
(recommended levels of physical activity 41% v. 38%; diabetes 4.7% v. 5.3%) (250, 
251). Another explanation for the contradictory findings can be that increased iron 
stores could lead to T2D via pathways other than the intermediate onset of MetS or 
its components, which are closely related to IR. This explanation is consistent with 
the finding from several studies that the ferritin-T2D association remains significant 
despite adjusting for variables related to MetS and IR, such as HDL-C level, blood 
pressure, and WC. Moreover, two studies involving Korean men reported an 
association between serum ferritin and T2D, independently of the effect of the IR 
index (HOMA-IR) at baseline and several covariates (252, 253). Despite the above 
hypotheses, it is also important to consider the greater potential for residual 
confounding in the prospective SHeS 95-98 study than in the cross-sectional 
VIKING, since there may have been variations in the BMI during the follow-up.  
The assessment of consistency in the relationship between serum ferritin and CEVD 
still requires further research since my review of the literature using relevant 
keywords identified only two longitudinal studies (196, 197).  
Specificity, coherence, and analogy are the remaining causality criteria to discuss. 
Currently, specificity, defined as the increased risk by an exposure variable for a 
particular outcome and no other outcomes, is uncommon given the complex 
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interactions between several risk factors for non-communicable chronic diseases. 
Iron excess has been related to cancer as well, under similar likely underlying 
mechanisms mentioned previously (254). The proposed relationship and underlying 
mechanism between iron and cardiometabolic risk are coherent with the development 
of CMD in terms of metabolic alterations derived from the pro-oxidant properties of 
iron. With regard the criterion of analogy, as with iron, antioxidant vitamin levels 
have also been evaluated as biomarkers of CMD risk on the basis of the hypothesis 
of the involvement of oxidative stress in the aetiology of these diseases. Previous 
large cohort studies have reported inverse associations between serum antioxidant 
vitamin concentrations such as vitamins C, E (tocopherol levels), and A (retinol 
levels) and development of CMD (255-257). However, supplementation with 
antioxidant vitamins has not shown an effect on prevention of CMD (258). Research 
on dietary intake of vitamin E intake as a protective factor for incident T2D has 
shown inconclusive results (259, 260).  
Increased iron stores, estimated as serum ferritin levels, appear to meet many of the 
Bradford –Hill criteria to be considered as a potential etiological factor for T2D, but 
with conflicting findings with respect to other CMDs. Combining the results of my 
doctoral research with existing literature, I agree with Jehn et al’s. (2007) comment 
that increased ferritin might be either a causal factor and/or one of the several 
metabolic abnormalities in the course to T2D (see Chapter 5 for a detailed discussion 
of the study and the limited power contributing to the failure of the study to 
determine a statistically significant independent association) (20). In my opinion, this 
flexible and more realistic conclusion could be extended to the relationships of serum 
ferritin with MetS, CHD, and CEVD as well as to the association with T2D. In 
addition, I found that low iron status appears to be associated with increased risk of 
CMD in some populations, but this pattern of association is observed much less 
frequently than with iron excess. The underlying mechanism behind this inverse 
associations remains to be explored. 
7.3 Conflicting findings among iron markers 
The directions of associations between different iron markers and variables of 
cardiometabolic risk were inconsistent. This observation provides a strong argument 
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against the notion of iron excess as cardiometabolic risk factor. If iron excess is 
involved in cardiometabolic risk, one would expect different iron markers to show 
complementary patterns of association with CMD. In line with my findings, Podmore 
et al. recently described positive associations between ferritin and transferrin and 
incident T2D and an inverse association between TSAT and incident T2D in the 
EPIC-InterAct study (195). A positive association with TSAT would be expected if 
iron excess were a risk factor for T2D. Podmore et al. suggested that inflammation 
may influence the association with TSAT, and that IR may lie on the causal pathway 
between ferritin or transferrin levels and T2D. This hypothesis is not supported by 
the finding that the ferritin-T2D relationship appears to be independent of the IR 
index (252, 253) as mentioned previously, although there are no studies on 
transferrin and T2D with similar adjustment. Podmore et al. also speculated a 
possible protective effect of TSAT on T2D risk, as higher TSAT indicates better 
scavenging of free circulating iron (195). These discordant association patterns show 
that iron proteins are accounting for something beyond iron metabolism in relation to 
cardiometabolic risk. This idea is even more plausible if we consider that although 
serum ferritin was inversely correlated with transferrin and sTfR as expected, this 
correlation was weak, not reaching more than 0.2–0.4, as described in Chapters 2 and 
4.  
7.4 Reliability of serum iron biomarkers as a 
measurement of iron status 
The majority of the analyses throughout this thesis have shown that serum ferritin, 
transferrin, and sTfR are associated with cardiometabolic risk or IR in unadjusted or 
adjusted analyses. Serum iron biomarkers might reflect physiological processes other 
than iron metabolism, as discussed above. If serum iron biomarkers are altered owing 
to underlying mechanisms in the sub-clinical phase of CMD, their concentrations 
may not entirely reflect tissue levels to assess iron deficiency in individuals with 
higher cardiometabolic risk or IR. The effect of hepatic disease or acute 
inflammation on ferritin levels is well known, and the role of these factors should 
always be considered when high ferritin levels are observed (68). However, serum 
ferritin could show a subtle increase and still remain within the normal range in 
individuals with higher cardiometabolic risk or IR, masking an iron deficient status. 
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Conversely, higher sTfR levels may not indicate true iron overload if 
hyperinsulinemia and not iron homeostasis increases the synthesis of this protein, as 
suggested in Chapter 4. Admittedly, testing the above hypothesis is difficult since the 
gold standard of iron measurement is iron present in bone marrow tissue (261). 
7.5 Complexity of the iron biomarkers-
cardiometabolic risk relationship  
Identifying biomarkers of cardiometabolic risk requires understanding of the 
complex interaction of many factors and it is challenging to reach a conclusion 
regarding causality. In my opinion, there are three main axes of influence on the 
iron-cardiometabolic risk association: adiposity, hepatic function, and inflammation. 
Figure 11 depicts the complex role of potential confounding and mediation by 
obesity (excess adiposity), inflammation and liver injury in the association between 
markers of iron status and cardiometabolic risk. As mentioned in the introductory 
chapter, excess adiposity can be considered a confounding factor since overweight or 
obesity increase the risk of MetS and CMD and at the same time, a person who is 
overweight may have higher ferritin owing to a higher number of adipocytes with 
stored iron. Overweight/obesity is unlikely to be a mediating factor between ferritin 
and CMD because so far and to my knowledge, there is no evidence that increased 
ferritin or iron stores directly or indirectly lead to increased adipogenesis or food 
intake. Inflammation is also a confounding factor since it has been associated with 
T2D and cardiovascular disease, and with higher serum ferritin because ferritin is an 
acute phase reactant as well. However, theoretically, inflammation may also be a 
mediating factor or intermediate variable if iron-induced oxidative stress triggered 
inflammatory pathways (262). This same circular relationship may occur with 
hepatic injury. Liver damage may lead to metabolic alterations and subsequent 
cardiometabolic risk along with the release of ferritin molecules from damaged 
hepatocytes to the bloodstream reflecting an apparent association between ferritin 
and cardiometabolic risk. On the other hand, if increased hepatic iron generates liver 
damage via oxidative stress (263), liver injury would be a meditating process 
between iron status and CMD. Overweight/obesity can promote subclinical 
inflammation and liver injury (as non-alcoholic fatty liver disease), so this covariate 
may be considered a predecessor of the confounding or mediating effects of 
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inflammation and liver injury on the ferritin-cardiometabolic risk association. 
Despite these interrelationships that may imply collinearity, I did not identify 
changes in effect estimates that suggested the presence of collinearity by using 
concomitant adjustments for BMI, CRP, and transaminase levels in the same model. 
However, formal collinearity tests were not conducted. In addition, adjusting for 
covariates that are intermediate variables may lead to over-adjustment and estimates 
of the effect that are biased towards the null (264). On the other hand, this kind of 
adjustment allows investigation of direct effects (264). The adjustments conducted 
across the studies in this thesis showed attenuating effects of transaminases as 
markers of liver injury and BMI, but not of inflammatory markers, on the association 
between higher serum ferritin and cardiometabolic risk variables. However, in at 
least half of the analyses in this thesis, the statistical significance of the association 
persisted. Therefore, liver injury and excess adiposity partially explain the ferritin-
cardiometabolic risk association, and there might be residual confounding or 
mediating effects owing to the limitations in the measurements of the covariates used 
or unknown factors still to be disclosed. These unknown factors are a key target to 
test alternative pathways from altered serum ferritin to development of T2D that 
differ from the intermediate phase of MetS. As described before, this is highly likely 
given that adjustments for MetS components do not abolish the statistical 
significance of the ferritin-T2D association. On the other hand, the association 
between ferritin and CHD appears to be confounded or mediated by adiposity and 
cardiovascular risk factors since the adjustment models with these covariates 
attenuate the association. Ferritin-CEVD relationship still requires further research 
for clearer conclusions.  
In terms of the data available, with the covariates of adiposity, inflammation, hepatic 
injury, and the rest of adjustment variables I attempted to cover a relevant set of 
factors of potential concomitant influence on exposure and outcome variables, to 





Figure 11 Diagram illustrating potential complex roles of confounding/mediating factors in the 
ferritin-cardiometabolic risk relationship 
 
 
7.6 Distribution of ferritin levels across study 
populations 
When compiling all the findings from each chapter of this thesis, it is important to 
compare the distribution of ferritin between the populations studied to consider 
whether these might contribute to the findings. Figures 12 and 13 show histograms of 
ferritin levels in women and men from the VIKING and Croatia-Vis study, in which 
I identified non-significant and significant associations of ferritin with MetS, 
respectively. Premenopausal and postmenopausal women from both studies had 
similar ferritin distributions (Figure 12), men from the VIKING study had a slightly 
more skewed distribution towards lower ferritin values than men in the Croatia-Vis 
study (Figure 13). The higher ferritin levels in the Croatia-Vis study may have 
influenced the significant association with MetS found, but as commented 
previously, the lack of adjustment for hepatic injury markers may also have 
contributed to a stronger association in the Croatia-Vis population than in the 
Shetland population. The distribution of ferritin levels was very similar in the 
Scottish population of VIKING and SHeS prospective study (Figure 14). Thus, 
differences in ferritin distribution do not seem to contribute to the lack of association 
between ferritin and MetS in VIKING and the positive association with incident T2D 
in the SHeS 95-98. I also compared the ferritin distribution in the Scottish population 
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of patients with T2D in the ET2DS and general population of the SHeS 95-98, since 
these studies showed opposite patterns in the direction of the associations between 
ferritin and CVD (Figure 15). I used an age range of 60-75 years in the SHeS for 
comparability with the ET2DS. In both postmenopausal women and men, there was a 
slightly higher density of cases in lower values of ferritin (<30 µg/L approximately) 
in the ET2DS than in the SHeS. However, the ferritin distribution in the highest 
levels was similar in both studies (Figure 15). In fact, cut-points for high ferritin 
(highest quintile) in the ET2DS and the SHeS were comparable [postmenopausal 
women: ET2DS 120 µg/L, SHeS 111 µg/L; men: ET2DS 198 µg/L, SHeS 183 µg/L]. 
Conversely, cut-points for low ferritin (lowest quintile) were slightly lower and much 
lower in postmenopausal women and men, respectively, of the ET2DS than in the 
SHeS study [postmenopausal women: ET2DS 21 µg/L, SHeS 31 µg/L; men: ET2DS 
36 µg/L, SHeS 60 µg/L]. The above observations suggest that the inverse association 
between ferritin levels and CVD in people with T2D does not appear to be explained 














Figure 12 Distributions of serum ferritin in women of the VIKING (Chapter 3) and Croatia-Vis 













































Figure 14 Distributions of serum ferritin in women and men of the VIKING and SHeS 95-98 
(Prospective study) 
 




Figure 15 Distributions of serum ferritin in subjects of the Scottish studies in people 





7.7 Strengths of the research 
This PhD thesis has made a unique contribution to the current knowledge base 
through the exploration of association patterns of serum ferritin and other iron 
markers with cardiometabolic risk in populations of children, adults, and people with 
T2D, by conducting several secondary data analyses. Different stages of 
cardiometabolic risk were investigated with both MetS, a key risk factor for CMD, 
and CMD outcomes, both considered depending on data availability. 
As a result of my collaborations with research groups leading projects in different 
countries, I was able to study the associations in datasets from populations of 
different geographical origins. These collaborations also allowed me to provide 
information on ferritin and cardiometabolic risk in Latin-American, Scottish, and 
Croatian populations for which there were few or no previous studies on the 
association between ferritin and cardiometabolic risk. Consequently, it was possible 
to investigate the consistency of the association across different populations with 
different distributions of iron markers and different baseline levels of CMD while 
taking into account differences in design, power, and the different variables available 
in the datasets. 
This PhD thesis adds new information on the association of iron markers and MetS 
in children, something that had not been explored in previous studies. The evaluation 
of the association of sustained patterns of high ferritin levels across childhood and 
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MetS in adolescence is another novel contribution of this doctoral thesis to the 
current literature on iron and cardiometabolic risk. This approach, using repeated 
measurements of ferritin was previously recommended by Jehn et al. (2007) to 
characterise the consistency of the association with T2D over time, and this applies 
to other CMDs as well. Cohort studies of cardiometabolic risk outcomes do not often 
have measurements of iron markers at several time points of follow-up. However, I 
had the opportunity of examining three measurements of ferritin at different time 
points from childhood to adolescence in the cohort of Chilean children. The 
association between serum ferritin and MetS appears to be consistent in 
children/adolescents as opposed to that observed in adults.  
The sixth chapter on ferritin and cardiovascular complications in people affected by 
T2D is another strength of this thesis since this is the first analysis of an association 
by reporting statistical adjustments, with a longitudinal design and multi-cohort 
approach.  
With the exception of the prospective analysis involving 170 Spanish children 
described in Chapter 2, the different studies in this doctoral study included relatively 
large samples. This observation also applies, to a less extent, to specific demographic 
groups I evaluated, such as children and people affected by T2D, for which very 
large datasets are not as common as for the general populations. Nevertheless, I was 
fortunate to work with a very large sample of people with T2D – the SIDIAP study. 
Most of the analyses included study samples of around 70–97 % of the original 
samples, except the analyses on ferritin and CMD in the SHeS 95–98 (37.6%) and on 
ferritin and CVD in people with T2D from the SIDIAP study (12.1%). Only in this 
latter study there was a considerable chance for selection bias since ferritin 
measurements were conducted in individuals who were suspected as having iron 
deficiency or anaemia. However, given that the associations in this study were 
similar to those found in the subjects affected by T2D from the ET2DS, it appears 
unlikely that the associations of the SIDIAP study have been affected by selection 
bias. Similarly, there were some differences between excluded and included subjects 
in the remaining analyses, which might indicate that the samples selected were not 
representative of the original populations. It is difficult to estimate to what extent 
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these differences may have influenced the findings, if that was the case. Since the 
criteria for selection consisted of having data available for outcome/exposure 
variables and covariates, this means that the valid cases in multivariable models 
would correspond at any rate to the samples selected. It is important to take into 
account that differences between included and excluded subjects are not always 
consistent, as described in Chapter 5, and may also be chance findings.   
7.8 Limitations of the research 
There are, however, various limitations to the analyses in this thesis. Although in 
general, the set of covariates was homogeneous across the different analyses in the 
chapters, there were some analyses in which hepatic injury markers were not 
available, so the magnitude of the independent association between serum ferritin 
and CMDs may be overestimated. Similarly, the estimation of ORs leads to 
overestimation of the risk ratio when the outcomes are common (around > 
10%)(266). There might have been overestimation of the cross-sectional associations 
in adults between the iron markers and MetS, since MetS prevalence was 18% in the 
VIKING study and higher than 50% in postmenopausal women and men from the 
Croatia-Vis study. This is not relevant to the cross-sectional analyses for associations 
between the iron markers and specific MetS components with low prevalence. 
However, overestimation of cross-sectional associations is not a major concern given 
that most of the associations described in the chapters 3 and 4 were not statistically 
significant and so the conclusions drawn are appropriate.  
The use of different populations in the various analyses was previously mentioned as 
a strength of this PhD thesis. However, it would have also been interesting to 
evaluate the consistency of the association of ferritin from early risk to development 
of CMD in the same population, since the heterogeneity from different data sources 
hinders us from arriving at more solid conclusions.  
I worked with available measurements of transferrin and sTfR as additional iron 
markers with respect to MetS in Spanish children and Croatian adults, respectively. 
Unfortunately, the data for iron markers other than ferritin were limited. In fact, at 
the beginning of my PhD, along with my supervisors, I looked for collaborations 
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with research groups in Cambridge and Potsdam which are part of the EPIC study, to 
accomplish a study with multiple iron biomarkers. However, we obtained negative 
answers since these groups already had plans for their own analyses. The recent 
EPIC-Interact study on multiple iron markers and T2D by Podmore et al. is an 
example of a PhD thesis conducted with the information I tried to work with. 
Investigations of the association between multiple iron markers with the outcomes of 
MetS, CHD, and CEVD are required in other large and robustly-adjusted multi-
cohort studies.  
While examining repeated measurements of ferritin across childhood and their 
relationship with MetS at adolescence is described as one of the strengths of this 
doctoral thesis, this kind of evaluation is also urgently needed in the adult population, 
in whom the link between iron and CMD has been more widely investigated. I made 
an effort to include this approach in my doctoral study after collaborating with the 
research group in charge of the Kuopio Ischemic Heart Disease Risk Factor Study 
(KIHD). This may be the only prospective cohort study with repeated measurements 
of serum ferritin (0, 4, 11, and 20 years’ follow-up) and outcomes of T2D, acute 
myocardial infarction, and stroke. However, there were only 725 men free of T2D at 
baseline for whom complete data were available. The limited statistical power meant 
that no significant association between ferritin levels at each time point and incident 
T2D during 11 or 20 years’ follow-up was identified after adjustment for covariates. 
The slope for change in ferritin level per year was not associated with T2D either. 
Since the basic association between ferritin at single time points and incident T2D 
was not successfully replicated in a cohort which has reported a significant 
association in larger samples (27), the repeated measurement analysis did not make 
sense. The findings from this exploration would have been inconclusive owing to 
type II error. Therefore, whether trajectories of serum ferritin in adults are associated 
with onset of MetS, T2D, or other CMD, should be explored in further research that 
will require specific grants to fund repeated measurements of iron markers in serum 
banks of large cohort studies. Along with my supervisors I applied for a grant from 
the Chief Scientist Office of Scotland in 2013 to fund repeated measurement of 
ferritin and hepcidin in serum samples across the follow-up of the Whitehall II study, 
but the application was unsuccessful.  
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Regardless of high statistical power and the longitudinal and/or independent nature 
of some associations, it is important to bear in mind that the findings described in 
this thesis are preliminary, in terms of making policy decisions about the value of 
iron markers for assessing cardiovascular disease risk.  
7.9 Future research 
This doctoral research addressed several questions, which in turn generated 
additional questions. There still are many gaps in the understanding of the iron-
cardiometabolic risk link that need further evaluation and which were not studied in 
this PhD research owing to reasons of space, time, and feasibility. The 
characterisation of the ferritin-cardiometabolic risk association needs additional 
observational studies and meta-analyses, mainly with regard to specific populations 
such as children and people affected by T2D. Mendelian randomisation and 
metabolomics are analytical tools that might provide new and better-quality evidence 
on the underlying mechanisms and/or mediating factors and I discuss these in more 
detail below.  
The association patterns found in paediatric populations require confirmation in other 
studies with pre-pubertal children and adolescents, with research designed to provide 
a clearer understanding of the biological mechanisms or the role of residual 
confounding. Studies in pre-pubertal children with narrower or more specific age 
ranges would clarify the coexistence of inverse and positive associations between 
ferritin and cardiometabolic risk factors observed in the Spanish cohort described in 
Chapter 2. As mentioned previously, whether patterns of the iron markers over time 
are related to risk for CMD in adults remains to be studied, but having found it to be 
related to MetS during childhood is a relevant insight for future research.  
The associations reported in children and people affected by T2D require more 
studies and subsequent systematic reviews/meta-analyses to provide more robust 
evidence about whether iron markers make a useful contribution to cardiometabolic 
risk. In particular, the association between serum ferritin and CEVD requires further 
large studies with a large number of participants given the ambiguity in the 
significance of this relationship in the Scottish cohort described in the thesis.  
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The adjustment models used throughout this PhD thesis were predetermined under 
the assumption of potential modifications or confounding effects on the associations 
evaluated, and the use of the covariates has been justified in the introductory chapter. 
However, it is important to conduct large longitudinal analyses looking for 
independent predictors of serum ferritin and other iron makers among a wide range 
of variables (nutritional, inflammatory, adipokines, lifestyle). These studies, which 
might be based on secondary data analyses, would help characterise the set of 
covariates and understand the role of circulating iron proteins in other possible 
physiological contexts. I noticed that the vast majority of the articles reviewed for 
this thesis did not provide any rationale for the covariates they used.  
As previously discussed, the involvement of different unknown pathways linking 
increased ferritin and cardiometabolic risk is highly likely. Therefore, the use of 
novel approaches to explore mediating processes or new metabolic pathways is 
extremely pertinent. 
One of these approaches is “metabolomics” which consists of the evaluation of the 
whole set of metabolites in a determined biological system (cell, tissue, organ, 
biological fluid, or organism), also known as “metabolome” (267). Metabolomics 
also allows researchers to compare the metabolites (low molecular weight molecules) 
in terms of their quantity or absence/presence according to given characteristic such 
as disease or exposure to a specific factor (267, 268). This approach takes advantages 
of large-scale measurements and identification technologies such as mass 
spectrometry and nuclear magnetic resonance to characterise metabolomes (268). 
Future research could focus on characterisation of metabolomes in baseline serum 
samples of individuals with high (not biased by inflammation) and normal ferritin 
levels, who have developed MetS or T2D during a follow-up in comparison with 
controls without these outcomes. With the metabolite patterns obtained from such 
measurements, it would be possible to conduct subsequent analyses to identify 
metabolic pathways that link iron biomarkers and development of the CMDs. A 
similar approach among people with low iron status instead of iron excess and 
cardiovascular diseases as outcomes in people with T2D may clarify the mediating 
factors for the association reported in Chapter 6.  
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In October 2016, I wrote a research proposal on metabolomics for ferritin and T2D in 
a sub-sample of the KIHD cohort as part of an application for the position of 
“Professor” at a Colombian university. Coincidentally, a few days later, a publication 
on this topic was released with MetS as the outcome but using a cross-sectional 
design plus a clinical trial arm with phlebotomy as the intervention to also 
characterise changes in the serum metabolome after iron depletion (269). The authors 
identified higher levels of sarcosine, methionine sulfoxide, and phosphatidylcholines 
and lower levels of citrulline in individuals with MetS and iron overload (n = 56) 
than in subjects with MetS but not iron overload (n = 54) and healthy lean controls (n 
= 53). They hypothesised a link between increased iron and sarcosine, an 
intermediate of glycine biosynthesis and degradation, which has recently been related 
to regulation of inflammation and lipid metabolism (269). The pattern of citrulline 
was described as possibly spurious since it appears that citrulline, an intermediate 
product in the urea cycle, is an indicator of erythrocyte mass, so it has a positive 
association with iron status. The authors failed to find beneficial effects after 
intervention with phlebotomy (until serum ferritin fell to 50–100 µg/L) on the 
HOMA index, fasting glucose, and lipid profile. However, the study reported higher 
circulating methionine and lower glutamate after the intervention (269). Longitudinal 
metabolomic studies with T2D as the outcome are required to establish whether 
reverse causality may have biased the cross-sectional findings on associations 
between ferritin and MetS in the above metabolomic study.  
Genetic studies can address some of the problems associated with observational 
studies including reverse causality and confounding when attempting to identify 
whether iron metabolism is a causal factor or simply a marker of other metabolic 
processes in the development of T2D and increased cardiometabolic risk. If the key 
assumptions are fulfilled, Mendelian randomisation studies can provide information 
about causality (270, 271). The first assumption is the correlation between serum 
ferritin and different genetic polymorphisms that modify serum ferritin so that the 
polymorphisms can be used as instruments (270). Second, there are no unmeasured 
common causes of the polymorphisms and CMDs. Third, every directed pathway 
from the polymorphisms to the CMDs has to pass through serum ferritin (271). To 
the best of my knowledge, only one study involving a Chinese population (n = 1,574) 
195 
 
used MR to investigate the link between serum ferritin and T2D(272). The authors of 
this study found that two variants (V736A and D521D) of the gene TMPSS6, which 
encodes the serine protease Matriptase-2 associated with up-regulation of iron 
absorption via suppression of hepcidin synthesis, were related to lower haemoglobin 
and serum ferritin and lower risk of T2D in a cross-sectional study(272). They also 
reported that the association between the TMPSS6 variants and T2D were attenuated 
by serum ferritin in a triangulation approach used in the MR study, concluding that 
ferritin might mediate the associations, and the ferritin-T2D relationship was causal 
and unconfounded(272). However, the authors acknowledged that the study was 
preliminary and further research involving larger sample sizes was needed. Future 
MR studies could target genetic variants related to predictors of ferritin other than 
TMPSS6, possibly including those unrelated to iron metabolism-related proteins to 
explore alternative pathways or confounders in the link between ferritin and T2D. 
This approach requires identification of genes that influence ferritin as proposed 
previously in this discussion.  
 
To conclude and summarise the findings and reflections of this PhD thesis, serum 
ferritin and other iron markers are associated with cardiometabolic risk, and it is 
likely that these markers are reflecting something else than iron homeostasis with 
regard to MetS or T2D, warranting further investigations. Second, the association 
between iron markers and an intermediate stage of cardiometabolic risk such as 
MetS, can differ by populations despite a trend of pooled positive association. Third, 
there could be the coexistence of inverse and positive associations in prepubertal 
children, and iron deficiency and not iron excess appears to be related to 
cardiovascular complications in T2D patients. This PhD project has therefore 
contributed to existing knowledge with additional information regarding the complex 
relationship between iron metabolism markers, MetS, and CMD. I hope the products 
of the work will encourage future research to provide deeper understanding of the 
underlying mechanisms and mediating or confounding factors in this relationship.  
7.10 Products of this PhD project 
Some findings from this PhD thesis have been disseminated through peer-reviewed 
publication and poster presentation at academic conferences. The analysis in Chapter 
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4 was published in the British Journal of Nutrition (BJN) with the title of “Soluble 
transferrin receptor levels are positively associated with insulin resistance but not 
with the metabolic syndrome or its individual components” (273). This article does 
not appear as an appendix since its copyrights belong to BJN and Cambridge 
University Press. The analyses from Chapter 3 on ferritin and MetS in the VIKING 
study and SHeS were presented in the 60th Annual Scientific Meeting of the Society 
of Social Medicine at the University of York in 2016 as a poster presentation 
(Appendix Abstract Poster presentation published in Journal of Epidemiology and 
Community Health).  
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Table 2. Differences between included and excluded children from the Spanish Cohort 
 Included  (n=726) Excluded (n=130) n for variables in 
excluded 
P value for difference P value for 
difference- 
Adjustment for age* 
Age (years) 8.0(6.5-9.7) 7.8(6.2-8.9) n=130 0.047  
Sex % female/male  48.2/51.8 39.9/48 n=130 0.553  
Cardio metabolic risk 
variables 
     
Waist (cm) 63(53.5-75) 56(52-70) n=122 0.014 0.278 
SBP (mmHg) 107(99-114) 103(94-109) n=125 <0.001 <0.001 
DBP (mmHg) 60(55-65) 58(53-65) n=124 0.098  
Glucose (mg/dL) 87(83-91) 87(83-90.5) n=109 0.545  
TG (mg/dL) 54(43-74) 55(42-74.5) n=113 0.926  
HDL-C (mg/dL) 55(47-64) 59(50.2-66) n=112 0.024 0.086 
Insulin (ulU/ml) 4.11(1.51-8.04) 3.04(0.52-7.85) n=62 0.292  
HOMA-IR 0.88(0.31-1.73) 0.84(0.14-1.84) n=57 0.659  
HbA1c(%) 5.3(5.1-5.5) 5.3(5.1-5.5) n=98 0.291  
Iron markers       
Ferritin (µg/L) 36(25-52) 32.8(22.9-45.4) n=108 0.123  
Transferrin (mg/dL) 274(251-298) 265.5(244-293) n=102 0.093  
Covariates   n=130   
BMI Z score 0.53(-0.55 to 1.70) -0.12(-0.75 to 0.83) n=127 0.001 0.004 
CRP (mg/L) 0.7(0.3-2.4) 1.0(0.2-3.4) n=55 0.849  
ALT(U/L ) 17(14-21) 16(13-19.7) n=112 0.193  
GGT(U/L)) 13(11-15) 12(11-14) n=109 0.035 0.348 
Data are median (interquartile range). SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. MetS, Metabolic 
syndrome.HbA1C, glycosylated haemoglobin. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass index. CRP, C reactive protein. ALT, 




Table 3. Differences between included children with and without follow-up from the Spanish Cohort 
 Included without follow-up 
(n=553) 
Included with follow-up 
(n=173) 
P value P value for 
difference- 
Adjustment for age* 
Age (years) 8.51(7.0-10.2) 6.5(6.0-8.0) <0.001  
Sex % female/male 45.5/51.9 52/48 0.211  
Cardio metabolic risk variables     
Waist (cm) 67(55-78) 54.5(50.7-61.0) <0.001 <0.001 
SBP (mmHg) 108(100-115) 103(95-108) <0.001 <0.001 
DBP (mmHg) 61(56-66) 56(52-62) <0.001 <0.001 
Glucose (mg/dL) 87(83-92) 85(82-89) 0.001 0.2631 
TG (mg/dL) 55(43-77) 51(42.5-62.5) 0.003 0.302 
HDL-C (mg/dL) 54(46-63.2) 56.5(48-65) 0.074  
Insulin (ulU/ml) 5.05(2.35-9.16) 2.0(0.50-4.14) <0.001 <0.001 
HOMA-IR 1.08(0.50-2.04) 0.39(0.10-0.88) <0.001 <0.001 
HbA1c(%) 5.3(5.2-5.5) 5.3(5.1-5.5) 0.160  
Iron markers      
Ferritin (µg/L) 39(27-54) 30.6(21.1-42.6) <0.001 0.005 
Transferrin (mg/dL) 276(253-300) 264(246-289) 0.001 0.004 
Covariates     
Height (cm)     
BMI Z score 0.86(-0.49 to 1.93) -0.16(-0.65 to 0.59) <0.001 <0.001 
CRP (mg/L) 87(83-92) 85(82-89) 0.003 0.756 
ALT(U/L ) 17(14-21) 17(14-20) 0.053 0.277 
GGT(U/L) 13(11-16) 12(11-14) 0.002 0.4537 
Data are median (interquartile range). SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. MetS, 
Metabolic syndrome.HbA1C, glycosylated haemoglobin. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass index. CRP, C 




Table 4. Relationship between age and sex-specific standardized values (or Z scores) of iron markers and MetS-related markers 
and insulin resistance at baseline (cross-sectional study) and their change (Δ) per year of follow-up (prospective study). 
[Spanish Cohort] 
 Ferritin SD units at baseline (µg/L) 
 Model 1 Model 2  Model 1 Model 2 




 (-0.14 to 0.004) 
0.038 -0.09 
 (-0.16 to -0.01) 
0.017 Δ / year -0.02  
(-0.06 to 0.009) 
0.137 -0.02 





(0.001 to 0.02) 
0.186 -0.003 
 (-0.009 to 0.01) 
0.163 Δ / year 0.0008  
(-0.005 to 0.007) 
0.801 0.0008 





 (0.005 to 0.01) 
<0.001 0.003  
(0.02 to 0.04) 
0.263 Δ / year 0.008  
(0.001 to 0.01) 
0.019 0.007  





 (0.01 to 0.16) 
0.015 0.03  
(-0.03 to 0.10) 
0.340 Δ / year -0.03  
(-0.07 to 0.0004) 
0.052 -0.03 





 (-0.16 to -0.02) 
0.009 -0.03 
 (-0.10 to -0.03) 
0.290 Δ / year 0.03 
 (-0.0008 to 0.06) 
0.056 0.02  





(0.10 to 0.24) 
<0.001 0.06  
(0.02 to 0.09) 
0.002 Δ / year -0.03  
(-0.06 to -0.002) 
0.036 -0.02  





(0.009 to 0.15) 
0.028 0.006  
(-0.05 to 0.07) 
0.837 Δ / year -0.002  
(-0.05 to 0.05) 
0.942 0.02  
(-0.03 to 0.08) 
0.382 
HbA1c(%)SD -0.11  
(-0.19 to -0.04) 
0.002 -0.14 
(-0.22 to -0.07) 
<0.001 Δ / year -0.01 
 (-0.06 to 0.02) 
0.447 -0.01 
 (-0.05 to 0.03) 
0.589 
 Transferrin SD units at baseline (mg/dL) 




(-0.06 to 0.08) 
0.767 -0.001  
(-0.07 to 0.07) 
0.960 Δ / year 0.007  
(-0.03 to 0.04) 






(-0.001 to 0.08) 
0.191 -0.003  
(-0.008 to 
0.001) 
0.193 Δ / year 0.009  
(-0.05 to 0.007) 
0.774 0.0009  





 (0.005 to 0.01) 
<0.001 0.003  
(0.002 to 0.008) 
0.250 Δ / year 0.008  
(0.01 to 0.01) 
0.019 0.007 
 (-0.0005 to 0.01) 
0.071 
log-TG (mg/dL) 0.08 0.019 0.03 0.314 Δ / year -0.002  0.914 -0.01  0.479 
221 
 




(-0.02 to 0.11) 
0.184 0.10 
 (0.03 to 0.16) 
0.004 Δ / year -0.05 
 (-0.08 to -0.019) 
0.002 -0.04 





(0.04 to 0.18) 
0.002 0.005 
 (-0.03 to 0.04) 
0.773 Δ / year 0.03  
(-0.0001 to 0.06) 
0.051 0.02 





(0.10 to 0.24) 
<0.001 0.11 
(0.04 to 0.17) 
<0.001 Δ / year 0.04  
(-0.006 to 0.10) 
0.083 0.02 
 (-0.02 to 0.08) 
0.314 
HbA1c(%)SD 0.11  
(0.04 to 0.18) 
0.002 0.09  
(0.02 to 0.17) 
0.008 Δ / year 0.009  
(-0.03 to 0.05) 
0.705 0.008  
(-0.04 to 0.05) 
0.742 
Model 1: adjusted for age and sex. Model 2: adjusted for model 1 plus CRP, ALT and GGT levels and BMI Z score. *Model 1 included also height.   
For the prospective associations, the above models also included the respective Z score of the outcome at baseline as covariate. Significant 
associations are shown in bold. Skewed variables were log- transformed [ferritin, CRP, ALT, GGT, WC(baseline),triglycerides and HOMA-IR], 
except CRP levels which were inverse log-transformed. SD, standard deviation units. SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, 
triglycerides. HDL-C, HDL cholesterol.HbA1C, glycosylated haemoglobin. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body 









Table 5. Relationship between age and sex-specific standardized values (or Z scores) of iron markers and MetS-related markers 
and insulin resistance at baseline (cross-sectional study) and their change (Δ) per year of follow-up (prospective study) by sex. 
[Spanish Cohort] (3 pages table) 
 Ferritin SD units at baseline (µg/L) 
 Model 1 Model 2  Model 1 Model 2 




(-0.17 to 0.02) 
0.136 -0.10  
(-0.20 to -0.004) 
0.041 Δ / year -0.01 
 (-0.07 to 0.04) 
0.590 -0.01  
(-0.07 to 0.04) 
0.548 
DBP(mmHg) SD*  0.005 
 (-0.09 to 0.10) 
0.920 -0.03 
 (-0.13 to 0.06) 
0.498 Δ / year 0.001 
 (-0.007 to 0.01) 
0.800 -0.00006 
 (-0.09 to 0.009) 
0.989 
SBP (mmHg) SD* 0.07  
(-0.02 to 0.17) 
0.133 0.04 
 (-0.05 to 0.14) 
0.401 Δ / year 0.01  
(0.0005 to 0.01) 
0.039 0.007  
(-0.002 to 0.01) 
0.153 
log-TG (mg/dL) SD 0.04  
(-0.05 to 0.14) 
0.376 -0.001 
 (-0.09 to 0.09) 
0.983 Δ / year -0.01  
(-0.07 to 0.04) 
0.661 -0.008 





(-0.13 to 0.06)  
0.483 0.01 
(-0.08 to 0.10) 
0.806 Δ / year 0.07  
(0.02 to 0.11) 
0.003 0.07 
 (0.02 to 0.11) 
0.003 
log-Waist (cm) SD 0.15 
 (005 to 0.25) 
0.003 0.06  
(0.05 to 0.11) 
0.030 Δ / year -0.04  
(-0.09 to -0.001) 
0.043 -0.04  
(-0.08 to 0.002) 
0.061 
log-HOMA-IR SD 0.11 
 (0.01 to 0.21) 
0.023 0.04  
(-0.04 to 0.13) 
0.290 Δ / year -0.03  
(-0.11 to 0.03) 
0.319 -0.008 
 (-0.08 to 0.07) 
0.844 
HbA1c(%)SD -0.12 
 (-0.22 to -0.02) 
0.013 -0.16 
 (-0.26to -0.06) 
0.002 Δ / year 0.003  
(-0.06 to 0.07) 
0.930 0.007  
(-0.06 to 0.07) 
0.836 
  




(-0.18 to 0.02) 
0.150 -0.07 
(-0.18 to 0.03) 
0.162 Δ / year -0.03 
(-0.09 to 0.01) 
0.126 -0.02 
(-0.07 to 0.03) 
0.398 
DBP(mmHg) SD*  0.13 
(0.02 to 0.23) 
0.013 0.08 
(-0.01 to 0.19) 
0.109 Δ / year 0.0005 
(-0.009 to 0.01) 
0.906 0.0008 
(-0.009 to 0.01) 
0.873 
SBP (mmHg) SD* 0.07 
(-0.02 to 0.18) 
0.140 0.03 
(-0.07 to 0.14) 
0.503 Δ / year 0.006 
(-0.004 to 0.01) 
0.247 0.004 
(-0.007 to 0.01) 
0.489 
log-TG (mg/dL) SD 0.13 
(0.03 to .0.24) 
0.010 0.07 
(-0.02 to 0.17) 
0.145 Δ / year -0.05 
(-0.11 to -0.006) 
0.027 -0.06 






-0.16 (-0.26 to -
0.05) 
0.002 -0.09 
(-0.19 to 0.08) 
0.072 Δ / year -0.001 
(-0.04 to 0.04) 
0.937 -0.006 
(-0.05 to 0.04) 
0.781 





(0.006 to 0.10) 
0.027 Δ / year -0.01 





log-HOMA-IR SD 0.04 (-0.06 to 
0.14) 
0.418 -0.04 
(-0.13 to -0.05) 
0.372 Δ / year 0.04 
(-0.04 to 0.12) 
0.345 0.05 
(-0.02 to 0.14) 
0.180 
HbA1c(%)SD -0.10 (-0.21 to -
0.0007) 
0.048 -0.12 
(-0.23 to 0.01) 
0.021 Δ / year -0.03 
(-0.09 to 0.02) 
0.274 -0.03 
(-0.09 to 0.02) 
0.257 
 Transferrin SD units at baseline (mg/dL) 
 Model 1 Model 2  Model 1 Model 2 




(-0.08 to 0.12) 
0.704 -0.004 
(-0.10 to 0.09) 
0.932 Δ / year 0.04 
(-0.01 to 0.09) 
0.147 0.05 
(-0.006 to 0.11) 
0.081 
DBP(mmHg) SD*  0.13 
(0.03 to 0.23) 
0.007 0.07 
(-0.02 to 0.17) 




(-0.009 to 0.010) 
0.977 
SBP (mmHg) SD* 0.11 
(0.01 to 0.21) 
0.022 0.05 
(-0.04to 0.15) 
0.316 Δ / year 0.01 
(0.0005 to 0.01) 
0.039 0.007 
(-0.002 to 0.01) 
0.141 
log-TG (mg/dL) SD 0.13 
(0.03 to 0.23) 
0.010 0.06 
(-0.03 to 0.15) 
0.221 Δ / year 0.0006 
(-0.06 to 0.06) 
0.982 -0.008 





(-0.06 to 0.13) 
0.492 0.11 
(0.01 to 0.20) 
0.020 Δ / year -0.02 
(-0.07 to 0.02) 
0.284 -0.02 
(-0.07 to 0.02) 
0.314 
log-Waist (cm) SD 0.17 
(0.07 to 0.27) 
0.001 0.03 
(-0.02 to 0.08) 
0.278 Δ / year 0.02 
(-0.02 to 0.07) 
0.365 0.01 
(-0.02 to 0.06) 
0.443 
log-HOMA-IR SD 0.16 
(0.06 to 0.26) 
0.001 0.07 
(-0.01 to 0.16) 
0.088 Δ / year 0.03 
(-0.03 to 0.10) 
0.358 0.006 
(-0.07 to 0.08) 
0.863 
HbA1c(%)SD 0.11 
(0.01 to 0.21) 
0.028 0.08 
(-0.01 to 0.18) 
0.101 Δ / year 0.02 
(-0.03 to 0.09) 
0.401 0.03 
(-0.03 to 0.10) 
0.350 
  






(-0.10 to 0.10) 
0.974 -0.006 
(-0.11 to 0.10) 
0.901 Δ / year -0.03 
(-0008 to 0.02) 
0.279 -0.02 
(-0.08 to 0.04) 
0.506 
DBP(mmHg) SD*  0.17 
(0.07 to 0.28) 
0.001 0.16 
(0.06 to 0.27) 
0.002 Δ / year 0.007 
(-0.009 to 0.01) 
0.880 0.0009 
(-0.009 to 0.01) 
0.866 
SBP (mmHg) SD* 0.06 
(-0.03 to 0.16) 
0.224 0.05 
(-0.04 to 0.16) 
0.276 Δ / year 0.006 
(-0.004 to 0.01) 
0.229 0.004 
(-0.007 to 0.01) 
0.460 
log-TG (mg/dL) SD 0.03 
(-0.06 to 0.14) 
0.480 0.01 
(-0.08 to 0.10) 
0.835 Δ / year -0.009 
(-0.06 to 0.05) 
0.761 -0.03 





(-0.04 to 0.16) 
0.231 0.08 
(-0.01 to 0.18) 
0.085 Δ / year -0.08 
(-0.12 to -0.03) 
0.001 -0.07 
(-0.12 to -0.02) 
0.003 
log-Waist (cm) SD 0.05 
(-0.05 to 0.15) 
0.325 -0.01 
(-0.06 to 0.03) 
0.571 Δ / year 0.04 
(-0.003 to 0.08) 
0.069 0.03 
(-0.007 to 0.08) 
0.096 
log-HOMA-IR SD 0.17 
(0.07 to 0.28) 
0.001 0.14 (0.05 to 0.23) 0.002 Δ / year 0.07 
(-0.01 to 0.16) 
0.107 0.05 (-0.03 to 
0.14) 
0.232 
HbA1c(%)SD 0.11 (0.01 to 
0.22) 
0.028 0.11 (0.008 to 0.21) 0.035 Δ / year -0.01 
(-0.07 to 0.05) 
0.761 -0.01 (-0.09 to 
0.05) 
0.634 
Model 1: adjusted for age. Model 2: adjusted for model 1 plus CRP, ALT and GGT levels and BMI Z score. *Model 1 included also height.   For the 
prospective associations, the above models also included the respective Z score of the outcome at baseline as covariate. Significant associations are shown 
in bold. Skewed variables were log- transformed [ferritin, CRP, ALT, GGT, WC(baseline),triglycerides and HOMA-IR], except CRP levels which were 
inverse log-transformed. SD, standard deviation units. SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL 
cholesterol.HbA1C, glycosylated haemoglobin. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass index. CRP,  C reactive 






Table 6. Differences between included and excluded children from the Chilean 
Cohort at the different points of follow-up 
At 16-17 years Included (n=567) 
Valid sample with no 
missing values at 16-17 
years 





Assigned to iron 
supplementation at 
infancy n(%) 
   
n=1223 
 
High iron 269(47.4) 449(36.7)   
<0.001 Low iron 14(2.5) 391(32)  
No iron 237(41.8) 297(24.3)  
No randomised 47(8.3) 86(7.0)  
Sex % female/male 47.6/52.4 46.2/53.8 n=1223 0.575 
Ferritin (µg/L) 26.3(15.7-39) 24.8(15.3-35.1) n=352 0.198 
Haemoglobin (g/dL) 14.7(13.6-15.9) 14.5(13.4-15.5) n=353 <0.001 
CRP (mg/L) 0.42(0.13-1.29) 0.44(0.14-1.48) n=110 0.830 
BMI Z score 0.60(-0.10 to 1.26) 0.53(-0.29 to 1.24) n=112 0.398 
Tanner stage   n=473  
2 2(0.4) 2(0.4)   
0.452 3 65(11.5) 40(8.5)  
4 313(55.2) 267(56.4)  
5 187(33) 164(34.7)  
Waist (cm) 78.7(73.2-87.6) 79.3(74.1-88) n=112 0.465 
SBP (mmHg) 110(104-120) 110(103-119) n=112 0.471 
DBP (mmHg) 70(65-74) 69(62-72.7) n=112 0.564 
Glucose (mg/dL) 88.1(82.6-94.2) 90.4(84.1-95.6) n=111 0.284 
TG (mg/dL) 74.2(57-101.1) 72.8(58.5-104.2) n=111 0.819 
HDL-C (mg/dL) 38.9(32.2-46.3) 40.2(32.8-47.5) n=111 0.296 
Insulin (ulU/ml) 6.83(4.64-10) 5.98(4.51-8.84) n=110 0.138 
HOMA-IR 1.45(0.98-2.17) 1.35(0.97-1.90) n=110 0.187 
     
At 5 years Included (n=565) 
Valid sample with no 
missing values at  5 and 
16-17 years 
Excluded ( n=1225)   
Assigned to iron 
supplementation at 
infancy n(%) 
  n=1225  
 
High iron 269(47.6) 449(36.7)   
<0.001 Low iron 13(2.3) 392(32)  
No iron 236(41.8) 298(24.3)  
No randomised 47(8.3) 86(7.0)  
Sex %  female/male 47.4/52.6 46.3/53.7 n=1225 0.651 
Ferritin (µg/L) 21.6(14.6-30.4) 20.8(13.2-28.8) n=333 0.161 
Haemoglobin (g/dL) 12.9(12.5-13.5) 129(124-13.5) n=335 0.808 
BMI Z score 0.84(0.19 to 1.56) 0.75(0.08 to 1.49) n=323 0.282 














Table 7. Alternative adjusted beta coefficients for variation in MetS Z score by 
combinations of high (H) and low/moderate (L/M) ferritin across intervals of 
the follow-up 
 
 Girls  Boys  
 Beta (95% CI) P value Beta (95% CI) P value 
5-10 years¥     
L/M-L/M 0(Reference)  0(Reference)  
L/M-H 0.12(-0.08 to 0.34) 0.242 0.07(-0.13 to 0.29) 0.464 
H-L/M -0.06(-0.29 to 0.15) 0.546 0.04(-0.17 to 0.26) 0.681 
H-H -0.03(-0.23 to 0.15) 0.694 0.28(0.06 to 0.49) 0.010 
     
10-16 years¶     
L/M-L/M 0(Reference)  0(Reference)  
L/M-H 0.09(-0.09 to 0.29) 0.312 0.02(-0.14 to 0.19) 0.801 
H-L/M 0.04(-0.13 to 0.23) 0.629 0.01(-0.15 to 0.18) 0.843 
H-H -0.02(-0.21 to 0.16) 0.774 0.32(0.14 to 0.50) <0.001 
     
5-16 years     
L/M-L/M 0(Reference)  0(Reference)  
At 10 years Included (n=381) 
Valid sample with no 
missing values at  10 and 
16-17 years 
Excluded (n=1409)   
Assigned to iron 
supplementation at 
infancy n(%) 
  n=1409  
High iron 206(54.1) 512(36.3)   
<0.001 Low iron 13(3.4) 392(27.8)  
No iron 128(33.6) 406(28.8)  
No randomised 34(8.9) 99(7.0)  
Sex %  female/male 48/52 53.7/46.3 n=1409 0.542 
Ferritin (µg/L) 26.5(20.4-35.7) 27.4(19.5-37.4) n=507 0.602 
Haemoglobin (g/dL) 13.7(13.1-14.1) 136(13.1-14.1) n=689 0.574 
BMI Z score 0.90(0.13 to 1.50) 0.71(-0.02 to 1.38) n=745 0.043 
Tanner stage   n=677  
1 212(55.6) 369(54.5)   
0.448 2 137(36) 257(38)  
3 31(8.1) 44(6.5)  
4 1(0.3) 3(0.4)  
SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. 




L/M-H 0.17(-0.002 to 0.36) 0.054 0.08(-0.09 to 0.26) 0.367 
H-L/M -0.01(-0.19 to 0.16) 0.857 -0.01(-0.20 to 0.16) 0.854 
H-H -0.16(-0.35 to 0.02) 0.089 0.24(0.05 to 0.43) 0.011 
¥ Beta are adjusted for BMI Z score and haemoglobin at 5 years, and the change in BMI Z score and 
haemoglobin during the interval. ¶ Beta are adjusted for BMI Z score, haemoglobin, and tanner stage at 10 
years, and the change in BMI Z score, haemoglobin, and tanner stage during the interval.  Beta are 
adjusted for BMI Z score, haemoglobin at 5 years, tanner stage at 16 years and the change in BMI and 
haemoglobin during the interval.  
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Table 8. Beta coefficients for MetS Z score by patterns of ferritin concentration combinations [high (H) and low/moderate (L/M)] 
across the three stages of follow-up 
 Girls Boys 
5-10-16-years Unadjusted P value Adjusted* P value Unadjusted* P value Adjusted P 
value 
L/M-L/M-L/M 
 (girls n =72; boys n=75) 
0 (Reference)  0 (Reference)  0 (Reference)  0 (Reference)  
L/M-L/M-H      
 (girls n =23; boys n=25) 
0.22(-0.02 to 0.47) 0.082 0.14(-0.06 to 0.35) 0.171 -0.005(-0.27 to 0.26) 0.969 -0.024(-0.22 to 0.17) 0.790 
L/M-H-L/M     
  (girls n =18; boys n=24) 
-0.01(-0.28 to 0.26) 0.932 0.01(-0.22 to 0.25) 0.902 0.006(-0.26 to 0.28) 0.964 -0.01(-0.22 to 0.19) 0.883 
L/M-H-H            
  (girls n =8; boys n=8) 
0.48(0.09 to 0.86) 0.015 0.28(-0.04 to 0.62) 0.087 0.62(0.18 to 1.05) 0.006 0.29(-0.02 to 0.62) 0.073 
H-L/M-L/M     
  (girls n =19; boys n=22) 
0.05(-0.21 to 0.32) 0.698 -0.07(-0.30 to 0.14) 0.489 -0.001(-0.28 to 0.28) 0.989 -0.08(-0.30 to 0.12) 0.424 
H-L/M-H          
   (girls n =6; boys n=10) 
-0.22(-0.67 to 0.21) 0.308 -0.20(-0.57 to 0.16) 0.282 0.35(-0.03 to 0.75) 0.077 0.09(-0.20 to 0.39) 0.512 
H-H-L/M         
   (girls n =14; boys n=11) 
0.13(-0.17 to 0.43) 0.308 0.04(-0.21 to 0.29) 0.743 0.36(-0.01 to 0.74) 0.059 0.06(-0.21 to 0.35) 0.648 
H-H-H              
   (girls n =21; boys n=23) 
-0.07(-0.32 to 0.18) 0.588 -0.15(-0.36 to 0.06) 0.166 0.45(0.17 to 0.73) 0.002 0.31(0.11 to 0.52) 0.003 







Table 9. Sex-stratified relationships of ferritin level Z scores at the three points of follow-up with Z scores of MetS-related 
markers and insulin resistance (as Z score) at 16-17 years by sex. [Chilean Cohort] 
 Girls Boys 
 Unadjusted  Adjusted  Unadjusted Adjusted 
 Beta(95% CI) P value Beta(95% CI) P value Beta(95% CI) P value Beta(95% CI) P value 
At 5 years         
Z SBP (mmHg)* -0.01(-0.13 to 0.11) 0.852 -0.01(-0.12 to 0.10) 0.854 0.03(-0.07 to 0.14) 0.538 0.007(-0.09 to 0.11) 0.890 
Z DBP (mmHg)* 0.006(-0.11 to 0.13) 0.920 0.01(-0.11 to 0.13) 0.851 0.01(-0.09 to 0.12) 0.831 -0.009(-0.11 to 0.10) 0.864 
Z Glucose (mg/dL) -0.03(-0.16 to 
0.087) 
0.544 -0.04(0.16 to 0.08) 0.503 0.07(-0.03 to 0.18) 0.163 0.07(-0.03 t0 0.19) 0.162 
Z TG (mg/dL) -0.09(-0.22 to 0.02) 0.131 -0.10(-0.22 to 0.02) 0.113 0.08(-0.02 to 0.19) 0.124 0.05(-0.04 to 0.16) 0.285 
Z HDL-C (mg/dL) -0.08(-0.20 to 0.04) 0.192 0.08(-0.04 to 0.20) 0.205 -0.24(-0.35 to 0.13) <0.001 -0.22(-0.33 to 0.11) <0.001 
Z Waist (cm) 0.03(-0.09 to 0.16) 0.586 0.02(-0.07 to 0.12) 0.593 0.12(0.01 to 0.23) 0.022 0.07(-0.01 to 0.16) 0.103 
Z HOMA-IR 0.03(-0.09 to 0.15) 0.601 0.03(-0.09 to 0.15) 0.617 0.12(0.01 to 0.23) 0.030 0.08(-0.01 to 0.19) 0.099 
         
At 10 years¶         
Z SBP (mmHg)* -0.01(-0.15 to 0.12) 0.844 -0.03(-0.16 to 0.09) 0.598 0.05(-0.09 to 0.20) 0.463 0.01(-0.11 to 0.15) 0.794 
Z DBP (mmHg)* -0.08(-0.23 to 0.05) 0.245 -0.08(-0.22 to 0.05) 0.211 -0.03(-0.17 to 0.10) 0.643 -0.04(-0.18 to 0.09) 0.548 
Z Glucose (mg/dL) -0.01(-0.16 to 0.13) 0.846 -0.01(-0.17 to 0.13) 0.807 0.12(-0.02 to 0.27) 0.109 0.13(-0.01 to 0.28) 0.077 
Z TG (mg/dL) 0.04(-0.09 to 0.19) 0.537 0.03(-0.11 to 0.17) 0.674 0.11(-0.01 to 0.25) 0.090 0.08(-0.04 to 0.21) 0.214 
Z HDL-C (mg/dL) -0.02(-0.15 to 0.11) 0.732 -0.006(-0.14 to 
0.13) 
0.924 -0.16(-0.30 to 0.02) 0.021 -0.13(-0.27 to 0.006) 0.062 
Z Waist (cm) 0.08(-0.06 to 0.22) 0.282 0.04(-0.06 to 0.15) 0.432 0.08(-0.06 to 0.22) 0.259 -0.01(-0.11 to 0.08) 0.785 
Z HOMA-IR 0.17(0.02 to 0.31) 0.025 0.14(0.002 to 0.29) 0.046 0.12(-0.02 to 0.26) 0.094 0.85(-0.05 to 0.22) 0.229 
         
At 16-17 years¥         
Z SBP (mmHg)* 0.009(-0.10 to 0.12) 0.868 -0.05(-0.16 to 0.05) 0.316 0.13(-0.01 to 0.27) 0.070 0.03(-0.10 to 0.17) 0.643 
Z DBP (mmHg)* -0.0004(-0.11 to 
0.11) 
0.994 -0.06(-0.17 to 0.05) 0.314 0.10(-0.03 to 0.35) 0.154 0.05(-0.09 to 0.20) 0.474 
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Z Glucose (mg/dL) 0.09(-0.02 to 0.20) 0.128 0.08(-0.04 to 0.20) 0.205 0.15(0.009 to 0.29) 0.037 0.19(0.045 to 0.34) 0.010 
Z TG (mg/dL) 0.07(-0.04 to 0.19) 0.199 0.02(-0.93 to 0.15) 0.640 0.27(0.12 to 0.41) <0.001 0.16(0.03 to 0.30) 0.015 
Z HDL-C (mg/dL) 0.09(-0.01 to 0.21) 0.102 0.11(-0.003 to 0.24) 0.058 0.03(-0.11 to 0.17) 0.658 0.12(-0.01 to 0.26) 0.078 
Z Waist (cm) 0.12(0.008 to 0.24) 0.035 0.04(-0.02 to 0.11) 0.199 0.23(0.09 to 0.37) <0.001       0.01(-0.05 to 
0.08) 
0.596 
Z HOMA-IR 0.18(-0.06 to 0.29) 0.002 0.14(0.02 to 0.25) 0.014 0.25(0.11 to 0.40) <0.001 0.18(0.05 to 0.31) 0.004 
 Estimates were adjusted for BMI Z score and haemoglobin level. ¶ Estimates were adjusted for BMI Z score, haemoglobin level and tanner stage. ¥ Estimates 
were adjusted for BMI Z score, CRP level, haemoglobin level and tanner stage. *Adjustment model also included height.   Significant associations are shown in 
bold. SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. HOMA-IR, homeostatic model assessment 






















Table 10. Differences between included and excluded subjects of the VIKING 





Age (years) 51(38.9-63.2) 51.2(41-55.9) n=87 0.696 
Pre-MW/ Post-MW/ 
Men % 
28.8/30.5/40.7 36.2/28.8/34 n=47  
BMI (kg/m2) 26.7(24.1-29.9) 27.0(23.7-31.4) n=81 0.457 
Ferritin(µg/L) 56(29-97) 47(23-75) n=57 0.043 
Fibrinogen (g/L) 3.35(2.91-3.89) 3.24(2.82-4.16) n=57 0.683 
GGT U/L 16(12-24) 14(11-19) n=55 0.041 
ALT U/L 22(17-29) 21(17-27) n=55 0.268 
AST U/L 22(19-26) 22(19-26) n=55 0.387 
HDL-C (mmol/L) 1.46(1.22-1.75) 1.61(1.30-1.79) n=57 0.026 
SBP (mmHg) 127(116-142) 127(117-143) n=81 0.898 
DBP (mmHg) 75(69-82) 77(69-84) n=81 0.227 
WC (cm) 91.2(81.5-100.8) 91.5(77.9-104.1) n=81 0.843 
Glucose  (mmol/L) 4.8(4.5-5.1) 4.7(4.4-5.0) n=57 0.200 
TG (mmol/L) 0.90(0.60-1.30) 0.80(0.50-1.00) n=57 0.067 
Insulin mU/mL 37.1(25.8-54) 35.4(22.9-48) n=57 0.264 
HOMA-IR 7.83(5.37-11.82) 7.20(4.80-10.24) n=57 0.199 
HbA1C (%) 5.30(5.10-5.50) 5.40(5.20-5.50) n=57 0.136 
Smoking n(%)   n=83  





747(36.5) 30(36.1)  
Current smoker 167(8.2) 9(10.8)  
Alcohol consumption 
n(%) 
  n=78  
Non-drinker or ex-
drinker 
84(4.1) 6(7.7)   
0.107 
trivial drinker 152(7.4) 9(11.5)  
drinker 1811(88.5) 63(80.8)  
Cardiovascular disease 
n(%) 
64(3.1) 5(5.6) n=89 0.157 
Diabetes n(%) 46(2.2) 2(2.2) n=87 0.975 
Data are median (interquartile range) or n(%). Comparison between groups by Mann-Whitney U and 
2 test. Pre-MW, premenopausal women. Post-MW, postmenopausal women. BMI, body mass 
indexTG, triglycerides. SBP, systolic blood pressure. DBP, diastolic blood pressure. WC, waist 
circumference. HOMA-IR, homeostatic model assessment insulin resistance. Trivial drinker (special 
occasions or 1 to 3 days per month). Drinker (1 or more days per week) ; SheS 95-98:  1) non-










Table 11. Differences between included and excluded subjects of the SHeS 










Age (years) 42(32-54) 40(28-56) n=8619 <0.001 
Pre-MW/ Post-
MW/ Men % 
33.6/20.1/46.3 33/22.6/44.4 n=8110 <0.001 
BMI (kg/m2) 25.6(23.1-28.7) 25.5(22.4-29.1) n=7052 0.001 
Ferritin(µg/L) 60(32-106) 59(32-29.1) n=3347 0.779 
Fibrinogen (g/L) 3.0(2.5-3.6) 3.1(2.6-3.8) n=2614 <0.001 
GGT U/L 20(15-32) 21(15-34) n=3524 0.005 
HDL-C (mmol/L) 1.4 (1.2-1.7) 1.4(1.1-1.6) n=3277 <0.001 
SBP (mmHg) 127(117-139) 127(116-140) n=3925 0.328 
DBP (mmHg) 71(64-79) 70(62-78) n=3925 <0.001 
WC (cm) 85(76-94.3) 85.3(75.3-95.6) n=5327 0.148 
Smoking n(%)   n=8287  





2376(27.5) 1939(23.4)  
Current smoker 2928(33.8) 3335(40.2)  
Alcohol 
consumption n(%) 
  n=8215  
Non-drinker or ex-
drinker 
687(7.9) 958(11.1)   
<0.001 
trivial drinker 1001(11.6) 9(13.8)  
drinker 6965(80.5) 63(74.6)  
Cardiovascular 
disease n(%) 
206(2.4) 434(5.0) n=8319 <0.001 
Diabetes n(%) 153(1.8) 241(2.8) n=8318 <0.001 
Data are median (interquartile range) or n(%). Comparison between groups by Mann-
Whitney U and 2 test. Pre-MW, premenopausal women. Post-MW, postmenopausal 
women. BMI, body mass index. TG, triglycerides. SBP, systolic blood pressure. DBP, 
diastolic blood pressure. WC, waist circumference. HOMA-IR, homeostatic model 
assessment insulin resistance. Trivial drinker < 1 rating unit per week. Drinker ≥ 1 
rating unit per week.  
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Table 12. Unadjusted odds ratios (95% CI) for cardiometabolic risk markers by sex- and menopausal-specific quartiles (Q) of 
serum ferritin in the study cohorts 
 VIKING (2013-2015) Scottish Health Surveys (1995 & 1998) 
 Q1 
 








≤  15 µg/L 16-25 µg/L 26-41 µg/L > 41 µg/L  2-18 µg/L 19-30 µg/L 31-47  µg/L 48-950 
µg/L 
 


















































0.196 1.0 (Ref)     






0.554 1.0 (Ref)     
           
Postmenopaus
al women 
≤  34 µg/L 35-54 µg/L 55-84 µg/L > 84 µg/L  3- 35 µg/L 36-59 µg/L 60-92 µg/L 93-1000 
µg/L 
 


















































0.254 1.0 (Ref)     
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0.012 1.0 (Ref)     
           
Men ≤ 58 µg/L 59-89 µg/L 90-138 µg/L >138 µg/L  3- 61 µg/L 62-96 µg/L 97-152 µg/L 153-2251 
µg/L 
 


















































0.004 1.0 (Ref)     






0.005 1.0 (Ref)     
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Table 13. Adjusted* odds ratios (95% CI) for MetS components by sex- and menopausal-specific quartiles (Q) of serum ferritin in 
the study cohorts 
  Viking Health study –Shetland (2013-2015) Scottish Health Surveys (1995 & 1998) 
 Q1 Q2 Q3 Q4 P for 
trend 




 16-25 µg/L 26-41 µg/L > 41-67.1 µg/L  19-30 µg/L 31-47 µg/L 48-950 µg/L  


















































0.654     






0.580     
          
Postmenopausal 
women 
 35-54 µg/L 55-82 µg/L > 84-450 µg/L  36-59 µg/L 60-92 µg/L 93-1000 µg/L  


















































0.623     






0.094     
          






















































0.089     






0.222     
* In both studies adjustment for age, glutamyl-transferase levels, fibrinogen levels, smoking, alcohol consumption, and BMI. In the VIKING the 
adjustment also included alanine-aminotransferase levels, aspartate-aminotransferase levels, Ref, reference. Significant associations are shown in bold 
P<0.05). Q, quartile.  
237 
 
Table 14. Unadjusted and adjusted odds ratios (95% CI) for MetS components by SD units of serum ferritin (log-transformed) in 
the study cohorts 
 VIKING (2013-2015) Scottish Health Surveys (1995 & 1998) 
 Unadjusted Adjusted* Unadjusted Adjusted* 
 Ferritin Z score P value Ferritin Z score P value Ferritin Z score P value Ferritin Z score P value 
Premenopausal women         
Low HDL-C 1.23 (1.05-1.49) 0.034 1.05 (0.86-1.30) 0.586 1.07 (0.96-1.19) 0.187 1.02 (0.90-1.16) 0.689 
High SBP and/or high 
DBP 
1.16 (0.94-1.44) 0.157 1.00 (0.79-1.27) 0.958 0.96 (0.86-1.07) 0.475 0.90 (0.81-1.00) 0.069 
High WC 1.19 (1.01-1.41) 0.034 0.81 (0.62-1.07) 0.155 1.10 (1.00-1.20) 0.029 1.03 (0.90-1.18) 0.593 
High fasting glucose 1.97 (104-3.74) 0.036 1.38 (0.73-2.68) 0.312     
High TG 1.25 (0.86-1.82) 0.157 1.00 (0.67-1.48) 0.998     
Postmenopausal women         
Low HDL-C 1.07 (0.87-1.31) 0.503 1.00 (0.80-1.25) 0.943 1.23 (1.08-1.41) 0.002 1.20 (1.03-1.40) 0.013 
High SBP and/or high 
DBP 
1.11 (0.94-1.30) 0.208 0.81 (0.65-1.01) 0.062 1.16 (1.05-1.29) 0.004 0.99 (0.88-1.12) 0.968 
High WC 1.56 (1.29-1.88) <0.001 1.53 (1.11-2.12) 0.009 1.38 (1.23-1.54) <0.001 1.22 (1.02-1.46) 0.023 
High fasting glucose 1.39 (1.008-1.93) 0.044 1.28 (0.91-1.79) 0.142     
High TG 1.33 (1.02-1.73) 0.030 1.21 (0.92-1.60) 0.168     
Men         
Low HDL-C 1.32 (1.04-1.66) 0.020 1.20 (0.95-1.52) 0.118 1.19 (1.06-1.32) 0.001 1.05 (0.93-1.18) 0.380 
High SBP and/or high 
DBP 
1.06 (0.95-1.22) 0.379 0.90 (0.74-1.09) 0.291 1.24 (1.15-1.33) <0.001 1.02 (0.93-1.12) 0.587 
High WC 1.34 (1.15-1.55) <0.001 1.09 (085-1.40) 0.481 1.54(1.42-1.67) <0.001 1.16 (1.04-1.29) 0.005 
High fasting glucose 1.27 (1.01-1.59) 0.038 1.13 (0.90-1.42) 0.275     
High TG 1.24 
(1.03-1.50) 
0.021 1.08 (0.89-1.31) 0.413     
* In both studies adjustment for age, glutamyl-transferase levels, fibrinogen levels, smoking, alcohol consumption, and BMI. In the VIKING the adjustment also 




Table 15. Beta coefficients (95% CI) for values of glycosylated haemoglobin (HbA1C) by ferritin levels (log-transformed) in 
subjects from VIKING 
 
 log-HbA1C  log-HOMA-IR 
 Unadjusted Adjusted* Unadjusted Adjusted* 
Premenopausal 
women 
-0.02(-0.03 to -0.007) -0.03 (-0.04 to -0.01) 0.09 (-0.03 to 0.15) -0.01 (-0.06 to 0.03) 
Postmenopausal 
women 
-0.01 (-0.02 to 0.003) -0.03 (-0.04 to- 0.01) 0.10 (0.03 to 0.16) 0.003 (-0.05 to 0.05) 
Men -0.03 (0.04 to -0.01) -0.03 (-0.05 to -0.02) 0.09 (0.03 to 0.16) -0.02 (-0.08 to 0.02) 
All** -0.005(-0.02 to -0.01) -0.03 (-0.04 to -0.02) 0.12(0.09 to 0.15) -0.01 (-0.04 to 0.01) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), and BMI ** Additionally adjusted for 
sex/menopausal status (premenopausal women/ postmenopausal women/men). Multivariate analyses were performed on transformed values of 
skewed variables: logarithm of sTfR , ferritin , HOMA-IR  values, body mass index  and fibrinogen values;  square of age and square root of 




Table 16. Information about exclusion criteria for factors of possible influence in exposure (iron markers) and the outcome 
(metabolic syndrome) 






















Jehn et al., 
2004 



















et al., 2007 
Yes No Yes 
(NAFLD) 
No No No No 
Shi et al., 
2008 





No No No 
Sun et al., 
2008 
No Yes No No Yes(ferritin>50
0 µg/L) 
No No 
Cho et al. 
,2011 
No No  No(but 
transaminase
s level was a 
covariate) 
No No No No 
Kim et al. , 
2011 
No Yes Yes Yes No No Yes 
Lee et 
al.,2001 








































Yes(hep B) No Yes(ferr>800) Yes Yes(Hypertensio
n excluded by 
treatment) 
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Li et al. , 
2013 




No  No  No No No 
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covariate) 







































level was a 
covariate) 









No No No No No 
Martinelli  
et al.,2012 














No No No No No 
Iwanaga et No No No No No Yes Yes 
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VIKING No Yes (but as a 
sensitivity 
analysis) 
Yes (but as a 
sensitivity 
analysis) 





















Yes Yes (but as a 
sensitivity 
analysis) 
Yes (but as a 
sensitivity 
analysis) 



























Table 17. Tertiles and quartiles of reported values for average ferritin levels and cut-offs for high ferritin levels (cross-sectional 




Pre-MW, premenopausal women. Post-MW, Postmenopausal women. M, men. Cut-off values defining the tertiles for average ferritin levels (percentiles 33.3th and 
66.6th) were for premenopausal women group 31.4 and 48.3 µg/L; for post-menopausal women 66.3 and 93.1 µg/L; for studies with category of women 48.1 and 56.3 
µg/L; for men 122 and 174 µg/L; and for studies describing levels in both sexes 93.5 and 159.9 µg/L. 
 Cut-off values defining the quartiles for average ferritin levels (percentiles 25th, 50th, and 75th) were for premenopausal women group 29.3, 35.4, and 54.6 µg/L; for 
post-menopausal women 64.7, 70.5, and 96 µg/L; for men 121.9, 146, and 178 µg/L; for studies with category of women 46.7 (25th  percentile ) and 51 µg/L (50 th 
percentile), 75th percentile was missing (few valuess); and for studies describing levels in both sexes 73.4(25th  percentile )  and 133.8 µg/L(50 th percentile), 75th 
percentile was missing (few values) 
Cut-off values for the tertiles of cut-offs defining high ferritin (percentiles 33.3th and 66.6th) were: for premenopausal women group 46 and 60 µg/L; for post-
menopausal women 83.7 and 148 µg/L; for studies with category of women 88.4 and 94.8 µg/L; for men 171.8 and 241 µg/L; and for studies describing levels in both 
sexes 125.4 and 184.4 µg/L.  
Cut-off values for the tertiles of cut-offs defining high ferritin (percentiles 25th, 50th, and 75th) were: for premenopausal women group 41.1, 51.5, and 75 µg/L; for post-
menopausal women 75.2, 97.9, and 168.7 µg/L; for men 162.1, 211 and 277.2 µg/L; for studies with category of women 86(25th percentile) and 93.2 µg/L (50th 
percentile), 75th percentile was missing (few values); and for studies describing levels in both sexes 100(25th percentile)  and 176.4 µg/L(50th percentile), 75th 














Pre-MW, premenopausal women. Post-MW, Postmenopausal women. M, men. Cut-off values defining the tertiles for average ferritin levels (percentiles 33.3th and 
66.6th) were: for premenopausal women group 33.9 and 54 µg/L; for post-menopausal women 66.6 and 94.5 µg/L; for studies with category of women 48.1 and 56.3 
µg/L; for men 138 and 175 µg/L; and for studies describing levels in both sexes 93.5 and 159.9 µg/L.  
Cut-off values defining the quartiles for average ferritin levels (percentiles 25th, 50th, and 75th) were for premenopausal women group 32, 37, and 55.2 µg/L; for post-
menopausal women 66.3, 81.1, and 100.2 µg/L; for men 121.9, 154.3, and 185.5 µg/L; for studies with category of women 46.7 (25th percentile) and 51 µg/L(50th 
percentile), 75th percentile was missing (few valuess) : and for studies describing levels in both sexes 73.4(25th percentile) and 133.8 (75th percentile) µg/L, 75th 
percentile was missing (few values). 
Cut-off values for the tertiles of cut-offs defining high ferritin (percentiles 33.3th and 66.6th) were: for premenopausal women group 49.7 and 70 µg/L; for post-
menopausal women 85 and 168 µg/L; for studies with category of women 88.4 and 94.8 µg/L; for men 210.2 and 251 µg/L; and for studies describing levels in both 
sexes 125.4 and 184.4 µg/L.  
Cut-off values for the quartiles of cut-offs defining high ferritin (percentiles 25th, 50th, and 75th) were: for premenopausal women group 47.3, 55.7, and 82.5 µg/L; for 
post-menopausal women 68.2, 110.8, and 169.5 µg/L; for men 192.3, 213 and 293.5 µg/L;  for studies with category of women 86(25th percentile) and 93.2 µg/L(50th 
percentile), 75th percentile was missing (few values): and for studies describing levels in both sexes 100(25th percentile) and 176.4 µg/L(50th percentile), 75th 
percentile was missing (few values). 
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1 1 1 1 1 1 1 7 
Vari et 
al., 2007 




1 1 1 0 1 0 0 4 
Shi et 
al., 2008 
1 1 1 0 1 1 0 5 
 Sun et 
al., 2008 
1 1 1 1 1 1 1 7 
Cho et 
al. ,2011 
1 1 1 0 1 0 0 4 
Kim et 
al., 2011 
0 1 1 0 1 0 0 3 
Lee et 
al.,2001 
1 1 1 0 1 1 0 5 
Ryoo et 
al. ,2011 




1 1 1 0 1 0 0 4 
Li et al. 
, 2013 
1 1 1 0 1 0 0 4 
Kilani et 
al. 2014 
1 1 1 0 1 0 0 4 
Ledesm
a et al., 
2015 
0 1 1 0 1 1 0 4 
Seo et 
al., 2015 
0 1 1 1 1 0 0 4 
Tang et 
al., 2015 
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Vari et al., 
2007 
1 0 1 1 1 0 0 4 
Yoon et al., 
2012 
1 1 0 0 1 0 0 3 
Park et al., 
2012 
0 1 0 0 1 1 0 3 
Tang et al., 
2015 
1 1 0 0 1 1 0 4 
Kilani et al., 
2015 
1 1 1 0 1 1 1 6 
Hamalainen et 
al.,2014 















Region     
Asia 16 (10) 1.86(1.55-2.22) 75.5  
Europe 11 (5) 1.28(0.96-1.71) 77.3  
America 3 (1) 2.22(1.60-3.09) 7.5 0.437 
Adjusted for BMI     
No 11 (7) 2.04(1.65-2.52) 79.2  
Yes 19 (9) 1.45(1.20-1.76) 71.1 0.030 
Adjusted for CRP     
No 19 (11) 1.77(1.62-1.92) 0.1  
Yes 11 (5) 1.58(1.07-2.33) 91.7 0.769 
Adjusted for some 
Inflammatory 
Marker 
    
No 15 (9) 1.02(1.16-2.04) 0.0  
Yes 15 (7) 1.54(1.16-2.04) 89.0 0.475 
Adjusted for some hepatic function 
marker 
    
No 13 (7) 2.09(1.74-2.50) 73.3  
Yes 17 (9) 1.35(1.11-1.65) 67.8 0.003 
Ferritin assay     
RIA 10(4) 2.08(1.60-2.71) 76.3  
QLA 5 (4) 1.72 (1.37-2.15) 56.2  
TIA 9 (5) 1.23(0.86-1.76) 82.8  
Other 6 (3) 1.64 (1.38-1.94) 0.0 0.065 
Sample size     
<1000 8 (4) 1.63(1.36-1.94) 79.2  









Risk of bias     
score < median 15(10) 1.63(1.25-2.12) 88.4  
score ≥ median 15 (6) 1.69(1.49-1.92) 16.2 0.896 
Mean/median ferritin levels 
(Sex/menopausal-specific tertiles) 
    
Tertile 1 11 1.64(1.17-2.30) 82.1  
Tertile 2 9 2.01(1.84-2.21) 81.6  
Tertile 3 10 1.33(0.95-1.86) 0.0 0.273 
Mean/median ferritin levels 
(Sex/menopausal-specific quartiles) 
    
Quartile 1 7 1.68(0.99-2.86) 86.9  
Quartile 2 8 1.82(1.62-2.05) 0.0  
Quartile 3 9 1.94(1.68-2.25) 33.2  
Quartile 4 6 1.25(0.81-1.96) 86.1 0.269 
Cut-off point reported for highest 
category of ferritin levels  
(Sex/menopausal-specific tertiles) 
    
Tertile 1 10 1.36(1.17-1.60) 0.0  
Tertile 2 9 2.22(1.76-2.80) 76.5  
Tertile 3 8 1.39(0.96-2.01) 86.2 0.868 
Cut-off point reported for highest 
category of ferritin levels  
(Sex/menopausal-specific quartiles) 
    
Quartile 1 7 1.37(1.13-1.67) 0.0  
Quartile 2 6 1.65(1.35-2.01) 40.5  
Quartile 3 8 2.38(1.83-3.10) 74.0  
Quartile 4 6 1.22(0.77-1.94) 88.1 0.809 




Table 22. Stratified odds ratio for association between ferritin and components of metabolic syndrome 




























Region                
Asia 1.70 
(1.42-2.03) 
81.5  1.66 
(1.30-2.11) 
74.7  2.16 
(1.62-2.89) 
91.6  1.62 
(1.34-1.94) 





0.0  1.48 
(1.26-1.75) 
47.5  1.67 
(1.41-1.97) 
19.4  1.36 
(1.18-1.57) 





74.3 0.542 1.36 
(0.64-2.88) 
78.3 0.310 2.46 
(1.63-3.71) 
35.9 0.691 1.14 
(0.87-1.50) 





               
No 1.77 
(1.39-2.25) 
83.2  1.72 
(1.41-2.09) 
73.3  2.05 
(1.54-2.74) 
90.8  1.61 
(1.29-2.01) 





68.4 0.609 1.39 
(1.14-1.69) 
55.6 0.170 1.88 
(1.50-2.35) 
63.9 0.580 1.37 
(1.22-1.53) 





               
No 1.53 
(1.37-1.72) 
74.7  1.50 
(1.33-1.70) 
33.8  1.74 
(1.52-2.00) 
58.0  1.40 
(1.28-1.54) 











64.5 0.002 1.47 
(1.04-2.10) 












74.7  1.60 
(1.44-1.77) 
0.0  1.81 
(1.52-2.17) 
64.3  1.52 
(1.37-1.70) 
0.0  1.10 
(0.95-1.28) 
56.7  
Yes 1.95 80.8 0.065 1.46 81.2 0.710 2.13 89.4 0.238 1.37 70.4 0.347 1.05 41.1 0.543 
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No 1.84 
(1.44-2.35) 
83.4  1.62 
(1.29-2.03) 
77.4  2.23 
(1.71-2.92) 
88.6  1.57 
(1.29-1.90) 





44.5 0.234 1.45 
(1.21-1.73) 
48.5 0.454 1.68 
(1.34-2.11) 
64.5 0.099 1.36 
(1.21-1.52) 





               
RIA 1.99 
(1.49-2.66) 
78.8  1.48 
(1.09-2.03) 
80.9  2.23 
(1.58-3.15) 
86.9  1.47 
(1.18-1.83) 





76.8  1.73 
(1.41-2.14) 
0.0  2.15 
(1.53-3.01) 
86.9  1.55 
(1.18-2.03) 





0.0  1.51 
(0.78-2.94) 
78.4  1.65 
(1.15-2.37) 
41.6  1.23 
(0.98-1.53) 





0.0 0.073 1.45 
(1.28-1.64) 
0.0 0.746 1.56 
(1.30-1.88) 
0.0 0.078 1.43 
(1.18-1.73) 





               
<1000 1.37 
(1.18-1.58) 
0.0  1.49 
(1.17-1.90) 
52.1  1.51 
(1.28-1.79) 
0.0  1.56 
(1.29-1.87) 





80.3 0.331 1.54 
(1.29-1.84) 
71.1 0.841 2.21 
(1.77-2.77) 
87.4 0.037 1.43 
(1.25-1.63) 










84.9  1.86 
(1.50-2.32) 
72.5  2.37 
(1.77-3.17) 
91.4  1.63 
(1.28-2.08) 






































59.0 0.564 1.37 
(1.17-1.60) 
45.9 0.039 1.67 
(1.41-1.96) 
35.6 0.034 1.35 
(1.22-1.50) 











               
Tertile 1 2.00 
(1.40-2.86) 
58.5  1.52 
(1.10-2.11) 
79.0  1.60 
(0.88-2.92) 
90.5  1.44 
(1.08-1.92) 
77.4  1.00 
(0.82-1.22) 
61.4  
Tertile 2 1.59 
(1.34-189) 
63.5  1.45 
(1.17-1.81) 
59.6  1.94 
(1.58-2.39) 
72.7  1.35 
(1.23-1.48) 
0.0  1.03 
(0.88-1.22) 
57.2  
Tertile 3 1.69 
(1.31-2.19) 
85.0 0.575 1.58 
(1.38-1.81) 
0.0 0.959 2.20 
(1.66-2.92) 
72.7 0.341 1.63 
(1.40-1.90) 











               
Quartile 1 2.57 
(2.04-3.23) 
0.0  1.51 
(1.01-2.26) 
83.9  1.77 
(0.80-3.94) 
88.0  1.45 
(1.04-2.03) 
80.2  0.98 
(0.78-1.24) 
66.9  
Quartile 2 1.61 
(1.40-1.85) 
5.9  1.21 
(0.94-1.55) 
15.4  1.62 
(1.37-1.92) 
36.1  1.31 
(1.17-1.47) 
0.0  0.91 
(0.70-1.18) 
64.5  
Quartile 3 1.68 84.1  1.59 23.8  2.05 75.2  1.41 0.9  1.17 0.0  
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(1.27-2.21) (1.38-1.83) (1.56-2.70) (1.24-1.60) (1.04-1.31) 
Quartile 4 1.59 
(1.25-2.02) 
75.1 0.344 1.67 
(1.40-1.99) 
0.0 0.535 2.45 
(2.06-2.90) 
0.0 0.430 1.76 
(1.46-2.13) 














               
Tertile 1 1.40 
(1.27-1.56) 
0.0  1.33 
(1.02-1.73) 
51.6  1.44 
(1.18-1.77) 
0.0  1.24 
(1.07-1.43) 
0.0  0.88 
(0.73-1.07) 
34.5  
Tertile 2 2.06 
(1.66-2.54) 
68.7  1.61 
(1.20-2.15) 
82.0  2.27 
(1.63-3.17) 
92.0  1.55 
(1.28-1.88) 
75.4  1.11 
(0.96-1.28) 
56.3  
Tertile 3 1.84 
(1.09-3.12) 
88.8 0.247 1.83 
(1.47-2.27) 
0.0 0.280 2.34 
(1.95-2.82) 
0.0 0.043 1.37 
(0.94-1.99) 
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Quartile 1 1.49 
(1.21-1.84) 
0.0  1.35 
(0.95-1.93) 
59.5  1.46 
(1.18-1.81) 
0.0  1.30 
(1.11-1.53) 
0.0  0.88 
(0.70-1.13) 
42.2  
Quartile 2 1.47 
(1.31-1.65) 
27.0  1.27 
(1.00-1.63) 
0.0  1.61 
(1.45-1.79) 
0.0  1.31 
(1.10-1.56) 
35.0  0.92 
(0.73-1.15) 
66.2  
Quartile 3 2.26 
(1.75-2.92) 
75.8  1.68 
(1.28-2.19) 
81.5  2.74 
(2.20-3.40) 
71.6  1.47 
(1.15-1.88) 
77.5  1.28 
(1.15-1.42) 
2.0  
Quartile 4 1.25 
(0.94-1.67) 
-- 0.243 2.04 
(1.22-3.41) 
-- 0.224 2.45 
(1.73-3.46) 
-- 0.004 2.15 
(1.27-3.63) 
-- 0.168 1.11 
(0.80-1.54) 
-- 0.028 
*P values are from meta-regression analysis. 
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Table 23. Differences between included and excluded subjects of the CROATIA-VIS STUDY 
 Included (n=725) Excluded (n=304) n for variables in 
excluded 
P value 
Age (years) 57(46-69.5) 55(45-67) n=193 0.275 
Pre-MW/ Post-MW/ Men % 20.8/40/39.2 22/30.9/47 n=304 0.018 
BMI (kg/m2) 27.1(24.1-30) 26.7(24-30.2) n=293 0.920 
sTfR (mg/L) 3.1(2.6-3.8) 3.0(2.7-145.1) n=49 0.881 
Ferritin(µg/L) 76.6(36.7-140.2) 73(42.9-145.1) n=102 0.571 
Fibrinogen (g/L) 3.7(3.1-4.3) 3.5(2.9-4.2) n=278 0.024 
HDL-C (mmol/L) 1.14(1.0-1.23) 1.15(1.0-1.23) n=283 0.642 
SBP (mmHg) 135(120-152.2) 130(120-149) n=293 0.063 
DBP (mmHg) 80(72-87) 80(72-87) n=293 0.752 
WC (cm) 96.7(86.7-103.5) 95.6(87.2-104) n=292 0.932 
Glucose  (mmol/L) 5.4(5.0-6.0) 5.3(4.8-6.1) n=286 0.290 
TG (mmol/L) 1.4(1.1-2.0) 1.4(1.2-2.0) n=286 0.179 
Insulin mU/mL 7.0(4.0-10) 6.0(4.0-10) n=281 0.928 
HOMA-IR 1.55(0.97-2.51) 1.52(0.92-2.47) n=281 0.688 
HbA1C (%) 5.3(5.0-5.6) 5.3(5.6) n=279 0.242 
Smoking n(%)   n=299  
Yes  196(27) 95(31.8)   
0.187 No 315(43.4) 113(37.8)  
Ex-smoker 214(29.5) 91(30.4)  
Alcohol consumption Yes  n(%) 308(42.5) 176(57.9)/113(37.2) n=289 0.324 
Cardiovascular disease n(%) 102(4.1) 41(13.5) n=304 0.439 
Diabetes n(%) 50(6.9) 17(5.6) n=304 0.805 
Data are median (interquartile range) or n(%). Comparison between groups by Mann-Whitney U and 2 test. Pre-MW, premenopausal women. 
Post-MW, postmenopausal women. BMI, body mass index. sTfR, soluble transferrin receptor. TG, triglycerides. SBP, systolic blood pressure. 
DBP, diastolic blood pressure. WC, waist circumference. HOMA-IR, homeostatic model assessment insulin resistance.  
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Table 24. Odds ratios(95% CI)  for MetS components per sex/menopausal-
specific SD units of the iron markers in the study subjects categorised by sex 
and menopausal status 
 Z score log-sTfR  Z score log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
Premenopausal 
women 
    
High glucose † 1.35 (0.87-2.09) 1.23 (0.77-1.95) 0.89 (0.59-1.36) 1.01 (0.65-1.58) 
Low HDL-C  1.18 (0.71-1.96) 1.14 (0.68-1.90) 0.95 (0.54-1.65) 0.96 (0.51-1.79) 
High TG 1.35 (0.87-2.12) 1.29 (0.80-2.08) 1.51 (0.96-2.39) 1.51 (0.94-2.44) 
High BP¶ 1.35 (0.91-1.99) 1.29 (0.84-1.92) 0.95 (0.66-1.36) 0.96 (0.66-1.40) 
High WC 1.07 (0.77-1.49) 1.01 (0.71-1.43) 0.79 (0.56-1.11) 0.79 (0.54-1.15) 
MetS 1.32 (0.90-1.92) 1.21 (0.81-1.79) 1.13 (0.80-1.59) 1.24 (0.85-1.80) 
Postmenopausal 
women 
    
High glucose † 1.08 (0.86-1.37) 1.009 (0.78-1.29) 1.23 (0.97-1.56) 1.20 (0.94-1.52) 
Low HDL-C  1.22 (0.66-2.28) 1.45 (0.74-2.84) 0.76 (0.41-1.40) 0.81 (0.45-1.45) 
High TG 0.99 (0.78-1.25) 0.97 (0.75-1.24) 1.26 (0.98-1.61) 1.28 (0.99-1.64) 
High BP¶ 1.13 (0.83-1.56)     0.94 (0.66-
1.34) 
1.14 (0.85-1.52) 1.08 (0.77-1.51) 
High WC 1.10 (0.59-2.03) 1.00 (0.50-1.97) 1.10 (0.63-1.94) 0.98 (0.51-1.90) 
MetS 0.99 (0.69-1.43) 0.83 (0.54-1.26) 1.65 (1.17-2.31) 1.65 (1.11-2.46) 
Men     
High glucose † 1.20 (0.94-1.52) 1.10 (0.85-1.41) 1.37 (1.07-1.75) 1.42 (1.10-1.84) 
Low HDL-C  0.93 (0.72-1.21) 0.94 (0.72-1.24) 1.61 (1.21-2.15) 1.60 (1.19-2.15) 
High TG 1.03 (0.81-1.30) 1.07 (0.84-1.38) 1.69 (1.29-2.21) 1.71 (1.29-2.26) 
High BP¶ 1.13 (0.87-1.46) 0.97 (0.72-1.29) 1.15 (0.89-1.48) 1.21 (0.91-1.61) 
High WC 1.30 (1.00-1.70) 1.16 (0.87-1.55) 1.53 (1.18-1.98) 1.62 (1.22-2.15) 
MetS 1.05 (0.83-1.33) 0.95 (0.74-1.22) 1.90 (1.44-2.50) 2.02 (1.51-2.70) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker) and alcohol consumption (no/yes). † 
Includes additionally individuals who reported current use of oral hypoglycemic medications or insulin 
regardless of fasting glucose values.¶ Includes additionally individuals who reported current use of 
antihypertensive medications regardless of blood pressure values. SD, standard deviation. TG, 
triglycerides. BP, blood pressure. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic 




Table 25. Odds ratios (95% CI)  for metabolic syndrome and its components 
per SD units  of sTfR and ferritin levels  in the whole sample 
 Z score log-sTfR  Z score log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
High glucose † 1.11 (0.95-1.29) 1.08(0.90-1.28) 1.48 (1.27-1.74) 1.27 (1.03-1.56) 
Low HDL-C  1.16 (0.98-1.36) 0.96 (0.74-1.23) 0.46 (0.38-0.56) 1.34 (1.01-1.78) 
High TG 1.02 (0.88-1.19) 1.01 (0.85-1.21) 1.71 (1.44-2.03) 1.62 (1.30-2.03) 
High BP¶ 1.09 (0.93-1.28) 1.02 (0.84-1.23) 1.52 (1.30-1.78) 1.09 (0.85-1.38) 
High WC 1.16 (0.97-1.39) 0.90 (0.71-1.15) 1.09 (0.91-1.29) 1.11 (0.80-1.56) 
MetS 1.09 (0.94-1.27) 0.91 (0.75-1.09) 1.41 (1.21-1.65) 1.93 (1.49-2.49) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), BMI and 
sex/menopausal status (premenopausal women/ postmenopausal women/men). † Includes additionally 
individuals who reported current use of oral hypoglycemic medications or insulin regardless of fasting 
glucose values .¶ Includes additionally individuals who reported current use of antihypertensive 
medications regardless of blood pressure values. SD, standard deviation. TG, triglycerides. BP, blood 
pressure. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic syndrome. Significant 




Table 26. Beta coefficients (95% CI) of relationship between log-sTfR and log-
transformed values of variables related to MetS components 




log-glucose  0.03 (-0.07 to 0.15) 0.01 (-0.09 to 0.12) 
log- HDL-C  -0.006 (-0.15 to 0.14) 0.008 (-0.14 to 0.16) 
log-TG 0.32 (0.01 to 0.63) 0.26 (-0.04 to 0.56) 
log-SBP 0.07 (-0.01 to 0.17) 0.04 (-0.04 to 0.12) 
log-DBP 0.01 (-0.07 to 0.11) -0.002 (-0.08 to 0.08) 




log-glucose  0.06 (-0.12 to 0.24) -0.04 (-0.22 to 0.14) 
log- HDL-C  0.04 (-0.08 to 0.17) 0.07 (-0.06 to 0.21) 
log-TG 0.01 (-0.37 to 0.40) -0.14 (-0.53 to 0.23) 
log-SBP 0.10 (-0.03 to 0.25) -0.007 (-0.13 to 0.12) 
log-DBP -0.01 (-0.12 to 0.09) -0.06 (-0.17 to 0.04) 
log- WC 0.15 (0.05 to 0.25) 0.05 (-0.004 to 0.10) 
Men   
log-glucose  0.18 (0.002 to 0.37) 0.09 (-0.09 to 0.27) 
log- HDL-C  -0.03 (-0.18 to 0.11) -0.02 (-0.18 to 0.12) 
log-TG 0.33 (-0.14 to 0.81) 0.34 (-0.13 to 0.82) 
log-SBP 0.10 (-0.03 to 0.25) -0.01 (-0.14 to 0.11) 
log-DBP 0.05 (-0.07 to 0.18) 0.01 (-0.11 to 0.14) 
log- WC 0.12 (0.02 to 0.22) 0.01 (-0.02 to 0.06) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption 
(no/yes), and BMI. Multivariable adjusted analyses were performed on transformed 
values of skewed variables: logarithm of sTfR , ferritin ,  body mass index  and 
fibrinogen values;  square of age. . TG, triglycerides. SBP, systolic blood pressure. DBP, 
diastolic blood pressure. WC, waist circumference. HDL-C, HDL cholesterol. Significant 









Table 27. Odds ratios (95% CI) for metabolic syndrome and its components 
per SD units of iron markers in women of the study 
 
 Z score log-sTfR  Z score log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
High glucose † 1.09 (0.90-1.33) 1.07 (0.85-1.36) 1.53 (1.24-1.88) 1.12 (0.88-1.43) 
Low HDL-C  1.17 (0.81-1.69) 1.16 (0.84-1.61) 1.05 (0.71-1.55) 0.83 (0.52-1.31) 
High TG 1.05 (0.86-1.28) 1.02 (0.80-1.30) 1.66 (1.32-2.08) 1.41 (1.08-1.83) 
High BP¶ 1.10 (0.90-1.34) 1.10 (0.85-1.42) 1.74 (1.41-2.14) 1.03 (0.77-1.36) 
High WC 1.01 (0.78-1.31) 0.90 (0.67-1.20) 1.53 (1.18-1.95) 0.90 (0.57-1.42) 
MetS 1.06 (0.86-1.30) 1.02 (0.78-1.30) 2.22 (1.77-2.80) 1.55 (1.13-2.13) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), BMI and 
menopause. † Includes additionally individuals who reported current use of oral hypoglycaemic medications 
or insulin regardless of fasting glucose values .¶ Includes additionally individuals who reported current use 
of antihypertensive medications regardless of blood pressure values. SD, standard deviation  TG, 
triglycerides. BP, blood pressure.. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic 














Table 28. Adjusted* Beta coefficients (95% CI)  for values of log-HOMA-IR and 





Dependant variable  log-HOMA-IR log-insulin log-HOMA-IR log-insulin 
In     
Premenopausal 
women 
0.07 (-0.12 to 0.27) 0.15 (-0.27 to 0.58) 0.05 (-0.05 to 0.16) 0.09 (-0.14 to 0.33) 
Postmenopausal 
women 
0.34 (0.05 to 0.63) 0.83 (0.23 to 1.43) 0.01 (-0.09 to 0.11) 0.01 (-0.19 to 0.23) 
Men 0.44 (0.14 to 0.75) 0.98 (0.34 to 1.63) 0.01 (-0.09 to 0.11) -0.03 (-0.26 to 0.18) 
All** 0.24 (0.09 to 0.39) 0.54 (0.23 to 0.86) 0.04 (-0.01 to 0.10) 0.06 (-0.06 to 0.19) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), treatment with insulin 
and/or hypoglycaemic drugs (yes/no), and BMI. ** Additionally adjusted for sex/menopausal status 
(premenopausal women [reference] / postmenopausal women/men). Multivariable adjusted analyses were 
performed on transformed values of skewed variables: logarithm of sTfR, ferritin, HOMA-IR  values, body mass 
















Table 29. Beta coefficients (95% CI) for values of glycosylated haemoglobin 
(HbA1C) by levels of iron markers in the study subjects 
 log-sTfR  log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
Premenopausal 
women 
-0.06 (-0.14 to 0.01) -0.06 (-0.14 to 0.01) 0.02 (-0.01 to 0.07) 0.02 (-0.01 to 0.07) 
Postmenopausal 
women 
0.02 (-0.13 to 0.17) -0.04 (-0.17 to 0.08) -0.007 (-0.06 to 0.04) -0.009 (-0.05 to 0.03) 
Men 0.18 (0.03 to 0.33) 0.03 (-0.09 to 0.16) 0.02 (-0.02 to 0.07) 0.001 (-0.04 to 0.04) 
All** 0.01 (-0.05 to 0.09) -0.03 (-0.10 to 0.02) 0.05 (0.01 to 0.08) 0.005 (-0.02 to 0.03) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), treatment with 
insulin and/or hypoglycaemic drugs (yes/no), and BMI. * Additionally adjusted for sex/menopausal status 
(premenopausal women [reference] / postmenopausal women/men). Multivariable adjusted analyses were 
performed on transformed values of skewed variables: logarithm of sTfR , ferritin ,  body mass index  and 
fibrinogen values;  square of age and square root(sqrt) of glycosylated haemoglobin. Significant associations are 











Table 30. Differences between included and excluded subjects of the SHeS 










Variables     
Age 41(31-52) 38(26-52) n=10775 <0.001 
Pre-W/Post-W/ Men (%) 34.5/20.7/44.9 32.6/21.7/45.7 n=10266 0.397 
Ferritin (µg/L) 61(32-108) 61(34-107) n=5503 0.312 
Fibrinogen (g/L) 2.9(2.4-3.5) 3.0(2.4-3.6) n=4770 0.042 
GGT (IU/L) 20(14-32) 21(15-32) n=5680 0.165 
Smoking  
status  (%) 
   
n=10443 
 
Never smoker 39 40.3   
0.009 Ex-regular or Ex-occasional 
smoker 
26.3 24.2  
Current smoker 34.7 35.5  
Alcohol consumption  
Categories of rating units/week 
Prevalence (%) 
  n=10371  




Ex-drinker 2.8 4.1  
Trivial drinker/Non-zero but 
under 1 
10.3 12.2  
1-20  63.4 59.1  
≥ 21 19.3 18.8  
BMI (Kg/mts2)  25.7(23.1-28.6) 25.4(22.5-
28.8) 
n=9208 <0.001 
HDL-cholesterol (mmol/L) 1.4(1.2-1.7) 1.4(1.1-1.6) n=5433 <0.001 
Total cholesterol (mmol/L) 5.4(4.7-6.2) 5.4(4.6-6.2) n=5559  
Systolic blood pressure (mmHg) 70(63-79) 70(62-78) n=6081 <0.001 
Diastolic blood pressure (mmHg) 126(117-137) 127(117-138) n=6081 0.025 
Incident diabetes (%)** 4.9 8.2 n=9171 <0.001 
Incident  coronary heart disease 
(%)** 
5.3 7.9 n=9171 <0.001 
Incident cerebrovascular disease 
(%)** 
2.4 3.3 n=9171 <0.001 
Survey 1995/1998 (%) 50.1/49.9 43.9/56.1 n=10775 <0.001 
*Samples sizes are based on unweighted values. Data are median (interquartile range) or %. 
Comparison between groups by Mann-Whitney U and 2 test. Pre-MW, premenopausal women. 




Table 31. Baseline characteristics of the SHeS 95-98 participants and incidence of outcome diseases by sex-and menopausal 
stats-specific quartiles of ferritin level in the study cohort (n=6497) [unweighted values]    
  Ferritin (µg/L)  
 All Q1 Q2 Q3 Q4 P for 
trend 
Ferritin levels range by 
sex/menopausal status (µg/L) 
      
Premenopausal women (n=2241) 2.0-950 2.0-18 19-30 31-47 48-950  
Postmenopausal women 
(n=1345) 
3.0-1000 3.0-34 35-58 58-91 92-1000  
Men 
(n=2924) 
3.0-2251 3.0-61 62-96 97-151 152-2251  
Variables       
Age 43(32-54) 41(32-52) 41(31-54) 42(32-54) 46(35-57) <0.001 
Pre-W/Post-W/ Men (%) 34.4/20.7/44.9 33.8/20.6/45.6 34.5/20.9/44.6 35.3/20.3/44.4 34.2/20.9/45 0.669 
Ferritin (µg/L) 59(32-105) 23(13-41) 51(27-76) 81(41.2-114) 156(82-209) <0.001 
Fibrinogen (g/L) 3.0(2.5-3.6) 2.8(2.4-3.5) 2.9(2.5-3.5) 3.0(2.5-3.7) 3.1(2.6-3.7) <0.001 





     
Never smoker 2474(38) 714(44.1) 640(39.7) 584(35.4) 536(32.9)  
 
<0.001 
Ex-regular or Ex-occasional smoker 1728(26.5) 408(25.2) 434(26.9) 440(26.7) 446(27.4) 
Current smoker 2308(35.5) 497(30.7) 539(33.4) 624(37.9) 648(39.8) 
Alcohol consumption  
Categories of rating units/week 
n (%) 
      




Ex-drinker 211(3.2) 61(3.8) 55(3.4) 55(3.3) 40(2.5) 
Trivial drinker/Non-zero but under 1 757(11.6) 231(14.3) 208(12.9) 166(10.1) 152(9.3) 
1-20  4102(63) 1023(63.2) 1009(62.6) 1065(64.6) 1005(61.7) 
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  Ferritin (µg/L)  
 All Q1 Q2 Q3 Q4 P for 
trend 
≥ 21 1151(17.7) 211(13) 258(16) 299(18.1) 383(23.5) 
BMI (Kg/mts2)  25.7(23.1-28.7) 25(22.7-27.8) 25.3(22.9-28.2) 25.8(23.3-28.7) 26.5(23.9-29.9) <0.001 
HDL-cholesterol (mmol/L) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.2-1.7) 1.4(1.1-1.7) 0.049 
Total cholesterol (mmol/L) 5.4(4.8-6.3) 5.3(4.6-6.1) 5.4(4.7-6.3) 5.5(4.8-6.3) 5.7(4.9-6.5) <0.001 
Systolic blood pressure (mmHg) 126.5(117-138) 126(117-1365) 125(116-137) 126(117-138) 129.5(119-142)  
<0.001 
Diastolic blood pressure (mmHg) 71(64-79.5) 70(63-78) 70(63-78.5) 71(64-79) 73(65-81) <0.001 
Development of diabetes (%) 340(5.2) 56(3.5) 67(4.2) 75(4.6) 142(8.7) <0.001 
Development of coronary heart 
disease  
n (%) 
375(5.8) 81(5.0) 81(5.0) 90(5.5) 123(7.5) 0.002 
Development of cerebrovascular 
disease n (%) 
183(2.8) 38(2.3) 38(2.4) 47(2.9) 60(3.7) 0.014 
Survey 1995/1998 
n  (%) 
49.8/50.2 44/56 50.1/49.9 52.9/47.1 52/48 <0.001 
Data are median (interquartile range) or %. Comparison between groups by Mann-Whitney U and 2 test. Pre-MW, premenopausal women. Post-








Table 32. HRs and 95% CI for the incidence of diabetes and cardiovascular diseases by serum ferritin levels [unweighted Cox 
regressions]    
 Type 2 diabetes  Coronary heart disease Cerebrovascular disease 




















































Ferritin           














1.00 (reference) 1.00 
(reference) 






















































P for trend P<0.001 P<0.001 P=0.009 P=0.002 P=0.070 P=0.708 P=0.015 P=0.125 P=0.562 
*Adjusted for age, sex/menopausal status, fibrinogen levels, GGT levels, alcohol intake, smoking, systolic blood pressure, diastolic blood pressure, total 





Table 33. Differences between included and excluded subjects in the ET2DS 
 Included (n=821) Excluded (n=118) n for variables 
in excluded 
P value 
Sex Male/Female n 422(48.6)/399(51.4) 66(55.9)/52(44.1) n=118 0.205 
Variables     
Age (years) 68.9(65.3-72.3) 69.4(65.3-73.4) n=118 0.332 
Duration of diabetes (years) 7.0(4.0-12) 7.0(5.0-13) n=110  
0.616 
Ferritin (µg/L) 73(32.5-141) 48(24-124) n=55 0.127 
Glucose mmol/L 6.4(5.4-7.9) 6.5(5.2-7.8) n=103 0.819 
HbA1C (%) 7.0(6.4-7.7) 7.4(6.7-8.2) n=118 <0.001 
Fibrinogen (g/L) 3.5(3.1-4.0) 3.4(3.1-4.0) n=118 0.134 
CRP(mg/L) 1.7(0.8-4.0) 1.8(0.6-4.4) n=99 0.737 
GGT(U/L) 17(10-31) 13(8.0-22.7) n=112 0.004 
ALT(U/L) 31(26-31) 29(23-35) n=112 0.007 
AST(U/L) 29(24-35) 26(21.2-31) n=112 <0.001 
Smoking [ever] n(%) 490(59.7) 72(61) n=118 0.432 
 







BMI (Kg/mts2)  30.6(27.4-34.4) 30.2(26.4-34.4) n=117 0.446 
SBP mmHg 132(112-142) 134(122-142) n=116 0.735 
DBP mmHg 68(62-76) 68(60.5-76) n=116 0.541 
HDL-cholesterol (mmol/L) 1.2(1.1-1.5) 1.3(1.1-1.6) n=110 0.055 
Total cholesterol (mmol/L) 4.2(3.7-4.7) 4.3(3.8-5.0) n=110 0.261 
eGFR, mL/min/1.73 m2 60(60-71) 66(59.7-82.2) n=106 0.012 
Oral hypoglycaemic drugs 
n(%) 
607(73.9) 92(78) n=118 0.206 
Antihypertensive drugs n(%) 705(85.9) 101(85.6) n=118 0.514 
Lipid-lowering drugs n(%) 691(84.2) 102(86.4) n=118 0.314 
Insulin therapy n(%) 123(15) 25(21.2) n=118 0.059 
Liver disease n(%) 12(1.5) 3(2.5) n=118 0.289 











Outcomes after follow-up     
Development of CHD  78(9.5) 13(16.9) n=118 0.351 
Development of CEVD  54(6.6) 9(7.6) n=118 0.394 
Development of CVD  123(15) 20(16.9) n=118 0.331 
Data are median (interquartile range) or n (%). Differences by groups by Mann-Whitney U test (continuous 
variables) and 2 tests (categorical variables). GGT, gamma-glutamyl transpeptidase, ALT, Alanine 
aminotransferase. AST, Aspartate aminotransferase. CRP, C reactive protein. HDL-C, HDL cholesterol. BMI, 
body mass index. eGFR, estimate glomerular filtration rate. HbA1C, glycosylated haemoglobin. SBP, systolic 








Table 34. Differences between included and excluded subjects in the SIDIAP 
study 
 Included 
(Those with no 
missing values) 




 (n=38617) (n=279403)   
Sex Male/Female n 16423/22194 154796/124607 n=279403 <0.001 
Variables     
Age (years) 73(64-80) 69(60-78) n=279403 <0.001 
Duration of diabetes 7(4-10) 6(3-9) n=279403 <0.001 
Ferritin (µg/L) 62(26-143) 69.7(28.8-163) n=23385 <0.001 
Triglycerides (mmol/L) 1.4(1.0-1.9) 1.4(1.0-2.0) n=209205 <0.001 
HbA1C (%) 6.9(6.3-7.8) 6.9(6.3-7.8) n=212353 0.216 
White blood cells count x 1000/µL 7.2(6.0-8.5) 7.2(6.1-8.6) n=202756 <0.001 
Smoking [ever] n(%) 11487(29.7) 101335(36.3) n=271566 <0.001 
Alcohol consumption [ever] n(%) 7882(20.4) 67462(24.1) n=279403 <0.001 
BMI (Kg/mts2)  29.3(26.4-32.9) 29.4(26.6-32.8) n=199640 <0.001 
SBP mmHg 134(125-141) 134(126-140) n=227881 0.065 
DBP mmHg 74(67-80) 76(70-81) n=227881 <0.001 
HDL-cholesterol (mmol/L) 1.2(1.0-1.4) 1.2(1.0-1.4) n=198687 0.624 
Total cholesterol (mmol/L) 4.6(4.0-5.2) 4.8(4.1-5.4) n=221018 <0.001 
eGFR, mL/min/1.73 m2 60(54-60) 60(60-60) n=217425 <0.001 
Oral hypoglycaemic drugs n(%) 29331(76.0) 195786(70.1) n=279403 <0.001 
Antihypertensive drugs n(%) 31064(80.4) 195551(70) n=279403 <0.001 
Lipid-lowering drugs n(%) 23770(61.6) 152157(54.5) n=279403 <0.001 
Insulin therapy n(%) 8815(22.8) 48831(17.5) n=279403 <0.001 
Cardiovascular diseases n(%)     
CHD  6143(15.9) 33692(12.1) n=279403 <0.001 
CEVD  2812(7.3) 16042(5.7) n=279403 <0.001 
CVD  (any cardiovascular event)  8286(21.5) 46478(16.6) n=279403 <0.001 
Data are median (interquartile range) or n (%). Differences by groups by Mann-Whitney U test (continuous 
variables) and 2 tests (categorical variables). HDL-C, HDL cholesterol. BMI, body mass index. eGFR, 
estimate glomerular filtration rate. HbA1C, glycosylated haemoglobin. SBP, systolic blood pressure. DBP, 










Table 35. Clinical and biochemical variables measured in the two studies of 





 (n=821) (n=38617) 
Sex Male/Female n 422/399 16423/22194 
Ferritin levels range by sex (µg/L)   
Men  7-1095 1.0-3507 
Women  5-605 1.0-3682 
Variables   
Age (years) 68 (65-73) 73(64-80) 
Duration of diabetes 7(4-12) 7(4-10) 
Ferritin (µg/L) 73(32.5-141) 62(26-143) 
HbA1C (%) 7.1(6.4-7.7) 6.9(6.3-7.8) 
Smoking [ever] n(%) 490(59.7) 11487(29.7) 
Alcohol consumption [ever] n(%) 673(82) 7882(20.4) 
BMI (Kg/mts2)  30.6(27.4-34.4) 29.3(26.4-32.9) 
SBP mmHg 132(122-142) 134(125-141) 
DBP mmHg 68(62-76) 74(67-80) 
HDL-cholesterol (mmol/L) 1.2(1.1-1.5) 1.2(1.0-1.4) 
Total cholesterol (mmol/L) 42(3.7-4.7) 4.6(4.0-5.2) 
eGFR, mL/min/1.73 m2 60(60-71) 60(54-60) 
Oral hypoglycaemic drugs n(%) 607(73.9) 29331(76.0) 
Antihypertensive drugs n(%) 705(85.9) 31064(80.4) 
Lipid-lowering drugs n(%) 691(84.2) 23770(61.6) 
Insulin therapy n(%) 123(15) 8815(22.8) 
CHD (%) 250(30.5) 6143(15.9) 
CEVD (%) 71(8.6) 2812(7.3) 
CVD (any cardiovascular event) (%) 285(34.7) 8286(21.5) 
Data are median (interquartile range) or n (%). HDL-C, HDL cholesterol. BMI, body 
mass index. eGFR, estimate glomerular filtration rate. HbA1C, glycosylated 
haemoglobin. SBP, systolic blood pressure. DBP, diastolic blood pressure. CHD, 
coronary heart disease. CEVD, cerevrovascular disease. CVD, cardiovascular disease.  
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Table 36 .Odds ratios and 95% CI for prevalent cardiovascular events by ferritin levels and sex in the SIDIAP study 
 Men  Women 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
CHD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.000 (reference) 1.00 (reference) 1.00(reference) 1.00(reference) 
Ferritin Quintile 2 0.82 (0.73-0.91) 0.81 (0.73-0.90) 0.82 (0.73-0.93) 1.11  (0.98-1.26) 1.02  (0.89-1.15) 1.02  (0.89-1.17) 
Ferritin Quintile 3 0.70 (0.62-0.78) 0.72 (0.64-0.80) 0.78 (0.69-0.88) 1.03  (0.90-1.17) 0.93  (0.81-1.06) 0.93  (0.81-1.07) 
Ferritin Quintile 4 0.49 (0.43-0.55) 0.52 (0.46-0.59) 0.60 (0.53-0.69) 0.86  (0.76-0.99) 0.79  (0.69-0.91) 0.83  (0.72-0.95) 
Ferritin Quintile 5 0.36 (0.32-0.41) 0.40 (0.35-0.46) 0.50 (0.44-0.58) 0.81  (0.71-0.93) 0.74  (0.65-0.85) 0.76  (0.66-0.88) 
P for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
CEVD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00(reference) 1.00(reference) 1.00 (reference) 1.00(reference) 1.00(reference) 
Ferritin Quintile 2 0.82  (0.70-0.95) 0.80  (0.68-0.94) 0.80  (0.68-0.94) 1.07  ((0.90-1.26) 0.97  (0.82-1.15) 0.97  (0.81-1.15) 
Ferritin Quintile 3 0.72  (0.61-0.84) 0.74  (0.63-0.88) 0.76  (0.65-0.90) 1.00  (0.84-1.18) 0.90  (0.76-1.07) 0.89  0.74-1.05) 
Ferritin Quintile 4 0.69  (0.58-0.81) 0.76  (0.65-0.90) 0.82  (0.69-0.97) 0.81  (0.68-0.97) 0.74  (0.62-0.89) 0.74  (0.62-0.89) 
Ferritin Quintile 5 0.55  (0.46-0.65) 0.64  (0.54-0.76) 0.73  (0.61-0.88) 0.73  (0.60-0.88) 0.67  (0.55-0.80) 0.64  (0.52-0.77) 
P for trend <0.001 <0.001 0.003 <0.001 <0.001 <0.001 
CVD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00(reference) 1.00(reference) 1.00 (reference) 1.00(reference) 1.00(reference) 
Ferritin Quintile 2 0.79  (0.72-0.88) 0.78  (0.70-0.87) 0.79  (0.71-0.89) 1.08  (0.97-1.20) 0.98  (0.88-1.10) 0.99  (0.88-1.11) 
Ferritin Quintile 3 0.66  (0.59-0.73) 0.68  (0.61-0.75) 0.72  (0.64-0.81) 1.02  (0.91-1.14) 0.91  (0.81-1.02) 0.91  (0.81-1.02) 
Ferritin Quintile 4 0.51  (0.46-0.56) 0.55  (0.50-0.62) 0.63  (0.56-0.71) 0.83  (0.74-0.93) 0.75  (0.67-0.85) 0.78  (0.69-0.88) 
Ferritin Quintile 5 0.37  (0.33-0.41) 0.42  (0.37-0.47) 0.51  (0.45-0.58) 0.77  (0.68-0.86) 0.69  (0.61-0.78) 0.70  (0.61-0.79) 
P for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
CHD, coronary heart disease. CEVD cerebrovascular disease. CVD, cardiovascular disease. Model 1: unadjusted. Model 2: adjusted for age. Model 3: adjusted for adjusted for age, 
duration of diabetes,  use  of specific anti-hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-lowering drugs, smoking status, alcohol consumption, 
BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c,  HDL-cholesterol, total cholesterol, white blood cells count, triglycerides level, and estimated glomerular 
filtration rate (eGFR). Significant associations are shown in bold (P<0.05). 
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Table 37. Odds ratios and 95% CI for prevalent cardiovascular events by ferritin levels and sex in the ET2DS (n=821) 
 Men Women 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
CHD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 1.02 (0.55-1.90) 1.10 (0.59-2.06) 1.36 (0.68-2.73) 0.41 (0.19-0.89) 0.42 (0.19-0.90) 0.38 (0.15-0.91) 
Ferritin Quintile 3 0.64 (0.34-1.22) 0.68 (0.36-1.30) 0.65 (0.31-1.33) 0.87 (0.44-1.71) 0.88 (0.45-1.73) 0.63 (0.28-1.40) 
Ferritin Quintile 4 0.90 (0.48-1.68) 0.96 (0.51-1.80) 0.94 (0.46-1.93) 0.57 (0.27-1.17) 0.57 (0.27-1.17) 0.52 (0.22-1.25) 
Ferritin Quintile 5 0.65 (0.34-1.24) 0.69 (0.36-1.32) 0.83 (0.39-1.79) 0.61 (0.30-1.24) 0.59 (0.29-1.21) 0.38 (0.15-0.97) 
P for trend 0.182 0.232 0.396 0.353 0.308 0.098 
CEVD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 0.66 (0.24-1.83) 0.67 (0.24-1.87) 0.77 (0.26-2.24) 1.64 (0.51-5.2) 1.61 (0.50-5.19) 1.33 (0.35-4.97) 
Ferritin Quintile 3 0.66 (0.24-1.83) 0.67 (0.24-1.87) 0.58 (0.19-1.75) 0.94 (0.26-3.41) 0.94 (0.26-3.38) 0.76 (0.18-3.19) 
Ferritin Quintile 4 1.60 (0.67-3.81) 1.63 (0.68-3.89) 1.92 (0.72-5.10) 0.76 (0.19-2.97) 0.76 (0.19-2.96) 0.68 (0.15-2.97) 
Ferritin Quintile 5 0.67 (0.24-1.86) 0.68 (0.24-1.89) 0.89 (0.29-2.77) 0.56 (0.13-2.46) 0.58 (0.13-2.56) 0.44 (0.07-2.45) 
P for trend 0.816 0.793 0.531 0.226 0.248 0.242 
CVD       
Ferritin 













Ferritin Quintile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile 2 1.02 (0.56-1.87) 1.01 (0.58-1.98) 1.29 (0.65-2.55) 0.52 (0.26-1.06) 0.53 (0.26-1.07) 0.48 (0.21-108) 
Ferritin Quintile 3 0.50 (0.27-0.95) 0.53 (0.28-1.00) 0.45 (0.22-0.93) 0.82 (0.43-1.59) 0.83 (0.43-1.60) 0.57 (0.26-1.23) 
Ferritin Quintile 4 0.86 (0.47-1.59) 0.90 (0.48-1.67) 0.84 (0.41-1.71) 0.55 (0.27-1.11) 0.55 (0.27-1.11) 0.47 (0.20-1.07) 
Ferritin Quintile 5 0.71 (0.38-1.31) 0.73 (0.39-1.37) 0.84 (0.40-1.76) 0.63 (0.32-1.25) 0.61 (0.31-1.22) 0.40 (0.16-0.96) 
P for trend 0.218 0.263 0.335 0.255 0.220 0.052 
CI, confidence interval. CHD, coronary heart disease. CEVD, cerebrovascular disease. CVD, cardiovascular disease. Model 1: unadjusted. Model 2: adjusted for age. Model 3: 
adjusted for adjusted for age, duration of diabetes,  use specific anti-hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-lowering drugs, 
smoking status, alcohol consumption, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, fasting glucose, HDL-cholesterol, total cholesterol, C 
reactive protein (CRP), fibrinogen, transferases levels, liver disease and estimated glomerular filtration rate (eGFR) at baseline. Significant associations are shown in bold. 
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Table 38. HRs and 95% CI for incident cardiovascular events by ferritin levels* at baseline in the ET2DS (n=536) 
 Model 1 Model 2 Model 3 
CHD    
Ferritin (Z score of log-ferritin) 0.75(0.54-1.04) P=0.092 0.76(0.54-1.06) P=0.115 0.82(0.55-1.23) P=0.360 
Ferritin Quintile 1 (n=95) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile2  (n=106) 0.28(0.09-0.90) 0.29(0.09-0.93) 0.36(0.10-1.18) 
Ferritin Quintile 3 (n=115) 0.69(0.29-1.64) 0.72(0.30-1.71) 0.76(0.30-1.90) 
Ferritin Quintile 4 (n=109) 0.72(0.30-1.71) 0.75(0.31-1.77) 0.90(0.34-2.35) 
Ferritin Quintile 5 (n=111) 0.20(0.05-0.74) 0.21(0.05-0.76) 0.28(0.07-1.14) 
P for trend 0.110 0.117 0.341 
CEVD    
Ferritin  (Z score of log-ferritin) 0.87(0.58-1.29) P=0.494 0.81(0.54-1.22) P=0.326 0.88(0.54-1.43) P=0.616 
Ferritin Quintile 1 (n=95) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile2  (n=106) 0.35(0.09-1.35) 0.41(0.10-1.60) 0.60(0.12-2.88) 
Ferritin Quintile 3 (n=115) 0.77(0.27-2.21) 0.87(0.30-2.50) 1.12(0.29-4.18) 
Ferritin Quintile 4 (n=109) 0.34(0.08-1.32) 0.36(0.09-1.43) 0.47(0.09-2.30) 
Ferritin Quintile 5 (n=111) 0.56(0.17-1.78) 0.59(0.19-1.89) 0.70(0.16-2.95) 
P for trend 0.366 0.373 0.545 
CVD    
Ferritin  (Z score of log-ferritin) 0.79(0.61-1.03) P=0.087 0.78 (0.60-1.02) P=0.077 0.80(0.59-1.09) P=0.163 
Ferritin Quintile 1 (n=95) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Ferritin Quintile2  (n=106) 0.32(0.13-0.78) 0.35(0.14-0.84) 0.44(0.17-1.09) 
Ferritin Quintile 3 (n=115) 0.73(0.36-1.44) 0.78(0.39-1.55) 0.83(0.40-1.72) 
Ferritin Quintile 4 (n=109) 0.57(0.27-1.19) 0.60(0.28-1.26) 0.64(0.28-1.45) 
Ferritin Quintile 5 (n=111) 0.36(0.15-0.84) 0.37(0.16-0.86) 0.42(0.16-1.08) 
P for trend 0.085 0.092 0.166 
HR, hazard ratio. CI, confidence interval. CHD, coronary heart disease. CEVD, cerebrovascular disease. CVD, cardiovascular disease. Model 1: 
unadjusted. Model 2: adjusted for age and sex. Model 3: adjusted for adjusted for age, sex, duration of diabetes,  use specific anti-hyperglycaemic 
agents, treatment with insulin, lipid-lowering drugs, blood pressure-lowering drugs, smoking status, alcohol consumption, BMI, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), HbA1c, fasting glucose, HDL-cholesterol, total cholesterol, C reactive protein (CRP), fibrinogen, transferases 
levels, liver disease and estimated glomerular filtration rate (eGFR) at baseline. Values of transaminases levels, glucose, cholesterol, CRP and duration 
of diabetes were log-transformed for the analysis. Significant associations are shown in bold (P<0.05). *Cut-offs for quintiles from the whole sample 





Figure 1. Forest plot describing the association between ferritin and metabolic 
syndrome in observational studies (cross-sectional only [Meta-analysis 2].  






Overall  (I-squared = 79.2%, p = 0.000)
Ledesma et al.
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Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 






Figure 2. Forest plot describing the association between ferritin and high 
fasting glucose in observational studies. 
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Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 







Figure 3. Forest plot describing the association between ferritin and increased 
waist circumference in observational studies. 
 
Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 








Figure 4. Forest plot describing the association between ferritin and high 
triglycerides in observational studies. 




























Subtotal  (I-squared = 74.8%, p = 0.046)





















































































Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 








Figure 5. Forest plot describing the association between ferritin and low HDL 
cholesterol in observational studies. 
 
Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 








Figure 6. Forest plot describing the association between ferritin and high 
blood pressure in observational studies. 
 
Studies are stratified by sex, menopausal status or both sexes according to the way the association was 
reported in each article. Diamonds are pooled estimates from inverse variance weighted effects 









Figure 8. Risk of type 2 diabetes (T2D), coronary heart disease (CHD) and 
cerebrovascular disease (CEVD) by several sex-specific upper (v. lowest) 
quantiles of ferritin levels  
 
Ferritin highest quintile: Premenopausal women (Pre-MW) 53-950 µg/L, Postmenopausal women 
(Post-M) 102-1000 µg/L, Men 169-2251 µg/L. Ferritin highest sextile: Pre-MW 58-950 µg/L, Post-
MW 114-1000 µg/L, Men 183-2251 µg/L.    Reference (lowest quintile, sextile).   Unadjusted.  
 Adjusted for age and sex/menopausal status.  Adjusted for age, sex/menopausal status, 
fibrinogen levels, GGT levels, alcohol intake, smoking, systolic blood pressure, diastolic blood 
pressure, total cholesterol, HDL cholesterol, body mass index and year of survey. The above analysis 
included survey weights.  
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Appendix Newcastle - Ottawa Quality Assessment 
Scale  
(Version modified by Orban and Huth (2014) and adapted for this systematic review/ 
meta-analysis) 
 
CASE CONTROL and CROSS-SECTIONAL STUDIES 
 
Note: A study can be awarded a maximum of one star (#) for each numbered item within the 
categories. The maximum score that can be reached is 7 stars. 
 
Selection 
1) Representativeness of the cases 
a) consecutive or obviously representative series of cases # 
b) potential for selection bias 
c) no description 
 
2) Selection of controls 
a) controls from the same source population as cases # 
b) controls from different source population than cases 
c) no description 
 
3) Definition of controls 
a) general population # 
b) having any particular condition or disease 
c) no description 
 
Exposure 
1) Ascertainment of exposure 
a) Method for ferritin measurement described and the according intra-assay or inter-assay 
coefficient of variation (CV)<15% # 
b) Method of ferritin measurement not described or intra-assay or inter-assay CV reported 
≥15%  
c) No description  
 
2) Same method of ascertainment for cases and controls (especially same time point and same 
laboratory) 
a) yes (assumed if cases and controls are from the same cross-sectional study) # 
b) no 
c) no description 
 
Outcome 
1) Is the case definition adequate? 
a) Definition used of metabolic syndrome described and methods of blood sample processing 
and biochemical and clinical measurements described with at least two readings of blood 
pressure, and at least two kind of medications recorded among anti-hypertensive, 
hypoglycaemic, and lipid-lowering agents to complement components of high blood 
pressure, glucose and triglycerides#.  
b) based on self report only 
c) no description 
 
Comparability of cases and controls 
1) Consideration of the most important confounding factors in the design or analysis by matching or 
adjustment 
a) study controls additionally for at least one inflammatory marker and body mass index  # 
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Note: A study can be awarded a maximum of one star (#) for each numbered item within the 
categories. The maximum score that can be reached is 7 stars. 
 
Selection 
1) Representativeness of the cohort 
a) representative of the general population # 
b) selected group, e.g. nurses, volunteers 
c) no description of the derivation of the cohort 
 
2) Demonstration that outcome of interest was not present at start of study 




1) Ascertainment of exposure 
a) Method for ferritin measurement described and the according intra-assay or inter-assay 
coefficient of variation (CV)<15% # 
b) Method of ferritin measurement not described or intra-assay or inter-assay CV reported 
and ≥15%  
c) No description  
 
Outcome 
1) Assessment of outcome 
a) Definition of metabolic syndrome described and methods of blood sample processing and 
biochemical and clinical measurements described, with at least two readings of blood 
pressure, and at least two kind of medications recorded among anti-hypertensive, 
hypoglycaemic, and lipid-lowering agents to complement components of high blood 
pressure, glucose and triglycerides#.  
b) based on self report only 
c) no description 
 
2) Was follow-up long enough for outcomes to occur? 
a) yes (follow-up was at least three years) # 
b) no 
c) no description 
 
3) Adequacy of follow-up of cohorts 
a) complete follow-up – all subjects accounted for # 
b) subjects lost to follow-up unlikely to introduce bias: ≥ 80% follow-up, or complete 
description provided of those lost # 
c) follow-up rate < 80% and no description of those lost 
d) no description  
 
Comparability of exposed and unexposed participants 
1) Consideration of the most important confounding factors in the design or analysis 
a) study controls additionally for at least one inflammatory marker and body mass index  # 
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